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ABSTRACT 
Background  
HIV-1 infection has become a chronic condition. Although people living with HIV-1 infection 
(PLHIV) now have near-normal life expectancies, walking-related impairments remain 
concerning as they occur early and may lead to falls. A poor understanding remains of how 
movement patterns are affected due to a lack of biomechanical studies. Three-dimensional 
(3D) motion analysis can provide insight into movement patterns and assist in identifying a 
valid performance-based screening test for detecting early motor impairments in PLHIV. 
Aim 
The aim of this research was to investigate gait and balance impairments existing in PLHIV 
using 3D motion analysis. It further aimed to correlate 3D analysis findings (via a gait summary 
score), as well as self-reported function and history and fear of falling, to physical performance 
tests which may be considered in clinical practice to screen for early functional decline in 
PLHIV.  
Methods 
The research was divided into three parts: 
Part I presented a systematic review describing objective gait and balance impairments in 
PLHIV. Results contributed to the theoretical groundwork for study conceptualisation and aided 
in selecting clinically relevant biomechanical outcomes and performance-based tests.  
Part II comprised validity and reliability testing of a portable 3D gait analysis (3DGA) system, 
newly obtained by the motion laboratory, in 16 healthy student volunteers, as well as in eight 
consecutively recruited PLHIV and eight community-matched seronegative participants (SNP). 
The studies determined the psychometric properties of specific 3DGA outcomes to aid 
appropriate data interpretation in the next phase.  
Part III comprised the main observational study to cross-sectionally describe key 
biomechanical characteristics in 50 PLHIV relative to 50 community-matched SNP 
(consecutively sampled). The study was conducted in a clinical setting, and performance-
based tests were assessed in addition to the 3D motion analysis. Gait analysis results, fall-
related outcomes and self-reported function were correlated to clinical test performance to 
identify the most valid performance-based screening test.  
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Main results 
The systematic review (Part I) revealed some agreement that PLHIV walk slower and have 
increased centre of pressure (COP) excursions and postural reflex latencies, particularly under 
challenging conditions. No included studies used 3DGA. The validity and reliability studies 
(Part II) demonstrated that, with regular recalibration, the 3DGA system reliably measures gait 
biomechanics in SNP and PLHIV, except for four discrete angles. The system/model highly 
compares to the reference model after accounting for modelling differences. The field study 
(Part III) revealed that the gait of PLHIV (median age: 36.61 years) was significantly slowed 
and rigid relative to SNP (median age: 31.10 years). This pattern manifested when walking at 
a usual pace or when performing a dual task. Dual task walking further revealed joint range of 
motion (ROM) changes at the hip and knee in a distal-to-proximal pattern-shift. PLHIV also 
demonstrated increased COP excursion in dual task single-leg stance. PLHIV were 
significantly slower in completing the Five-Times Sit-To-Stand (5STS) Test. Slowed sit-to-
stand was significantly related to gait rigidity, worse self-reported function, and fear of falling. 
Conclusion 
Relatively young PLHIV present with biomechanical gait and balance impairments that 
resemble patterns noted in elders, especially under dual task conditions. The 5STS test is 
recommended as a valid clinical screening test. These findings improve understanding of 
movement impairments in PLHIV and highlight the need for early screening. Further research 
is needed to determine whether the 5STS test predicts falls, and whether the impairments 
noted in PLHIV are reversible. Early identification and rehabilitation can reduce healthcare 
utilisation needs in PLHIV.  
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OPSOMMING 
Agtergrond 
MIV-1 infeksie het ontaard in ‘n kroniese toestand. Alhoewel persone wat leef met MIV-1 
infeksie (PLMIV) nou ‘n bykans normale lewensverwagting het, is loopverwante aantastings 
steeds kommerwekkend aangesien dit vroeg voorkom en kan lei tot valverwante beserings. 
Tans heers ‘n swak begrip van hoe bewegingspatrone aangetas word, weens ‘n tekort aan 
biomeganiese studies. Drie-dimensionele (3D) bewegingsanalise kan insig verleen 
aangaande beweginspatrone en bydra tot die identifisering van ‘n geldige verrigtings-
gebaseerde siftingstoets vir die waarneming van vroeë bewegingsaantastings in PLMIV. 
Doel 
Die doel van hierdie navorsing was om looppatroon- en balansaantastings in PLMIV te 
ondersoek deur middel van 3D-bewegingsanalise. ‘n Verdere doelwit was om die 3D-analise 
bevindinge (via ‘n looppatroon opsommings-telling), selfvermelde funksie, asook geskiedenis 
van en vrees vir neerval te korreleer met fisiese verrigtings-toetse wat in kliniese pratkyk 
oorweeg mag word om te sif vir vroeë funksionele agteruitgang in PLMIV.  
Metodes 
Die studie het drie dele behels: 
Deel I het ‘n sistematiese oorsig behels wat objektiewe looppatroon- en balansaantastings in 
PLMIV beskryf. Resultate het bygedra tot die teoretiese grondwerk vir die studie se 
konsepsualisering en ook tot die keuse van klinies-relevante biomeganiese uitkomste en 
verrigtingsgebaseerde toetse. 
Deel II het bestaan uit geldigheids- en betroubaarheids-toetsing van ‘n 3D-loopanalise (3DLA) 
stelsel, nuut aangeskaf deur die bewegingslaboratorium, in 16 gesonde studente vrywilligers 
asook in agt opeenvolgend-vervorwe PLMIV en agt gemeenskaps-ooreenstemmende 
seronegatiewe deelnemers (SND). Die studies het die geldigheid en betroubaarheid van 
spesifieke 3DLA uitkomste bepaal om gepaste data interpretasie in die volgende fase moontlik 
te maak. 
Deel III het die hoof waarnemingstudie behels wat ‘n dwarssneebeskrywing verskaf het van 
die kern biomeganiese kenmerke in 50 PLMIV vergeleke met 50 gemeenskap-
ooreenstemmende SND (opeenvolgende steekproefneming). Die studie is uitgevoer in ‘n 
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kliniese omgewing en verrigtingsgebaseerde toetse is geëvalueer bykomstig tot die 3D-
bewegingsanalise. Resultate van die looppatroonanalise, valverwante uitkomste en 
selfvermelde funksie is gekorreleer met die kliniese toetsverrigting om die mees geldige 
verrigtingsgebaseerde siftingstoets te bepaal. 
Hoofresultate 
Die sistematiese oorsig (Deel I) het ‘n mate van konsensus bevind dat PLMIV stadiger loop en 
‘n verhoogde middelpunt van drukking (MVD) omvang van beweging (OVB) het, asook 
posturale reflekslatentheid, veral onder uitdagende toestande. Geen ingeslote studies het 
gebruik gemaak van 3DLA nie. Die geldigheid- en betroubaarheid-studies (Deel II) het 
demonstreer dat, met gereelde herkalibrering, die 3DLA stelsel looppatroon-biomeganika 
betroubaar meet in SND en PLMIV, met die uitsondering van vier diskrete gewrigshoeke. Die 
stelsel/model is hoogs vergelykbaar met die verwysingstelsel na die inagneming van die 
verskille in die biomeganiese model. Die veldwerkstudie (Deel III) het getoon dat die 
looppatroon van PLMIV (mediaan-ouderdom: 36.61 jaar) beduidend stadiger en oormatig 
rigied was vergeleke met SND (mediaan-ouderdom: 31.10 jaar). Hierdie patroon het 
manifesteer tydens ‘n selfgekose loopspoed of tydens die uitvoer van ‘n dubbele taak. 
Dubbeltaak-loop het verder veranderinge getoon in heup- en kniegewrigs OVB in ‘n distaal-
tot-proksimale patroon-aanpassing. PLMIV het ook verhoogde MVD OVB getoon tydens 
dubbeltaak-eenbeenstaan. PLMIV was beduidend stadiger om die Vyfmaal Sit-Tot-Staan 
(5STS) Toets te voltooi. Stadiger sit-tot-staan het ‘n beduidende verwantskap getoon met ‘n 
meer rigiede looppatroon, laer vlakke van selfvermelde funksie en ‘n vrees vir val.  
Gevolgtrekking 
Relatiewe jong PLMIV toon verskeie aantastings van looppatroon- en balansbiomeganika wat 
tot ‘n mate ooreenstem met patrone wat gewoonlik in ouer volwassenes waargeneem word, 
veral tydens die uitvoer van ‘n dubbele taak. Die 5STS-toets word aanbeveel as ‘n geldige 
siftingstoets. Hierdie bevindinge verbeter die begrip van bewegingsaantastings in PLMIV en 
beklemtoon die belang van vroeë siftingstoetsing. Verdere navorsing word benodig om te 
bepaal of die 5STS-toets val-insidente kan voorspel, en of die aantastings in PLMIV 
omkeerbaar is. Vroeë identifisering en rehabilitasie kan die behoeftes aan gesondheidsorg 
onder PLMIV verminder.  
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INTRODUCTION 
1.1. Background 
HIV-1 infection has evolved into a manageable chronic condition due to the success of highly-
active antiretroviral therapy (HAART).1 Despite the fact that people living with HIV-1 infection 
(PLHIV) treated with HAART now have a near-normal life expectancy, age-related 
comorbidities and declines in physical function remain of concern as they occur relatively 
early.2,3 HIV/AIDS was the 33rd most important cause of disability-adjusted life years (DALYs) 
globally in 1990, but increased steeply to fifth position in 2010.4 In Sub-Saharan Africa, 
including South Africa, a high prevalence of HIV-associated disability, including impairments 
in mobility and motor function, is reported.5–7 The prevalence of HIV-1 infection is most 
prominent and rising amongst working-aged (20 to 60 year-old) adults in South Africa.8 The 
younger Sub-Saharan population living with HIV-1 infection implies that costly, long-term 
morbidity management will be needed in PLHIV. 
1.1.1. Motor impairments related to HIV-1 infection: Early 
origins 
June 5, 1981, marks the first official reporting of what was to become one of the most 
devastating and widespread infectious pandemics to have emerged in recent history.9 A 
retrovirus, now termed human immunodeficiency virus type 1 (HIV-1), was subsequently 
confirmed as the principal aetiological agent and in September 1982 the US Centres for 
Disease Control and Prevention (CDC) coins the term “AIDS” (Acquired Immune Deficiency 
Syndrome) for the first time. Ever since this first definition of AIDS, motor function impairments, 
often along with cognitive dysfunction, were noted and described as defining characteristics 
of HIV/AIDS.10,11 Psychomotor slowing (for example slowed motor and verbal responses; 
potentially progressing to an akinetic state) was described as the most common prodromal 
presentation of AIDS, along with impaired memory and concentration.10,12 At that time, it was 
estimated that about half of PLHIV had a motor or cognitive impairment, or both.10 Functional 
capacity in PLHIV was severely reduced by psychomotor impairments – which were described 
as being progressive in nature. Signs and symptoms became severe in the late stages of the 
disease. These impairments were thought to indicate direct brain infection by the AIDS-
causing retrovirus.10 
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Two landmark papers10,12 initially described the early motor impairments observed in AIDS. 
These researchers indicated that during the asymptomatic stages of HIV-1 infection, motor 
signs were already present, albeit less apparent. The initial signs of motor impairment that 
were observed included tremor, slowing of alternating movements of the extremities and loss 
of rapid and fine motor function of the fingers. During these early stages of the syndrome, 
gross motor functional ability was also affected, since gait was typically slower and mildly 
unsteady, with rapid turns being performed with less control and confidence. As the syndrome 
progressed into the later stages, walking difficulties became more notable and included gross 
weakness and general hypokinesia.10 In severe cases, gait slowness and instability 
necessitated use of a walking aid to prevent falling. Gait problems were exaggerated by ataxia, 
leg weakness, abnormal reflexes and tremors.10 These significant impairments, particularly in 
association with cognitive impairments, were indications for aggressive antiretroviral 
chemotherapy to reduce symptoms and enhance function.12 
1.1.2. Motor impairments related to HIV-1 infection: The 
antiretroviral (ARV) treatment era  
Advances in the treatment of opportunistic infections were observed following the advent of 
antiretroviral (ARV) therapy in 1987.13 As a result, the lifespan of PLHIV improved 
significantly.14,15  Despite an improvement in the severity of many of the HIV-defining motor 
impairments which were initially observed, the incidence and prevalence of ARV side effects 
such as sensory distal peripheral neuropathies increased.16 These effects were arguably due 
to the neurotoxic effects of specific ARV drugs such as stavudine.17–19 Although largely phased 
out, as recommended by the World Health Organisation (WHO), a substantial proportion of 
South African PLHIV are currently still prescribed stavudine due to lack of a cost-effective 
alternative.19,20 The most common signs and symptoms of peripheral neuropathies among 
South African PLHIV include pain of the feet or just proximal to the feet, numbness and 
paraesthesia, absent ankle reflex and reduced vibration sense.19 The presence of such 
symptoms significantly reduces quality of life and function.19,21 Since peripheral neuropathies 
primarily affect the lower limbs and feet, it often impairs balance control and subsequently 
functional walking performance.22 
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1.1.3. Motor impairments related to HIV-1 infection: The 
highly-active antiretroviral therapy (HAART) era  
Twenty-two years ago, in 1996, early forms of combination antiretroviral therapy (cART) were 
introduced,23 leading in the current treatment era of HAART. HAART entails the use of 
combination ART, typically comprising three or more drugs, aimed at reducing plasma virus 
levels below limits of detection.24 Modern HAART regimens have less neurotoxic effects than 
older versions, and thus there is a lower risk of developing peripheral neuropathy.25 However, 
the prevalence of peripheral neuropathy remains quite high among PLHIV (between 30% and 
62%), and the prevalence of locomotor impairments remains a concern26–29 – regardless of 
the presence of peripheral neuropathy.30 In a Cape Town-based study by Joska et al.,26 
participants with severe neurocognitive impairment (indicated by a high global deficit score 
[GDS] achieved in a neurocognitive test battery) at the commencement of HAARTillustrated 
significant improvement (indicated by a lowered GDS) within a one-year treatment period. 
However, mild-to-moderate neuro-motor impairments were still noted in one-quarter of the 
sample; particularly in domains associated with deep grey nuclei31 such as psychomotor 
processing and learning. Thus, the prevalence of neuro-motor impairments remains a concern 
despite HAART. Persistent neuro-inflammation of the central nervous system (CNS) has been 
hypothesised as a major explanatory phenomenon – especially of frontal and subcortical grey 
areas which indirectly contribute to locomotion and balance26,31 and perhaps more so than 
impairment of the peripheral nervous system.32 In addition, HAART may also impose direct 
drug toxicity.25 Individuals with persistent neurocognitive effects may therefore continue to 
demonstrate fine as well as gross motor impairments.33 
1.1.4. Evolution of HIV-1 infection into a chronic condition 
Over the past 30 years, significant improvements have been made in the management of HIV-
1 with drug-related therapies to reduce infections. Due to powerful HAART suppressing viral 
replication, HIV has now evolved into a long-term chronic disease. Furthermore, in Sub-
Saharan Africa specifically, PLHIV are relatively younger compared to developed countries, 
are usually engaged in full-time employment and have domestic, family and social 
responsibilities. Symptoms such as pain and poor functional ability have a profound negative 
effect on health, work productivity and healthcare utilisation.34 These younger Sub-Saharan 
and South African populations will likely live well into older age with HIV-1 infection, with the 
implication that the management of morbidity will be needed at an earlier age and for a longer 
period. This underscores the need for clinicians and researchers alike to reprioritise 
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investigations into understanding the impact of this chronic condition on the individual’s quality 
of life. Indeed, optimisation of quality of life is now a priority goal as part of the comprehensive 
care for PLHIV.25 From an ethical point of view, extending the lifespan of individuals without 
sufficient efforts to significantly enhance quality of life accordingly, cannot be justified. 
Improved management of functional problems related to HIV-1 infection to enhance quality of 
life is thus warranted.6 
1.1.5. In summary 
This background illustrates the plausible advances in HIV-1 management, paralleled by 
challenges related to morbidity and its consequences for PLHIV residing in Sub-Saharan 
Africa. It illustrates that efforts to enhance quality of life and function in PLHIV is a pressing 
concern. Despite the extraordinary success of HAART in extending the lives of PLHIV and 
reducing many morbidities, motor impairments remain prevalent. Adding years to life without 
substantial concurrent efforts to maximise quality of life for these added life years cannot be 
ethically justified. This behoves scientific investigations to understand the interplay of 
neuromotor impairments and functional trajectories towards disability in PLHIV. Such 
investigations can make a meaningful humanistic contribution towards the lives of PLHIV, 
particularly those living in Sub-Saharan Africa. In addition, addressing morbidity can ultimately 
yield substantial economic gains due to reduced healthcare utilisation and improved 
adherence to HAART, which is a secondary effect to improved quality of life.35   
1.2. Research motivation 
South Africa has the highest prevalence of HIV-1 infection in the world, with an estimated 7,52 
million PLHIV in 2018, meaning that about one in every eight South Africans is HIV-1 
seropostitive.36 These alarming statistics, along with the fact that HIV-1 now manifests as a 
chronic condition, highlight the substantial burden of HIV-1 on the population’s well-being and 
the healthcare system.  
In the context of South Africa, reduced physical functional performance may be prevalent in 
PLHIV. This may be because some individuals have limited access to ART or present late for 
treatment due to the stigma of the disease or cultural issues. No or delayed treatment leads 
to earlier progression of the disease into advanced stages. In these advanced stages, declines 
in function is marked.37,38 South African PLHIV may also be subjected to earlier functional 
decline as neurocognitive dysfunction is often reported in relatively young individuals (mean 
ages ranging from 29.75 to 38.50 years in a systematic review39), which is often associated 
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with depression, mobility problems and activity limitations39,40 The onset and rate of functional 
decline is thus of concern among South African PLHIV.  
Due to the many and complex effects that the virus itself or its treatment can have on the body, 
everyday functioning of PLHIV may be severely affected by HIV-1 infection.37,41 South African 
PLHIV receiving HAART have been reported to experience a mean of ten HIV-associated 
symptoms.42,43 These commonly include psychological and physical symptomsi such as 
“feeling sad”, sleep disturbances, weight maintenance (unwanted weight loss), numbness or 
tingling of the hands and feet, pain, and muscle weakness.37,42 Subsequently, activity levels 
are often affected, especially in the domains of mobility, domestic life, self-care and ability to 
work44,45 and quality of life (including the ability to function) is noticeably reduced.43,46 Of further 
concern is that PLHIV with more self-reported symptoms are less adherent to HAART.35 The 
number of symptoms experienced is also associated with substance abuse and psychiatric 
illness.47 There are indications that symptom management improves quality of life and even 
virologic suppression.48 Understanding of HIV related symptoms which impact on functional 
performance is crucial to improve the quality of life. 
Many functional activities are dependent on the integrity of lower limb neuromusculoskeletal 
structures49 and lower limb function is predictive of future disability.49,50 PLHIV in high-, as well 
as in lower-middle income countries, have shown to have some form of lower limb impairment, 
despite controlled viral load.2,38,51 Despite effective viral suppression, PLHIV also experience 
non-AIDS-defining complications, resembling geriatric processes.52,53 This hypothesised 
accelerated or accentuated ageing may manifest in middle-aged PLHIV as low muscle mass, 
low bone mineral density (BMD) and low insulin-like growth hormone (IGF-1) and IGF-1 
binding protein 3.54 Low BMD, in addition to muscle weakness, is associated with balance 
problems and increased fall risk.2,55 People with reduced functional performance are less likely 
to participate in regular physical activities, amplifying the decrease in BMD and muscle 
strength.54 The compounded effect of these factors may explain the fourfold increased risk for 
hip fractures in PLHIV relative to seronegative individuals.56 These problems face relatively 
young South African PLHIV compared to their seronegative peers.57 Functional decline and 
its consequences (such as falls) increases morbidity in people with HIV/AIDS as well as their 
healthcare needs or utilisation.  
                                               
i Symptoms defined using either the Memorial Symptom Assessment Scale-Short Form (MSAS-SF) or 
International Classification of Functioning, Disability and Health (ICF) checklist. Data from cross-
sectional self-report studies.37,42,43 
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Functional performance related to impaired walking ability is a particular concern in 
PLHIV.2,32,51,58,59 It has been reported that a quarter of PLHIV have a reduced six-minute 
walking distance.2 Peripheral neuropathies related to ARVs can lead to decreased walking 
ability and speed22,32 and reduced balance is also evident independent of such neuropathies.30 
In addition to walking problems, about half of PLHIV also have difficulty in performing other 
functional movements such as rising from a chair.2 Successful and safe occupational, societal 
and domestic functions may thus be threatened in PLHIV. 
1.2.1. The knowledge gap 
It is clear that the motor system is affected in PLHIV; yet a poor understanding of exactly why 
and how it is altered remains; and several gaps exist in the literature. In Sub-Saharan Africa, 
published literature about functional performance is limited to subjective self-reports such as 
“difficulty walking”.7,37,38,45 The international literature also primarily reports on temporal 
information such as how long it takes to perform a specific clinical functional test (e.g. duration 
of a four-metre walk).2,30,59,60 Despite the recommendation to standardise clinical tests in 
PLHIV in order to provide comparable objective information, clinical tests such as a timed gait 
test in isolation remain mere proxy measures and do not allow the identification of the specific, 
perhaps subtle, underlying movement impairments or quality of a gait pattern. Instrumented 
motion analysis may allow greater sensitivity and precision in the description of motor 
impairments in PLHIV; potentially unveiling currently undocumented changes in movement 
quality. Unfortunately, there is also a dearth of research published on quantitative 
biomechanical analyses of walking gait in PLHIV. Using sophisticated 3D-movement analytical 
techniques, instrumented analyses can improve understanding of contributors to functional 
decline by unlocking underlying scientific contributors. Three-dimensional gait analysis 
(3DGA) is one of the few measurement approaches allowing quantification of the dynamic 
implications of relevant impairments during a functional activity such as gait.61 Such 
quantitative information may assist in identifying the most valid clinical screening tests for 
detecting early functional decline, to prevent consequences such as falls. In addition, it can 
inform the design of effective interventions by directing rehabilitation protocols towards key 
deficits. 
1.3. Overall aim of the dissertation 
The overarching aim of this dissertation was to provide novel quantitative information about 
the locomotor impairments found among PLHIV residing in the Cape Winelands District of the 
Western Cape, South Africa, using state-of-the-art 3DGA technology. It further aimed to 
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correlate the findings of 3DGA (via a quantitative summary score of gait), as well as self-
reported function and history and fear of falling, to selected physical performance tests which 
may be considered in clinical practice to screen for early functional decline in PLHIV.  
1.4. Significance of the research 
Using state-of-the-art technology in a clinically relevant context, this novel project provides 
new scientific information about the locomotor impairments of PLHIV relative to SNP. It is also 
the first project aimed at correlating clinical performance-based tests to quantitative 3DGA, 
self-perceived functional ability and history and fear of falls in PLHIV. The comprehensive 
dataset allowed for the identification of the most valid clinical test which may be used in clinical 
practice to screen for functional decline in PLHIV. Early identification of functional decline will 
reduce morbidity and healthcare utilisation among South African PLHIV. Improved functional 
ability is also positively associated with treatment adherence in people affected by this 
prevalent syndrome.  
1.5. Research questions 
The primary research question was two-fold: 
i. Are there differences in walking gait biomechanics and in static postural stability in 
PLHIV compared to HIV-seronegative participants (SNP)?  
ii. Which clinical test correlates best with a quantitative 3D-analysis of gait, subjective 
self-perception of functional ability and/or history and fear of falls in PLHIV? 
 
As groundwork towards answering the primary questions, the following research question was 
also assessed: 
i. Is the concurrent validity, as compared to the current reference standard, and within-
session reliability of 3DGA outcomes measured by a frequently recalibrated inertial 
motion capture (IMC) system clinically acceptable in healthy adults, and can these 
results be assumed in a community sample including PLHIV?  
1.6. Methodology overview  
The project was divided into three parts, comprising of a theoretical background and three 
distinct but related primary observational studies. Part I involved a literature review and a 
Stellenbosch University  https://scholar.sun.ac.za
 8 | P a g e  
 
systematic review and meta-analysis. The systematic review established and synthesised the 
current available evidence regarding objective impairments of gait and balance in PLHIV. Part 
II involved laboratory-based primary research and consisted of two observational concurrent 
validity and within-session reliability studies. These were aimed at ascertaining the reliability 
and concurrent validity of gait analysis outcomes using a newly-acquired portable IMC system 
in healthy volunteers (Study One, Chapters 4 and 5) and in a community sample of PLHIV 
and SNP (Study Two, Chapters 4 and 6). Part III comprised of an observational cross-
sectional design with an analytical component. The IMC system was implemented in a clinical 
setting to measure the 3D gait biomechanics of 50 PLHIV and 50 SNP from the same 
community. A pressure mat captured quantitative balance (postural stability) data. Clinical 
functional test performance was also recorded, along with collecting data on self-reported 
function and retrospective fall-history. These data were correlated to establish the validity of 
the clinical test as compared to a quantitative 3DGA, and ascertain its ability to screen for self-
reported functional problems and/or fall risk. 
1.7. Structure of the dissertation 
According to the three-phased study methodology, the dissertation is divided into three parts 
(Chapters 2 to 8). Figure 1.1 provides a schematic overview of how the research process is 
presented in the dissertation. The three Parts are preceded by this general introduction 
(Chapter 1) and followed by the comprehensive discussion chapter (Chapter 9), study 
limitations (Chapter 10) and recommendations (Chapter 11). The dissertation briefly 
concludes with Chapter 12 (the Conclusion).  
1.7.1. Part I: Theoretical groundwork 
Part I of the dissertation introduces the reader to HIV-1 infection, its current manifestation as 
a chronic condition and the neuromusculoskeletal consequences posing some unique 
challenges to patients and rehabilitation therapists alike. To this effect, Chapter 2 is presented 
as a traditional literature review, and explores concepts underlying the current research, 
including an hypothesis of accelerated or accentuated ageing in chronic HIV-1 infection. In 
Chapter 3, the current knowledge gap regarding objective and quantitative movement 
impairments in PLHIV is systematically explored by means of a published systematic review 
and meta-analysis of observational studies.62 The chapter presents the methodological 
procedures and results of the systematic review, as well as a discussion of the implications of 
the findings for research to follow. The outcome of Part I is a clarification of how HIV-related 
locomotor impairments may be understood within a framework of accelerated or accentuated 
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ageing. These reviews also informed the definition of clinically relevant gait outcomes 
(commonly observed in elderly gait) for clinometric assessment in Part II, and in-field use in 
Part III. 
1.7.2. Part II: Determining the validity and reliability of a 
newly-acquired portable 3D motion analysis system for in-
field use 
Part II of the dissertation presents the validation of a portable 3DGA system, newly acquired 
by the Stellenbosch University (SU) Central Analytical Facilities (CAF) 3D Human 
Biomechanics Unit, versus the current reference standard. The specific methodology 
underlining the two interlinked observational laboratory-based primary studies is contained in 
Chapter 4, while the results of the studies in healthy volunteers and a community sample are 
presented separately in Chapters 5 and 6, respectively. Part II resulted in determining (1) the 
validity and reliability of 3DGA outcomes and (2) the measurement error of the IMC system, 
to aid appropriate interpretation in the cross-sectional field study. 
1.7.3. Part III: In-field biomechanical analysis of gait and 
balance in people living with HIV-1 infection (PLHIV) 
relative to HIV-seronegative participants (SNP) 
Part III of the dissertation presents the main cross-sectional primary study and incorporates 
the theoretical hypotheses derived from Part I along with the technical insights gained from 
Part II. Part III reports the procedures and outcomes of the in-field use of the IMC system to 
cross-sectionally describe clinically relevant motion analysis outcomes in PLHIV relative to 
community-matched SNP. An analytical component was included to correlate 3D-analysis 
results, fall-related outcomes and self-reported function to clinical test performance. Chapter 
7 presents the study methodology while Chapter 8 presents the results of the comparisons 
and correlations. The outcome of Part III was the description of key biomechanical 
characteristics of gait in PLHIV. A quantitative dataset was established, which assisted in 
determining the most valid clinical screening test which may be used to detect early motor 
impairments in PLHIV. 
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Figure 1.1. Schematic representation of the dissertation structure. 
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  PART I 
 
LITERATURE REVIEW 
2.1. Introduction 
HIV-1 infection remains incurable, but has evolved from an acute and rapidly fatal disease into 
a manageable chronic condition. This has mostly been due to the success of introducing highly 
active antiretroviral therapy (HAART). Modern-day regimens are powerful and mostly well-
tolerated. However, despite the fact that HAART can rapidly suppress HIV blood 
concentrations to being undectable13 it does not fully restore health.63 Thus, along with HIV-1 
becoming a chronic disease, much of HIV research has shifted its focus to the increasing rate, 
and consequences, of non-AIDS morbidity – which has also been termed “early ageing”.54,64,65  
The following literature review is the first of two chapters constituting Part I of the dissertation 
(Figure 2.1). This chapter presents an overview of the literature regarding chronic HIV-1 
infection, including the causes and consequences of HIV-related motor impairments. HIV-1 is 
introduced by means of briefly reviewing its natural history and HAART pharmacotherapy, 
where after the effects of chronic HIV-1 infection, its associated comorbidities and HAART on 
bodily systems is described. The question of an accelerated or accentuated ageing phenotype 
is raised, and fall risk amongst PLHIV is reviewed. Next, the reader is introduced to the 
conceptualisation of HIV-1 into a framework of rehabilitation, along with a working definition of 
“function” as used in this dissertation. The assessment of lower limb impairments and function, 
including instrumented (quantitative) assessment, and its proposed utility in PLHIV is briefly 
reviewed. The chapter concludes with a description of gait and balance patterns indicative of 
advancing age or fall risk in the general population, which served to inform the selection of 
analysis outcomes in PLHIV.  
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Figure 2.1. Schematic layout of the structure of Part I of the dissertation. 
 
2.2. Introduction to HIV-1 
2.2.1. Prevalence 
Home to only 12% of the global population, Sub-Saharan Africa accounts for 71% of the 
enormous worldwide pandemic of HIV-1 infection.66 Nearly one in every eight South Africans 
(13.10%) is living with HIV infection36; the total estimated adult prevalence (ages 15 to 49 
years) being 19% in 2018.36 South African women aged 30 to 34 and men aged 35 to 39 
account for the majority of the adult prevalence.67 Although working-aged PLHIV still bear the 
brunt of the burden in South Africa, closer inspection of the trends in prevalence suggests an 
ageing HIV-population much like trends in high-income countries. Despite a 44% reductionii 
the rate of new HIV infections over the past five years,68 the total number of South Africans 
living with HIV-1 infection has increased from about 4,25 million in 2002 to 7,52 million by 
2018.36 Prevalence among young South Africans (15 to 24 age bracket) has decreased from 
6.7% in 2002 to 5.5% in 2018.36 The ageing of the HIV epidemic in Sub-Saharan Africa has 
                                               
ii Along with HAART scale-up, universal test-and-treat initiatives aimed at realising the Sustainable 
Development Goal of ending the AIDS epidemic by 2030 contributed to these statistics516 – such 
as the UNAIDS-endorsed 90-90-90 target (also included in South Africa’s National Strategic Plan 
for HIV, TB and STIs 2017 – 2022). 
 
 
 
 
PART i 
Literature review and 
meta-analysis 
 
 
Background 
information and 
framework for motion 
analysis. 
Figure Part I Preface. Schematic layout of the structure of Part I of the dissertation 
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not been as extensive as in high-income countries: 14.3% of PLHIV in Sub-Saharan Africa 
are currently aged over 50 years69 (versus  about 50% in the USA).70 Yet, trends are expected 
to follow suit and South African statistics are projected to triple within the next couple of 
decades.71  
Unfortunately, there has also been a large global and local increase in the burden caused by 
HIV. The Global Burden of Disease Study 201572 alarmingly showed that in 1990, HIV-1 
infection was the 33rd highest ranking cause of disability-adjusted life years (DALYs) globally, 
but that it has increased steeply to tenth position in 2015. Regarding South Africa, in 2015, 
HIV-1 infection was the top nonfatal cause of health loss.73 
2.2.2. Natural history 
Genetically, HIV Type 1 (HIV-1; globally the most prevalent and pathogenic of the two types 
of HI virus) belongs to the genus Lentivirus, of the family Retroviridae.74 Lentiviruses cause 
persistent infections, with an extended clinical latency period, ongoing viral replication and 
central nervous system (CNS) involvement.74 The virus resides in bodily fluids and is 
transmitted either during sexual contact across mucous membranes, by mother-to-child 
exposure, or by needlestick injury.75 HIV-1 RNA (viral load; undetectable when falling below 
50 HIV-1 RNA copies/mL) and CD4+ T lymphocyte (CD4+) cell count (normally ranging 
between 500 and 1400 cells/μL) are surrogate HIV disease markers.76 Following infection, HIV 
initially binds to target CD4+ cells where after it is transported to regional lymph nodes.13 Along 
with incipient and rapidly progressing viral replication, ongoing and productive infection 
commences. CD4+ cells are rapidly (and possibly permanently) destroyed. Additionally, 
penetration of microbial translocation products into the systemic circulation occurs as the gut 
mucosa ruptures.13 At the same time all body compartments, including the CNS, become 
infected.  
Primary HIV-1 infection is often overlooked due to the non-specific symptoms.13 Early 
diagnosis is however important; for the patient and the larger community, as the viral load  is 
usually high, with a high risk of transmitting the disease. After this so-called acute HIV 
syndrome, a chronic, asymptomatic phase of clinical latency is entered, which may last for 
decades if viral load is effectively suppressed by HAART.75 Usually, symptomatic disease only 
develops when CD4+ count declines to below 350 cells/μL, at which stage AIDS-associated 
events such as tumors or opportunistic infections start to occur.13 If left untreated, AIDS is 
inevitably fatal.   
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2.2.3. Highly active antiretroviral therapy (HAART) 
Antiretroviral drugs (ARVs) were introduced in South Africa in 1996; however, the national roll-
out of HAART (combining multiple ARVs that act on different viral targets) only officially began 
in 2003. By June 2017, globally, 20.9 million PLHIV were using HAART.77 Today South Africa 
has the world’s largest Government-sponsored HAART rollout programme and currently 56% 
of South African PLHIV are receiving HAART.78  
HAART entails the use of combination ARV treatment, typically comprising three or more 
drugs, with the main aims of reducing plasma virus levels below detectable limits, restoring 
immune function, reducing opportunistic infections, enhancing quality of life, and reducing the 
community impact of HIV transmission.24 The health benefits of early HAART initiation are 
increasingly recognised. Since 2016, South African guidelines, in accordance with those of 
the World Health Organisation (WHO), recommend immediate HAART-initiation following HIV 
diagnosis, regardless of CD4+ count.79 If taken as directed, HAART effectively suppresses 
viraemia by acting directly on the HI virus and impairing viral multiplication (i.e. by blocking, at 
different points in the virus’ life cycle, the action of enzymes used by the virus to replicate itself 
within CD4+ cells). Viral destruction of CD4+ T-cells is thus mitigated, allowing functional 
reconstitution of the immune system.80 However, the virus is not eradicated and re-emerges 
in almost all cases when HAART is ceased (due to persistent infected cell reservoirs despite 
the absence of viruses in the blood)81 which highlights the importance of adequate adherence.  
Antiretroviral agents are categorised into various classes according to their molecular 
mechanism and resistance profiles.82 Table 2.1 summarises the classes of HAART currently 
available in South Africa, along with their main mechanism of action. 
Table 2.1. Summary of the classes of HAART available in South Africa. 
Generic name Class Mechanism of 
action 
Specific action 
Tenofovir (TDF) NtRTI Reverse 
transcriptase 
inhibition 
Nucleic acid analogues mimic 
normal DNA building blocks, 
inhibiting viral RNA transcription 
to DNA. 
 
Lamivudine (3TC) NRTI 
 Emtricitabine (FTC) 
Abacavir (ABC) 
Zidovudine (AZT) 
Stavudine (d4T) 
Didanosine (ddl) 
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Efavirenz (EFV) NNRTI Inhibits final maturation stages of 
HIV replication, resulting in non-
infective viral particles. 
Nevirapine (NVP) 
Rilpivirine (RPV) 
Etravirine (ETR) 
Atazanavir (ATV) PI Protease 
inhibition 
Inhibits the final maturation stages 
of HIV replication, resulting in non-
infective viral particles forming. 
Darunavir (DRV) 
Saquinavir (SQV) 
(rarely used) 
Lopinavir/ritonavir 
(LPV/r) 
Boosted 
PI 
Raltegravir (RAL) InSTI Inhibition of viral 
integration 
Prevents transfer of proviral DNA 
strands into host chromosomal 
DNA. 
Dolutegravir (DTG) 
Maraviroc (MVC) CCR5 
blocker 
Entry inhibition Binds to viral gp41, gp120, host 
cell CD4+ or chemokine (CCR5) 
receptors. 
Abbreviations: CCR5 = C-C chemokine receptor type 5; InSTI = integrase inhibitor (integrase 
strand transfer inhibitor); NNRTI = non-nucleoside reverse transcriptase inhibitors; NRTI = 
nucleoside reverse transcriptase inhibitor; NtRTI = nucleotide reverse transcriptase inhibitors; PI = 
protease inhibitor. 
The chronicity of HIV-1 implies that more PLHIV are being placed on HAART and will remain 
on these drugs for longer (as HAART is required for the rest of a person’s life).83 Unfortunately, 
HAART usually involves a rather complex medication regimen and is often associated with 
adverse reactions.84 Short-term adverse reactions such as pain, fatigue and gastro-intestinal 
effects potentially threaten successful HAART initiation and maintenance.84 Long-term toxicity 
is still an emerging area of research, but often includes mitochondrial toxicity (which could 
lead to myopathies, neuropathy, pancreatitis, lactic acidosis, hepatic steatosis, and 
lipodystrophy),84,85 pain and hypersensitivity, bone mineral density (BMD) deficits and 
more83,86 (see also the next sections of this review). Specific adverse effects vary between 
drugs, drug classes, and patients. Nucleoside reverse transcriptase inhibitors (NRTIs), for 
example, may theoretically also inhibit non-viral enzymes involved in DNA formation, including 
human DNA polymerase γ, with subsequent disruption of mitochondrial function.84 In addition, 
overlapping and additive toxicities due to concomitant medication use, comorbidities that 
exacerbate adverse effects, drug-drug interactions and genetic factors that predispose 
patients to specific reactions may all add to the risk and impact of adverse effects.84 Such 
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morbid effects negatively affect adherence, which can lead to drug resistance and treatment 
failure - and thus even further morbidity and mortality.87 
2.3. Effects of chronic HIV-1 and HAART on the human 
body  
HIV-1 can persist in HAART-treated PLHIV because of latent infection of long-lived cellular 
reservoirs (resting memory CD4+ cells), immune dysfunction, persistent residual viral 
replication in lymphoid tissues (in some individuals), and anatomical reservoirs (mainly the 
CNS).88 Chronic HIV infection is typically accompanied by other comorbid non-communicable 
diseases. Until fairly recently, the high mortality rates caused by AIDS have mostly masked 
the emerging burden of non-communicable diseases associated with HIV-infection; which 
adds substantially89 to the transitioning and quadruple disease burden in SA.89 The following 
sections review the various effects of chronic HIV-1 infection as well as HAART on the body. 
2.3.1. Chronic inflammation and immune activation 
Despite viral suppression, HIV-1 infection is associated with persistent immune activation 
(involving the innate, adaptive and intrinsic immune systems), inflammation and abnormalities 
in coagulation; all of which increases morbidity and mortality.90,91 This residual and abnormally 
regulated inflammatory state is thought to be driven primarily by toll-like receptor activation, 
telomere shortening, continuing low-level viraemia, gut epithelial damage and microbial 
translocation, as well as co-infections (such as the cytomegalovirus or hepatitis C virus). In 
addition, multimorbidity, substance use and lifestyle factors (such as physical inactivity and 
diet) also adds to chronic inflammation and immune activation.91,92 
2.3.1.1. Functional ramifications of chronic inflammation and immune 
activation 
Evidence is building that persistent inflammation and immune activation is associated with the 
increasing occurrence of non-AIDS morbidity, including physical functional ramifications.93,94 
The first study93 to compare immune activation, immunosenescence and microbial 
translocation markers in PLHIV with physical functional performance and frailty, found that 
functional impairment (assessed via a composite Frailty Phenotype and the Short Physical 
Performance Battery [SPPB]) during successful HAART was associated with higher CD8+ T-
cell activation and IL-6 levels. Furthermore, Erlandson et al.95 demonstrated that increased 
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inflammatory markers (IL-6 and high-sensitivity CRP) were associated with frailty in PLHIV. In 
fact, it seems that frailty, not HIV serostatus, is associated with inflammation, as demonstrated 
by studies incorporating HIV-seronegative control groups.95 Although harmful behaviours and 
comorbidities have been shown to account for much of the immune activation in PLHIV, CRP 
levels (regulated by IL-6) seem to remain elevated in those with frailty independent of these 
factors.96 
2.3.2. HIV-Associated Non-AIDS (HANA) comorbidity  
The following subsections review the literature explaining the increased risk in PLHIV for 
specific body system involvement and co-morbidity which may impact on motor function.	 
2.3.2.1. Central nervous system (CNS)  
HIV-1 damages the blood-brain barrier via paracellular and transcellular mechanisms, with 
subsequent HIV-entry into the CNS within days of infection.97 While no evidence exists for 
cytolytic HIV-infection of neurons, indirect local damage results from specific viral proteins 
(e.g. gp120, Tat, or Vpr) produced by infected cells.12 Several aetiologies have been 
suggested to underlie the continuing HIV-associated neurostructural alterations despite 
controlled viraemia, such as permanent pre-HAART brain injury, chronic subclinical 
neuroinflammation,98 drug neurotoxicity,99 various HANA conditions100 as well as virus-
associated neurodegenerative processes similar to those seen in ageing.101 
Diffuse CNS degeneration has been reported in chronic HIV infection, involving the frontal 
lobes, basal ganglia, cerebellum and pons.33,101–104 A recent meta-analysis of HIV 
neurostructural studies (including reports from 1993 to 2016)100 found that HIV-1 was 
associated with reduced total brain volume and grey matter volume (both cortical and 
subcortical), along with collateral cerebrospinal fluid volume increases, although modern 
HAART seems to have substantially reduced these macroscopic neurostructural changes. 
This regional CNS structure atrophy may be associated with established or progressive motor 
impairment.100 
Changes in white matter, including pontocerebellar tract integrity deficits, have been 
demonstrated in PLHIV by structural magnetic resonance imaging (MRI) studies. Such 
changes were associated with static postural instability and impaired tandem walking 
(especially with eyes closed), as well as psychomotor slowing.33 Postural instability in PLHIV 
has also been associated with cerebellar pathology. Axonal injury (even without myelin 
damage) or primary idiopathic cerebellar atrophy has been cited as potential mechanisms.33 
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HIV may also affect the basal ganglia,105–108 although perhaps less severely so in recent 
times.100 Apart from motor slowing, clinical manifestation of basal ganglia involvement includes 
voluntary movement impairment and compromised executive function. A South African 
study104 found that HIV infection is associated with specific dysfunction of the more basic basal 
ganglia/putamen functions during reactive inhibition of voluntary movement, while more 
normal higher cortical functioning during proactive inhibition were evident. The authors 
suggested that HIV infection may thus mostly involve basic striatal-mediated motor execution 
control processes.104 
Hakkers et al.101 noted in their systematic review of the effect of HIV infection on brain function 
(measured by blood-oxygen-level dependent [BOLD] functional magnetic resonance imaging) 
that, even without clinical signs or symptoms (e.g. impaired neuropsychological test 
performance), PLHIV present with an altered amount of functional brain activation (mostly 
fronto-striatal) as measured by BOLD response. These authors offered the “brain reserve 
theory” as a possible explanation. This involves using more neural effort (due to 
hyperactivation or activation of adjacent structures) to achieve the same “normal” behavioural 
results.109 PLHIV may hyperactivate some brain areas and recruit additional brain areas to 
maintain the same physical performance. However, this mechanism may fail under more 
challenging task conditions.101 This inefficiency of hyperactivation is possibly due to HIV-1-
related interfering processes (involving specific viral proteins produced by infected cells), such 
as compartmentalisation of HIV in the CNS and associated local persistent neuro-
inflammation, or HAART toxicity (especially Efavirenz).101 
2.3.2.2. Peripheral nervous system (PNS) 
 Current HAART regimens are less neurotoxic versus older regimens, and so there is a lower 
risk of developing peripheral neuropathies.25 However, the prevalence of HIV-1 related distal 
symmetric polyneuropathy (DSP) remains high.26–29 Risk factors for DSP in PLHIV include 
ageing, HAART regimen, longer HIV infection duration, and substance abuse.110 Two 
potentially neurotoxic mechanisms are mostly described regarding the pathophysiology of 
DSP: neurotoxicity resulting from the virus itself; as well as neurotoxic adverse effects of 
HAART.111 Although neuropathies resulting from viral or HAART mechanisms are clinically 
indistinguishable, different pathophysiologic processes have been implicated.111  
Clinical signs and symptoms of DSP include a combination of reduced ankle deep tendon 
reflexes and sensory deficits in the distal extremities, paraesthesia, dysesthesia, and 
symmetric stocking–glove pain distribution.111 Reduced levels of self-reported lower extremity 
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function have also been described.110 Additionally, associated balance and gait impairments 
may be observed112 although it seems that lower limb neuropathy does not necessarily 
account for postural instability in PLHIV.113 It has been suggested that locomotor impairments 
in PLHIV may be more related to CNS dysfunction rather than the PNS (at least regarding the 
specific outcomes assessed) since some studies failed to find associations between motor 
performance and peripheral neuropathy, whilst others often required eyes-closed conditions 
to elicit group differences in postural balance.2,33,113–115 
2.3.2.3. Lower limb musculature 
Although still present in PLHIV, muscle wasting is less problematic since the introduction of 
HAART compared to the pre-HAART era.116 The persistent occurrence of muscle wasting, 
including sarcopenia, in about 30% of PLHIV44 may in part reflect high systemic concentrations 
of inflammatory cytokines leading to increased energy expenditure and proteolysis.117 Notably, 
the initial loss of muscle mass associated with untreated HIV-1 infection may not fully recover 
even after establishing effective HAART.118 This failure to completely restore muscle protein 
synthesis to normal is possibly due to an inability to completely eliminate the suppressive 
effects of factors associated with high viral loads (e.g. HIV-1 accessory protein Vpr) on muscle 
amino acid metabolism.119 Furthermore, HAART-treated PLHIV may develop T-cell-mediated 
inflammatory myopathies (such as Inclusion body myositis and polymyositis – broadly 
characterised by proximal muscle weakness and quadriceps atrophy) related to immune 
restoration or drug-induced mitochondrial toxicity, especially with zidovudine treatment.116  
Although appendicular muscle mass losses in PLHIV are associated with functional 
impairments,120 dynapenia (loss of muscle strength  and power) may contribute more to 
functional decline.121 A study by Neto et al. found that 50% of PLHIV with undetectable viral 
loads had poor lower limb muscle performance.122 Dynapenia may specifically affect the 
quadriceps muscles of PLHIV,121 is associated with functional deficits such as poor chair-rise-
time123 and a South African study noted that lower limb weakness, particularly of the proximal 
muscles, impacts on self-perceived function in PLHIV.44 The impaired central activation 
observed in PLHIV appears to be related to disease progression, as a stronger association 
has been noted with viral load and AIDS-defining disease history than with HAART 
medications.121 
Cardiovascular fitness impairments are known to occur in HAART-treated PLHIV.124 
Therefore, deconditioning may also contribute to intra-muscular deficits, including fatty muscle 
infiltration, and a poorly understood impairment of central coordinated motor unit activation 
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(the ability to activate the available muscle mass and a component of dynapenia) noted in 
PLHIV.121,124,125 Oxidative stress/impaired oxygenation and mitochondrial toxicity (which may 
affect intramuscular calcium-handling processes and limit muscle oxygen extraction-
utilisation) constitute widely-reported pathological processes underlying muscle weakness 
and fatigue in PLHIV, particularly those on HAART.32,126 Specifically, PIs and NRTIs (such as 
tenofovir and abacavir) have been associated with mitochondrial myopathies.126 A premature 
and upregulated expression of genes associated with muscle ageing has been described in 
middle-aged (30 to 55 years old) male PLHIV (and not seronegative controls), with a prominent 
fibrotic axis.127 The authors noted this chronic inflammation-driven muscle fibrosis as an 
understudied potential mediator of functional decline in PLHIV.127 
Despite the cited research, results regarding significant lower limb muscle strength differences 
per se between PLHIV and their HIV seronegative counterparts remain controversial and 
studies are often limited by small sample sizes, unequal gender distributions or cross-sectional 
design. Oliveira et al.128 reported differences in dynamic and isokinetic strength in male PLHIV 
versus SNP, but not in female participants. The authors attributed the observed differences to 
the presence of comorbidities and impaired muscle activation; however, the study was limited 
by a small sample size. Similarly, a South African study129 noted that lower limb muscle 
strength was not significantly different between female PLHIV and SNP. The similarities may 
have been due to the controlled viraemia and good general health of participants. In contrast 
to Oliveira et al.128, two cross-sectional studies130,131 found similar musculature and strength 
between male PLHV and SNP. Wallet et al.130 partly attributed the observed similarities in 
lower limb muscle morphology and strength to the well-controlled disease markers, despite 
strong evidence for increased inflammation noted in the HIV-1 group. Raso et al.131 found 
similar peak aerobic power and muscle strength when comparing groups, apparently 
uninfluenced by CD4+ nadir or HAART-use, although isokinetic strength was lower in those 
PLHIV with current low CD4+ counts. These studies were all conducted in middle-aged 
cohorts of virologically-controlled PLHIV on HAART, and were all limited by small sample 
sizes.  
2.3.2.4. Bone status 
Earlier and a higher rate of osteopaenia and osteoporosis is evident in PLHIV,132 with a 
prevalence of resultant fractures.132–136 Emerging research regarding increased fracture rates 
in PLHIV report rates of 30% to 70% higher in PLHIV compared to seronegative controls137; 
and a 38% increased risk for hip fractures in PLHIV.136 Low BMD, in addition to lower limb 
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impairment (including sarcopenia), is associated with balance problems and increased fall 
risk. 
HIV-associated reductions in bone size, mass and strength have been attributed to altered 
metabolism and infection of bone cells,86 HAART exposure (e.g. tenofovir disoproxil fumarate 
[TDF]) and additional risk factors have been cited including smoking, substance abuse 
(especially alcohol), sedentary lifestyle, low body weight, menopause and vitamin D 
deficiency.86 A meta-analysis135 reported the prevalence of osteopaenia and osteoporosis in 
PLHIV as 67% and 15% respectively. 
It has been suggested that uncontrolled viraemia may impact BMD, possibly mediated by 
effects of persistent systemic inflammation on bone remodelling; this is evident as osteopaenia 
and osteoporosis is highly prevalent in HAART-naïve (i.e. not previously exposed to HAART) 
PLHIV.132 HIV-proteins impair bone formation by promoting both osteoclast activity and 
osteoblast apoptosis.86 In addition, elevation of tumour-necrosis factor-α (TNF α) promotes 
bone resorption mediated by osteoclasts, without collateral bone formation increases.132 
However, relationships between BMD and HIV duration, viral load, or CD4+ count has not 
been consistently observed.138 
HAART initiation seems to amplify bone loss and is typically followed by a 2% to 6% BMD 
reduction (the largest losses occurring within 24 to 48 weeks).86,138 Subsequent plateauing is 
reported by various studies, although follow-up was mostly less than three years.132,138 All ART 
seem to decrease BMD, although greater reductions have been observed with the use of TDF 
and ritonavir-boosted PIs. Although the exact reason for BMD loss after HAART initiation 
remains unclear, it has been attributed to increased bone catabolism after viral load 
suppression and immune reconstitution,138 and it has been suggested that activation of CD4+ 
cells along with immune reconstitution after treatment lead to higher levels of pro-
inflammatory, pro-resorptive cytokines.134 
Although BMD loss seems to be largely irreversible,86 a 2018 systematic review by Chisati et 
al.139 found that research is lacking and that it may be worth investigating effective non-
pharmacological interventions to prevent and treat BMD loss in PLHIV on HAART. 
Pharmacological regimens (e.g. bisphosphonates, teriparatide, denosumab) are unfortunately 
often associated with adverse reactions (e.g. tumours, infection, osteosarcoma and bronchitis) 
and increase the pill burden in PLHIV; negatively affecting adherence and limiting their 
effectiveness.139 Exercise-based strategies to mitigate decreased BMD resulting from HAART, 
such as progressive resistance exercise, have been suggested as a safe and effective 
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alternative approach that could be used to manage bone loss resulting from ART in PLHIV – 
although at present only one such study has been identified from the literature.139 
2.3.2.5. Metabolic and endocrine complications 
Metabolic diseases, including type II diabetes mellitus, dyslipidaemia, obesity, and the 
metabolic syndrome are becoming more prevalent among PLHIV in high- and low-to-middle 
income countries alike.32,70,140,141 These disorders often occur in concert in PLHIV and may 
share underlying pathogenic features. BMD and frailty status amongst PLHIV have been 
reported to be substantially affected by metabolic disorders and resultant changes in body 
composition.  
The functional consequences of a change in body composition in PLHIV were first investigated 
by Shah et al.,140 who proposed a new frailty phenotype in PLHIV that is associated with 
obesity rather than the traditional observation of wasting. The study data suggested that 
excessive hypertrophy of visceral fat and lipolysis contribute to fat infiltration in the muscle, 
and consequently reduces muscle quality and a decline in physical function among PLHIV. 
2.3.2.6. Neuromotor impairments associated with HIV-1 
Movement disorders are conspicuous in the constellation of impaired function in PLHIV.2 The 
association of motor impairments and function was demonstrated early-on (1996) by The 
Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.142 In a 
cohort of 271 PLHIV (mean ages ranging from 38 to 41 years), it was demonstrated that it was 
rare to have functional impairment (as measured by the MOS-HIV physical function domain) 
without associated neuromotor deficits.142 
Neurocognitive impairments have historically been associated with HIV-1 infection. However, 
over the last couple of decades, the increasingly widespread availability of HAART has 
changed the clinical features of HIV-associated cognitive syndromes and studies have started 
to separate the entities of cognitive impairment and motor impairment, whilst acknowledging 
that clear associations do exist.143 Although the prevalence of motor deficits has still not been 
sufficiently examined in the current treatment era,144 it is estimated that 35% to 70% of all 
PLHIV (HAART and HAART-naïve) are at least subtly impaired on neuropsychological 
assessments, which includes motor function.145–148  
In 2008, the first objective assessment tool of motor deficits traditionally associated with HIV-
associated neurocognitive disorders (HAND) was developed.143 These deficits included, 
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amongst others, movement slowing, gait impairments and uncoordinated limb movements. 
The authors143 developed this tool in recognition of the fact that motor abnormalities remained 
prevalent and of clinical importance in the HAART era despite the relatively milder 
presentations of HAND.143 The tool revealed that motor abnormalities (for example strength 
deficits, gait and coordination problems, tone and reflex abnormalities) can predict cognitive 
impairment in PLHIV.143 Ten years later, the authors longitudinally re-explored motor 
dysfunction in medically complex PLHIV with ages ranging from 29 to 80 years (mean age 52 
years) and found that motor function (including gait) declined over time and was accompanied 
by an accrual of comorbid medical illnesses.144 However, over a four-year period of 
assessment, no significant decline in cognitive function was observed. The authors 
emphasised the importance of the accumulation of motor impairments, as motor impairment 
substantially impacts on successful ageing and maintenance of independence.149  
Joska et al.26 conducted the first South African descriptive follow-up study to establish the 
effects of HAART on neuropsychomotor impairment among a group of PLHIV. Adults (median 
age 30 years) in late stage HIV-1 infection and commencing HAART were prospectively 
investigated. Participants with severe impairment at baseline improved significantly in various 
domains, including gross motor speed and fine motor function, within a one-year treatment 
period. However, mild to moderate neuro-motor impairments persisted in a quarter of the 
sample, emphasising that HAART does not completely reverse these effects.  
2.4. A model of accelerated or accentuated ageing?  
There is an emerging trend amongst researchers and clinicians to use terms such as 
“accelerated ageing” or “accentuated ageing” when referring to the plethora of HIV-associated 
comorbidities, given that many of these diseases are usually age-associated in the general 
population and observed in elders. Yet whether HIV truly causes premature or advanced 
ageing remains controversial.64,70,150 It has been questioned whether HIV physiologically 
hastens ageing processes in general or whether HIV acts as a factor to synergistically increase 
the risk of developing illnesses such as cardiovascular disease at any age in PLHIV.151 In 
addition, cohort studies investigating ageing effects in PLHIV have often not included 
appropriate comparison groups to enable meaningful conclusions.152 
However, the similarities between HIV-1 and the normal ageing process are compelling. 
Arguments stating that there may be a biologic plausibility of HIV-1 causing accelerated ageing 
has pointed out the similarities between the pathophysiology of treated HIV-infection and the 
general process of ageing, including the prognostic value of a low CD4:CD8 ratio, telomere 
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shortening, immunosenescence manifestations, oxidative stress, chronic inflammation and 
hypercoagulability, ongoing immune activation and the roles of coinfections such as 
cytomegalovirus.64,65,70,153 In addition, multi-morbidity, geriatric syndromes, polypharmacy, as 
well as traditional risk factors are prevalent in older but also middle-aged PLHIV. These factors 
may all contribute to the increased risk of developing the clinical manifestations of ageing in 
the general population and presumably earlier, or in an accentuated manner, in PLHIV.  
Of course, data from high-income countries related to biological ageing and HIV may not be 
directly translatable to low-to-middle income countries, as biological ageing in PLHIV in such 
resource-limited settings can also be affected by lower socioeconomic status, malnutrition, 
coexisting morbidities, opportunistic coinfections and epigenetic variation.154 Yet a case-
control study154 assessed biological ageing in South African PLHIV (median age 39 years) and 
HIV-seronegative individuals (median age 40 years) and found increased biological ageing in 
PLHIV (after adjusting for age, gender and other confounders) confirmed by two validated 
biomarkers. Also, a study by Horvath and Levine155 observed epigenetic age acceleration as 
early as adolescence in a cohort of Capetonian adolescents living with HIV-1 infection (mean 
age 10 years); and that these epigenetic changes were associated with poorer cognitive 
functioning. Keeping in mind the controversies, the similarities observed between HIV infection 
and ageing are intriguing and imply that valuable insights may be gained from the geriatric 
literature, that is likely to usefully inform research and rehabilitation strategies in PLHIV.53,156 
2.5. HIV-1 infection and falls 
Despite a large research focus on the interactions between HIV-1, HAART and low BMD, the 
risk of falls in PLHIV has not yet been adequately described. A quick exploratory PubMed 
search in June 2018 revealed over 5 000 publication citations in reference to “HIV and bone”. 
In contrast, only 22 PubMed citations included “HIV” and “accidental falls” and only nine of 
these hits reported rates of falls or characteristics of HIV-infected fallers – these studies are 
summarised in Table 2.2. 
The first study to report the rate and risk factors for falls among PLHIV was published in the 
USA in 2012.55 Results indicated that 30% of study participants aged 45 to 65 years had fallen 
in the previous year (a rate similar to HIV-seronegative persons aged 65 years or older). 
Subsequent studies consistently note falls among middle-aged PLHIV, but report varying rates 
ranging from 1.6% to 41% (Table 2.2). Notably, the three studies that included HIV-
seronegative controls157–159 found similar fall rates in PLHIV and HIV-seronegative controls 
after adjusting for covariables. These observations may reflect that PLHIV and the HIV-
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seronegative participant groups were demographically similar regarding the overall burden of 
fall risk; whereas more significant results (as  in Erlandson et al.55) may  be due to the fact that 
comparisons were made using normative data obtained from a different demographic. The 
lower fall rates in Sharma et al.160 and Erlandson et al.158 compared with the other studies may 
be explained in part by volunteer bias (healthier individuals agreeing to participate), and the 
very low rate in Ruiz et al.161 may be due to potential underreporting among healthcare 
providers who completed the patient records. 
Falls are the consequence of multiple interrelated factors. In PLHIV, common risk factors for 
falls include frailtyiii,162,163 peripheral neuropathy,159,162 functional impairment (e.g. slowed gait, 
grip strength deficits [a good predictor of general muscle strength] or impaired balance 
symptoms),55,162 multimorbidity,55,161 and polypharmacy55,157,161,164; although it seems unclear 
whether these risk factors are unique to PLHIV. In contrast to the strong associations between 
HIV-specific factors and low BMD discussed in Section 2.3.2.4 of this review, HIV-disease 
markers appear to have minimal effect on fall risk. However, falls pose a particular concern 
for PLHIV because of their reduced BMD, and the fact that many risk factors for falls and BMD 
overlap, translating to a compounded high risk of fractures secondary to falling.  
                                               
iii Frailty refers to a clinical state (syndrome) of greater vulnerability due to dysregulated reserve and 
function across various physiologic systems, compromising the ability to cope with everyday stressors. 
Frailty is often operationally defined according to Fried’s phenotype.53 
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  Table 2.2. Sum
m
ary of studies reporting falls in people living w
ith H
IV-1 infection (PLH
IV). 
 
Erlandson 
2012
55 
Ruiz 2013
161 
G
reene 
2015
52 
Sharm
a 
2016
160 
Erlandson 
2016
158 
Tassiopoulos 
2017
162 
Kim
  2018
164 
Ssonko 
2018
163 
Sharm
a 
2018
159 
D
esign 
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ross-
sectional. 
R
etrospective 
review
. 
C
ross-
sectional. 
C
ross-
sectional. 
C
ross-
sectional. 
Prospective, 
m
ulticenter 
cohort study. 
Secondary 
analysis. 
C
ross-
sectional. 
Longitudinal. 
C
ountry 
U
SA 
U
SA 
U
SA 
U
SA 
U
SA 
U
SA 
U
SA 
U
ganda 
U
SA 
Aim
 
To investigate 
w
hether 
increased fall 
risk factors 
w
ould increase 
fall rates 
am
ong m
iddle-
aged PLH
IV. 
To investigate 
fall incidence 
and risk factors 
in PLH
IV. 
To describe 
geriatric 
syndrom
es in 
PLH
IV aged 
≥50 w
ith 
undetectable 
VL. 
To determ
ine 
fall frequency 
and risk 
factors am
ong 
m
iddle-aged 
w
om
en w
ith 
H
IV and H
IV- 
controls. 
To (1) 
com
pare fall 
rates in PLH
IV 
or adults at 
risk for H
IV, (2) 
determ
ine if 
H
IV infection is 
an 
independent 
fall risk, and 
(3) determ
ine 
other fall risk 
factors 
potentially 
unique to H
IV. 
To investigate 
frailty-to-fall 
risk am
ong 
PLH
IV. 
 
To determ
ine 
w
hether 
polypharm
acy is 
associated w
ith 
falls and 
fractures am
ong 
PLH
IV and 
substance 
dependence or 
injection drug 
use. 
To determ
ine 
polypharm
acy 
prevalence, 
associated 
factors and 
w
hether 
polypharm
acy 
w
as 
associated 
w
ith adverse 
effects am
ong 
older PLH
IV 
on AR
T.  
To determ
ine 
the 
longitudinal 
occurrence 
and risk 
factors for falls 
in w
om
en w
ith 
H
IV, and 
explore 
associations 
w
ith cognition. 
Fall definition 
U
sing slightly varying term
inology, all studies but one included the follow
ing: “U
nintentionally/unexpectedly com
ing to rest on the ground or other low
er level”. 
O
ne study
164 included falls caused by an external hazard w
hile seven studies used the qualifier “not as a result of a m
ajor intrinsic event or external hazard”. 
O
ne study
163 did not m
ention their definition of a fall.  
Falls 
assessm
ent  
All studies (except the tw
o longitudinal follow
-ups) used retrospective self-report (history of one or m
ore falls during past 12m
o). Sharm
a et al. 159 and 
Tassiopoulos et al. 162 used sem
i-annual retrospective self-report at each study visit starting at 6m
o follow
-up (history of falls since previous visit).    
Sam
ple 
description 
PLH
IV aged 
45 to 65 years, 
receiving 
effective AR
T. 
Patient records 
of PLH
IV from
 
an academ
ic 
urban H
IV 
clinic, w
ho fell 
during prior 
12m
o. 
PLH
IV from
 
SC
O
PE cohort 
aged ≥50 
years, on AR
T 
w
ith 
undetectable 
VL. 
H
IV+ and H
IV- 
W
IH
S 
participants 
w
ith available 
falls data. 
H
IV+ and H
IV- 
m
en and 
w
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en 
participating in 
the H
earing 
and Balance 
Substudy of  
H
IV+ m
en and 
w
om
en aged 
≥40 years. 
PLH
IV w
ith 
substance 
dependence or 
injection drug 
use, from
 Boston 
AR
C
H
 C
ohort 
study. 
O
lder PLH
IV 
on AR
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≥50 attending 
an outpatient 
H
IV/AID
S care 
centre. 
H
IV+ and H
IV- 
W
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S 
participants 
w
ith available 
falls data and 
attending  
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 the M
AC
S and 
W
IH
S.   
 sem
i-annual 
study visits. 
Sam
ple size 
359 
32 
155 
2062 (1 412 
H
IV+ and 650 
H
IV−) 
536 (303 H
IV+ 
and 233 H
IV-) 
967 
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IV-) 
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25%
 
6%
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M
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H
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H
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M
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M
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 44-56)  
N
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ple 
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participants 
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H
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H
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100%
  
100%
 
88%
  
69%
 
100%
 
100%
 
100%
 
88%
 
Viral load  
95%
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<LD
L. 
M
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379 copies/m
L. 
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 had VL 
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65%
 had VL 
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L. 
69%
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<LD
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N
R
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L. 
M
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70%
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no falls, 30%
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 w
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recurrent 
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m
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32 faller cases 
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analysis 
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>3 
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as 
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Factors 
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C
N
S active  
 
≥1 fall reported 
in 24%
 of 
PLH
IV vs. 18%
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IV-. PLH
IV 
w
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likely to report 
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balance 
sym
ptom
s. 
Sm
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polypharm
acy, 
and im
balance 
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independent 
fall predictors 
in PLH
IV. 
C
urrent PI use 
w
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18%
 had ≥1 
fall, and 7%
 
had recurrent 
falls. In 
m
ultivariable 
m
odels, pre-
frailty and 
frailty w
ere 
associated 
w
ith recurrent 
falls. 
Significant 
associations 
w
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w
ith recurrent 
falls and 
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ed w
alk 
and w
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The 
association 
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een frailty 
and falls w
as 
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am
ong i 
 
In 
PLH
IV/substance 
dependence, a 
higher num
ber of 
system
ically 
active 
m
edications w
as 
associated w
ith 
greater odds of 
having a fall 
requiring m
edical 
attention. The 
association 
appeared to be 
driven largely by 
sedating 
m
edications.  
Polypharm
acy 
w
as not 
associated 
w
ith falls. 
Frailty and 
m
ild and 
m
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cognitive 
decline w
ere 
significantly 
associated 
w
ith falls in 
m
ultivariate 
analyses. 
C
urrent PI use 
w
as 
associated 
w
ith falls. 
≥1 fall 
reported in 
41%
 H
IV+ vs. 
42%
 H
IV-, 
including ≥2 
falls in 25%
 
H
IV+ and 24%
 
H
IV-. Factors 
associated 
w
ith falls 
included: 
depression, 
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 (H
IV+ and 
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IV-); age, 
m
arijuana use, 
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ultiple C
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C
V infection 
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IV+ only). 
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 difficulty 
predicted falls. 
 agents and 
study site.  
 individuals w
ith 
PN
. 
Adjustm
ent 
for covariates 
All studies reported extensively on the various relevant variables that w
ere adjusted for, including dem
ographic, H
IV-related, clinical, m
edication-related and 
general health variables. The reader is referred to the individual texts for detailed lists. 
Abbreviations: AR
C
H
 = Alcohol R
esearch C
ollaboration on H
IV/AID
S; AR
T = antiretroviral therapy; C
N
S = central nervous system
; H
C
V = hepatitis C
 virus; LD
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er than detectable lim
it; 
M
AC
S = M
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S C
ohort Study; m
o = m
onths; PI = protease inhibitor; PLH
IV = people living w
ith H
IV-1 infection; PN
 = peripheral neuropathy; SC
O
PE = O
bservational Study of the 
C
onsequences of the Protease Inhibitor Era; U
SA = U
nited States of Am
erica; VL= viral load; W
IH
S = W
om
en's Interagency H
IV Study.  
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2.6. The conceptualisation of HIV-1 into a framework of 
rehabilitation 
Rehabilitation has been declared by the WHO as the key health strategy of the 21st century.165 This 
is in acknowledgement of the fact that the sequela of survivorship with an increasing burden of 
chronic diseases (HIV included) involve limitations in functioning and participation. A new paradigm 
in HIV management is increasingly advocated166,167 with the aim to maximise functional status, 
minimise functional decline, and optimise quality of life over the extended life years of PLHIV.  
The changing face of HIV and its presentation has led to the reconceptualisation of HIV from a 
biomedical model into a rehabilitation framework.167,168 Attention has shifted towards the related 
“impairments” (body structure or functional deficits), “activity limitations” (problems at the whole-body 
level) and “participation restrictions” (difficulties related to the individual and their environment); as 
defined by the WHO’s International Classification of Disability, Functioning and Health (ICF) (see 
Figure 2.2).169 
The concept of rehabilitation in the context of HIV is still emerging,170 but already the role of 
rehabilitation specialists such as physiotherapists are increasingly advocated in the management 
and prevention of HIV-related disability; both locally and internationally.171,172 In illustration of this 
trend, the South African Society of Physiotherapy (SASP) has recently aligned itself with the South 
African Department of Health in achieving the National HIV/AIDS and STI strategic plan, by 
emphasising HIV care within physiotherapy practice.173 In a further example, an open-access online 
resource on rehabilitation for PLHIV in Canada has recently been adapted for Sub-Saharan Africa 
(http://ssa.hivandrehab.ca/).174 
Rehabilitation is a field designed to aid individuals in addressing challenges to function and well-
being, and thus plays a role in the lives of people living longer with HIV and experiencing motor 
impairments. In this dissertation, when referring to rehabilitation, it is done with reference to the 
definition by Worthington et al.,168 namely that it is a dynamic process and includes any treatment 
activities and/or services that may tend to or prevent impairments, activity limitations or social 
participation restrictions experienced by an individual. There is a need to engage in research in Sub-
Saharan Africa that explores rehabilitative care, especially in terms of early screening and prevention 
of functional impairments, as a cost-effective means of improving well-being and quality of life for all 
PLHIV experiencing (or at risk for) disability. 
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2.7. Defining function  
The ICF uses the umbrella term “functioning” to describe body structures and functions, activities, 
and participation.169 “Disability”, on the other hand, describes compromised functioning by referring 
to impairments (a loss or abnormality in an anatomical structure or physiological function), activity 
limitations ([in]ability to execute a task or action) and participation restrictions ([non]involvement in 
life situations within society).169 Environmental and personal contextual factors may extenuate or 
aggravate disability.169  
Impairments may manifest at the body structure level as, for example, motor- or muscle function 
deficits and impaired joint mobility. Such impairments, individually or combined, may contribute to 
activity limitations and eventually, a trajectory towards functional decline and disability.175  
In the geriatric literature, declining physical and cognitive function is commonly termed “functional 
decline”. Beaton at al.176 described functional decline as an insidious onset, complex manifestation 
of ageing; easily overlooked in its early stages. These authors extensively explored the complex 
domains and constructs underlying early functional decline in the general population. Performance 
capacity was identified as one of the (many) domains of functional decline, including physical 
constructs such as balance, chair rise, gait speed, step length and more.176 
The term “functional decline” has been used interchangeably in the HIV literature as referring to 
frailty or disability, to indicate decreases in physical function performance or self-reported function 
or a combination of functional domains.  To the author’s knowledge, no formal reference has been 
made in the HIV literature to the proposed definition of functional decline as it is used within geriatrics, 
although it mostly seems to intuitively refer to reductions in physical and/or cognitive function 
performance in the patients studied. Throughout this dissertation, the concept of function is used to 
describe body functions, body structures, and activities alike and “functional decline”, as used in this 
dissertation, relates to deteriorations in these functions.  
Figure 2.2 presents the ICF model as applied to chronic HIV-1 infection and illustrates how some of 
the specific variables of interest (or contributors to motor function) in this study interact within the 
ICF framework, and the potential consequent influence of such interactions on activity limitations, 
physical functioning and social participation. 
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Figure 2.2. The International Classification of Functioning, Disability and Health (ICF) model 
as applied to chronic HIV-1 infection. 
 
2.8. Assessing lower limb impairments and function 
2.8.1. Objective (clinical performance) and subjective (patient-
reported) outcome measures 
Given that (i) even virologically-controlled PLHIV commonly demonstrate some degree of lower limb 
impairment at earlier-than-expected ages,2,38,51 (ii) the fact that many functional activities depend on 
the integrity of lower limb neuromusculoskeletal structures,49 and (iii) the importance of lower limb 
function in predicting future disability;49,50 early assessment of lower limb function in chronic HIV may 
be of value. Indeed, to better understand health in chronic diseases, it is important to extend 
assessment beyond conventional disease measures, and use clinical assessments of function.177,178 
Measurement of impairments or functional limitations using either self-report (which is an evaluation 
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of perceived dysfunction) or standardised objective measures of physical performance (such tests 
mostly measure impairments or functional limitations) is crucial for understanding the dynamics of 
the functional pathway leading from disease to early functional decline and disability.177,179 The 
concept of a preclinical transitional phase existing in the trajectory of functional decline (i.e. early, 
subtle losses in function which act as precursors to disability) in the general population was first 
prospectively tested by Fried et al.,178 using a cohort of high-functioning older adults with no mobility-
related disability at baseline. These authors confirmed that early declines in function can be identified 
by self-report180 and objective performance measures,181 and that both are (complementary) 
predictors of incident disability. Self-reported function was found to correlate better with impairments 
and physical performance tests (i.e. clinical tests of impairments and functional limitations) than with 
underlying disease status180; with those participants reporting modified activities (i.e. preclinical 
declines in function) demonstrating a high risk of incurring mobility-related disability over 18 months. 
These findings support the predictive validity of self-perceived function at the stage of preclinical 
disability.iv However, self-report and objective assessments are considered complementary and both 
have been shown to predict outcomes, although they may not always measure the same physical 
function constructs.156,178,180 
It is evident from the literature reviewed thus far that PLHIV experience non-AIDS-defining 
complications, resembling geriatric processes52,53 and that this hypothesised accelerated or 
accentuated ageing may manifest in middle-aged PLHIV as neuromotor impairments and low BMD. 
Such impairments are associated with balance problems and increased fall risk.2,55 A response to 
the shift in HIV survivorship was to reconceptualise HIV into a rehabilitation framework, and 
assessments of physical (lower limb) function based on geriatric principles may prove useful tools 
for HIV clinicians and researchers to help identify those at risk of functional decline. Walking speed 
is a predictor of preserving independence with ageing182 and may be easily derived using short walk 
tests (e.g. six metres) and a stopwatch. The Short Physical Performance Battery (SPPB) is another 
widely validated and used physical functional measure in older adults.183 It measures various aspects 
of lower limb function such as balance (static and dynamic), lower limb muscle performance and gait 
speed. Performance on each of these aspects are then merged into an overall physical function 
score with a maximum of 12 points. SPPB score predicts problems with activities of daily living, as 
well as the existence of disability in community-dwelling older adults.50,184 For example, small 
                                               
iv Preclinical disability involves progressive loss of function and refers to an intermediate phase prior to the 
onset of disability. The individual does not yet identify as experiencing impairment or disability in everyday 
tasks but adapts (consciously or unconsciously) the frequency or manner in which the task is completed so 
that they may function optimally.178  
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improvements in gait speed (differences >0.05 m/sec) and SPPB performance (differences >0.5 
points) translate to meaningful improvements in ADL.185  
Functional assessment in PLHIV may help to understand the impact of the concomitant processes 
of ageing, HIV-1 infection and its treatment, comorbid diseases and lifestyle on successful ageing 
and preservation of independence59 and measures from geriatrics have indeed been proposed to be 
of clinical use in middle-aged and ageing PLHIV.2,3,53,58–60,156 For example, the SPPB has been used 
in multiple cross sectional HIV studies and proved to be associated with mortality60 and fall-risk.55 
Schrack et al.58 reported a faster rate of functional gait speed decline in male PLHIV versus 
seronegative controls, suggesting greater risks of disability and death with advancing age. Selecting 
the most appropriate test depends on the desired measurements and goals of assessments 
including correlations with lower limb tasks, measuring strength, or assessing fall risk.156 
It should be noted that a physical performance-based test does not necessarily correspond to a loss 
in function, as it often does not render information beyond what a person is able to do (as opposed 
to how they do it); potentially limiting such tests to predict functional consequences.179 This is 
unfortunately a limitation of all clinical testing, and an ongoing area of investigation.179 Nonetheless, 
functional limitation tests substantially contribute to knowledge about patient populations156 and are 
practical for implementation in the clinical setting. Further research is thus warranted to assess and 
promote their utility and standardisation in HIV research and clinical settings alike.177 
2.8.2. Considerations for PLHIV 
It is important to keep in mind that even when traditional geriatric assessments are used in (younger- 
or older-age) PLHIV, results may be different than in the general population of elderly.156 In their 
comprehensive review of functional and geriatric assessment in PLHIV, Greene et al.156 illustrated 
that a different pattern of disability or functional decline may manifest in middle-aged or younger 
adults dealing with complex chronic illness and social situations compared to the general population 
of older adults. Ongoing studies of specific assessments from geriatrics applied to, and potentially 
modified for, PLHIV are needed.156 
As the population of PLHIV is still predominately young to middle-aged in Sub-Saharan countries, 
assessments in these contexts should be tailored to test a higher level of function.53 Objective 
assessment of functional limitations to capture the subtler spectrum before full disability (like an 
expanded and more challenging SPPB) may for example be appropriate. Additionally, the use of 
dual task activities186 has been advocated but not yet widely applied. The performance difference 
between single- and dual tasks represent the demands placed on the processing system when 
attention is divided between two tasks simultaneously, and thus may be used as an indication of the 
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attention demands (cognitive compensation) required by the primary task.187 In PLHIV, this might 
reveal more subtle movement impairments in higher functioning individuals.186 These techniques 
may be especially relevant in studies which include PLHIV under the age of 50, as is the case in this 
project.  
2.8.3. Instrumented (quantitative) assessment methods  
Three-dimensional (3D) instrumented motion analysis provides sensitive, accurate and 
comprehensive data on normal and pathological functional movements such as walking gait. 
Instrumented motion analysis is one of the few measurement approaches that quantifies functional 
limitations, with analysis allowing insight into the dynamic implications of a particular impairment 
such as muscle weakness.61 As the technology supporting the 3D analysis of human motion has 
advanced dramatically over the past couple of decades, in-field quantitative gait analysis by means 
of lightweight, compact, portable motion capture systems has become a possibility for collecting 
kinematic data and is now proposed as a clinically useful tool.188,189  
Instrumented motion analysis outcomes have been emphasised as markers of function in various 
patient populations such as neurological,190 musculoskeletal,191,192 and endocrine193 conditions, as 
well as in the elderly,194 people at risk for neurocognitive dysfunction,195 and fallers.196,197 For 
example, in the elderly, increased accuracy of fall prediction models based on common clinical fall 
risk assessment tests (fall questionnaires and physical performance tests such as the SPPB), has 
been demonstrated when gait measures from comprehensive gait analysis are included.198,199 These 
authors found that gait analysis variables derived from trunk accelerometry may predict fall risk 
independently of physical performance.198 
In PLHIV, abnormal gait patterns may be hypothesised to result from combined effects of a primary 
impairment, such as muscle weakness, and the secondary compensation for preserving locomotion 
as efficiently as possible.200–202 The relationships between primary impairments and their locomotor 
manifestations, including secondary compensations, cannot yet be quantified from existing data on 
locomotion in PLHIV. However, based on the data reviewed thus far, one might expect the motor 
impairments in PLHIV to manifest biomechanically as a pattern of gait or balance control that 
resembles that of older adults and/or fallers. Comprehensive quantitative analysis of gait deviations 
in PLHIV may distinguish such pathologic patterns,203,204 potentially helping to inform associations 
between pathologies, neuromusculoskeletal contributions, movement patterns and functional 
consequences.203,205 Studies in other pathologies have investigated correlations of clinical 
instruments with spatiotemporal and kinematic variables. A study by Roiz et al.190 demonstrated that 
some clinical tests (e.g. the motor Unified Parkinson’s Disease Rating Scale [UPDRS], Timed Up-
and-Go [TUG] Test and Berg Balance Scale [BBS]), correlate well with, and were thus able to 
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perceive, certain biomechanical alterations (e.g. ankle, pelvis and hip angular deviations) in 
Parkinson’s Disease.  
An important complexity of gait analysis is the inter-dependence of many gait variables.201 Gait 
speed, for example, influences lower limb kinematics and increased joint ROMs are observed at 
faster gait speeds. This effect of gait speed depends on the specific  angle and also on the phase of 
the gait cycle.206 Knee flexion in stance and swing show particularly strong positive correlations with 
gait speed.207 The effect of speed thus needs consideration when comparing gait data from patient 
populations walking at slower self-selected speeds than the comparison group by adjusting 
kinematics according to gait speed.206 Comparing gait data without doing so makes it difficult to know 
whether reduced joint excursion is due to the slower gait speed, or co-occurring as an independent 
pathological feature. Another consideration is that individual gait patterns vary by age, 
anthropometrics, personality, mood and sociocultural factors: for example, people living in urban 
neighbourhoods or cities walk significantly faster than those living in rural settings.208–210 Norms in a 
certain population may thus not necessarily hold true in individuals from different communities – 
highlighting the need for appropriate comparison groups in research studies. The comprehensive 
data provided by 3D motion analysis are therefore often not straightforward to interpret.  
Effective rehabilitation of gait and balance impairments in PLHIV, as in other patient populations, 
largely depends on an understanding of the underlying deficits and their interactions. Given the 
knowledge gap regarding quantification of how PLHIV perform walking- and balance tasks, it seems 
that there is potential for 3D motion analysis to explore the uncertainties regarding the nature of 
locomotor impairment. It must be noted, however, that kinematic motion analysis presents the 
observer with effects and not causes. What is observed as a gait pattern, is therefore not a direct 
result of the pathological processes at hand. Rather, it is the net result of a complex interplay 
between causes and compensatory actions of the body202 or the remnants following the exhaustion 
of all available compensatory mechanisms.201 What this implies, is that the determination of causes 
require an initial theory, which then has to be tested by inflicting some interference to the system.202 
Although the 3D gait analysis performed in this dissertation did not involve additional measures (such 
as gait kinetics or electromyographic measurements) other than kinematic angles and TSPs of gait, 
the research assessed additional more challenging conditions over and above the baseline activities 
of walking at habitual speed and SLS with eyes open. Also, the literature was consulted regarding 
clinically relevant gait analysis outcomes (including key events and phases) for joint angles in the 
elderly and fallers to inform the conceptual framework underlying this research – these are presented 
in the following section.  
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2.8.4. Gait deviations indicative of advanced age and/or fall risk 
The following sections review gait deviations indicative of advancing age and/or fall risk in the 
general population. Understanding the effects of normal ageing on locomotor function and lower limb 
gait biomechanics will contribute towards a conceptual framework for interpreting gait deviations in 
PLHIV; given the feasible similarities reviewed thus far. Such a framework may aid in confirming (or 
refuting) deviations resembling an elderly or fall-risk phenotype in young-to-middle-aged PLHIV. 
Relative to younger adults, older adults tend to walk slow and with changes in their kinematics as 
well as their kinetics.201,211–216 Reductions in total joint excursions are common.217 Although such 
changes have been widely reported, the causes of the observed adaptations are not well 
understood.218 This may in part be due to the difficulties associated with experimentally determining 
cause and effect in the study of human physiology.218 Some previous gait studies in elders have 
failed to account for covariables such as gait speed when describing biomechanical differences 
between older and younger adults.194 When controlling for gait speed, a normal gait pattern has been 
suggested in the elderly as compared to younger adults. For example, Ferrandez et al.219 analysed 
gait parameters during different speed conditions in a group of 67 older adults (aged 60 to 80+ years) 
and young participants. The authors found that shorter stride and an increased double support phase 
were the main characteristics of elderly gait, but that these were likely speed-related, since similar 
characteristics were also observed in the young participants when asked to walk slowly. The study 
concluded that elderly gait is normal if gait speed is accounted for.219  
2.8.4.1. Temporal, spatial, temporophasic and temporospatial parameters 
(TSPs) 
Blanke and Hageman220 found no significant differences in gait speed, step length or stride length 
between older and younger men. However, this study was limited by a very small sample size in 
terms of studying gait differences (n = 12 per group) and may thus have been underpowered to show 
statistical significance. In addition a 1% level of significance was chosen (a p-value of 0.01) which 
may have been too restrictive – as pointed out by Prince et al.,221 p-values of 0.05222 are traditionally 
selected for gait studies. Blanke and Hageman’s paper220 was one of the only studies failing to show 
a difference in gait speed between older and younger ages – indeed, one of the most consistent 
differences demonstrated is gait speed and multiple-regression analysis has demonstrated that age 
accounts for 30% to 45% of the variability in gait speed.223 Oberg et al.224,225 assessed basic gait 
parameters in 233 healthy participants aged 10 to 79 years, under slow, normal, and fast gait speeds. 
Using two-way analysis of variance (ANOVA) they demonstrated that age-variability was significant 
for gait speed and step length at usual-paced and fast speeds (reduced in elderly), but not for 
cadence. Step length showed a significant interaction effect of age and gender at normal and fast 
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speeds. Unfortunately, the study does not report on the health status of the participants, or method 
of recruitment. The validity of the gait speed conditions is also uncertain, as the authors fail to 
mention the specific instructions given to participants about the gait speed needed to be obtained 
(slow, normal or fast).  
In addition to the studies already mentioned, various other studies have also reported shorter step 
length in older adults226–229 although yet others negate this finding.230,231 A review by Beijersbergen 
et al.232 noted that shorter steps and slower gait speed may be the most functionally meaningful 
changes in elderly gait.  
2.8.4.2. Kinematic variables 
Both Winter222 and Oberg et al.224 found very small differences in joint angle patterns between 
younger and older adults, with subtle changes occurring in amplitudes. Oberg et al.,224 in their sample 
of 233 healthy persons aged 10 to 79 years, demonstrated minor changes in lower limb joint angles 
with age, no differences between right and left legs, significant gender differences, and significant 
changes with increasing gait speed.  
Dynamic ankle ROM is lower in older adults (e.g. 24.9° in older versus 29.3°  in younger adults – a 
4.4° difference). A reduced peak plantarflexion angle has also been found in older adults (e.g. 13°  
versus 17° - a 4° difference).227 This decrease has been associated with a general weakness of 
plantarflexor muscles in elders.218,233 Other studies also found a significantly reduced maximum 
ankle plantarflexion at both comfortable and fast walking speeds211 and during late stance227; and 
demonstrate reduced ankle plantarflexion power226,227,234; although some argue that this finding may 
not remain significant when correcting for differences in step length.227  
Knee extension at mid-stance has been show to increase with age (by about 0.5° per decade) while 
this angle decreases by 0.5° to 0.8° per decade during swing.225,227 Elderly people also maintain 
some knee flexion at terminal swing (e.g. 5.3°)222 whereas younger adults reach close to full 
extension (e.g. 0.5°). Prince et al.221 noted that this flexed angle in elders is associated with a 
significantly shorter step length, and that it is performed in order to reduce quadriceps demand during 
loading response. Total knee ROM during the gait cycle is also decreased in the elderly (e.g. 55° in 
older versus 59° in younger adults – a 4° difference).227  
In contrast, dynamic hip ROM is increased in older age222 (e.g. 40° versus 32° – an 8°difference). 
Oberg et al.,224 in contrast, failed to demonstrate any significant differences in hip angles between 
age groups. Along with reduced ankle plantarflexion, Increased hip ROM noted with advancing age 
has been noted as a distal-to-proximal shift in muscle function to compensate for distal weakness 
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(called the biomechanical plasticity of ageing gait).218,232 Reduced peak hip extension and increased 
pelvic tilt have also been observed; however, these changes may be speed-induced rather than 
standing postural characteristics.201,235 The increased anterior pelvic tilt has however also been 
attributed to the need for placing the hip extensors, which demonstrate an age-associated weakness, 
at a more favourable length to meet the demand.221 Reduced pelvis motion in the coronal and 
transverse planes has also been noted, being about 3° lower in older relative to younger adults.227  
The gait characteristics specifically associated with falls is less clear, likely because of the fact that 
collecting data about an unpredictable event, which thus cannot be observed, is a pragmatic 
challenge. It has however been proposed that the gait characteristics predisposing a person to falls 
are an exaggeration of the changes noted with ageing.218 A systematic review236 found that linear 
variability of temporal gait parameters (stride, swing and stance time) constitutes the best 
discriminators between fallers and non-fallers. On the other hand, variability in step width, stride time 
and speed were best suited to differentiate between older and younger adults.  
Gait variability is thought to indicate underlying motor control.237 Variability may thus quantify age- 
as well as disease-related changes in the motor control system and in addition serve as a clinically 
relevant measure of mobility and functional status.237 Maki et al.238 furthermore demonstrated the 
impact of emotional state on fall risk. These authors found that changes in gait parameters (e.g. 
shorter stride length and slowed speed, and increased double support time) showed an independent 
association with the fear of falling, instead of actual falling per se. Table 2.3 summarises the changes 
in TSPs and kinematics proposed in the elderly and fallers, including results from systematic 
reviews.236,239,240 
Table 2.3. Gait characteristics commonly proposed to differentiate older from younger adults, 
and fallers from non-fallers. 
 Elderly Fallers 
Kinematic angles 
Pelvis • Increased anterior pelvic tilt221 
• Reduced pelvic rotation in coronal 
and transverse planes during 
stance227 
• Increased peak anterior pelvic tilt  
• Peak anterior pelvic tilt increases 
with fast walking (not the case in 
elderly non-fallers)241 
Hipa • Overall increased ROM221,239  
• Increased flexion at initial contact239  
• Increased peak flexion239  
• Decreased extension during push-
off; decreased peak extension239,242 
• Peak extension independent of 
walking speed241 
• Prolonged adduction during stance 
phase227 
• Flexion ROM during GC 
significantly lower  
• Decreased flexion angles between 
mid-stance and late stance 
phases243 
• Peak extension even lower in 
elderly fallers compared with non-
fallers241 
• Peak hip extension independent 
from walking speed241 
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• From SR: small  SE of age on hip 
kinematics; SE ranged from small 
for hip flexion angle at initial 
contact, overall hip ROM and peak 
hip flexion to moderate for peak hip 
extension239 
• Decreased abduction angles during 
mid-stance phase243 
• Increased variability of angles 
during entire swing phase in all 
planes243 
• Increased variability of angles 
during stance phase in coronal 
plane243 
Kneea • Gait speed plays critical role on 
knee kinematics239 
• Overall decreased ROM221,227 
• Increased extension angle at mid-
stance221,227 
• Decreased extension during swing 
phase221  
• Maintenance of slight flexion at end 
of swing221  
• Increased flexion at initial contact239 
• From SR: current literature does not 
support a moderate or large 
difference in knee kinematics239  
• Small overall SE of age on knee 
kinematics. However, when 
accounting for gait speed, SE for 
knee ROM was moderate, 
indicating a larger ROM for older 
adults239 
• SEs for angle at initial contact, mid-
stance peak flexion and peak 
flexion in swing were not 
significant239 
 
• No statistically significant 
differences in mean joint angles 
between fallers and non-fallers244 
• Greater variability of knee joint 
angles during entire swing phase in 
all planes243 
Anklea • From SE: overall reduced ROM 
(large SE)221,239  
• Reduced peak plantarflexion angle 
(moderate SE)221,239 
• Reduced plantarflexion ROM during 
push-off 242 and reduced 
plantarflexion angle at toe-off 
(moderate SE)239 
• Reduced ankle dorsiflexion at initial 
contact (small  yet significant SE)239 
• Reduced overall dynamic ROM244 
• Dorsiflexion during second phase of 
double support (A1 – A2 power 
phases/mid-stance to terminal 
stance) significantly reduced 
• Plantarflexion at start of swing 
phase (A3 – A2 power phases) 
significantly lower for fallers244  
• Increased inversion between mid-
stance and late stance243 
• Greater variability of angles during 
entire swing phase in all planes243 
• Greater variability of angles during 
stance phases in coronal plane243 
 
Temporal, spatial, temporophasic and temporospatial parameters 
Gait 
speedb,c 
• Reduced gait speed (fallers even more so than non-faller elderly)240,244,245 
• Reduced gait speed also associated with fear of falling238  
• Most consistent finding218,221 
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Cadenceb,c • Contradictory findings 
• No significant difference compared 
to younger adults214,215 
• Some findings for differences in 
variability 
• Tendency toward a reduced 
cadence240,245,246 
Step and 
stride 
timeb,c 
• Longer duration240 
Double 
support 
timeb,c 
• Longer double support duration (thus delaying the swing phase)240,244,245 
(fallers even more so than non-faller elderly) 
• Longer double support also associated with fear of falling238 
Stride and 
step 
lengthb,c 
• Shorter length226,240,242,244,247 (fallers even more so than non-faller elderly) 
• Reduced length also associated with fear of falling238 
Stance 
time 
• Increased in geriatric gait and fallers 222,244,247–249 
Double 
support 
time 
• Increased in geriatric gait and fallers222,250 
Variability 
in gait 
parameters 
• Results of a SR236 demonstrated that the variability in stride time was able to 
identify both age- and fall-related differences236 
• Linear variability of temporal measures of swing and stance was most capable 
of distinguishing between fallers and non-fallers236  
• Stride-to-stride variability increases fall risk238,251,252 - stride-to-stride variability 
in speed single best independent predictor of falling238 
 
Abbreviations: GC = gait cycle; SE = standardised effect; SR = systematic review. 
aNote limitations of SR by Boyer et al.239: The review did not quantify differences in gait between young, 
middle-aged and elderly adults and included adults considered as being middle-aged in some cases in the 
meta-analysis. It is thus difficult to draw conclusions regarding the gait alterations that may be associated 
with physiological changes brought about by ageing. 
b Effect size analysis from SR by Mortaza el al.240 showed that stance time variability, gait speed, stride 
length and step length were the spatiotemporal parameters that differed most between elderly fallers and 
non-fallers. 
cNote limitations of review by Mortaza el al.240: The precision of the ES results may be questioned as 
some included studies and variables lacked mean and SD data - reported effect sizes were thus the 
average across varying numbers of studies (e.g. only two studies for stride time variability vs. 10 studies 
for gait speed). Heterogeneity existed between studies regarding methodology, participant selection 
criteria and definitions for discriminating fallers from non-fallers; and the majority of studies concluded that 
results regarding the parameters were controversial. Thus, while the review provides a perspective on the 
current understanding of gait parameters associated with fall risk, results should be interpreted with 
caution. 
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2.9. Chapter summary 
The evidence regarding the pathophysiology of HIV-1 infection suggests a complex chronic 
disease in a predominantly middle-aged population. The virus itself, along with various non-
communicable comorbidities, HAART, traditional risk factors and synergistic mechanisms to 
usual ageing all contribute to the motor impairments observed in PLHIV, which in turn 
contribute to declines in lower limb function. Motor impairments in PLHIV include muscle 
weakness/dynapenia, motor slowing, postural imbalance and peripheral neuropathy; all of 
which may influence gait and balance. This might be predictive of adverse outcomes such as 
falls, which are consistently reported in middle-aged PLHIV and complicated by a high fracture 
risk in this population. A response to the shift in HIV survivorship was to reconceptualise HIV 
into a rehabilitation framework, and the importance of prevention (e.g. early screening for 
functional impairment) is increasingly recognised. Assessments of physical function based on 
geriatric principles may prove useful tools for HIV clinicians and researchers to help identify 
those at risk of functional decline. Instrumented analysis of gait and balance in PLHIV may 
distinguish pathologic patterns, potentially helping to establish associations between 
pathologies, neuromusculoskeletal contributions, movement patterns and functional 
consequences. The next chapter will systematically review objective impairments of gait and 
balance in PLHIV (as evaluated by both clinical functional tests and instrumented analysis), 
highlighting those potentially related to an increased fall risk. 
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PART I 
 
Objective impairments of gait and balance in adults 
living with HIV-1 infection: 
A systematic review and meta-analysis of observational 
studiesv 
3.1. Introduction 
Both globally and in Sub-Saharan Africa (SSA), the increased survivorship of people living with HIV-
1 infection (PLHIV) is paralleled by increasing morbidity. Gait and balance deficits are reported in 
adults with HIV infection and are associated with reduced quality of life.6 Gait and postural balance 
rely on a complex interaction of the motor system, sensory control, and cognitive function. However, 
due to disease progression and complications related to ongoing inflammation, these systems may 
be compromised in PLHIV.  
Information is building that PLHIV demonstrate gait and balance impairments that can contribute to 
higher-than-expected fall rates in younger-than-expected cohorts. However, owing to the plethora of 
observational data, it is difficult to quantify the extent of impairment and to gain insight into which 
parameters are truly affected and clinically relevant. In elderly populations, several gait and balance 
parameters have been identified as independent predictors of fall risk, including temporal and spatial, 
kinetic, kinematic and clinical.253–256 To the authors’ knowledge, no previous systematic review has 
yet investigated objectively-measured impairments of gait and balance in PLHIV.  
The aims of the systematic review undertaken during Phase I of this project were therefore to:  
i. synthesise the evidence of objective impairments of gait and balance associated with HIV-
1 infection, emphasising those that could contribute to increased fall risk;  
ii.  describe the evidence in relation to disease severity, treatment association, task difficulty, 
and peripheral neuropathy. 
                                               
v This chapter was published in a peer-reviewed journal as: Berner K, Morris L, Baumeister J, Louw Q. 
Objective impairments of gait and balance in adults living with HIV-1 infection: a systematic review and meta-
analysis of observational studies. BMC Musculoskelet Disord 2017;18(1):325 (Appendix N). 
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3.2. Methods 
This systematic review was conducted according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.257 
3.2.1. Criteria for considering studies for this review   
Cohort, case control and cross-sectional studies published in English as peer-reviewed journal 
articles were considered. Studies were included if they aimed to assess instrumented or non-
instrumented objective parameters of gait and/or balance in adults (18 to 65 years of age) with HIV-
1 infection, irrespective of gender. Given the expectation that there would be a paucity of information, 
studies with and without comparison groups were considered. Quantitative gait outcomes were 
included, but were not limited to, kinematics, kinetics, spatiotemporal measures or clinical tests. 
Quantitative balance outcomes included, but were not limited to, biomechanical parameters such as 
centre of pressure (COP) measures, and temporal measures via clinical tests. Studies were 
excluded if participants' age exceeded 65 years, as the prevalence of locomotor impairments is 
known to increase in older age even in healthy populations.258 Studies aiming to assess HIV-
Associated Neurocognitive Disorder using a neuropsychological test battery were also excluded, 
regardless of the use of a gross motor component, in an attempt to focus on studies with the primary 
aim of objectively assessing and describing gait or balance in PLHIV. 
3.2.2. Search methods for identification of studies   
3.2.2.1. Information sources 
Six computerised bibliographic databases were searched, namely PubMed, Science Direct, 
EBSCOhost (CINAHL, MEDLINE, Africa-Wide Information), Scopus, ProQuest Medical Library and 
Google Scholar. Following a preliminary search of PubMed, a comprehensive search strategy, 
including all relevant key word/terms and medical subject headings (MeSH) was developed and 
adapted for use in subsequent searching of the remaining databases. Search terms included: (HIV-
1 OR HIV Infection*) AND (motor function OR biomechanical phenomena OR gait OR postural 
balance OR locomotor function). The search was restricted to papers published from inception of 
the database to April 2016. Reference lists of all identified documents were hand-searched to identify 
additional relevant evidence. In the event of missing data, an attempt was made to contact the 
authors.  
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3.2.2.2. Study selection 
Titles and abstracts of all initial hits were screened by one reviewer (the PhD candidate, KB). When 
necessary, consultation with a second reviewer (the promotor, QL) was pursued. All potential full 
texts were subsequently screened by these two reviewers, and eligibility criteria were applied 
independently. Any discrepancies regarding eligibility were discussed between reviewers to reach 
consensus. 
3.2.3. Data collection and analysis   
3.2.3.1. Methodological quality appraisal 
One reviewer (the PhD candidate) appraised the methodological quality of each included study using 
the National Institutes of Health (NIH) Quality Assessment tool for Observational Cohort and Cross 
Sectional Studies.259 The tool is designed to aid appraisal of internal validity (potential risk of 
selection-, information-, or measurement bias, or confounding) of cross-sectional and cohort studies 
and was therefore appropriate for this review. It comprises 14 criteria. All criteria can be answered 
as "yes", "no", "cannot determine", "not applicable" or "not reported". All responses other than "yes" 
indicate risk of bias. Inherent to the design, cross-sectional studies automatically score "not 
applicable" on criteria 6, 7, 10 and 13. After all 17 articles were scored by the first reviewer, two of 
these were randomly selected for audit and independently scored by a second reviewer (the co-
promotor, LM). The scores assigned by each reviewer were compared by specifically discussing 
those criteria with discrepant scores. Consistent discrepancies were noted specifically for criteria 6, 
10 and 13 for both studies – which were resolved after agreeing that these criteria should be scored 
as “not applicable” as per the instrument’s instructions. Resultant total scores were similar; thus, it 
was not deemed necessary for the second reviewer to score the remaining 15 articles as well. Each 
criterion was weighted equally in the overall grading, and studies were not excluded based on quality 
score, due to the expected dearth of information.  
3.2.3.2. Data extraction 
Data extracted from each study were summarised using a customised Excel spreadsheet, based on 
Cochrane forms. Information about sample demographics as well as the study aims, study design, 
known confounders to gait and balance, descriptors of HIV-disease, gait or balance analysis tool or 
test used, specific objective gait or balance outcomes, dose-response evidence, associations with 
treatment, associations with disease severity, association of peripheral neuropathy, findings and 
limitations of each study were extracted. Principle summary measures were means and standard 
deviations (SD). 
Stellenbosch University  https://scholar.sun.ac.za
 45 | P a g e  
 
3.2.3.3. Data analysis or synthesis 
Narrative description of data was done using text summaries or tables as appropriate. For outcomes 
that were reported in at least two studies, a meta-analysis was conducted in Revman version 5.2, 
provided that homogeneity in the outcomes and samples existed regarding units of measurement, 
test conditions, gender and disease severity. Mean differences and 95% confidence intervals (CI) 
were calculated via a random effects model, provided that means and SD were reported; these were 
presented graphically as forest plots. Symptomatic (presenting with various symptoms of chronic 
HIV disease) and asymptomatic (asymptomatic HIV infection/clinically latent phase of HIV) 
subgroups of PLHIV were analysed. 
3.3. Results 
3.3.1. Study selection 
The initial search in March 2016 produced 799 total hits (Figure 3.1). After removing duplicates and 
applying eligibility criteria, 93 potential titles remained. Thirty studies were subsequently excluded 
upon reading the abstracts. The main reasons for exclusion were that the outcome measures were 
not relevant to the review question, participants were not within the specified age range, and study 
design was inappropriate. Following full text review, the number of studies for inclusion was reduced 
to 17. Primary reasons for exclusion were inability to obtain full text, ineligible participants, no raw 
data and outcomes that were not relevant to the review question.  
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Figure 3.1. PRISMA flow diagram of literature search and selection process. 
 
3.3.2. Study characteristics 
3.3.2.1. Critical appraisal of study quality 
Table 3.1 presents the methodological quality appraisal scores of the included studies, which ranged 
from fair to poor. A mean score of 40.34% was obtained, ranging from 7.14% (lowest internal validity 
amongst the included studies) to 57.14% (strongest internal validity amongst the included studies).  
3.3.2.2. Study sample description 
Participant numbers varied from 19 to 447. Six studies did not include a control group.2,3,55,59,121,260 
Mean ages ranged from 28.0 to 54.7 years. Two studies included males only.121,261  Only one study51 
was conducted in Sub-Saharan Africa. Table 3.2 summarises the sample characteristics of all 
participants, while HIV-specific sample characteristics are presented in Table 3.3. 
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TI = non-nucleoside reverse transcriptase inhibitor; N
R
 = not reported; N
R
TI = nucleoside reverse 
transcriptase inhibitor;  N
R
x = no treatm
ent; PG
L = P
ersistent generalized lym
phadenopathy; P
I = protease inhibitor; P
N
 = peripheral neuropathy; S
D
 = Standard 
D
eviation; S
X
 = sym
ptom
atic; U
SA
 = U
nited States of A
m
erica; W
R
 = W
alter R
eed stages. 
*R
etrospective control group of healthy volunteers from
 previous study. #M
edian (IQ
R
). 
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Table 3.3. Sample characteristics: people living with HIV-1 infection (PLHIV). 
Study ID Disease staging CD4 cell 
count, 
cells/mm3 
(SD) 
Viral load (SD) Treatment 
Trenkwalder 
1992114 
WR I-II (N=17); WR 
III-V (N=19); WR VI 
(N=14)  
NR NR NR 
Arendt 
1994115 
CDC II (N=12); CDC 
III (N=12); CDC IV 
C1 (N=5); CDC IV 
C2 (N=5); CDC IV D 
(N=2); CDC IV B 
(N=10) 
NR NR NR 
Beckley 
1998262 
ASX (N=2); CDC 
Stage A (N=2); CDC 
Stage B (N=2); CDC 
Stage C (N=3) 
Range 65 - 
701; 
5 participants 
had AIDS-
defining CD4 
counts (<200) 
NR Most were on 
zidovudine 
maintenance therapy 
Bauer 200530 NR NRx: 351(282); 
NNRTI: 
457(375); PI: 
320(200) 
HIV burden x 
1000 copies/ml: 
NRx: 93.8 
(163); NNRTI: 
35.5 (102); PI: 
20.1 (48.2) 
NRx: N=28; NNRTI: 
N=25; PI: N=37 
Simmonds 
200549 
Based on CD4 
count 
ASX (CD4>200) 
(N=52); AIDS 
(CD4<200) (N=48) 
 
Range 189.83 
(183.27) 
 -  386.36 
(302.39) 
Virions: 
ASX 33 545.25; 
AIDS 193 
401.00 
 
NR 
Dellepiane 
2005263 
CDC classification 
ASX (N=15); AIDS 
(group IV) (N=15)  
NR NR NR 
Scott 2007121 NR 408 (293)  
 
log copies/ml  
2.18 (0.94)  
 
All were on a NRTI-
based regimen, with 
82% receiving a PI 
as a third agent  
 
Richert 
20112 
CDC category C: 
23% 
#520 (348, 
709) 
<500 copies/ml: 
83% 
89%  
Bauer 201132 NR BMI <21: 280 
(52); BMI 21-
29: 422 (40); 
BMI>29: 361 
(64) 
Log10 viral load 
BMI <21: 3.06 
(0.34); BMI 21-
29: 2.19 (0.26); 
BMI>29: 2.08 
(0.39) 
% no ART/NNRTI-
based ART/ PI-
based ART: 
BMI <21: 
38.2/26.5/35.3; BMI 
21-29: 31.7/26.7/ 
41.7; BMI>29: 
37.0/18.5/44.4 
Sullivan 
201133 
NR M 537.4 
(258.97); F 
583.4 (103.55) 
M 13597.6 
(4654.88); F 
HAART: N=25; Non-
HAART: N=6; NRx: 
N=9 
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4609.7 
(3226.36) 
Erlandson 
2012a59 
NR #551 (361, 
768) 
Detectable (≥48 
copies/mL):  
5% 
NR 
Erlandson 
2012b55 
NR 594 (16) 95% had 
plasma HIV-1 
RNA < limits of 
detection 
Any didanosine: 
Non-fallers: 57 (23); 
Single fallers: 10 
(23); Recurrent 
fallers: 24 (36)  
Any stavudine: Non-
fallers: 93 (37) 
Single fallers: 22 
(51); Recurrent 
fallers: 33 (50)  
Efavirenz: Non-
fallers: 86 (34); 
Single fallers: 10 
(23); Recurrent 
fallers: 22 (33)  
Cohen 
2012264 
NR 556.4 (284)   
 
Log10 HIV RNA: 
#3.50 (2.68, 
4.42)  
 
HAART: 76.9%   
 
Beans 
2013261 
NR #445 (265, 
531) 
Non-detectable 
(<400 
copies/ml): 91% 
Majority were 
receiving cART 
Mbada 
201351 
All: Clinical stage I 
of HIV/AIDS (ASX 
HIV infection, with 
PGL) 
NR NR 100% HAART 
Richert 
20143 
CDC stage C 24% #506 (340, 
715) 
HIV RNA level 
<500 copies/ml: 
84% 
89% on ART 
Erlandson 
2014260 
NR 594 (303) HIV-1 RNA < 
limits of 
detection: 95% 
All participants 
taking effective 
cART 
Abbreviations: AIDS = acquired immunodeficiency syndrome; ART = antiretroviral therapy; ASX = 
asymptomatic; BMI = Body Mass Index; cART = combination antiretroviral therapy; CDC = Centre for 
Disease Control; F = female; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency 
virus; IQR = interquartile range; M = male; N = number of participants; NA = not applicable; NNRTI = non-
nucleoside reverse transcriptase inhibitor; NR= not reported; NRTI = nucleoside reverse transcriptase 
inhibitors; NRx = no treatment; PGL = Persistent generalized lymphadenopathy; PI = protease inhibitor; 
PLHIV = people living with HIV; SD = standard deviation; SX = symptomatic; WR = Walter Reed staging. 
# Median (IQR).  
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3.3.2.3. Study design, aims and outcomes 
Sixteen studies were cross-sectional, and one was a prospective cohort.3 Study aims varied (Table 
3.4), but all included objective measurement of balance and/or gait as part of the primary aim. 
Balance was assessed using both clinical and instrumented tests. All studies used timed clinical 
tests for assessing gait. No studies assessed gait kinetics or kinematics. Outcomes varied 
substantially. Table 3.5 (balance) and Table 3.6 (gait) present the outcomes assessed per study. 
Summaries of the results for individual outcomes are presented briefly in Table 3.7 (balance) and 
Table 3.8 (gait), and presented in more detail as additional files to the published document (see 
Addendum N). 
Table 3.4. Aims of included studies. 
Study ID Design Aim 
Trenkwalder 1992114 Cross-sectional To measure postural performance quantitively 
in PLHIV (in different disease stages) versus 
seronegative controls, using a force plate. 
Arendt 1994115 Cross-sectional To determine if stance control is impaired in 
early versus late HIV infection, using a force 
plate, and to compare results with the COG 
patterns in pyramidal or extrapyramidal 
disease. 
Beckley 1998262 Cross-sectional To evaluate postural reflexes with EMG in 
PLHIV without obvious neurological disease, in 
order to determine whether postural reflexes 
are early markers of CNS involvement. 
Bauer 200530 Cross-sectional To assess sensorimotor function in PLHIV and 
seronegative controls. 
Simmonds 200549  Cross-sectional To characterize physical performance in 
PLHIV, and to examine group differences by 
pain and fatigue. 
Dellepiane 2005263 Cross-sectional To investigate whether posturography can 
detect the presence of possible disorders of the 
vestibulo-spinal reflex. 
Scott 2007121 Cross-sectional To determine the extent of neuromuscular 
activation of selected lower limb muscles of 
male PLHIV receiving ART, and its relationship 
to performance in clinical functional tests. 
Richert 20112 Cross-sectional To provide standardized assessments of 
locomotor function in PLHIV, focusing on lower 
limb muscle performance and balance, and on 
potential determinants of functional impairment. 
Bauer 201132 Cross-sectional To compare balance and gait in participants 
who differ in BMI and the presence or absence 
of HIV/AIDS. 
Sullivan 201133 Cross-sectional To investigate whether infratentorial brain 
volume would be marked by regional tissue 
shrinkage in PLHIV versus seronegative 
controls, and whether tissue deficits would be 
related to impairment in postural stability or 
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psychomotor speed, using structural MRI and 
quantitative tests of postural stability, finger 
movement, psychomotor speed and dexterity. 
Erlandson 2012a59  Cross-sectional To compare the FFP, SPPB, and 400-m walk in 
PLHIV.  
Erlandson 2012b55  Cross-sectional To determine fall-rate and -risk factors among 
PLHIV by correlating fall history, medical 
diagnoses, and functional tests. 
Cohen 2012264 Cross-sectional To determine whether PLHIV on HAART had 
an increased prevalence of vestibular disorders 
versus seronegative controls, using standard 
screening tests of vestibular and balance 
function. 
Beans 2013261 Cross-sectional To compare locomotor function in male PLHIV 
versus seronegative controls, and test the 
association with aerobic exercise capacity. 
Mbada 201351 Cross-sectional To compare HRQOL and a performance-based 
measure of functional capacity between a 
homogenous sample of clinical stage I PLHIV 
versus seronegative controls. 
Richert 20143 Prospective cohort To prospectively assess the changes in 
locomotor function in PLHIV over time and to 
evaluate the determinants of variations in lower 
limb muscle performance. 
Erlandson 2014260 Cross-sectional To assess the impact of physical function 
impairments on HRQOL in PLHIV using ART. 
Abbreviations: ART = antiretroviral therapy; BMI = body mass index; CNS = central nervous system; COG 
= centre of gravity; EMG = electromyography; FFP = Fried’s Frailty Phenotype; HRQOL = health-related 
quality of life; PLHIV = people living with HIV; SPPB = Short Physical Performance Battery. 
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 Table 3.5. Studies assessing balance outcom
es. 
 
Trenkwalder 
1992114 
Arendt 
1994115  
Beckley 
1998262  
Bauer 200530 
Dellepiane 
2005263 
Simmonds 
200549 
Richert 20112 
Bauer 201132 
Sullivan 
201133 
Cohen 
2012264 
Erlandson 
2012a59 
Erlandson 
2012b55 
Richert 20143 
Erlandson 
2014260 
Total 
studies 
assessing 
outcom
e 
Balance outcome 
M
ean sw
ay path (m
/m
in) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Sw
ay velocity (m
/sec) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Sw
ay area (µVxs) 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
2
a 
AP 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
LAT 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
AP/LAT quotient 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
2
b 
R
om
berg ratio of sw
ay velocity; 
R
W
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
2
a 
R
om
berg area of sw
ay; R
A 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
W
ay 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
SO
T sw
ay strategy score 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
1 
SO
T EQ
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
1 
SO
T num
ber of falls; tim
e 
before fall 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
1 
FBO
S; LO
S 
 
 
 
X 
 
 
 
X 
 
 
 
 
 
 
2
c 
Latencies of postural reflexes 
(m
s) 
 
X 
X 
 
X 
 
 
 
 
 
 
 
 
 
3
a 
D
uration of postural reflexes 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
Am
plitude of postural reflexes 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
Area of single EM
G
 potential 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
1 
N
orm
alized am
plitude of M
L-
response 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
1 
Standardized LL Z-scores 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
1 
R
om
berg EC
F (sec) 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
1 
Tandem
 stance (sec) 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
1 
Single leg stance tim
e (sec) 
 
 
 
 
 
 
X 
X 
X 
 
 
 
X 
 
4
d 
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Berg balance score 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
1 
TU
G
 tim
e (sec) 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
2
e 
5STS tim
e (sec) 
 
 
 
 
 
 
X 
X 
 
 
 
 
X 
 
3
f 
5STS pace (rises/sec) 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
1 
360° turn tim
e 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
1 
W
alk heel-to-toe (num
ber of 
steps) 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
1 
Forw
ard reach distance (cm
) 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
2
g 
A
bbreviations: 5S
TS = 5-Tim
es S
it-To-S
tand Test; AP
 = average velocity in an anterior-posterior direction; cm
 = centim
eters; E
C
F = eyes-closed-on-foam
; EM
G
 = 
electrom
yography; EQ
 = equilibrium
 quotient; FBO
S = functional base of support; LAT = average velocity in a m
edial-lateral direction; LL = long loop; LO
S = lim
its 
of stability; m
 = m
etres; m
in = m
inute; M
L = m
edium
 loop; m
s = m
illisecond; R
A
 = R
om
berg area of sw
ay; R
W
 = R
om
berg ratio of sw
ay velocity; sec = second; 
S
O
T = S
ensory O
rganisation Test; TU
G
 = Tim
ed-U
p-And-G
o Test. 
aM
eta-analysis perform
ed; bM
eta-analysis not done as A
rendt 1994 does not report S
D
 values; cM
eta-analysis not done as B
auer 2005 does not report values for 
control group; dM
eta-analysis not done due to heterogeneity in m
ethodologies: R
ichert 2011 uses established norm
ative values as com
parison; S
ullivan 2011 
uses m
ax tim
e of 60 sec, R
ichert 2014 has no com
parison values; eM
eta-analysis not done as R
ichert 2014 has no com
parison group; fM
eta-analysis not done as 
R
ichert 2011 &
 2014 has no com
parison groups; gM
eta-analysis not done as R
ichert 2011 uses established norm
ative values as com
parison.  
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  Table 3.6. Studies assessing gait outcom
es. 
 
B
auer 
2005
30 
Sim
m
onds 
2005
49  
Scott 
2007
121  R
ichert 
2011
2 
B
auer 
2011
32 
Erlandson 
2012a
59  
Erlandson 
2012b
55  
B
eans 
2013
261  
M
bada 
2013
51  
R
ichert 
2014
3 
Erlandson 
2014
260  
Total 
studies 
assessing 
outcom
e 
Gait outcomes 
G
ait 
speed 
(m
/sec), 
preferred 
and/or 
fast 
 
 
 
 
X 
X 
X 
 
 
X 
X 
5
a 
Tim
ed 
gait (sec) 
X 
X 
 
 
 
 
 
X 
 
 
 
3
b 
C
adence 
(tim
e in 
sec for 5 
steps), 
fast and 
preferred 
X 
 
 
 
X 
 
 
 
 
 
 
2 
G
ait 
initiation 
tim
e 
(sec), fast 
and 
preferred 
 
 
 
 
X 
 
 
 
 
 
 
1 
6M
W
D
 
 
 
X 
X 
X 
 
 
 
X 
X 
X 
 
6
c 
A
bbreviations: 6M
W
D
 = 6-M
inute W
alk D
istance; m
 = m
etre; sec = second. 
aM
eta-analysis not possible as B
auer 2005 did not report m
ean results for gait speed and R
ichert 2014 included no com
parison group or norm
 values. bM
eta-
analysis not possible as B
auer 2005 did not report m
ean for gait speed and E
rlandson 2012a, 2012b &
 2014 included no com
parison groups or norm
 values. 
cO
nly 4 out of 6 studies included in m
eta-analysis, as R
ichert 2011 &
 2014 included no com
parison groups or norm
 values (note heterogeneity betw
een sam
ples 
of the 4 studies included m
eta-analysis). dM
eta-analysis not possible, as B
auer 2005 did not report m
ean results for cadence or gait initiation tim
e.  
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 Table 3.7. Sum
m
ary of objective balance outcom
es and results. 
Study ID 
R
esults 
M
ethod of m
easurem
ent 
O
utcom
es assessed 
Trenkw
alder 1992
114 
a, b 
4 conditions on force plate: Bilat 
stance EO
 + stable; Bilat stance EC
 
+ stable; Bilat stance EO
 + foam
; 
Bilat stance EC
 + foam
. 
M
ean sw
ay path (m
/m
in): EO
 & EC
 + foam
b (all PLH
IV except W
R
 I-
II) / EC
 + stable or foam
b (all PLH
IV) / All other conditions
a 
A
rendt 1994
115 
a, b 
2 conditions on force plate: Bilateral 
stance EO
; Bilateral stance EC
. 
Sw
ay velocity (m
/sec) b / AP/LAT quotient a  
B
eckley 1998
262 
a, b 
Leg reflexes elicited in participants 
w
hile standing upright on m
ovable 
force plate - surface EM
G
 recordings 
obtained from
 left tibialis anterior and 
m
edial gastrocnem
ius 
O
nset latencies (SL, M
L and LL) (m
s) / N
orm
alised am
plitude of M
L
a 
/ LL-am
plitude scaling (predictable
a; unpredictable
b) 
B
auer 2005
30 
a, b 
1) SO
T, 3 conditions: EO
, EC
, 
inaccurate visual input 
2) Forw
ard/backw
ard lean tests  
3) (Single-leg stance test) 
1) SO
T, for each condition: EQ
 (EO
a, EC
b, inaccurate
a) / N
um
ber of 
falls
a / Tim
e before a fall (seconds) a 
2) FBO
S (Lean am
plitude/foot length
b 
3) (Single Leg Stance tim
e (s) - results not presented) 
Sim
m
onds 2005
49 
a 
Loaded forw
ard reach 
U
nloaded forw
ard reach  
D
istance reached (cm
) a 
R
ichert 2011
2 
a, c 
1) BBS 
2) TU
G
 test 
3) FR
 test 
4) SLS, EC
 
5) 5STS 
1) Berg score
a 
2) TU
G
 tim
e (sec) a 
3) R
each distance (cm
) a 
4) SLS tim
e (sec) c 
5) 5STS tim
e (sec) c 
D
ellepiane 2005
263 
a, b 
1) Static posturography: R
om
berg’s 
position on force plate; EO
 & EC
 
2) D
ynam
ic posturography: EO
 & 
EC
; leg reflexes elicited via sudden 
tilts of m
oveable force plate, EM
G
 
recorded  
1) Static: 
W
ay (EO
 & EC
, SX
b), Area, AP (ASX in EC
b, SX in EO
b & EC
b), LAT 
(SX in EC
b), AP/LAT
a, R
W
, R
A
b  
2) D
ynam
ic (SL, M
L and LL): 
Latency (SL: EO
 & EC
, all H
IV groups
b) (M
L: EO
, SX, both legs
b; EO
, 
ASX, left leg
b; EC
, all groups
a) (LL: EC
, SX
b; EC
, ASX
a) / D
uration 
(SL: EO
, all PLH
IV
a; EC
, SX, left leg
b) (M
L: EO
, all PLH
IV
a; EC
, all 
PLH
IV, bilat b) (LL, EC
, all PLH
IV
b) / Am
plitude
a /Area of single EM
G
a 
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 B
auer 2011
32 
a, b 
1) SO
T, 3 conditions: EO
, EC
, 
inaccurate visual input 
2) Forw
ard/backw
ard lean tests 
3) SLS test  
4) 360-degree turn test  
5) 5STS test  
1) SO
T: D
ependent variables calculated for each condition w
ere: 
   EQ
 (EC
b, inaccurate input b) 
   Sw
ay strategy score (EC
b) 
2) LO
S (lean am
plitude/foot length) b 
3) SLST tim
e (seconds) (only obese PLH
IV, non-preferred leg
b) 
4) 360 deg turn tim
e (seconds) (only obese PLH
IV
b) 
5) 5STS tim
e (seconds) a 
Sullivan 2011
33  
a, b 
W
alk-a-Line Battery. C
onditions: 
Stand H
eel-to-Toe; W
alk H
eel-to-
Toe; and SLS. 
1)  Stand H
eel-to-Toe tim
e (seconds) a 
2) SLS tim
e (seconds) (non-preferred leg
b) 
3) W
alk-H
eel-to-Toe - num
ber of steps out of 10 (EC
b) 
C
ohen 2012
264  
c 
R
om
berg tests on stable and on 
foam
, 4 conditions: EO
 + stable, EC
 
+ stable, EO
 + foam
, EC
 + foam
. 
R
om
berg tim
e, EC
 + foam
 (seconds) c 
Erlandson 2012a
59 
c 
Tandem
 stand and 5STS as part of 
SPPB 
5STS tim
e (part of SPPB score) † / Tandem
 stance tim
e (part of 
SPPB score) c 
Erlandson 2012b
55  
c 
Tandem
 stand and 5STS as part of 
SPPB 
5STS tim
e (part of SPPB score) c / Tandem
 stance tim
e (part of 
SPPB score) c 
R
ichert 2014
3 
c 
1) 5STS test 
2) TU
G
 test 
3) SLS test 
1) 5STS tim
e (seconds) c 
2) TU
G
 tim
e (seconds) c 
3) SLS tim
e (seconds) c 
Erlandson 2014
260 
c 
5STS 
5STS pace (rises/second) c 
A
bbreviations: 5S
TS = 5-Tim
es-S
it-To-S
tand; A
P
 = A
verage velocity in anterior-posterior direction; AS
X
 = asym
ptom
atic; B
B
S = B
erg B
alance S
cale; B
ilat = 
bilateral; C
O
P
 = centre of pressure; deg = degree; E
C
 = eyes closed; E
M
G
 = electrom
yography; E
O
 = eyes open; E
Q
 = equilibrium
 quotient; FBO
S
 = 
functional base of support; FR
 = functional reach; LA
T = average velocity in m
edial-lateral direction; LL = long loop; LO
S
 = lim
its of stability; M
L = m
edium
 
loop; P
LH
IV
 = people living w
ith H
IV
; R
W
 = R
om
berg index reported to w
ay = ratio of w
ay w
ith E
O
 &
 E
C
; R
A = R
om
berg index reported to area = ratio of 
area w
ith E
O
 &
 E
C
; S
L = short loop; S
LS
 = single leg stance; SO
T = S
ensory O
rganisation Test; S
X
 = sym
ptom
atic; TU
G
 = Tim
ed-U
p-A
nd-G
o. 
O
utcom
es included in m
eta-analyses are not included in this table. 
a no significant difference betw
een P
LH
IV
 and controls. b P
LH
IV
 significantly im
paired com
pared to controls or norm
ative reference values. c N
o com
parison 
provided/im
pairm
ent quantified by reporting proportion of P
LH
IV w
ith deficits.  
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Table 3.8. Summary of objective gait outcomes and results. 
Study ID Results Method of assessment Spatiotemporal outcome 
Bauer 
200530 
a 8-m walk (preferred and 
fast) 
Gait speed: time (sec) to cover distancea 
Cadence (time in sec for 5 steps)a 
 
Simmonds 
200549 
b 50-foot (15.24-m) walk 
(preferred and fast) 
 
Gait speed: time (sec) to cover distanceb 
 
Scott 
2007121 
b 6MWD Distance covered (m) in 6 minb 
Richert 
20112 
c 6MWD Distance covered (m) in 6 minc 
Bauer 
201132 
b 8-m walk (preferred and 
fast)   
Preferredb and fast gait initiation time 
(sec) 
Fastb and preferred gait speed (m/sec) 
Fast and preferred cadence (time in sec 
for 5 steps) 
Erlandson 
2012a59 
c 4-m walk as part of SPPB  
400-m walk (fast) 
Only presented as part of SPPB score 
Gait speed (m/sec)c 
Erlandson 
2012b55 
c 1) 4-m walk as part of 
SPPB 
2) 400-m walk (fast) 
1) Only presented as part of SPPB score 
2) Gait speed (m/sec)c 
Beans 
2013261  
a, d 1) 6MWD 
2) 400-meter long distance 
corridor walk 
1) Distance covered (m) in 6mina 
2) Gait speed: time (sec) to cover 
distanced 
Richert 
20143 
b 1) 6MWD 
2) 10-m walk 
1) Distance covered (m) in 6minb 
2) Gait speed (m/sec) 
Erlandson 
2014260 
c 400-m walk (fast pace) Gait speed (m/sec)c 
Abbreviations: 6MWD = Six-minute walk distance; m = metres; min = minutes; sec = seconds; SPPB = short 
physical performance battery. 
Outcomes included in meta-analyses are not included in this table. 
a No significant difference between PLHIV and controls. b PLHIV significantly impaired compared to 
controls or normative reference values. c No comparison provided/impairment quantified by reporting 
proportion of PLHIV with deficits. d Controls performed worse. 
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3.3.3. Static balance 
Five studies assessed static balance using clinical tests. One study264 assessed Romberg 
eyes-closed-on-foam and found the frequency of impairment to be higher in PLHIV. Tandem 
stance time was normal in PLHIV.33 Four studies assessed single leg stance time.2,3,32,33  
Impairments were noted either only with eyes closed, or with synergistic obesity, or when 
standing on the non-preferred leg (eyes open and closed).  
One study114 assessed COP sway path using a force plate, and found the incidence of 
increased values to be  larger in advanced stages of infection and task difficulty. Sway velocity 
was examined by another study.115 A significant increase was found in neurologically 
symptomatic PLHIV regardless of visual condition, and about 25% of PLHIV with 
asymptomatic HIV infection also demonstrated increased values.  
Average velocity in anterior-posterior (AP) and average velocity in lateral (LAT) directions were 
assessed by one study.263 PLHIV with asymptomatic HIV infection had significantly increased 
AP only in the eyes closed condition, while PLHIV with symptoms of chronic HIV disease had 
significantly increased AP both with eyes open and eyes closed, as well as significantly 
increased LAT (only with eyes closed). 
Two studies115,263 assessed the coefficient of the preferential direction of movement (AP/LAT 
ratio) and found this to be normal in PLHIV. Romberg ratio of area (RA) as well as Way 
(average velocity of movement) was found to be increased in all HIV groups.263 
Sensory Organisation Test (SOT) sway strategy score was found to be lower (which is worse, 
as it indicates more reliance on the hip strategy as opposed to the ankle strategy) for bilateral 
stance (eyes closed) in PLHIV.32 Two studies32,113 reported on SOT Equilibrium Quotient (EQ) 
and reported significant impairments in PLHIV during the most difficult SOT subtests (eyes 
closed or inaccurate visual input).  
Meta-analyses (Figures 3.2 and 3.3) were performed for postural sway area.115,263 With eyes 
open, asymptomatic PLHIV and controls had similar sway areas, while PLHIV with symptoms 
of chronic HIV disease demonstrated a significant increase. Overall, sway area was 
significantly increased in PLHIV (combined group of those with and without symptoms of HIV). 
With eyes closed, PLHIV with asymptomatic HIV infection had normal sway areas, while 
PLHIV with symptoms of chronic HIV disease demonstrated a significant increase. Overall, 
sway area was increased in PLHIV. 
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Thus, the observed overall strength of association for treatment in the combined group differed 
across the different subgroups. Homogeneity seems to exist between the sample estimates 
within the subgroups (I2 = 0.00% for all groups), while a significant interaction existed between 
the subgroups (I2 = 86.40% & 87.90% for the two outcomes, respectively), suggesting that the 
population parameters estimated by the subgroups are different. It should however be noted 
that the conjecture about homogeneity between sample estimates in these subgroup does not 
necessarily mean that the presence/absence of symptoms in PLHIV fully explains the 
heterogeneity observed across studies. In fact, the small number of studies and sample sizes 
for these outcomes might not provide adequate statistical power in demonstrating 
heterogeneity. 
 
Figure 3.2. Meta-analysis of sway area (µVxs) in PLHIV, eyes open. 
 
Figure 3.3. Meta-analysis of sway area (µVxs) in PLHIV, eyes closed. 
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A meta-analysis (Figure 3.4) was done for Romberg ratio of sway velocity (sway with eyes 
closed/sway with eyes open).115,263 PLHIV with asymptomatic HIV infection had normal values, 
while PLHIV with symptoms of chronic HIV disease demonstrated a significantly larger 
Romberg ratio (which is worse as it indicates a higher amount of visual dependency). Overall, 
Romberg ratios were similar between the combined group of PLHIV and controls. 
Substantial heterogeneity was found within the combined group (I2 = 88.00%, p = 0.004 and 
I2 = 91.00%, p = 0.00001, respectively). When splitting the subgroups according to presence 
of symptoms, PLHIV with asymptomatic HIV infection still showed evidence of high 
heterogeneity and non-significant results regarding impairment, while symptomatic PLHIV 
produced no evidence of heterogeneity (I2 = 0.00%) whilst showing significant impairment for 
this outcome.  
The high heterogeneity that exists particularly in the asymptomatic subgroup of PLHIV might 
be attributed to differences in the study populations used by the two studies. Differences 
existed in the sample sizes used (36 asymptomatic PLHIV in Arendt et al115 versus only 15 in 
Dellepiane et al.263). Also, the age of the asymptomatic participants in these studies differed 
(mean of 36.33 versus 28.00 years). Finally, although both studies had similar definitions of 
“symptomatic” participants, only Arendt et al.115 further classified the asymptomatic group into 
CDC disease stages.  
 
Figure 3.4. Meta-analysis of Romberg ratio of sway velocity in PLHIV. 
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3.3.4. Dynamic balance 
Both the Berg Balance Scale (BBS)2 and Timed-Up-And-Go (TUG) test2,3 were normal in 
PLHIV. For Five-Times Sit-To-Stand (5STS) time, one study32 found no group differences, 
while another2 reported poor performance in PLHIV. The prospective cohort3 reported an 
impaired 5STS time at baseline, and that 31% of PLHIV had a decline in performance over 
one year that was greater than the empirically defined threshold. Only PLHIV who were also 
obese performed worse in the 360-Degree-Turn test.32 Walk-Heel-To-Toe was significantly 
impaired in PLHIV with eyes closed.33 Two studies2,49 evaluated forward-reach distance, with 
no significant deficits noted.  
The Functional Base of Support (FBOS) or Limits of Stability (LOS) tests were assessed by 
two studies32,113; both reported significant impairments in all PLHIV. 
Duration of postural reflexes was assessed by one study.263 With eyes closed, there was a 
significant reduction for medium loop (ML) duration and long loop (LL) duration in all HIV 
groups. Amplitude of postural reflexes and area of single electromyography (EMG) potential 
were normal in PLHIV.263 Neurologically intact PLHIV showed abnormal regulation of postural 
reflexes (LL amplitude scaling) under unpredictable, but not predictable, perturbations.262 
Meta-analyses were conducted for postural sway latencies115,262,263 (Figures 3.5 to 3.9). For 
the left leg (only specified as the non-dominant leg in one study33), short loop (SL) latencies 
for combined PLHIV groups were normal, with significantly increased values only in PLHIV 
with symptoms of chronic HIV disease upon further analysis. These findings were similar for 
the right leg. ML latencies, only assessed in two of the studies262,263 and only for the left leg, 
were significantly increased in combined PLHIV groups. In both legs, LL latencies were 
significantly increased in symptomatic, but not asymptomatic, PLHIV. The combined PLHIV 
group still showed a significant increase in LL latencies.  
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Figure 3.5. Meta-analysis of left leg postural reflex latencies in PLHIV: short loop 
latencies (ms). 
 
 
Figure 3.6. Meta-analysis of left leg postural reflex latencies in PLHIV: medium loop 
latencies (ms). 
 
 
Figure 3.7. Meta-analysis of left leg postural reflex latencies in PLHIV: long loop 
latencies (ms). 
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Figure 3.8. Meta-analysis of right leg postural reflex latencies in PLHIV: short loop 
latencies (ms). 
 
 
Figure 3.9. Meta-analysis of right leg postural reflex latencies in PLHIV: long loop 
latencies (ms). 
 
3.3.5. Gait  
Gait speed was assessed in eight studies.3,32,49,55,59,113,260,261 PLHIV demonstrated slowing of 
fast gait speeds.49,55,261 One study113 found no significant differences between PLHIV and 
controls, regardless of pace. 
Meta-analysis49,51 (Figure 3.10) indicated that Six-Minute Walk Distance (6MWD) was 
significantly shorter (worse) in PLHIV compared to controls. The likelihood of high 
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heterogeneity in this meta-analysis should be considered (I2 = 65.00%, p = 0.09) and might be 
due to the use of historical controls in one study49 and differences in disease staging between 
the two studies. Among the un-pooled studies, three reported a decreased (worse) 
6MWD,2,3,121 and one study found no impairment in PLHIV.261 One study reported no 
impairments in PLHIV in cadence113 and another reported that only PLHIV who were also 
obese were significantly impaired.32 This study also reported that PLHIV had significantly 
delayed (worse) normal gait initiation time.  
 
3.3.6. Falls 
One study262 reported that fall incidence during unpredictable perturbations was similar in 
PLHIV versus controls. Similarly, another study113 found no group differences in falls during 
SOT conditions. In contrast, one study reported a similar fall rate in middle-aged PLHIV (mean 
52 years) and seronegative older adults (≥65 years).55 Impaired balance was a major 
associated factor. In addition, recurrent fallers had significantly slowed gait versus non-fallers. 
Furthermore, in a prospective cohort,3 it was reported that 12% of PLHIV experienced a 
minimum of one fall in the previous year. In PLHIV with recurrent falls, baseline 5STS time 
and 6MWD were significantly impaired, compared to non-fallers. 
3.3.7. Measurement conditions and task difficulty 
Twelve studies included some form of increasing task difficulty, such as different visual input, 
stable versus unstable support surfaces, decreased base of support, predictable and 
unpredictable external perturbations, and walking at preferred versus fast gait speeds. Of 
these, nine (75%) demonstrated that both balance and gait impairments were more evident in 
more difficult task conditions, when comparing PLHIV to controls.32,33,49,55,59,113,114,262,264 
Figure 3.10. Meta-analysis of 6-Minute Walk Distance (m) in PLHIV. 
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3.3.8. Disease severity 
Fifteen studies reported on the relationship between HIV-disease severity and locomotor 
performance. Of these, eight (53%) indicated a relationship between HIV-disease severity and 
impairments.2,59,113–115,121,262,263 In contrast, seven studies (46%) found no significant 
differences based on CD4+ counts or viral loads.3,32,33,49,261,262,264 
3.3.9. Treatment association 
Seven studies reported on the relationship between ART and impairments in gait and/or 
balance, and none of these found any association.2,3,32,33,59,113,121 
3.3.10. Peripheral neuropathy 
Five studies reported on the association between peripheral neuropathy and impairments in 
gait and/or balance in PLHIV, and none of these found statistically significant correlations 
between peripheral neuropathy and impairments of gait, dynamic balance or static 
balance.2,33,113–115 
3.4. Discussion   
The aim of this review was to establish the current state of knowledge regarding objective 
impairments of gait and balance in PLHIV, and to emphasise those which could contribute to 
increased fall risk. To the authors’ knowledge, this is the first work to do so. The findings 
indicate that certain aspects of gait and balance are impaired in middle-aged PLHIV, 
resembling those proven to predict increased fall risk in elderly populations.  
The methodological quality of articles ranged from fair to low, partly as a direct consequence 
of observational design. Earlier studies in particular had a high risk of selection bias due to 
omitting important information such as participant demographics and exclusion criteria. The 
psychometric properties of the different tests used to assess outcomes have not yet been 
evaluated in PLHIV; therefore, they cannot be assumed to be valid and reliable in this specific 
population. Balance and gait in PLHIV may be influenced by various factors apart from HIV-
status. Although studies on average controlled and adjusted for many key confounders such 
as age, gender, BMI, markers of HIV and co-morbidities, very few reported on covariates such 
as level of education or adherence to treatment, and none on level of physical activity. 
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Various gait and balance parameters, including slowed gait speed,255 cadence,265 slowed gait 
initiation time,266 slowing of postural reflexes,267 and increased COP displacement and 
velocity268 have been established to be associated with increased risk of falls in the elderly. 
Similarly, some of these variables are associated with risk of falls in PLHIV, namely slowed 
gait speed and impaired dynamic balance.55 It has been reported that the best fall risk 
predictors in PLHIV are those proven to be predictors of fall risk in the elderly.55 
3.4.1. Static balance 
Static balance is often quantified in terms of COP movement,269 which reflects neuromuscular 
control to keep the COM within the base of support’s limits of stability.270–272 Increased COP 
movement and velocity is associated with increased fall risk in the elderly.268 In this review, 
evidence of increased postural sway or velocity was found in all studies evaluating these 
parameters, especially under challenging conditions,114,115,263 and was confirmed by meta-
analyses. Impaired COP sway in PLHIV with asymptomatic HIV infection may suggest early 
involvement of postural control due to direct infection of the CNS by HIV. However, in 
neurologically symptomatic PLHIV, it cannot be assumed that anatomical structures or direct 
HIV-involvement of the CNS causes the observed deficits.114 Lower limb muscle impairment 
might impair a person’s ability to correct a shift in the body's COP to effectively prevent a 
fall.273 In the elderly, it has been proposed that increased COP movement may be interpreted 
as an increase in hip abductor muscle activity to control postural stability on the medial-lateral 
direction.273 It has also been suggested that decreased postural control with larger body sway 
increases tibialis anterior/soleus muscle co-activation, inducing the hip-strategy to preserve 
balance.274 Greater co-activation may be partly be a compensation for decreased lower limb 
muscle strength and power.275 As lower limb muscle impairments occur in PLHIV, this might 
contribute to the impaired COP parameters observed. HIV-associated vestibular dysfunction 
has also been reported.276 Vestibular disorders have a deleterious effect on postural 
stability277. However, vestibular conditions are not characterised by impaired COP excursion, 
but rather by an increased frequency of movement, indicating poor control of COP.277 
A lower sway strategy score (the relative amount of high-frequency ankle versus low-
frequency hip movement) for bilateral stance with eyes closed was found in PLHIV, albeit only 
reported in a single study in this review,32 indicating a greater reliance on the hip-strategy. In 
the general population, individuals without balance impairments will change their balance 
strategy from the normally employed ankle strategy, to relying on the hip strategy270 when 
faced with more challenging conditions. Individuals with impaired balance, who already rely 
more heavily on the hip strategy, are less able to adapt to challenging conditions.270 
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The SOT Equilibrium Quotient (EQ) is a calculation of the average COP sway, with lower EQ 
scores having been associated with increased fall risk in the elderly.278 The two studies 
evaluating this outcome32,113 reported significantly lower EQ scores in PLHIV, especially with 
more challenging conditions.  
Reduced single leg stance time is predictive of some (i.e. injurious), but not all, falls in the 
elderly279; however, the clinical value of this test might be called into question. The test might 
suffer from learning effects,280 leading to possible ceiling effects even in individuals with 
substantial impairment when only performed as a clinical test. Due to differences in the 
reporting of results among the included studies assessing this outcome, it is difficult to draw 
conclusions regarding impairment and the value of the test in PLHIV.  
3.4.2. Dynamic balance 
Dynamic balance is often assessed using dynamic posturography, which involves external 
perturbations being induced while a person tries to maintain an upright posture.270 A common 
postural synergy in this scenario is the distal-to-proximal ankle strategy, involving a short loop 
(SL) and medium loop (ML) response in the gastrocnemius, followed by a long loop (LL) 
response in the tibialis anterior.281,282 Prolonged stance-stabilising LL responses have been 
documented in elderly fallers.283 Meta-analyses indicated that LL latencies were increased in 
symptomatic but not asymptomatic PLHIV, and upon combining all groups of PLHIV, LL 
latencies were still significantly increased. It is suggested that the early-observed prolonged 
LL latencies in PLHIV with asymptomatic HIV infection may indicate alterations in the central 
dopaminergic system (basal ganglia, caudatus nucleus and nigrostriatal system).263 
Scaling of LL latency-amplitude, referring to the ability to adjust the size of postural stabilising 
reflexes and another important factor associated with falls,267 was assessed in one study.262 
Neurologically intact PLHIV showed abnormal postural reflex regulation under unpredictable, 
but not predictable, perturbations. Under random conditions, PLHIV automatically selected a 
LL response of a relatively similar size to one needed for medium perturbations. This response 
may not be sufficient to correct for large perturbations, leading to an increased risk of falling. 
However, the authors noted that the impairment in PLHIV was “mild” and did not appear 
clinically significant in early HIV infection.  
The Limits of Stability (LOS) or Functional Base of Support (FBOS) test involves instrumented 
measurement of a forward leaning task and evaluates voluntary control of the center of gravity 
(COG).  Instrumented LOS or FBOS, unlike the clinical Functional Reach test,2,49 was impaired 
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in PLHIV.32,113 Similarly, the Functional Reach test has been proven not to be an indicator for 
differentiating elderly fallers from non-fallers,284 while instrumented LOS is an early indicator 
of increased fall risk in the elderly.285 These observations may be attributable to the differences 
in the task involved in the clinical versus the instrumented tests (although both assesses 
LOS).285 
The 5STS test is an indicator of dynamic balance. Impaired performance was noted in two of 
the three studies evaluating this outcome.2,3 In addition to impaired central sensorimotor 
components being proposed to play a role,3 impaired 5STS time also implies poor lower limb 
muscle performance, which is associated with falls and disability both in HIV-seronegative 
elderly populations and in middle-aged PLHIV.2,55 Low appendicular muscle mass is prevalent 
in PLHIV and associated with functional impairment.120 However, a decline in the ability of 
muscles to produce strength and power (dynapenia) might have a bigger contribution to 
functional decline in the elderly and is associated with poor chair-rise-time.123 Intra-muscular 
impairments, including fatty muscle infiltration, and low central activation are reported in 
PLHIV121,124,125 and premature expression of genes associated with muscle aging is 
upregulated in PLHIV.127 Grip strength might correlate with dynapenia in the elderly,286 and an 
accelerated decline in grip strength has been reported in PLHIV.287 
Owing to the dichotomous assessment by clinical tests of the ability to maintain standing 
balance, such tests only detect impaired balance once compensation strategies fail.270  
Selection of effective compensation strategies to restore balance (especially by persons who 
are physically active), might hide impairments, potentially hampering the use of such tests in 
active individuals or at an early stage of disease.270 Level of physical activity was not assessed 
by any studies included in this review; ceiling effects in the results provided by the clinical 
balance tests can therefore not be excluded.  
Although more suited to quantification of balance, interpretation of the results of instrumented 
posturography is complex. Generally, an increase in COP movement is assumed to reflect 
impaired balance; but this may not be true.288,289 Due to the interdependent relationship of the 
underlying systems, selection of an alternative compensation strategy to maintain stance 
could lead to observation of either increased or decreased COP movement, which in fact 
would reflect optimal balance control.270 Second, altered COP movement can result from 
deterioration of several underlying systems. Thirdly, COP movement is affected by training 
and learning effects, for example, individuals (and even more so those trained in sports)  might 
be able to maintain a position very well, despite severe system deterioration, due to becoming 
familiar with the task or using selecting proper strategies for efficient compensation.270 Results, 
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especially from singular studies, must thus be considered cautiously and in the context of the 
assessment protocol, e.g. number of trials, and participant characteristics, such as activity 
level.  
3.4.3. Gait 
In this review, PLHIV exhibited impaired fast, but not preferred, gait speeds, despite being on 
successful HAART.32,49,59,260 PLHIV who were also recurrent fallers, had an even slower fast-
paced gait.55 Gait speed is reported as a predictor of falls in geriatric populations, with a linear 
relationship between slow gait speed and increased fall risk often assumed.250,290,291 However, 
a non-linear relation has also been proposed.255 Growing evidence show that gait and 
cognition, specifically attention and executive function292 are interrelated. Neurocognitive 
decline occur in HIV,6,25,293–295 is in part associated with reduced dopaminergic function,296 and 
has been associated with slow gait speeds in this population.297 Executive function, motor 
skills and attention/working memory are some of the domains that are affected by HIV.298 Gait 
slowing is suggested to be an adaptive mechanism to prevent falls, to the effect that a slow 
gait speed might actually be associated with a reduced fall risk.255 
Six-Minute Walk Distance, which is actually an indicator of functional aerobic capacity, has 
been shown to correlate well with gait speed.299 Meta-analyses of two studies49,51 suggests 
decreased 6MWD, and thus decreased gait speed under fast conditions, in PLHIV. Six-Minute 
Walk Distance was also reported to be decreased in PLHIV in the majority of un-pooled studies 
assessing this outcome2,3,121 – however all of these studies used predicted values from the 
literature. This is of concern, as community-specific or cultural factors influence gait speed.261 
Gait initiation time was reported to be significantly slowed in PLHIV, albeit data from a single 
study.32 Gait initiation time has been associated with increased fall risk in the elderly.266 
Cadence, which also has an association with gait speed and falls in the elderly,300 was 
assessed by two studies,32,113 but owing to contradicting results, no firm conclusions can be 
drawn.   
3.4.4. Measurement conditions and task difficulty 
Evaluating performance under conditions of varying difficulty can provide more “real-life” 
insight into the quality of the specific underlying sensory systems.270,301 Studies assessing 
balance included in this review employed different sensory conditions, eliminating or disturbing 
the information of three main sensory systems. These included variations in visual input, 
different base-of support sizes and variations in support surfaces. For dynamic balance 
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assessments, perturbations of varying amplitudes and predictability were induced using 
platform tilts. There was an overall tendency of PLHIV to perform similar to controls in easier 
conditions, and significantly worse with increased task difficulty. A correlation between static 
balance deficit and eyes closed conditions was demonstrated by clinical as well as 
instrumented tests.32,113,263 Unstable conditions with eyes closed showed the greatest 
abnormalities in postural balance.114,264 Sullivan et al.33 found impaired performance among 
PLHIV during clinical tests involving reduced base of support. Postural reflex synergies also 
appear to be task-dependent. Unpredictable perturbations resulted in worse dynamic balance 
performance.262 It thus seems that PLHIV may have impaired response to unexpected 
perturbations or more complex tasks, predisposing them to falls. In the case of impairment of 
any of the systems contributing to postural balance, alternative compensation strategies are 
used by an individual to maintain postural control and orientation.270,302 Sensory reweighting 
comes into play, i.e. the nervous system will rely on more accurate sensory input, rather than 
less accurate, conflicting information303. Individuals relying more on one particular balance 
system are thus less able to adapt to situations where input to that system is disturbed, and 
have to rely on only the remaining systems.270 This sensory reweighting seems impaired in 
PLHIV. Also, impaired dual-task performance has been demonstrated in PLHIV,186 although 
none of the included studies assessed this condition. 
All gait tests in included studies were conducted on level, unobstructed walkways. During 
walking, many falls occur not during normal walking, but rather when negotiation challenging 
terrains. Results might have been more clinically relevant had irregular or unfamiliar surfaces 
been assessed, especially since dynamic balance in PLHIV seem to be more impaired under 
challenging circumstances. However, both self-selected and fast gait speed conditions were 
evaluated, with group differences mostly found when comparing fast gait. It has been 
suggested that walking at different speeds likely influences both the noise level in human 
motor performance as well as dynamic error corrections.236 Thus, impairments at fast paced 
conditions may indicate deficits under more challenging conditions.  
3.4.5. Disease severity  
A dose–response relationship between HIV disease severity and locomotor impairment was 
suggested in 53% of studies. In addition, subgroup analyses highlighted impairments in 
postural reflex latencies that were inconspicuous in a combined group of all PLHIV, but 
became apparent in only those with symptoms of chronic HIV disease when compared to 
controls. However, methodologically it remains a challenge to attribute observed differences 
between PLHIV and controls directly to HIV infection, as evident from the discussion thus far. 
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Comparison populations most likely always differ in terms of many confounding factors.2 It 
cannot be assumed with certainty that observed impairments are purely related to severity of 
HIV infection, and the contribution of various comorbidities and opportunistic infections should 
be considered. This is especially true for the older studies, where eligibility criteria did not 
control for various confounders and comorbidities.  
3.4.6. Treatment associations: antiretroviral therapy (ART), 
combination antiretroviral therapy (cART) or highly active 
antiretroviral therapy (HAART) 
The majority of studies reporting on treatment associations failed to find significant 
relationships with balance or gait outcomes in PLHIV, regardless of the different combinations 
of drugs (terms used for combination use of ARV including ART, cART or HAART). Thus, 
antiretroviral therapy does not appear to be significantly associated with impairments in 
locomotor function.  
3.4.7. Peripheral neuropathy 
None of the five studies reporting on the association between peripheral neuropathy and 
locomotor impairments found any significant relationships. A possible explanation for balance 
abnormalities among PLHIV, at least for those parameters measured by the included studies, 
might thus indicate involvement of the central rather than peripheral nervous system.2,33,113–115 
The fact that eyes closed conditions were often necessary to elicit group differences in 
balance, further motivates CNS dysfunction as an underlying mechanism.113 It is reported that 
deficits in infratentorial brain tissue volume and disruption of the pontocerebellar fibre system 
microstructure, at least in part, may contribute to locomotor impairments in PLHIV.33 It can, 
however, not be concluded with certainty that no association exists between gait or balance 
and peripheral neuropathy in PLHIV. It is possible that peripheral neuropathy adversely affects 
gait and balance parameters that were not measured in these studies. For example, 
impairments in joint kinematics (assessed by none of the included studies in this review) have 
been associated  with peripheral neuropathy in Type 2 diabetic patients.112 
3.4.8. Implications for future research 
While the importance of identifying spatiotemporal deficits is acknowledged, the associated 
kinematic and kinetic data can provide more insight into underlying mechanisms of the 
observed impairments. Some locomotor impairments related to early functional decline might 
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be too small to be detected by visual observation alone in the clinical setting.265,304 These 
subtle impairments may however have substantial consequences for the individual. Thus, 
there is a need for more robust quantitative assessment, such as three-dimensional 
biomechanical motion analysis. Dual tasking should also be evaluated in PLHIV to assess the 
subtler changes in function, as well as more challenging gait assessment conditions. 
Furthermore, a need exists for higher quality research. Carefully selected, representative 
samples will make results more homogeneous, relevant and generalisable. In addition, 
valuable information can be extracted from the geriatric literature that is likely to inform 
research in PLHIV, especially with regards to data on falls and specific movement 
impairments. This should be further explored, and the psychometric properties of both 
instrumented and clinical gait and balance assessments should be determined specifically in 
PLHIV. Lastly, we found the lack of studies conducted in Sub-Saharan Africa, the epicentre of 
the HIV epidemic, surprising. More research is needed in developing countries to address this 
gap. 
3.4.9. Review limitations  
Language bias is likely in this review, as only studies published in English were considered. 
Another limitation of the review is that only two included articles were appraised by more than 
one reviewer, meaning that fifteen of the seventeen articles were scored for methodological 
quality by only one reviewer. In addition, ceiling effects might have hampered results from 
clinical tests. No studies in this review measured COM movement, with a subsequent 
incomplete representation of balance in PLHIV at present. Results of this review should be 
interpreted with caution as substantial statistical heterogeneity existed between the included 
studies, albeit expected, as evident in the meta-analyses (indicated by high I2 values). Due to 
the small number of studies per outcome, all sources of heterogeneity could not be accounted 
for, but some possible explanations for variation in results have been discussed. Clinical 
heterogeneity was evident in the majority of studies, particularly in terms of setting, sample 
sizes, age groups, gender distributions, and HIV-staging. A wide variety of study outcomes 
and measurement methods were used. Given the paucity of research on existing impairments 
and the optimal method of evaluating these in PLHIV, the wide variation in assessment tests 
used was to be expected. Although the diversity in populations, especially regarding disease 
definition and subgroups, might seem surprising, it must be kept in mind that HIV classification 
systems have evolved substantially since the earliest included study and that HAART regimes 
did not yet exist in those earlier periods. Furthermore, publication- and reporting biases are 
suspected in this review, due to many authors collaborating on different papers and the same 
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populations possibly used in different studies. However, formal assessment using funnel plots 
was not possible due to the low number (<10) studies assessing a similar outcome.  
3.4.10. Chapter summary 
This review found that young to middle-aged PLHIV have impairments in certain aspects 
of gait and balance, which are similar to those that predispose elderly seronegative 
populations to falls. The impairments are more pronounced during challenging 
conditions, might be associated with HIV disease severity, are not influenced by ART, 
and might not necessarily be associated with peripheral neuropathy. Results should be 
interpreted with caution due to the overall fair to low methodological quality, substantial 
heterogeneity and many outcomes being assessed by singular studies only. The effect 
of HIV on gait and balance parameters, and in particular biomechanical outcomes, are 
currently insufficiently quantified and this review provides a first step to inform future 
research. Further investigation involving more methodological uniformity is warranted to 
better identify and understand relevant locomotor impairments in PLHIV. Only then can 
more clinically relevant conclusions, such as appropriate strategies for fall-prevention in 
this population, be drawn. 
The next part (Part II) of the dissertation sought to ascertain the validity and reliability of 
a newly-acquired portable three-dimensional gait analysis system for measuring 
custom-defined gait analysis outcomes. Gait assessment was the major focus of this 
dissertation, given the large gap in knowledge and the fact that gait outcomes were also 
to be used in calculating summary score to validate selected clinical tests (Chapter 7).  
Based partly on the results from this review, four traditional centre of pressure (COP) 
metrics were also chosen for evaluation of postural stability (excursion and velocity, in 
two movement directions). Given that these were not complex measures, and since the 
motion laboratory was already in possession of a validated pressure mat that has been 
widely used in clinical practice and research, the psychometric properties of the mat 
were not assessed in these participants, as there was no reason to doubt its validity and 
reliability. 
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PART II 
Establishing validity and reliability for clinically 
relevant gait analysis outcomes in a South 
African population including people living with 
HIV-1 infection 
Preface 
In this dissertation, gait biomechanics were quantified in people living with HIV-1 infection 
(PLHIV) relative to seronegative participants (SNP) using a newly acquired commercial inertial 
motion capture (IMC) system. Due to its portability and ease-of-use, such a system overcomes 
many of the accessibility constraints associated with laboratory-based gait analysis. This 
system offered a pragmatic solution for translating state-of-the-art gait analysis research into 
a rural clinical setting. 
 This methodology required an evidence-based approach to data collection, variable definition 
and extraction and data interpretation. Three-dimensional optical stereophotogrammetry (from 
here on forth referred to simply as “optical motion capture” [OMC]) is currently considered the 
gold standard in instrumented gait analysis305 and was thus employed as a reference standard 
in the process of establishing a set of valid, reliable, clinically relevant 3DGA outcomes that 
could be measured in-field with the IMC system.  
Part II of the dissertation subsequently presents two primary interlinked validity and reliability 
studies, spread over three chapters (Chapters 4 to 6, see Figure below). The first set of testing 
was performed in healthy volunteers recruited from the university setting to explore the 
system’s validity and reliability for measuring basic gait analysis outcomes. Following this, the 
second set of testing involved participants recruited from a rural community (including PLHIV) 
and a more clinically-orientated gait analysis. This was done to ascertain validity and reliability 
(including measurement error) specific to the population and outcomes used in the main study 
of this project (Chapters 7 to 8). As much of the methodology between the first and second 
studies overlap, Chapter 4 presents the combined methodology – indicating relevance to the 
specific study where necessary. Chapters 5 and 6 respectively present the results of the first 
and second validity and reliability studies. 
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Introduction to the validity and reliability studies 
Over recent years, developments in nano- and microprocessor technologies, computing and 
digital signal processing have led to extensive technological advances in Micro-
Electromechanical Systems (MEMS) and resulted in the development of miniaturised portable 
inertial motion capture (IMC) systems.189 These systems are based on small yet powerful 
integrated circuits called Inertial Measurement Units (IMUs), which typically comprise of on-
board tri-axial gyroscopes, magnetometers and accelerometers.189 
IMC systems are increasingly used for 3DGA in research and clinical settings.189 Despite 
providing high quality data and remaining the golden standard in motion capture technology,  
the appeal of OMC in clinical care is hampered by several issues such as high costs, 
requirement for expert operation, lengthy and cumbersome setup and post-processing 
procedures, the problem of marker occlusion and limited ecological validity due to capture 
volumes being restricted to laboratory settings.204 Since such systems present a barrier to 
access to clinicians as well as patients, a growing need has arisen for a more pragmatic 
alternative that is better suited to in-field use. Relative to OMC, IMC systems are compact, 
 
 
 
PART II 
Lab-based research –
validity and reliability of 
IMC system  
 
 
 
Defining a valid set of 
specific biomechanical 
gait outcomes with known 
measurement error.  
 
 
 
Figure Part II Preface. Schematic layout of the structure of Part II of the dissertation. 
IMC = inertial motion capture; PLHIV = people living with HIV-1 infection; TSPs = 
temporal and spatial parameters. 
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portable, affordable and user-friendly; increasing clinical appeal. Using sensor fusion 
techniques, the ability of inertial measurement units (IMUs) to accurately track orientation has 
become advanced, with tracking accuracies of ±1° being reported.306,307 
The increasing appeal of IMC-use has behoved researchers to further assess the validity and 
reliability of such systems, and good performance has been demonstrated for specific 
protocols in healthy participants and patient groups.308–312 The underlying assumptions and 
body models associated with testing accuracy and reliability in healthy participants only may 
not necessarily hold true in pathologic conditions or participants from different communities, 
as gait characteristics can be varied by anthropometric, racial and cultural factors.209 Similarly, 
validity and reliability proven in people living with a specific condition may not be the same for 
other pathologies. Recent recommendations for standardising validity testing protocols for 
body-worn motion capture devices emphasise the importance of demonstrating validity and 
reliability in the specific population of intended use.313 Measurement error should thus be 
determined for both healthy participants and patients, to improve the quality of data collection 
and interpretation; failing to do so may result in misdiagnosis and misinterpretation of clinical 
impairments and biomechanical gait data.313 
Data acquired from IMC are known to suffer from various error sources which may reduce 
their accuracy of analysis. Although theoretically, the motion data measured by IMUs (once 
processed using relevant algorithms) can estimate important information including orientation, 
rotation, acceleration and distance, challenges remain in utilising IMUs for quantifying human 
motion patterns in practical scenarios. Schwartz et al.313 proposed classifying the potential 
sources of error as being of intrinsic (occurring naturally via intra-session or inter-participant 
variability) or extrinsic (due to experimental errors and subject to quality control) origin. Intrinsic 
errors cannot be reduced but should at least be quantified as a comparison baseline, whereas 
extrinsic variation may be improved by addressing the underlying methodological sources. 
Besides natural intra- and inter-individual gait variability (intrinsic variability), it is important to 
consider the various potential extrinsic error sources during participant preparation, data 
collection (e.g. anatomical frame calibration errors, soft tissue artefact [STA]), data processing 
(such as definition of foot contact events) and data interpretation (for example, according to 
the system-specific biomechanical model).308,314 IMUs suffer from time-increasing drift in the 
presence of magnetic disturbances (e.g. induced by ferromagnetic material), necessitating 
controlled test protocols and efforts to avoid such disturbances whenever possible (as this drift 
may affect the accuracy of orientation measures by the magnetometer).189 IMC systems track 
the angular position of coordinate systems on the body relative to north and gravity (roll, pitch 
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and course). Joint/segment kinematics can thus be calculated using body segment-mounted 
IMUs, but due to an inability to measure absolute skeletal position kinematics (i.e. linear 
position in space), initial calibration is required to determine the heading of the body relative 
to magnetic north and to compensate angular offset between IMU- and segment axes. Only 
after model calibration can estimates of translation be made via mathematical techniques.315 
Various IMC calibration approaches exist, ranging from static single- or double-poses, to 
dynamic functional calibrations.189 Single-poses, involving determination of IMU orientations 
relative to a reference posture,189 are often utilised by commercial IMC systems such as the 
myoMOTION (the system used in this research), as they are quick and easy to implement. 
Importantly, differences in joint segment definitions mean that OMC biomechanical models 
typically demonstrate angular offsets from the assumed IMC reference neutral pose (N-pose). 
Although IMC ROM and movement patterns do not seem to be significantly affected, absolute 
values are often not directly comparable between systems/models.189,308,316 N-pose accuracy 
and repeatability may be compromised by skeletal alignment constraints and instructor skills 
in setting up the posture, and errors introduced during calibration may affect subsequent 
kinematic measurements. Clearly, such errors need quantification in order to make clinical 
sense of IMC output. 
The reliability and concurrent validity of IMC systems likely depend on the combination of IMUs 
and biomechanical model. Confirming the validity and reliability of IMC to investigate human 
locomotion is imperative to future applications outside of the laboratory. At present, no 3D 
motion analysis system is available that can non-invasively and exactly reflect the orientation 
of the underlying bone.317 Results from available systems should thus adequacy exceed the 
measuring error to provide clinically meaningful results. For instrumented motion capture, 
absolute errors of less than of 5° has been proposed as reasonable.318 
The current research used different instrumented outcome measures to assess gait and 
balance in PLHIV, including a pressure mat (for balance), and the newly-acquired 
myoMOTION system (for gait). At the stage of its acquisition, the myoMOTION was the first 
of its kind in South Africa and offered potential enhanced performance,319 portability and a 
user-friendly interface relative to other IMC systems available at the time. The system 
presented a promising opportunity to extend 3D gait analysis to outside the laboratory and 
without the presence of a laboratory engineer. Although the MatScan pressure mat has 
previously been validated for measuring COP data during a single-leg stance task,320 and used 
for balance assessments in South African populations321 as well as proven useful for 
assessing COP data from single leg stance tasks in PLHIV,322–324 the myoMOTION system 
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has not been previously validated in a South African population or for the gait outcomes of 
interest in the current research. Considering that the speed and pattern of gait is dependent 
on anthropometrics, community and culture,325 it is important that 3DGA systems are validated 
in the same or similar populations as the intended future study population.313 
The purpose of the following two studies were therefore to determine the concurrent validity 
of the myoMOTION IMC system, using the VICON OMC system as the reference standard, 
and the within-session reliability of the myoMOTION – first in a set of healthy volunteers, and 
subsequently in a population including PLHIV and recruited from a rural area in the Cape 
Winelands of South Africa. Absolute reliability of the outcomes in the population of interest 
would indicate the change required (in degrees or in the relevant measurement units) to 
exceed measurement error for gait outcomes used in the evaluation of gait deviations in 
PLHIV. 
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  PART II 
 
METHODOLOGY: VALIDITY AND RELIABILITY 
STUDIES ONE AND TWO 
Two validation and reliability studies were conducted in a sequential fashion, so as to have 
findings from Study One refine the hypotheses and practical aspects of Study Two. 
4.1. Aims and objectives: Study One 
4.1.1. Aim 
The first study aimed to determine the concurrent validity and within-session reliability of 
clinical gait analysis outcomes measured by the myoMOTION system, using optical motion 
capture (OMC) and the VICON-Plug-in-Gait (PiG) biomechanical model as reference 
standard. 
4.1.2. Objectives 
1. To establish concurrent validity for the myoMOTION system by determining whether 
differences in average kinematic joint/segment angles across the gait cycle would 
fall below a 5° minimum clinically important difference (MCID) when comparing 
kinematic angles using (i) direct myoMOTION output and (ii) after removing offsets 
between the myoMOTION and VICON-PiG models, in a sample of healthy, able-
bodied volunteers. It was hypothesised that differences would exceed the MCID for 
direct comparisons, and fall below it for model-corrected comparisons. 
2. To determine whether within-session reliability of the myoMOTION-model-based 
average joint/segment kinematic angles across the gait cycle would fall below a 5° 
MCID, using six repeated gait trials. 
3. A secondary outcome was to use VICON-PiG to quantify the accuracy and 
repeatability of a calibration N-pose as set up by a trained instructor, as a source of 
extrinsic error potentially affecting gait outcomes. 
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4.2. Aims and objectives: Study Two 
4.2.1. Aim 
Study Two expanded the findings of Study One in a sample recruited from a rural community 
(the same that would be accessed for the main study in Chapter 7), including PLHIV and 
seronegative participants (SNP). The aim was to explore whether similar levels of concurrent 
validity and within-session reliability to that achieved in healthy volunteers, can also be 
achieved when assessing clinically relevant gait outcomes in a community-specific cohort 
including PLHIV and SNP from the Cape Winelands District, Western Cape, South Africa.  
4.2.2. Objectives 
1. To establish concurrent validity for the myoMOTION system by determining whether 
differences in joint/segment kinematic ROM and discrete angles would fall below a 
5° MCID when comparing angles using (i) direct myoMOTION output and (ii) after 
adjusting for offsets between the VICON-PiG and myoMOTION models in a sample 
of PLHIV and SNP. It was hypothesised that differences in discrete angles would 
exceed the MCID for direct comparisons, and fall below it for model-adjusted 
comparisons, while angular ROM differences would remain unchanged and below 
the MCID regardless of model adjustment. 
2. To establish concurrent validity for the myoMOTION system by determining whether 
differences in temporal, spatial, temporophasic and temporospatial gait parameters 
(TSPs) would fall below the relevant MCID for each when comparing TSPs using 
direct myoMOTION output to VICON-PiG outcomes in a sample of PLHIV and SNP. 
It was hypothesised that differences in TSPs would be minimal and display excellent 
percentage errors (<5%). 
3. To determine whether intra-session reliability of joint/segment kinematic ROM and 
discrete angles measured by the myoMOTION would fall below a 5° MCID, using 
six repeated gait trials. 
4. To determine whether intra-session reliability of TSPs estimated by the myoMOTION 
would fall below a 5% percentage difference, using six repeated gait trials. 
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4.3. Ethical considerations 
Study approval was granted by the Stellenbosch University (SU) Human Research Ethics 
Committee (HREC, N15/05/043) (Appendix A) (Studies One and Two) and the Western Cape 
Department of Health (WC_2016RP10_878) (Appendix B) (Study Two). Written informed 
consent was obtained from all participants in their preferred language prior to data collection 
(separate forms for the two studies) (Appendices D and E). 
4.4. Study design 
Both studies followed an observational design, incorporating an agreement and offset 
component for concurrent validity testing and a within-session repeated measures 
observational component for reliability testing. A single testing session was conducted per 
participant. Study Two forms part of the sub-study (i.e. this PhD project) to a larger longitudinal 
cohort being conducted by the SU Department of Physiological Sciences/Division of Medical 
Physiology (Section 4.7.2 provides further details of the overhead study; here on forwards 
referred to as only the “EndoAfrica” study). 
4.5. Study setting 
Data collection for both studies was performed in the SU Central Analytical Facilities (CAF) 
3D Human Biomechanics Unit, Tygerberg Medical Campus, Cape Town, South Africa, where 
the VICON system is hosted. For Study One, participants were responsible for their own 
transport to and from the test facility. For Study Two, participants were transported between 
Worcester and Tygerberg campus using official SU transport services. 
4.6. Sample size 
Sample size was based on the standard error of measurement (SEM) for lower limb kinematic 
angles across the gait cycle, considering an SEM of 4.1°.326 This was the maximum SEM (hip 
rotation) reported across tri-planar lower limb angular ROM in a healthy population during 
habitual walking. An MCID of 5° is suggested for lower limb gait kinematics.327 To establish 
that a measured SEM of 4.1° is lower than 5° at a one-sided 95% confidence interval, the 
recommendations by Stratford and Goldsmith328 were followed. The variance ratio	#$%&%' was 
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calculated as #(.*%+.,%' = 1.5. Using Table 7 in Stratford and Goldsmith328 the required sample 
size was estimated for a protocol using four to six measurements per participant: a sample 
size of nine to 15. For Study One, 16 participants were recruited to increase precision and to 
allow for any data loss due to technical failure or invalid trials. For Study Two, sample size 
was restricted by pragmatic constraints including the limited and targeted participant pool and 
the fact that participants had to be transported approximately 94 km between the laboratory 
and the town of Worcester. Thus, a limited sample comprising both PLHIV and SNP could be 
accommodated and a convenience sample of 16 adults (eight PLHIV and eight SNP) was 
deemed practical.  
4.7. Study population and sample 
4.7.1. Study One 
The sample population comprised of able-bodied, HIV-seronegative adults (students and staff) 
from the SU Tygerberg Medical Campus, Cape Town, South Africa. This population was 
considered appropriate to facilitate an initial and technical investigation of measurement error 
between systems in an easily accessible population with normal motor function and minimal 
gait variability, as well as the assessment of variability on repeat measures of the same 
individuals,  
4.7.2. Study Two 
Study Two investigated how the instruments compare in the same population being accessed 
for the cross-sectional field study, which meant accessing the same population as the 
overhead EndoAfrica study. The EndoAfrica study is a prospective, longitudinal cohort of 
PLHIV and SNP followed in community health care centres (CHC) and/or HIV clinics of the 
Cape Winelands District, Western Cape Province, South Africa. The cohort aims to determine 
whether HIV-1 infection and antiretroviral therapy (ART) are associated with alterations in 
cardiovascular risk and in vascular endothelial structure and function. The EndoAfrica study 
was initiated in April 2015 and includes male and female adults aged ³ 18 years; excluding 
females who are pregnant, or less than three months post-partum. Details of the EndoAfrica 
protocol have been described in detail elsewhere.329  
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4.8. Eligibility criteria 
4.8.1. Both studies 
Participants were eligible for the study if they were: 
1. Adults (aged 18 to 65 years). The upper age limit was based on the observation that, 
in the general population, gait changes associated with ageing become more prevalent 
in adults older than 65.330 
2. Had a BMI < 25kg/m2. This criterion was introduced to limit the effects of soft tissue 
artefact (STA) on gait measures. Subcutaneous tissue movement influences the data 
captured by markers or sensors applied to the skin and this is less likely with lower 
BMI ranges.331 In addition, evidence suggests that a higher BMI is a confounder to gait 
and balance impairments in PLHIV, whereas this is not the case for lower (including 
underweight) BMI ranges.32 
3. Were independently ambulant (without any walking aids). 
4. Were able to consent and participate in all study procedures. 
Participants were excluded if they: 
1. Were pregnant (if female). 
2. Had an acute illness. 
3. Suffered from any neuromusculoskeletal impairments or injury that might affect gait. 
4. Had a history of seizures, mental retardation, head injury, stroke, epilepsy, cerebral 
palsy or other major neurological conditions. 
5. Had used alcohol on the day of testing. Acute alcohol consumption has a known 
detrimental effect on locomotor performance.332 
4.8.2. Specific to Study One 
For study One, in addition to the criteria listed above, participants had to have their HIV 
serostatus confirmed as HIV-seronegative via a blood test (see Section 4.9.1.1. below). 
4.8.3. Specific to Study Two 
For Study Two, in addition to the criteria listed above, participants had to fulfill the following 
criteria: 
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1. For the HIV-1 seropositive group, participants had to be included in the EndoAfrica 
cohort with a confirmed diagnosis of HIV-1 infection (via blood test). In accordance 
with the field study criteria (Section 7.6.2), PLHIV were included regardless of HAART 
use. The systematic review presented in Chapter 362 found that gait and balance 
impairments are not likely associated with HAART use. 
2. For the HIV-seronegative group, participants had to be HIV-seronegative adults from 
the same community as the HIV-1 seropositive group (either EndoAfrica participants 
or not). Gait pattern and speed is dependent on community, anthropometrics and 
culture325; therefore, in order to make valid extrapolations, study groups need to 
originate from the same population as the population of intended future use (hence the 
decision to extend the testing in healthy volunteers from the university, to healthy 
participants recruited from the Worcester community). It was considered unlikely that 
differences would exist between EndoAfrica participants and non-participants, as the 
same research nurse recruited all participants in the same manner used for the 
EndoAfrica study. Once screened for the present study by the research nurse, and 
after agreeing to blood tests, those individuals who did not already have their status 
confirmed as part of the EndoAfrica study, were counselled by the research nurse and 
a rapid HIV test (SD Bioline HIV 1/2 3.0 immunochromatographic test kit; Standard 
Diagnostics, Republic of Korea) was performed at the CHC to confirm their status as 
seronegative. 
4.9. Sample recruitment 
4.9.1. Study One 
Convenience sampling was used to recruit sixteen HIV-seronegative participants from the SU 
Tygerberg Medical Campus. A letter of invitation was e-mailed to each university department, 
as well as to student class representatives, an advertisement was placed in the Faculty 
newsletter, and flyers were posted on university notice boards. The first 16 consecutive 
individuals who showed an interest to participate were sent a follow-up e-mail with detailed 
study information (informed consent form) as well as a checklist with eligibility criteria. One 
potential participant had to be excluded due to a BMI > 25 kg/m2, and thus the next volunteer 
on the list was contacted. If an individual was deemed potentially eligible, a convenient date 
and time for a brief interview for screening and explanation of the study procedures was 
agreed upon. Potential participants were made aware of the need for HIV testing, and after 
signing the informed consent form in person, was referred to Campus Medical Services to 
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undergo the blood test (see Section 4.9.1.1). All those referred for testing had a result negative 
for HIV-1-infection. Subsequently, for each participant, a date and time for testing was agreed 
upon. A reminder text message and e-mail were sent to each participant the day before the 
scheduled data capturing session. All participants received compensation for time or 
discomfort caused in the form of a supermarket gift voucher. 
4.9.1.1. HIV testing 
Linked confidential HIV testing was implemented to confirm participants’ HIV-status as HIV-
seronegative. Specific written informed consent for HIV-testing was obtained from each 
potential participant as part of the study consent form. Participants were specifically alerted to 
this clause in the informed consent form and any questions or concerns were addressed. HIV 
screening was performed only after the potential participant signed the informed consent form. 
Testing was done at the Tygerberg Campus Health Services (CHS), situated in the student 
centre on Tygerberg Campus, by a qualified medical nurse. Appropriate pre- and post-HIV-
test counselling was offered to participants. A rapid HIV blood test (blood sample via finger 
prick) was performed. Should a potential participant, who was unaware of his or her status, 
have tested HIV-seropositive, they would have been excluded from this study (as stipulated 
in the informed consent form) and referred to Tygerberg CHS for ongoing psychosocial 
support and medical care. This was however not necessary for any of the potential 
participants. 
Linked testing involves linking the HIV test results with the individual tested and allows them 
to receive his or her results.333 A unique study code was assigned to every participant, which 
was linked to personal identifying information. Thus, while the HIV result was linked to the 
participant’s name via the unique study code, the participant remained anonymous to all but 
the testing nurse and the researcher (PhD candidate). After the linked confidential HIV testing 
was performed, the test result was given to the participant. This procedure of confidential (as 
opposed to anonymous) HIV-testing was a necessary step, as any potential participant who 
may have tested HIV seropositive would have had to be excluded from the study by the 
investigator. 
4.9.2. Study Two 
A convenience sample of 16 adults (eight PLHIV and eight SNP) was recruited from 
Worcester.  Participants were enrolled from a local CHC in Worcester, making use of a shared 
(with EndoAfrica study) Health Professions Council of South Africa (HPCSA)-registered 
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research nurse. Participation in the laboratory-based study was proposed to potential 
participants by the research nurse, who also performed eligibility screening. For the HIV-1 
seropositive group, participation was proposed consecutively to individuals already 
participating in the EndoAfrica study (until eight suitable participants were identified). For the 
HIV-seronegative groups, current participants in the EndoAfrica study were similarly 
approached; however, due to a lack of available HIV-seronegative EndoAfrica participants at 
the time, individuals from the local community and attending the CHC were also invited to 
participate by the research nurse. The same strategy was used as for recruiting control 
participants for the EndoAfrica study. Study information was provided, including the need for 
HIV-testing as part of the eligibility criteria. Following the explanation of study information and 
once the participant signed the informed consent form, participants with unconfirmed 
serostatuses were counselled for HIV testing and screened for HIV infection using a rapid HIV 
test (SD Bioline HIV 1/2 3.0 immunochromatographic test kit; Standard Diagnostic, Republic 
of Korea). Should this test have been found positive, the individual would have been excluded 
from the study, counselled and managed further at the HIV clinic – however, this was not 
necessary for any of the screened participants. Following confirmation of a negative HIV-
serostatus, enrolled participants’ availability during the testing period was confirmed; this was 
also done at the time of enrolment for the HIV-seropositive EndoAfrica participants. The most 
convenient dates and times for transport to Tygerberg Medical Campus and testing was 
agreed upon and participants received a card with the date and time to report to Worcester 
CDC for transport to Tygerberg Medical Campus. The PhD candidate, assisted by the 
research nurse in Worcester, arranged for participants to be transported by a University 
vehicle to the SU Tygerberg Medical Campus. For those with mobile phones, a reminder text 
message was sent the day before the scheduled data capturing were to take place. 
Participants were transported to the motion laboratory using official SU transport services (in 
groups of two to four, depending on participants’ availability) and received a light lunch as well 
as compensation for time and inconvenience in the form of a grocery store gift voucher.334 
Figure 4.1 illustrates the eligibility criteria and recruitment of participant groups in Study Two  
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Figure 4.1. Sample recruitment and eligibility criteria for Study Two. 
 
4.10. Instrumentation 
Data were collected concurrently at 200 Hz using an eight-camera OMC system (MX T-series, 
VICON Motion Systems Limited) and a seven-IMU IMC system (myoMOTION Research Pro, 
Noraxon USA Inc.). Gait events were detected for VICON outcomes using a time-
synchronised, floor-embedded force plate (Model FP9060-15, Bertec Corporation) and for 
myoMOTION using an IMU-based algorithm provided by the system software 
(myoRESEARCH 3.10.64). The reference and index systems are presented in more detail in 
the following two sections. 
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4.10.1. VICON optoelectronic motion capture system (reference 
standard) 
The VICON OMC system (MX T-series, VICON Motion Systems Limited, Oxford, UK) was 
used to concurrently collect the same data as the myoMOTION index system, thus serving as 
reference standard in both studies. OMC systems, along with the Conventional Gait Model 
(CGM; commercially implemented as the Plug-in-Gait [PiG] model by VICON) are often used 
as a ‘‘gold standard’’ in human motion analysis. This is due to the accurate positional 
information provided by OMC systems and the fact that the CGM constitutes the most widely 
used and validated biomechanical model in clinical research.335 The VICON has previously 
demonstrated high validity and reliability,336 with a measurement error of less than 1.5°.337,338 
The high-resolution, high-speed VICON cameras are specifically designed for motion tracking. 
The VICON T-series uniquely combines high-speed accuracy and resolution; possessing a 
resolution of 1-mega pixels, capturing 10-bit grey scale images using 1120 × 896 pixels, and 
having the ability to capture speeds of up to 250 frames per second. The system uses the 
multiple synchronised cameras to reconstruct body posture and provides body segment 
position (origin) and orientation (axis directions) relative to a global fixed coordinate system 
(GCS).189  
VICON motion tracking is marker-based, utilising passive skin markers (coated with a 
retroreflective material) to reflect infra-red light that is generated near the observing cameras’ 
lenses, back to the various cameras. The markers are placed on pre-specified anatomical 
landmarks of the body segments to be tracked. The three-dimensional position of a marker 
can be calculated once it is visible to two cameras at the same point in time. By estimating the 
coordinates of individual markers and using triangulation, the 3D position of a participant can 
be modelled within a virtual motion capture volume between at least two cameras calibrated 
to provide overlapping projections.339 The cameras are calibrated relative to a ground-fixed 
reference frame to obtain their position; this is done using an inanimate calibration object with 
markers attached at pre-defined positions. For motion analysis, at least three markers must 
be attached to the same rigid body segment to enable tracking of the angulation of that 
segment’s technical frame within the reference frame.339 VICON Nexus software (Nexus 1.8.5) 
automatically determines the centre of each marker and reconstructs their position in the GCS; 
a process typically accomplished in less than seven milliseconds.337 
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This research made use of eight infrared tripod VICON T-20 cameras (Figure 4.2, left) with 
Nexus 1.8.5 software. The system captured 200 frames per second at 200 Hz. Passive retro-
reflective markers with a diameter of 9.5 mm were used (Figure 4.2, right) and biomechanical 
outcomes were calculated according to the VICON Plug-in-Gait (VICON-PiG) model (using a 
validated lower body modified version of PiG). The VICON capture volume consisted of a 10-
metre walkway (Figure 4.8). Gait events were detected for VICON outcomes using time-
synchronised, floor-embedded force plates (Model FP9060-15, Bertec Corporation, Ohio, 
USA), each sized 0.4 m x 0.6 metres. The Bertec system’s high-resolution provision of gait 
event timing renders it a suitable reference standard for gait event detection.340 
 
 
4.10.2. The myoMOTION system (index system) 
4.10.2.1. Description 
The myoMOTION 3D IMC system (Noraxon USA Inc., Scottsdale, Arizona) is a fully portable 
IMC system comprising a combination of hardware and software which enables human motion 
capturing in three or six degrees of freedom. The system uses a receiver and compact Inertial 
Measurement Units (IMUs) (Figure 4.3 [A]), which are placed on body segments to provide 
3D angular orientation data of that segment. The IMUs are small, lightweight and wireless and 
can be mounted on any segment of the body without using specific anatomical landmarks and 
Figure 4.2. The VICON T-20 infrared cameras used in the laboratory-based studies (left) 
and the passive retro-reflective markers used with the VICON system (9.5 mm diameter) 
(right). 
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without restricting movement. Although individual IMUs are functionally identical, each is 
identified by a unique serial number. Thus, each IMU (serial number) can be assigned to any 
body segment during system configuration. 
 
IMUs are proprioceptive electronic devices incorporating a combination of miniaturised 
sensors: a 3D tri-axial gyroscope (measuring angular velocity or rate of rotation), a tri-axial 
magnetometer (measuring magnetic field vector), and a tri-axial accelerometer (measuring 
acceleration).341,342 The IMUs utilise built-in sensor fusion algorithms to combine 
measurements from these sensors to measure the 3D rotation angles of each IMU in absolute 
space (“yaw-pitch-roll”, also known as orientation or navigation angles). This concept can be 
visualised via an airplane flight manoeuvre (Figure 4.4). By measuring these 3D rotation 
angles, body segment tracking is achieved. Given that IMUs can track the Earth’s gravitational 
and magnetic fields - which constitute universal reference signals343 - an inertial north-east-up 
reference frame can be established anywhere; and since calibration of the capture volume is 
not required, a potentially unlimited capture volume is implied.339  
Figure 4.3. A: A single myoMOTION Inertial Measurement Unit (IMU). Dimensions: 
37.6mm (length) x 52mm (width) x 18.1mm (height); 34 g (weight). B: The myoMOTION 
receiver. 
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Each body segment is mounted with an individual IMU. With proper calibration, the axes of 
the IMU local coordinate system represent a mutually orthogonal and normalised base that 
may constitute the segment technical frame, such that a network of two or more IMUs can be 
used to retrieve data from multiple body segments synchronously and track a multi-segment 
body relative to the same initial reference frame.189 
 
 
The motion-related signals (IMU data) are transmitted wirelessly by a small radio module to 
the Noraxon data acquisition and analysis software (myoRESEARCH 3.10.64 [MR3]) on the 
recording laptop. The software uses these data to construct a scaled full body model (Figure 
4.5, top picture). Segment dimensions of the model are calculated using participant height 
(which is entered by the user into the software) to estimate anthropometric dimensions. The 
IMU data are transformed into segment kinematics within MR3 software using the 
biomechanical model provided (i.e. myoMOTION). The software converts the raw data into a 
readable format and provides the facility of exporting the data in the form of Microsoft Excel 
files (refer to Section 4.12: “Three-dimensional data acquisition and processing”, for further 
Figure 4.4. “Yaw-pitch-roll”: representation of the three Inertial Measurement Unit 
(IMU) coordinate axes used to determine its own orientation in space, visualised as 
an airplane flight manoeuvre. 
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information). Movements can also be viewed in real-time in the software by means of a 3D 
skeletal avatar (Figure 4.5, bottom picture). 
Figure 4.5. Top picture: The full body model viewed in MR3 software. Bottom picture: 
A screenshot showing the graphical interface of the MR3 software, including the 
skeletal avatar for the lower body model, which mimics the participant’s movement in 
real time. 
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For this study, data were collected at 200 Hz using a seven-IMU lower body setup of the 
myoMOTION IMUs. Gait events were detected using an IMU-based algorithm provided by the 
MR3 system software.  
4.10.2.2. MyoMOTION IMU technical performance 
The wireless myoMOTION IMUs have a transmission range of 30 metres and sample rates of 
100 Hz or 200 Hz (depending on the configuration). According to the manufacturers, the IMUs 
are capable of measuring angles with a static accuracy of ±0.4o and dynamic accuracy of 
±1.2°.344 The accuracy of the myoMOTION IMUs was also determined independently in the 
SU CAF motion laboratory during a technical pilot study prior to Study One. The results of this 
experiment demonstrated that static IMU tracking errors were 0.4°±0.2° (inclination) and 
0.8°±0.4° (heading), while dynamic tracking errors were 0.9°±0.2° (inclination) and 2.0°±0.8° 
(heading). 
Gyroscope tracking demonstrates good performance during short-term motions but is prone 
to a time-increasing drift over longer measurement periods. The reason for this is that IMU-
measured signals are inherently characterised by an unpredictable accumulation of low-
frequency random-walk noise during numerical integration.189 IMU sensor-fusion algorithms 
are prone to fail after only a few minutes in the presence of interferences that are continuous 
and time-varying and thus detrimental to the correction of gyroscope drift errors.339 Although 
commercial systems such as the myoMOTION come equipped with drift correcting sensor 
fusion algorithms, it is recommended that when collecting data over extended time periods, 
regular reset of the drift affecting the angular displacement should be done by means of 
recalibrating the system.345  
4.10.2.3. Drift compensation and determination of kinematic joint angle 
estimation 
Calculation of rotational angles and positions by the myoMOTION requires that values from 
the accelerometer, magnetometer and gyroscope be combined. Data from the accelerometer 
and magnetometer are used for initial positional determination, and the gyroscope’s angular 
acceleration value is then integrated to calculate the angle. Any initial offset in the gyroscope's 
output will result in a gradually increasing amplitude drift, which distorts the motion information. 
On the other hand, accelerometers may suffer from noise during movement initiation or 
sudden directional changes. A robust sensor fusion algorithm (Kalman filter) compensates for 
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drift errors that might occur during the numerical integration process and combines various 
elemental sensor component axes readings into four-element vectors called quaternions.345 
By combining sensor outputs, the aforementioned shortcomings are to some extent resolved. 
This mathematical optimisation happens inside the IMU and not at the personal computer 
(PC)-level. The benefit of quaternions is that such data are able to represent all orientations 
without discontinuity, as opposed to Euler angles, which become limited in differentiating 
between some orientations when one of the angles has a value of 90° (called Gimbal lock).339 
Euler angles, which are geometrically more intuitive to interpret, may be calculated from 
quaternion data.339 The quaternion data are automatically converted by the MR3 software into 
anatomical angles using a rigid body model with 16 joint segments (for the full body model) or 
seven segments (for the lower body model as used in this research). Each IMU’s orientation 
angles and linear acceleration data are also recorded by the MR3 software, for later off-line 
use. 
4.10.2.4. IMU orientation and position 
As mentioned above, the information from a 3D accelerometer, gyroscope, and magnetometer 
is used to measure 3D rotation angles of each IMU in absolute space – which is then assumed 
to represent body segment orientation. In contrast to OMC, which provides positional 
information based on marker position and rate of change in position, the myoMOTION system 
directly measures the angular velocity of body segments via each IMU’s on-board tri-axial 
gyroscope. Orientation is determined by mathematically integrating this angular velocity 
signal; that is, angular velocity of the IMU is integrated over time to provide the angular change 
from an initially determined angle.346 The IMUs’ on-board accelerometers are filtered 
simultaneously (at the same time as integration) such that the (downward) gravity vector is 
accurately separated from the IMU’s linear acceleration vector. The drift accumulated during 
the gyroscope integration procedure is then corrected by using this gravity vector, while the 
linear acceleration is utilised as an almost direct metric of segment acceleration. Each IMU’s 
position in the GCS (in relation to the calibrated starting point) is calculated at the IMU level 
by using measurements from both linear accelerometers and the gyroscopes used in 
calculating orientation. 
4.10.2.5. Determining body segment orientation and position 
The lower body myoMOTION biomechanical model used in this research consists of six joints 
connecting seven body segments. Each segment is considered to be a rigid unit with 
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interlinking joints; and a rigid attachment between IMUs and body segments are assumed. 
Therefore, the orientation of each IMU is assumed to represent the orientation of the segment 
that it is attached to. In contrast to these segment orientations, segment position requires 
some calculation with correction of drift errors and limitation of the freedom of movement of 
each IMU relative to its starting position. The myoMOTION assumes segments to form a 
kinematic chain with the pelvis as the segment of reference. Each subsequent proximal 
segment then forms the reference for the segment distal to it. Joint centre positions are 
calculated from the proximal segment reference position, the IMU orientation (representing 
the segment orientation) and the segment length (anthropometrically calculated by the MR3 
segment using the inputted height data for each participant). Statistical constraints are applied 
to limit illogical joint movements such as large varus-valgus knee movement – which may 
occur due to the fact that body segments are not actually rigid units.  For lower body angles 
the underlying Cardan rotation sequence adopted by the myoMOTION follows the 
recommendations of the International Society of Biomechanics (ISB). Considering the knee, 
the rotation sequence is thus flexion, abduction, and rotation. For this study, myoMOTION 
data were thigh-corrected, meaning that the axial rotation of the thigh segment was corrected 
to match the orientation of the shank, so that the resulting knee angles were always pure 
flexion (i.e. restricted to one degree of freedom). 
4.10.2.6. Definition of myoMOTION body model segment axes and polarity 
The myoMOTION system defines anatomical angles according to the rules and regulations of 
the medical neutral/zero method.345 The underlying principle is that in a normal upright 
standing position, all joints are at the zero position, despite possessing an offset angle. An 
example is the ankle joint, which is normally in some degree of dorsiflexion (orientation) during 
upright standing, yet the neutral definition is 0°. 
Each anatomical angle motion is comprised of positive or negative data in the angle curves. 
This polarity of movement is dependent on the plane of motion (Figure 4.6 [left] illustrates the 
three cardinal planes of movement, namely the sagittal, coronal and transverse plane). 
Starting from the neutral zero position, flexion at the knee joint, for example, causes positive 
signals, while extension causes negative signals (Figure 4.6, right). 
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Although the myoMOTION biomechanical model is based on the standards for joint rotations 
sequences as set out by the ISB, some differences in conventions exist regarding polarity. For 
example, the myoMOTION defines positive angular values, depending on the joint/segment 
and axis/plane, as flexion, abduction, external rotation, dorsiflexion, and inversion; whereas 
the VICON-PiG convention defines positive directions as flexion (same as MR), adduction 
(opposite to MR), internal rotation (opposite to MR), dorsiflexion (same as MR) and inversion 
(same as MR). These issues were resolved by manually inverting (“flipping”) the opposing 
angular polarities in myoMOTION output before comparison to VICON data. A description of 
all anatomical angle and polarity definitions, including those myoMOTION polarities that 
needed inversion to match the VICON definitions, is provided in Table 4.1. 
Table 4.1. MyoMOTION/MR3 and VICON-PiG joint definitions and polarities. MR3 data 
were inverted in certain cases to comply with conventional VICON-PiG definitions.  
Axis 
(plane) 
MR 
positive 
direction 
VICON-PiG positive direction MR data 
inverted? Positive angle Definition (PiG convention) 
X (sagittal) Pelvic pitch Pelvic tilt  A positive sign (up) corresponds 
to the normal situation in which 
the PSIS is higher than the ASIS. 
No 
Y (coronal) Pelvic roll Pelvic 
obliquity 
(up) 
A negative pelvic obliquity value 
(down) relates to the situation in 
which the opposite side of the 
pelvis is lower.  
No 
Figure 4.6. The three cardinal planes of human movement (left) and a representation of 
knee flexion/extension in the sagittal plane (right) (note the positive and negative 
angular degrees on the y-axis). 
 7 
 
­Flexion (+) 
¯ Extension (-) 
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Z 
(transverse) 
Pelvic 
course 
(yaw) 
Pelvic 
rotation 
(internal) 
A negative (external) pelvic 
rotation value means the opposite 
side is in front (anterior).  
Yes 
X (sagittal) Hip flexion Hip flexion A positive sign corresponds to the 
situation in which the knee is in 
front of the body (flexion). 
No 
Y (coronal) Hip 
abduction 
Hip 
adduction 
A positive sign corresponds to an 
adducted (inwardly moved) leg. 
Yes 
Z 
(transverse) 
Hip rotation 
(external) 
Hip rotation 
(internal) 
A positive sign corresponds to an 
internally rotated thigh. 
Yes 
X (sagittal) Knee flexion Knee flexion A positive sign corresponds to a 
flexed knee. 
No 
Y (coronal) Knee 
abduction 
Knee 
adduction 
(varus) 
A positive sign corresponds to 
varus (outward bend of the knee). 
Yes 
Z 
(transverse) 
Knee 
rotation 
(external) 
Knee 
rotation 
(internal) 
A positive sign corresponds to 
internal rotation. If a tibial torsion 
value is present in the Session 
form, it is subtracted from the 
calculated knee rotation value. A 
positive tibial torsion value 
therefore has the effect of 
providing a constant external 
offset to knee rotation. 
Yes 
X (sagittal) Ankle 
dorsiflexion 
Ankle 
dorsiflexion 
A positive sign corresponds to 
dorsiflexion. 
No 
Y (frontal) Ankle 
Inversion 
Ankle 
adduction 
(inversion) 
Different nomenclature between 
systems/models confirmed using 
MR3 software. Frontal plane - 
adduction corresponds to internal. 
No 
Z 
(transverse) 
Ankle 
abduction 
(external 
rotation) 
Ankle 
internal 
rotation 
 
A positive sign corresponds to 
internal rotation. Different 
nomenclature between 
systems/models were confirmed 
using MR software. Transverse 
plane - adduction is internal.  
Yes 
VICON definitions from official VICON motion systems online resources.347,348  
Due to differences in terminology between systems/models, directions corresponding to 
nomenclature were verified by simple practical movement experiments using IMUs and MR3 
software. 
4.10.2.7. TSP determination by the myoMOTION 
The gait events of initial contact and toe-off were detected by the myoMOTION using an IMU-
based contact detection algorithm provided by the MR3 software. The algorithm utilises foot 
angular velocity as well as acceleration measurements from the foot-mounted IMU to identify 
periods when the foot is in contact with the ground. TSPs are subsequently calculated in 
MATLAB software (R2017a, MathWorks) from each foot-contact signal. 
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4.11. Study procedures 
The following study procedures were followed for both studies One and Two, unless 
specifically stated otherwise. 
4.11.1. Laboratory preparation and system calibration 
Standard laboratory protocol was followed using a VICON T-wand for dynamic VICON 
calibration, with a laboratory technician moving the wand in sweeping movements while 
walking through the capturing volume. The software then calculated the cameras’ motion 
detection ability inside of the capturing volume. Subsequently, the cameras’ accuracy in 
detecting the marker orientation relative to one another and within the capturing volume was 
determined: system-marker orientation was undertaken by placing the T-wand on the force 
plate system, which was synchronised with the VICON. 
4.11.2. Participant preparation and clinical assessment 
Participants were welcomed and introduced to the laboratory and the logistics of the 
subsequent testing procedures. Each participant was scheduled for a single test visit and a 
maximum of four participants were tested per day (both studies). For Study Two, all 
participants to be tested on a specific day were transported together in a minibus between 
Worcester and Tygerberg campus. Participants were provided with beverages, a light lunch 
and magazines and relaxed in a private waiting room in the physiotherapy clinic adjacent to 
the motion laboratory while testing was conducted on one participant at a time. 
Basic sociodemographic information and medical history was recorded for each participant. 
For EndoAfrica participants (Study Two), data were extracted from the overhead study, along 
with laboratory results confirming HIV status. HIV-specific data extracted from the EndoAfrica 
database included: CD4 cell count, viral load, date of HIV diagnosis and antiretroviral 
treatment history, in order to obtain a descriptive disease profile of PLHIV in which validity and 
reliability was determined. 
Women were tested in sleeveless sports tops and shorts, and men wore shorts only, to obtain 
accurate marker and IMU placement and optimal visibility. Participants remained bare footed 
during physical evaluation, calibrations and all subsequent motion analysis. A standardised 
physical assessment was conducted on each participant at the start of the data collection 
session: Lower limb joint range of motion (ROM) was screened (Section 4.11.2.1) and 
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essential VICON-specific anthropometric measurements were taken (height, weight, leg 
length from ASIS to medial malleolus, knee- and ankle width) (Section 4.11.2.2), as required 
by the PiG model.  
4.11.2.1. Lower limb range of motion screening 
In addition to subjectively inquiring about joint restrictions hampering the participant’s 
functional gait (which constituted an exclusion criterion as stated previously), the lower limbs 
of each participant were briefly screened for gross joint range discrepancies using a manual 
international standard goniometer with a 360° scale marked in one-degree increments (Model 
G300, Whitehall Manufacturing Hydrotherapy and Health Care Products, CA, USA). Joint 
ranges of motion (ROM) specifically screened included the major drivers of gait in a forward 
direction (hip flexion and extension, knee flexion and extension, ankle dorsi- and 
plantarflexion; any other obvious ROM restrictions or hypermobility noted for a specific 
participant were also recorded. 
4.11.2.2. Anthropometric measurements 
Height was measured barefoot by having the participant stand in the anatomical position with 
their feet together, heels, buttocks and back against a wall, looking straight ahead and with 
the head in the Frankfurt horisontal plane (achieved when the orbitale is in the same horisontal 
plane as the tragion).349,350 A wall-mounted calibrated stadiometer was used to record height 
to the nearest 0.5 centimetres (cm). 
Body weight was measured to the nearest 0.1 kilogram (kg) using a Safeway electronic body 
scale (maximum capacity of 150 kg). Participants were measured barefoot and wearing light 
clothing, with feet equally spaced on the scale platform. 
BMI was calculated as: 
012 = (4567ℎ9	6:	;6<=7>?@A)(ℎ567ℎ9	6:	@59>5A)C  
Leg length was measured in supine from the ASIS (most inferior aspect) to the medial 
malleolus (most inferior aspect) via the knee joint and with the leg resting in neutral, using a 
measuring tape. Measurements were made to the nearest 0.1 cm, and left and right sides 
were averaged.351 Knee joint width between lateral and medial joint lines at the flexion axis 
was measured using calipers and to the nearest 0.1 cm, with the participant lying supine. 
Ankle width was also measured in supine, using calipers, from the most medial point of the 
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medial malleolus to the most lateral point of the lateral malleolus and recorded to the nearest 
0.1 cm. 
4.11.3. Marker/IMU placement 
Acting as the single rater of the index system in both studies, being a registered 
physiotherapist with prior experience with the VICON system (from MSc research) and having 
completed the VICON Optical Motion Capture Workshop and myoMOTION Training 
Workshop offered by the SU CAF Training Initiative (2015), the researcher (PhD candidate) 
performed all marker and IMU placements throughout the studies.  
The markers and IMUs were placed on the participant simultaneously to enable concurrent 
measurements by both systems for validity determination. Prior to placement, the relevant skin 
areas were wiped with surgical alcohol to facilitate good contact between the markers/IMUs 
and the skin. Twenty passive retro-reflective markers (9.5 mm diameter) were placed on 
anatomical landmarks according to a validated modified lower body PiG model provided by 
the VICON software (Nexus 1.8.5). Using medical grade double-sided adhesive tape, the 
markers were placed on the heels (calcaneus, at the same height above the plantar surface 
of the foot as the toe marker), medial malleoli, lateral malleoli, second metatarsals (on the mid-
foot side of the equinus break), shanks (using wands, along the alignment of the ankle flexion 
axis), tibial tuberosities, lateral knees (on the flexion/extension axis), medial knees (on the 
flexion/extension axis), lateral thighs (lower lateral one third surface), anterior superior iliac 
spines (ASIS’s) and posterior superior iliac spines (PSIS’s) (Figure 4.7). These markers were 
not removed during any trials and thus could not introduce bias due to variation in placement. 
Seven IMUs were placed on the various lower limb segments according to the rigid lower body 
model; taking care to not interfere with the reflective markers. For the lower body setup of the 
myoMOTION, the IMUs were placed on the pelvis (posteriorly on the sacral surface), thighs 
(lateral attachment to the lower quadrant of the segment, i.e. the area of lowest muscle belly 
displacement during walking), shanks (anteromedial surface of the tibia), and feet (dorsally 
and sufficiently proximal to the equinus break to avoid excessive IMU motion) (Figure 4.7). 
IMUs were attached with a fixation strap (pelvis), elasticated Velcro straps (thighs and shanks) 
(all these straps are provided standard along with the myoMOTION) and double-sided tape, 
firmly reinforced using elastic adhesive bandage (feet). These placements were done in such 
a manner that no movement restrictions were imposed on the participants. All markers/IMUs 
were checked by the researcher and the laboratory technician throughout measurement 
procedures to ensure that they remained in place. 
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Although IMUs distal to the pelvic IMU can be mounted to any position of the selected body 
segments, standardised guidelines were followed in this project to promote quality and 
fidelity of the collected data: 
• Areas susceptible to excessive soft tissue movement (e.g. muscle bellies, where 
muscle contraction would most likely move the IMU) and bony prominences (where 
uneven surface attachment would cause IMU movement) were avoided. IMUs were 
thus placed on flat surfaces of the relevant body segments with the least muscle tissue 
between the bone and sensor. 
• IMUs were applied symmetrically on both sides of the body to ensure measurement 
under the same conditions. 
• Medical-grade double-sided tape was used to secure the contact area of the straps 
containing the IMUs and prevent “tilting” of the IMU with regards to the body surface. 
The thigh poses a particular threat to IMU motion due to an increased risk of soft tissue artefact 
(STA) – which may affect 3D knee angle measurements. After troubleshooting different IMU 
placement options using two pilot participants (not included as part of the analysed participants 
in any of the primary studies), it was decided that the best data would be collected by securing 
the thigh IMUs to the lateral aspect of each thigh (Figure 4.7).  
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Figure 4.7. Standardised N-pose and positioning of reflective markers and IMUs. Twenty 
passive retro-reflective markers were placed on the relevant anatomical landmarks. 
IMUs were attached with a fixation strap (pelvis), Velcro straps (thighs and shanks) and 
double-sided adhesive tape, and firmly reinforced using elastic adhesive bandages (not 
shown here) over foot IMUs. Standardised instructions were provided by the rater, 
namely to (1) stand straight with arms crossed, (2) vertically align centers of the hip-, 
knee- and ankle joints (to position feet hip-width apart), (3) place feet perfectly parallel 
and facing forward (key criterion) and (4) have the pelvis facing directly forward in the 
same direction as the feet (key criterion). Participants were instructed to remain static 
until completion of the ~15s system calibration (indicated by an audio signal). 
4.11.4. Practice trials  
Participants were allowed sufficient time to become familiar with the testing procedures and 
gait trials and were explicitly instructed to walk “as normal as possible”. To familiarise 
participants to the feeling of walking with the IMU/markers fixated to their bodies, practice trials 
were performed along the capture volume, noting specific starting positions for optimal force 
plate foot strikes, and until the researcher was satisfied that the participant assumed a relaxed, 
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normal gait. To avoid any potential force-plate targeting, participants were instructed to look 
ahead and focus on the laboratory wall in front of them at eye level. 
4.11.5. Biomechanical model calibration 
4.11.5.1. VICON-PiG 
After the practice trials, a static anatomical VICON-PiG calibration was performed with the 
participant standing on the force plate according to standard laboratory protocol (once-off per 
participant and prior to myoMOTION calibration; therefore, ferromagnetic interferences were 
not a concern). Each calibration trial was reconstructed by the laboratory technician to produce 
3D reconstructions of all markers used. The reconstructed 3D markers were associated with 
marker labels from the modified PiG labelling model, allowing manual labelling of the markers 
and construction of a participant image. To allow the PiG model to calculate key parameters, 
all markers placed on the participant were included in the VICON skeleton template, which 
was calibrated to the VICON skeleton file created for each participant. All trials were 
reconstructed to graphically represent participants, and were subsequently rechecked for 
accuracy of the labelling of the anatomical marker positions. 
4.11.5.2. MyoMOTION 
The myoMOTION model was calibrated as per the user guide instructions by having the 
participant remain stationary in a neutral reference posture during calibration (Figure 4.7), in 
order to establish the local coordinate system and provide a reference angle on which to base 
the collected kinematic data. The calibration pose was arranged as accurately as possible to 
minimise subsequent measurement errors. Calibrations were performed on a 30 cm-high 
wooden platform, minimising exposure to potential floor-based magnetic distortions, and with 
the participant facing in the same direction as the subsequent walking trials. Substantial 
attention was paid to postural setup and standardised instructions were provided (see Figure 
4.7 caption).The researcher inspected the N-pose in three planes, enforcing neutral joint 
angles. MyoMOTION calibration was then initiated, requiring the participant to remain static 
for about 15 seconds (a successfully completed calibration procedure is indicated by system 
by emitting an auditory signal). 
The myoMOTION system allows the calibration data to be used for repeated measure series 
of data collection (using the option “Use last calibration” in the software); however, frequent 
re-calibration of sensors within test series is recommended to avoid drift over time, and 
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therefore the system was recalibrated each time in-between gait trials (as would be the case 
in the field study as well). 
4.11.6. Experimental protocol and data collection 
Figure 4.9 outlines the procedures for the gait and N-pose validation and reliability studies. 
The recording protocol lasted approximately 35 to 40 minutes per participant. 
4.11.6.1. N-pose 
VICON measurements were recorded concurrently during myoMOTION calibrations. A quality 
check was performed before initiating each calibration (activating the “Calibrate” command in 
the software) to ensure that no VICON markers were occluded, and that no ferromagnetic 
interference was present with regards to the IMUs (indicated by IMUs turning red on the 
operating screen). The recorded data were used in VICON Nexus software to define the static 
kinematic angles maintained during the calibration pose, according to the PiG model. 
MyoMOTION postural measurements are not available during calibration; however, 
myoMOTION joint/segment angle values of zero in all planes were used for later analysis 
(Study One) since the system assumes these for the reference posture. VICON-recorded data 
of the N-poses were recorded in both studies, but only analysed in Study One (for intra-rater 
accuracy and repeatability) while being used for offset removal between systems in both 
studies. Standardised instructions for the N-pose setup are briefly summed in the caption of 
Figure 4.8. 
4.11.6.2. Gait 
The VICON capture volume consisted of a straight, level 10-metre walkway with the force 
plate system embedded midway (Figure 4.9). Participants started walking approximately one 
metre before a taped line on the floor and ended after crossing a second line; myoMOTION 
recordings were confined to the same distance by manual start and stop. Each participant 
performed six myoMOTION-recalibrated gait trials (one N-pose before each trial). Gait trials 
immediately followed myoMOTION calibrations. Participants walked barefoot, and at a usual-
paced (comfortable self-selected) gait speed to imitate performance in a clinical setting. Six 
clean force plate strikes were needed, with alternating feet (three strikes per side). Participant 
were thus instructed to alternate the starting foot with each trial. A gait trial was deemed 
successful if the participant’s entire landing foot made contact with at least one of three force-
plates and if they did not target the force-plate by looking down at it or by noticeably changing 
their stride length. The intercepted gait trials were performed in the same direction each time 
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and after each trial, the participant returned immediately to the wooden platform for the next 
calibration. Figure 4.10 shows the graphical interfaces of each system, viewed for a gait trial. 
 
 
 
Figure 4.8. The laboratory space where both validity and reliability studies were 
conducted. 
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1. Participant changed into appropriate apparel and removed footwear
2. Antrhopometric measurements and lower limb joint ROM screening (performed by a 
single rater).
3. Reflective markers (reference system, VICON) and IMUs (index system, myoMOTION) 
were applied simultaneously to specific anatomical landmarks and body segments of the 
partipant.
4. VICON calibration: a static standing pose calibration was conducted once-off on a force 
plate according to laboratory protocol.
Start of accuracy and repeatability study of N-pose implementation.*
5. Setup of the static standing calibration pose (N-pose) for the myoMOTION by the rater 
using standardised instructions.
6. MyoMOTION calibration: the participant was instructed to statically maintain the N-pose 
during the calibration procedure of the myoMOTION system, while the VICON system 
simultaneously captured the static lower limb joint/segment angles. 
7. The participant performed a single practice walk.
Start of myoMOTION reliability and concurrent validity study of lower limb gait 
outcomes.
8. Start of concurrent VICON and myoMOTION recordings: the participant walked along 
the length of a ten-metre capture volume at a usual-paced speed (first and last one-metre 
sections not recorded to exclude acceleration and deceleration effects).
9. Steps 5, 6 and 8 were repeated until six VICON-recorded N-poses (six repeated setup 
procedures by the same rater under the same conditions) were done for the N-pose 
accuracy and repeatability study, and six repeated calibration-intercepted gait trials for the 
gait reliability (IMC output) and concurrent validity (myoMOTION versus VICON output) 
study.
Figure 4.9. Data collection procedures per participant (Studies One and Two). 
*N-pose data were recorded using VICON in both studies, but only analysed 
in Study One (for intra-rater accuracy and repeatability) while being used for 
offset removal between systems/models in both studies. 
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Figure 4.10. Screenshots during gait recordings to show the graphical interface for 
each system (top = VICON Nexus; bottom = myoMOTION MR3). 
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4.12. Three-dimensional data acquisition and processing 
Data processing was performed by a qualified neuromechanics laboratory analyst, in 
continuous close consultation with the researcher. Pre-processing of individual static N-pose 
trials (recorded by VICON during myoMOTION calibration) and gait trials was done in Nexus 
software.  
Each static VICON calibration trial (performed only once per participant for the purposes of 
VICON calibration), as well as individual gait trials, was reconstructed by the laboratory 
technician, using a validated modified lower body marker set contained in the VICON skeleton 
template. By manually labelling the markers, the technician created an image of the 
participant, which was then screened for accuracy of the labelling of the anatomical markers. 
Gaps in marker trajectories were inspected and filled using the Woltring gap filling algorithm 
(Quintic spline; mean square error setting of 20mm2) built in to Nexus software. If gaps 
remained in the marker trajectories (due to poor visibility or occlusion of markers) further, 
manual gap filling was done. 
 
Gait events (foot contact and toe-off) were inserted using the force plate data and auto-
correlated to the rest of the trial where necessary. A threshold of 20 Newtons (N) was used to 
determine the points of foot contact and toe-off. If the events are not repeatable or were 
inaccurately correlated, they were manually corrected within Nexus software using time-
synchronised video. 
 
The PiG model was then executed and the model outputs determined. Joint/segment 
kinematics and calculation of joint motion were obtained from the VICON-PiG model using the 
standard dynamic PiG operation in the VICON Nexus software, which determines hip joint 
centres relative to the associated embedded coordinate system origin using the Davis 
equations352 (i.e., the hip centre location relative to the origin of the pelvic embedded 
coordinate system, which is located midway between the ASIS markers).352 Knee axis 
estimation was performed by optimising the thigh-rotation offset parameter during gait353 and 
ankle axis estimation by determining the shank-rotation offset parameter during the static N-
pose trial using medial and lateral malleolus markers. These data were filtered using a 4th 
order zero-lag low pass Butterworth filter with a cut-off frequency of 6 Hz. The Bertec force 
plate data were filtered at 100 Hz with the same filter. 
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The motion related signals from the myoMOTION were transmitted wirelessly to the MR3 
software on a recording laptop (200 Hz). The software automatically filters the raw data using 
a robust fusion algorithm (Kalman filter) optimised for IMU data. IMU angular orientation is 
estimated by a combining the elemental sensor component axes readings into four element 
quaternion values. As mentioned before, these calculations are performed at IMU-level. Thus, 
pre-processing was not needed, but data were corrected for magnetic drift (distortion) on the 
foot, shank and thigh segments. MyoMOTION gait events were also determined within the 
software (using the built-in algorithm). Raw myoMOTION data were filtered using a 4th order 
zero-lag low pass Butterworth filter with a cut-off frequency of 6 Hz, to attenuate any noise 
within the signals. 
 
 The data recorded in MR3 (myoMOTION) were exported to single .csv files (for each trial). 
The data recorded in Nexus (VICON) were saved as .c3d files. All data were subsequently 
imported into MATLAB software (R2017a, MathWorks), a high-performance software for 
processing and analysis. In cases where a gait trial contained more than one complete and valid 
gait cycle for one or both legs, only the gait cycle for each leg judged to contain the best data 
quality was retained for analysis, discarding the rest of the gait cycles in the trial. Data 
segmentation was subsequently performed, which involved using the cyclical gait events, 
defined by the foot contact and foot off events, to segment trial data into cycles normalised in 
time to 101 data points from initial contact (0%) to ipsilateral initial contact (100%) at time 
intervals of 1%.  
 
Prior to determining myoMOTION outcomes, the relevant data were inverted (“flipped”) 
according to the positive definitions of each joint/segment motion (as defined in Table 4.1). 
Model-adjustment of myoMOTION data was also done at this point. Data outcomes were then 
determined using custom analysis scripts, including the construction of visualisations in 
MATLAB that can be exported to image files or MS Word documents. Finally, using a macro 
routine, all outcomes were exported to MS Excel for further statistical analysis.  
4.12.1. Offset correction of myoMOTION data 
For model-corrected comparisons, a second myoMOTION data set was created wherein gait 
kinematics were adjusted by the Euler angle offset measured by VICON during myoMOTION 
calibration. The myoMOTION data were adjusted using the static standing trials recorded 
between each walking trial in Nexus. This was done at the same stage as data inversion. The 
angles of each joint/segment (in each plane) in the static trials were considered the neutral 
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(natural standing posture) and were used to offset the myoMOTION data (shifting the data to 
the same neutral joint/segment positions as for the VICON-PiG model). This was done using 
the simple equation for each joint/segment and plane:  
 
offset_angle = mean angle in static trial  
MM_angle_adjusted = MM_angle(whole cycle) + offset_angle 
 
The correction was applied slightly differently for pelvis rotation and foot progression heading 
(third plane) angles because of their relationship with the global co-ordinate system and given 
the limitations of IMUs (inability to measure absolute skeletal position kinematics).  
This approach is less accurate than using matrix mathematics to reorient anatomical frames 
of the myoMOTION model using VICON data. However, the matrix approach would not have 
allowed for an evaluation of the commercial myoMOTION model and calibration, which were 
being validated for the current research. In addition, access to the source code was not 
available. The Euler angle approach can be considered conservative for validation purposes, 
as it would presumably remove model differences less effectively. Therefore, if the Euler angle 
offset method was to produce sufficiently valid myoMOTION comparison results, the matrix 
approach would most likely have produced slightly better (not worse) results. 
Since time-shifts in the gait cycle data (due to differences in gait event detection and thus 
segmentation) could lead to comparison errors, a third myoMOTION dataset was created (in 
Study One only) wherein the model (angular offset)-corrected gait kinematics were adjusted 
for time-segmentation differences due to between-system gait event detection differences. 
MyoMOTION time-series data from the biomechanical model were time-synchronised to OMC 
data offline by aligning a common event (VICON foot contact event): 
offset_angle = vicon_angle(@ Vicon foot strike) MM_angle(@ Vicon 
foot strike) 
MM_angle_adjusted = MM_angle(whole cycle) + offset_angle 
The myoMOTION data were thereafter segmented and time-normalised using VICON events 
to allow for comparison of the systems’ data independent of event detection error. 
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4.12.2. Outcome angles and TSP parameters 
As a first exploration into system performance, Study One compared the average angular 
values achieved during the N-pose setup, as well as the average arithmetic means of 
kinematic gait waveforms commonly included in a gait analysis. For the knee and ankle, 
secondary angles (coronal and transverse planes) were not analysed for gait as these 
outcomes are less reliable even using OMC, hampering correct interpretation of the 
kinematics354 (especially knee ab-adduction and rotational data are associated with poor 
signal-to-noise ratios).352 
Calibration pose data were also collected in Study Two, but not analysed (as intra-rater 
repeatability for setting up these poses using standardised instructions was already confirmed 
in Study One). These data were thus only used to correct offset error (as in Study One) for 
comparison of raw and corrected system outputs. Study Two compared discrete kinematic 
angles and ROMs considered clinically relevant in discriminating elderly and/or fall-prone gait, 
so as to confirm the measurement error of the myoMOTION for these outcomes which were 
to be collected in-field in the subsequent cross-sectional field study. In addition, selected TSPs 
were assessed for concurrent validity and reliability.  
The following kinematic waveforms, presented in Table 4.2 below, were calculated and 
analysed in Study One, and used for extraction of selected clinically relevant discrete angles 
and ROMs for Study Two as well as the cross-sectional field study (Chapters 7 to 8).  
 
Table 4.2. Kinematic waveforms extracted and analysed in Study One. 
Anatomical angle Description Polarity 
Pelvic tilt Pelvic motion in the sagittal plane (X) Anterior tilt (+); 
posterior tilt (-) 
Pelvic obliquity Pelvic motion in the coronal plane (Y) Upward obliquity 
(+); downward 
obliquity (-) 
Pelvic rotation Pelvic motion in the transverse plane (Z) Internal rotation 
(+); external 
rotation (-) 
Hip 
flexion/extension 
Hip motion in the sagittal plane (X) Flexion (+); 
extension (-) 
Hip abd/adduction Hip motion in the coronal plane (Y) Abduction (+); 
adduction (-) 
Hip rotation Hip motion in the transverse plane (Z) Internal rotation 
(+); external 
rotation (-) 
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Knee 
flexion/extension 
Knee motion in the sagittal plane (X) Flexion (+); 
extension (-) 
Knee 
abd/adductona 
Knee motion in the coronal plane (Y) Adduction (+); 
abduction (-) 
Knee rotationa Knee motion in the transverse plane (Z) Internal rotation 
(+); external 
rotation (-) 
Ankle 
dorsi/plantarflexion 
Ankle motion in the sagittal plane (X) Dorsiflexion (+); 
plantarflexion (-) 
Foot progressiona Foot motion in the transverse plane (Z)  
aThese angles were not included in the gait analysis. 
 
4.12.3. Definition and extraction of kinematic key events  
The kinematic angles extracted from the relevant software for each participant consisted of 
time-varying gait curves normalised to 101 data points, as presented in Table 4.2 above. Since 
no data exist regarding instrumented gait analysis in PLHIV, for Study Two (this chapter and 
Chapter 6) and the field study (Chapters 7 to 8), key events and phases from each kinematic 
curve were selected based on data from previous studies in the elderly and fallers (reviewed 
in Chapter 2). A large number of variables were included to facilitate data exploration in the 
validation and reliability studies as well as in the cross-sectional field study. This approach has 
previously been used by a number of 3D gait analysis studies, particularly in populations 
whose gait characteristics had not previously been assessed in detail using instrumented 
analysis.355,356 
Extraction of the key points from the time-normalised average of each assessment was 
performed using a customised routine in MATLAB, based on key event definitions listed in 
Table 4.3 and key phase definitions in Tables 4.4. Table 4.5 lists and defines the kinematic 
angular outcomes used in the second validation and reliability study and considered for the 
cross-sectional field study. The definitions used for gait analysis outcomes were based on 
conventions as per Whittle’s Gait Analysis.201 
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Table 4.3. Key events used to define kinematic outcomes, based on Whittle’s 
classification of the gait cycle.201 
Event Abbreviation Description Definition for use in MR 
Initial 
contact 1 
IC1  First contact of the foot with 
the ground (marks 
beginning of loading 
response) 
Defined by 
myoRESEARCH software 
(MR3) 
Toe-off TO Point when the foot breaks 
contact with the ground 
Defined by MR3 
Heel rise HR Point when heel starts to lift 
from ground (marks 
transition from mid-stance 
to terminal stance) 
Defined at maximum knee 
extension during stance  
Opposite 
toe-off 
OTO Point in stance of the 
ipsilateral limb when the 
contralateral limb begins 
swing (marks the end of the 
first double support period 
and start of mid-stance) 
Defined by MR3 
Opposite 
initial 
contact 
OIC Point in stance of the 
ipsilateral limb when the 
contralateral limb begins 
stance (marks end of single 
support period and start of 
pre-swing/second double 
support) 
Defined by MR3 
Feet 
adjacent 
FA Point when the swinging 
leg passes the stance leg 
and the feet are side-by-
side (separates initial swing 
from pre-swing) 
Defined at maximum knee 
flexion during swing  
Tibia vertical TV  Point when the tibia of the 
swinging leg becomes 
vertical (separates mid 
swing and terminal swing) 
Defined using the shank 
angle in MR3 (manually 
checking for verticality 
during swing) 
Initial 
contact 2 
IC2 Next initial contact of the 
same foot, marking the end 
of the GC  
Defined by MR3 
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Table 4.4. Delamination and definition of gait phases, including defining events. 
Phase or sub phase Definition Defining events 
Gait cycle (stride) Constitutes the basic unit of 
gait and is defined as the 
time period between two 
successive occurrences of 
one of the repetitive events 
during walking; by 
convention foot contact with 
the ground 
IC1 to IC2 
Stance phase IC1 to TO 
Loading response/first 
double support 
Period of weight 
acceptance, starting from 
initial contact to opposite 
toe-off. Corresponds to first 
double support phase. 
IC1 to OTO  
Mid-stance The first half of single 
support, lasting from 
opposite toe-off to heel rise 
of ipsilateral foot. 
OTO to HR  
Terminal stance The second half of single 
support, lasting from 
ipsilateral heel rise to 
opposite initial contact. 
HR to OIC 
Pre-swing/second double 
support 
The second double support 
phase, lasting from opposite 
initial contact to ipsilateral 
toe-off. 
OIC to TO 
Swing phase TO to IC2 
Initial swing Period from toe-off to instant 
when swing leg is adjacent 
to stance limb. 
TO to FA  
Loading response and 
mid-stance periods 
 LR (begin) to MSt (end) 
Mid-stance and terminal 
stance periods  
 MSt (begin) to TSt (end) 
A1 Portion of the GC 
corresponding to the A1 
power phase of the ankle: a 
region of negative power, 
corresponding to eccentric 
plantar flexor activity at the 
ankle during midstance and 
terminal stance 
Maximum ankle 
plantarflexion in MSt to 
maximum ankle dorsiflexion 
in TSt  
A2 Portion of the GC 
corresponding to the A2 
power phase of the ankle: a 
region of positive power, 
corresponding to the 
concentric burst of 
propulsive plantar flexor 
activity during pre-swing. 
HR to TO 
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K1 Portion of the GC 
corresponding to the K1 
power phase of the knee: a 
region of negative power, 
corresponding to eccentric 
knee extensor activity at 
during loading response. 
IC1 to maximum knee 
flexion in stance   
K2 Portion of the GC 
corresponding to the K2 
power phase of the knee: a 
region of positive power, 
corresponding to concentric 
knee extensor activity during 
midstance. This is followed 
by a period of negligible joint 
power during that period of 
time when the ground 
reaction force stabilizes the 
knee in extension. 
Maximum knee flexion in 
MSt to maximum knee 
extension in TSt  
K3 Portion of the GC 
corresponding to the K3 
power phase of the knee: a 
region of negative power, 
corresponding to eccentric 
activity in the rectus femoris 
during pre-swing. At normal 
or slightly faster walking 
speeds, rectus femoris 
controls knee flexion. 
Maximum knee extension in 
TSt to maximum knee 
flexion in swing 
H3 Portion of the GC 
corresponding to the H3 
power phase of the hip: a 
region of positive power, 
corresponding to concentric 
activity in the hip flexors 
during pre-swing and initial 
swing. Sometimes called 
"pull off", this is the 
muscular system's second 
largest contribution of 
propulsive power during the 
gait cycle. 
Maximum hip extension in 
stance to maximum hip 
extension in swing 
Abbreviations: A1/A2 = A1/A2 power phases of ankle; FA = foot-adjacent; GC = gait cycle; H3 = H3 
power phase of hip; HR = heel rise; IC = initial contact; K1/K2/K3 = K1/K2/K3 power phase of knee; 
LR = loading response; MSt = mid-stance; ROM = range of motion; TO = toe-off; TS = terminal 
stance. 
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Table 4.5. Kinematic outcomes used in the second validation and reliability study and 
the cross-sectional field study. 
Joint/segment Discrete angle/ROM Corresponding 
GC event/phase 
Pelvis Pelvis tilt ROM during the GC GC 
Pelvis obliquity ROM during the GC  GC 
Pelvis rotation ROM during the GC GC 
Peak anterior pelvis tilt angle during the GC GC 
Pelvis rotation angle at initial contact IC1 
Hip Hip flexion ROM during the GC GC 
Hip internal rotation ROM during the GC GC 
Hip flexion ROM during loading response LR 
Hip flexion ROM from pre-swing to initial swing H3 
Hip abduction ROM during mid-stance MSt 
Hip adduction ROM during loading response LR 
Peak hip joint flexion during stance Stance 
Peak hip joint flexion during swing Swing 
Hip joint flexion angle at initial contact IC1 
Knee Knee flexion ROM during the GC GC 
Knee flexion ROM during stance K1 
Knee extension ROM, mid-stance to terminal 
stance 
K2 
Knee flexion ROM, stance to swing K3 
Knee joint flexion angle at initial contact IC1 
Peak knee joint flexion during stance Stance 
Peak knee extension angle during stance Stance 
Peak knee flexion angle during swing Swing 
Ankle 
 
 
Ankle dorsiflexion ROM during stance A1 
Ankle plantarflexion ROM, heel rise to toe-off A2 
Ankle dorsiflexion ROM during swing Swing 
Peak ankle plantarflexion during the GC GC 
Ankle dorsiflexion angle at initial contact IC 
Ankle plantarflexion angle at toe-off TO 
Abbreviations: A1/A2 = A1/A2 power phases of ankle; GC = gait cycle; H3 = H3 power phase of 
hip; HR = heel rise; IC = initial contact; K1/K2/K3 = K1/K2/K3 power phase of knee; LR = loading 
response; MSt = mid-stance; ROM = range of motion; TO = toe-off; TS = terminal stance. 
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For Study Two and the field study, but not for Study One (relevant MR3 algorithms were under 
development at the time), TSPs that have been reported to be of clinical relevance in 
discriminating elderly and fall-prone gait were included in the analyses. For both systems, TSP 
data were normalised to leg length into dimensionless quantities as recommended by Hof.357 
This scaling of gait data is often used to minimise the inter-participant variation by correcting 
as much as possible for differences in stature, which directly influences parameters.358 
According to Hof357: 
:=>@?<6A5D	<5:79ℎ = <5:79ℎ<*  :=>@?<6A5D	AE55D = AE55D7 × <*	 
where 7	is acceleration due to gravity (9.81m/s2) and <* is leg length (ASIS to medial 
malleolus). These normalisations resulted in the non-dimensional variables included in Table 
4.6.  
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Table 4.6. TSPs extracted from MATLAB for both measurement systems.  
 
4.13. Statistical analysis  
Statistical analysis was performed using the IBM Statistical Package for Social Sciences 
(SPSS Statistics) for Macintosh, Version 25.0 (International Business Machines Corporation, 
Armonk, NY) and MS Excel V16.12. The distribution of each variable was tested for normality 
using histograms and the Shapiro-Wilk test, and homogeneity of variances (for ANOVA) were 
 
Parameter   Description Units 
Spatial parameters 
Step length Distance between corresponding successive initial 
contact of opposite feet, measured parallel to the 
direction of progression for the ipsilateral stride 
 
cm 
Normalised 
step length 
Dimensionless normalisation of step length to leg 
length: !"#$	&#'("ℎ × 1&0 Dimensionless 
Stride length Distance travelled during one stride (or GC); 
measured as the length between ipsilateral 
successive initial contact of the foot 
 
cm 
Normalised 
stride length 
Dimensionless normalisation of stride length to leg 
length: !"-./#	&#'("ℎ × 1&0 Dimensionless 
Temporal parameters 
Stance time Time period when the foot is in contact with the 
ground 
 
Seconds 
Step time Time taken for one step, measured from initial 
contact of one foot to corresponding successive 
initial contact of contralateral foot 
 
Seconds 
Single support 
time 
Time period when only one foot is in contact with 
the ground 
Seconds 
Double 
support time 
Initial and final periods of the stance phase when 
two feet are simultaneously in contact with the 
ground; considered here as a global time  
Seconds 
Temporophasic parameters 
Stance 
percentage 
Duration of the stance phase relative to the GC time %GC duration 
Single support 
percentage 
Duration of single support relative to the GC time %GC duration 
Double 
support 
percentage 
Duration of double support (including both in initial 
and terminal double support) relative to the GC time 
 
%GC duration 
Temporospatial parameters 
Gait speed Speed covered by the entire body in a given time; a 
product of step length and cadence 
m/s (or cm/s 
where indicated) 
Normalised 
gait speed 
Dimensionless normalisation of gait speed to leg 
length: !$##/ × 1(×&0 Dimensionless 
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verified using Levene’s test. Data were averaged for left and right limbs227,359 as the N-poses 
were symmetrical and no significant differences were apparent between left and right joint 
angles. Statistical significance was set at an alpha-level of p < 0.05. An MCID of > 5°318 was 
considered for kinematic angles, while TSPs were interpreted in terms of percentage 
differences. 
Descriptive statistics were mean and standard deviation (SD) for normally distributed data, 
median and interquartile range (IQR) for non-normal data and percentages for frequencies. 
Kinematic and TSP outcomes were averaged for each participant across trials, and then 
averaged across participants. For Study Two, the two participant groups’ self-selected gait 
speeds were compared for a statistically significant difference between PLHIV and SNP using 
an independent t-test (two-tailed, significance level α = 0.05). 
4.13.1. Study One 
For the first study, six repeated N-poses and six walking strides (one valid mid-walk stride 
from each of the recalibrated trials) were analysed per participant. For each participant, six 
valid strides were used for analysis, resulting in 96 strides for analysis, alongside six 
calibration repetitions.  
4.13.1.1. Concurrent validity (gait data) 
Concurrent validity of the gait data was assessed by comparing kinematic waveforms in terms 
of offset and waveform dissimilarity among the joint angles time histories for raw, calibration-
adjusted and calibration-and-time-adjusted myoMOTION output versus VICON-PiG.  
Offset error was evaluated using the root-mean-square error (RMSE). The average RMSE 
value between joint kinematic curves estimated by the myoMOTION and VICON-PiG was 
computed over the gait cycle and averaged across trials and participants. The RMSE was 
calculated, for each joint/segment angle, by taking the square root of the mean squared 
differences between the myoMOTION and VICON-PiG data sets at each timeframe:  
G1HI =	J1KL(M, − O,)CPQR,  
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where MQ and OQ are the angular values (in degrees) of the myoMOTION and VICON at time 
frame 9, respectively, and T is the number of time points across the gait cycle (i.e. 101 time 
points due to being normalised to every 1% of the gait cycle).  
To determine agreement between myoMOTION and VICON-measured kinematics for walking 
gait trials, Bland-Altman analyses were conducted for each gait outcome. This method is 
based on interpretation of residual-like plots and simple calculations.360 The mean difference 
(D) between measurements of the same outcome by the two systems (indicating the estimated 
bias and thus the systematic difference between the systems) and its SD (HST) were used to 
estimate the 95% limits of agreement (LoA): 
     [D] ± 1,96HST      
It is expected that 95% of the differences between the reference and index systems for any 
participant will fall within these limits. The mean differences between myoMOTION and VICON 
measurements were plotted against the mean of the values measured by the two systems. 
Plots were assessed for the extent of the difference between systems and the distribution 
around the 0 line. The 95% LoA as displayed on the plots were used for visual estimation of 
how well the two systems agreed. A smaller range between the upper and lower LoA and a 
closer spread of the estimates around the zero line indicates better agreement between 
systems.360 There are no statistical guidelines for a cut-off where the estimated bias and LoA 
are considered acceptable; this cut-off is based on clinical knowledge and depends on the 
outcome of interest. Therefore, the MCID of 5° was accepted as a cut-point318 for angular data.  
The effect of a bias error due to the different modelling and calibration processes between 
systems was evaluated by repeating the statistics mentioned above (RMSE and Bland 
Altman) using model-corrected (see Section 4.12.1) data. 
4.13.1.2. Reliability and repeatability (gait data and N-pose data) 
Absolute intra-rater repeatability for setting up the N-pose and absolute myoMOTION within-
session reliability during gait was quantified using the standard error of measurement (SEM). 
For each outcome, a two-way repeated-measure analysis of variance (ANOVA) was 
performed using data from the six repeat measurements from each of the 16 participants. 
The SEM was calculated as the square root of the mean-square-error (MSE) from the 
ANOVA.361–363 
SEM = 	^MS_   
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This approach is robust to between-participant variability and thus preferable to calculations 
based on the intraclass correlation (which is commonly used for SEM calculation).361,362 By 
accounting for within-participant variability, the SEM provides an indication of how precisely a 
test measures a participant’s true score.361,362 The upper 95% confidence limit (CL) of the SEM 
was calculated by multiplying the SEM by a multiplying factor (i.e. 1.2) which is an SEM-
specific parameter based on the number of participants and trials362: 
`abcde(% = g Dh5iC(1 − j, Dh5) × HI1 
where the degrees of freedom are given by: 
Dh5 = :k(:l − 1) 
where :k is the number of participants and :l is the number of trials per participant. For the 
upper 95% CL, 1-α equals 0.05.328 The upper 95% CL indicates the certainty of the estimated 
SEM by specifying the highest value that it might have.  
The SEM is preferable to other indices (including the intraclass correlation coefficient [ICC]) 
because the SEM gives a direct indication of measurement uncertainty in degrees, and is thus 
clinically meaningful.318 For each trial, parameters were extracted from one mid-walk stride – 
resulting in six repeated IMC measures of each angle/segment, which were averaged per 
participant and used for the analysis. Reliable angular results were identified as results that 
do not differ significantly in clinical terms (i.e. differed by 5° or less) between trials within the 
session. 
4.13.1.3. Accuracy (N-pose data) 
The accuracy of a trained rater’s ability to set up neutral joint angles and segments for the six 
N-poses was assessed by comparing, for each joint/segment, the angles obtained from the 
data provided by the VICON, averaging the six N-pose calibrations, and true anatomical zero 
(representing the zero-degree angles assumed by the myoMOTION during calibration). To 
this purpose, the absolute value of the differences (mean absolute difference [MAD]) was 
calculated and the relevant descriptive statistics (mean and SD) determined. This was done 
using the data collected during the upright N-pose. Using absolute measures such as RMSE, 
mean absolute difference and absolute percentage error implies  a stricter evaluation since 
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relative measures may introduce a degree of compensation (having both positive and negative 
values).364 
4.13.2. Study Two 
For the second study, all analyses were performed separately in PLHIV and SNP, because 
potential (albeit subtle) differences in consistency and reliability between methods were 
hypothesised between groups a priory. Stride length, step length and gait speed were 
normalised to participants’ leg lengths to enhance comparability (as explained in Section 
4.12.5 and Table 4.6). For each participant, six valid strides were used for analysis, resulting 
in 48 strides for analysis per study group.  
4.13.2.1. Concurrent validity 
As for Study One, the concurrent validity of myoMOTION gait kinematic angular data 
(comparison with and without angular offset correction), and additionally for TSPs, was 
evaluated using RMSE and Bland Altman analyses. Comparative analyses between systems 
were assessed for SNP and PLHIV separately to evaluate whether gait patterns in a clinical 
sample with potential gait deviations would affect the system’s validity. Additionally, 
considering the different measurement units between the various TSPs, absolute percentage 
error (%D) was calculated for these outcomes:  
%S = mSdn,opqrops m 
where Sdn,opq  is the difference between the parameter values as measured by myoMOTION 
and VICON-PiG, divided by the parameter value ropq as measured by VICON-PiG.  
In order to interpret percentage error outcomes (including the % SEM – see Section below), 
a classification criterion of acceptability was used,364 based on standard statistical thresholds 
for significance analysis (namely values of 5%, 10%, and 20%).365 Also, a reference threshold 
of 5% has been proposed for accuracy error in step length and distance.366 Four categories 
were considered: (i) a percentage error of <5% was considered excellent, (ii) between 5% and 
10% as good, and (iii) between 10% and less than 20% as sufficient. Values of (iv) 20% or 
higher were deemed unacceptable.364  
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4.13.2.2. Reliability 
Absolute myoMOTION within-session reliability during gait was quantified using the standard 
error of measurement (SEM), as in Study One. Reliable angular results were again identified 
as results that do not differ significantly in clinical terms between trials (within-session). In 
addition, considering that the SEM is presented in terms of the units of measurement of the 
relevant outcome, for TSPs, the absolute percentage SEM (% SEM) was calculated to enable 
comparison between the various parameters367,368: 
%HI1 = mtHI1ru vm × 100 
where ru is the arithmetic mean of the correspondent parameter across the repeated sessions. 
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  PART II 
 
RESULTS: STUDY ONE 
5.1. Participant characteristics 
Sixteen conveniently selected healthy, able-bodied adults participated in the first validity and 
reliability study. The full set of kinematic data of all participants could be analysed for both 
systems (myoMOTION and VICON) as there were no invalid trials or gait cycles and/or 
technical failures. 
Table 5.1 presents the age, gender and anthropometric data of each participant. The 
predominantly female sample, consisting of fifteen women and one man, had a mean ± 
standard deviation (SD) age of 20.88 ± 2.39 years. Participants’ mean ± SD stature was 1.64 
± 0.08 metres; mean ± SD body mass index (BMI) was 21.68 ± 1.55 kg/m2 and all participants 
had a medically confirmed HIV seronegative status. 
 
Table 5.1. Participant characteristics (Study One) 
Study code Age (years) Gender HIV status Height (m) Weight (kg) BMI  
HIVP1-03a 20 Female Seronegative 1.58 56.40 22.59 
HIVP1-04 20 Female Seronegative 1.63 57.10 21.49 
HIVP1-05 22 Female Seronegative 1.66 60.10 21.81 
HIVP1-06 18 Female Seronegative 1.69 56.40 19.75 
HIVP1-07 19 Female Seronegative 1.72 54.60 18.46 
HIVP1-08 20 Male Seronegative 1.77 64.90 20.72 
HIVP1-09 20 Female Seronegative 1.64 59.40 22.09 
HIVP1-10 20 Female Seronegative 1.63 61.20 23.18 
HIVP1-11 21 Female Seronegative 1.62 51.40 19.71 
HIVP1-12 20 Female Seronegative 1.75 70.60 23.05 
HIVP1-13 22 Female Seronegative 1.70 57.60 19.93 
HIVP1-14 21 Female Seronegative 1.68 65.90 23.35 
HIVP1-15 21 Female Seronegative 1.45 45.80 21.78 
HIVP1-16 21 Female Seronegative 1.56 53.90 22.15 
HIVP1-17 20 Female Seronegative 1.65 63.30 23.25 
HIVP1-18 29 Female Seronegative 1.56 57.00 23.57 
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; kg = kilograms; m = metres. 
aThe first two participants (coded as HIVP1-01 and 02, respectively) were volunteers who were recruited separately and participated 
in two separate initial pilot studies (one as a shared pilot study along with another project) with the sole purpose of determining study 
pragmatics and technical requirements – the data of these two pilot participants were not included in the analysed dataset and therefore 
the first participant listed is HIVP1-03. 
 
Table 5.1. Participant characteristics (Study One). 
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5.2. MyoMOTION validity (gait) 
For direct (unadjusted model) comparisons of the systems/models, only pelvic rotation and 
obliquity root-mean-square errors (RMSEdirect) were below 5° (Table 5.2). Pelvic tilt and hip 
flexion/extension (sagittal plane motion) demonstrated the highest RMSEdirect and pelvic 
rotation the lowest. Direct-comparison Bland-Altman analyses revealed biases of ≤ 4.2°, 
except for sagittal plane pelvic, hip and ankle angles (> 5°). Direct-comparison LoA (LoAdirect) 
were below 5° for all secondary angles (except hip rotation); while all sagittal plane LoAdirect 
exceeded 5°. Figures 5.1 to 5.3 show the Bland Altman plots for the agreement analyses. 
Figure 5.4 shows the unadjusted kinematic waveform comparison over one gait cycle for a 
representative participant, graphically demonstrating shape correlations despite model offsets 
(i.e. direct comparison between system/models). 
Calibration-offset corrected (model adjusted) myoMOTION output demonstrated a statistically 
significant reduction in RMSE for hip flexion/extension: RMSEcorrected for all angles were below 
5°; except hip rotation. Further time-offset corrections did not produce significant RMSEcorrected 
changes, except for knee flexion/extension (a statistically, but not clinically, significant 
difference of 1.6°, p < 0.001). Calibration-and-time-offset corrections resulted in a maximum 
bias of 4.7° for pelvic tilt; all other biases were ≤ 1.6°. All calibration-and-time-offset corrected 
LoA (LoAcal+time) were < 5°, except for pelvic tilt which demonstrated an upper limit of 11.8° 
(Table 5.2). 
5.3. MyoMOTION reliability (gait)  
Standard error of measurement (SEM) values ranged from 1.1° to 3.8° and were generally 
below 2°, except for knee flexion/extension, hip rotation and pelvic rotation (Table 5.2).  
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Table 5.2. Concurrent validity and within-session reliability of myoMOTION-measured 
kinematic gait angles. Concurrent validity was assessed using direct myoMOTION 
model (MR3) output, as well as modelling- and time-offset corrected outputs. 
Anatomic
al angle 
Validity: offset (degrees) Validity: agreement 
(degrees) 
myoMOTI
ON 
reliability 
(degrees) 
RMSEdire
ct 
RMSEcal RMSEcal+tim
e 
Bias 
(LoA)direct 
Bias 
(LoA)cal+time 
SEM 
(upper 
95%CL) 
Pelvis 
A/P Tilt 
14.8°± 
5.4° 
2.2° ± 2.1°* 2.2°±1.2° -8.8° (-
21.5° to 
3.9°) 
4.7° (-2.4° 
to 11.8°) 
1.1° (1.3°) 
Pelvis 
Obl  
4.2°±1.3
° 
4.3°±1.4° 4.6°±1.5° -0.0° (-0.3° 
to 0.2°) 
0.0° (-0.1° 
to 0.1°) 
1.2° (1.4°) 
Pelvis 
Rot 
2.9°±1.0
° 
3.8° ± 1.8°* 3.7° ± 1.8° 0.1° (-0.5° 
to 0.7°) 
0.1° (-0.4° 
to 0.5°) 
3.8° (4.6°) 
Hip F/E 9.6°±5.8
° 
3.8° ± 1.4°* 3.6° ± 1.2° -7.8° (-
22.6° to 
7.1°) 
-0.9° (-4.8° 
to 3.1°) 
1.8° (2.2°) 
Hip Ab/Ad 5.0°±1.9
° 
3.2° ± 1.2°* 3.6° ± 1.3° 3.5° (0.2° 
to 6.9°) 
-0.8° (-2.6° 
to 0.9°) 
1.4° (1.7°) 
Hip Rot 8.1°±3.7
° 
6.0° ± 2.2°* 6.1°± 2.2° -4.2° (-
13.7° to 
5.3°) 
-1.2° (-4.6° 
to 2.2°) 
3.4° (4.1°) 
Knee F/E 7.1°±4.0
° 
4.9°± 2.1°* 3.3°±1.2°* 2.8° (-8.0° 
to 13.8°) 
1.6° (-1.4° 
to 4.5°) 
2.4° (2.9°) 
Ankle 
DF/PF 
7.1°±2.8
° 
3.7° ± 1.4°* 3.0° ± 1.1° -6.0° (-
12.0° to -
0.1°) 
0.1° (-2.5° 
to 2.6°) 
1.9° (2.3°) 
Abbreviations: 95%CL = 95% Confidence Limits of the standard error of measurement; A/P = 
anterior/posterior; Ab/Ad = abduction/adduction; cal = model adjusted for calibration; cal+time = 
model adjusted for calibration and time; DF/PF = dorsiflexion/plantarflexion; direct = direct 
comparison of model output; F/E = flexion/extension; LoA = limits of agreement; Obl = obliquity; 
RMSE = root-mean-square-difference; Rot = rotation; SEM = standard error of measurement. 
RMSE presented as mean ± standard deviation. 
* indicates a statistically significant difference between direct and cal-adjusted, or between cal-
adjusted and cal+time-adjusted RMSE (p < 0.05, paired t-test). 
Bold print indicates clinically significant joint angle values (> 5°). 
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Figure 5.1. Bland Altman plots for pelvis tilt, obliquity and rotation, showing bias (blue solid 
line) and Limits of Agreement (red dashed lines) between the myoMOTION and VICON 
systems in Study One. The left column shows the unadjusted results, and the right column 
the model-corrected results. 
 
 
       Unadjusted myoMOTION model          Adjusted myoMOTION model 
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Figure 5.2. Bland Altman plots for hip flexion/extension, ab/adduction and rotation, showing 
bias (blue solid line) and Limits of Agreement (red dashed lines) between the myoMOTION 
and VICON systems in Study One. The left column shows the unadjusted results, and the 
right column the model-corrected results. 
 
 
       Unadjusted myoMOTION model             Adjusted myoMOTION model  
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Figure 5.3. Bland Altman plots for knee flexion/extension and ankle dorsi/plantarflexion, 
showing bias (blue solid line) and Limits of Agreement (red dashed lines) between the 
myoMOTION and VICON systems in Study One. The left column shows the unadjusted 
results, and the right column the model-corrected results. 
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5.4. N-pose accuracy 
Mean absolute difference (MAD) values were below 5° for all coronal angles and transverse 
ankle, hip and pelvic angles (Table 5.3). Although knee flexion demonstrated a low MAD 
(1.1°), its SD indicated clinically significant random error, and visual inspection revealed a 
 
 
Figure 5.4. Comparative gait traces produced by the (unadjusted) myoMOTION model (black) 
and VICON-PiG (grey) for a representative participant. Solid lines represent the mean angles 
over one gait cycle. The dashed lines represent the standard deviation (SD) of the 
myoMOTION, and the grey shaded areas the SD of the VICON mean. Systematic angular 
offsets between mean values produced by the different systems/models are most apparent 
for pelvis tilt and hip flexion/extension. 
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single outlier (13.9°). MAD exceeded 5° for ankle dorsiflexion and knee rotation; SDs (< 5°) 
confirming systematic offset. The hip and pelvis both demonstrated clinically significant 
sagittal MAD with high SDs. These angular means demonstrated large ranges with no clear 
outliers. Foot and pelvic errors demonstrated small MAD values. 
5.5. N-pose repeatability 
All SEM values were below 2.2°; the highest value being observed for knee rotation and the 
best repeatability (lowest SEM) for ankle inversion (0.3°). Knee rotation showed the highest 
upper 95% confidence limit (CL), namely 2.6° (Table 5.3).    
 
 
 
 
Table 5.3. Accuracy and repeatability for six repeated N-pose implementations. 
Anatomic angle Accuracy (degrees) Repeatability (degrees) 
MAD SEM 
Mean SD Mean Upper 95% 
Confidence 
Limit 
Ankle dorsiflexion 6.1° 2.5° 1.1° 1.3° 
Ankle inversion 0.2° 1.2° 0.3° 0.4° 
Ankle rotation 3.8° 4.7° 1.0° 1.2° 
Hip flexion 6.9° 8.3° 1.7° 2.0° 
Hip adduction 4.4° 2.3° 0.9° 1.1° 
Hip rotation 2.9° 4.8° 1.6° 1.9° 
Knee extension 1.1° 5.3° 1.9° 2.3° 
Knee varus 3.5° 2.6° 0.4° 0.5° 
Knee rotation 6.5° 4.6° 2.2° 2.6° 
Pelvic anterior tilt 13.4° 6.3° 1.2° 1.4° 
Pelvic obliquity 0.0° 1.1° 0.7° 0.8° 
Pelvic rotation 0.5° 3.0° 1.5° 1.8° 
Foot progression  1.8° 1.9° 1.4° 1.7° 
Abbreviations: MAD = mean absolute difference; n = number of participants; SEM = standard error of 
measurement. 
MAD values are presented as the mean ± standard deviation. 
Bold values indicate results of clinical significance (>5°). 
 
 
 
 
Table 5.3. Accuracy and repeatability for six repeated N-pose implementations. 
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5.6. Chapter summary 
This chapter presented the results of Study One regarding the validity and reliability 
testing conducted using the myoMOTION system for analysing standard kinematic gait 
analysis outcomes, using a convenience sample of university volunteers. Findings 
demonstrated that frequently recalibrated myoMOTION measurements provide reliable 
lower limb gait kinematics in healthy adults and highly compare to VICON-PiG output 
after accounting for inherent biomechanical modelling differences. N-pose calibrations 
can be implemented/instructed accurately (for most outcomes) and consistently using 
standardised instructions. The repeated N-pose setups in-between gait trials did not 
adversely affect the reliability of the gait outcomes. Because of an inherent modelling 
offset existing between systems, low concurrent validity (>5° difference) was observed 
for some direct model comparisons (i.e. sagittal plane ankle, hip, knee and pelvis angles, 
and transverse plane hip angles). However, good agreement was consistently observed 
once the modelling differences were accounted for. Chapter 6 describes the results from 
the next phase of testing, involving additional and clinically relevant gait outcomes 
(particularly in terms of describing elderly gait) assessed in a community-specific sample 
including PLHIV and SNP. 
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  PART II 
 
RESULTS: STUDY TWO 
6.1. Participant characteristics 
A total of sixteen adults (eight people living with HIV-1 infection [PLHIV] and eight seronegative 
participants [SNP]) participated in the second laboratory-based validity and reliability study. 
The full set of kinematic data as required for the study (i.e. six gait cycles per participants) of 
all participants was analysed for both systems (myoMOTION and VICON).  
Characteristics of the participants in the PLHIV and SNP groups are presented in Table 6.1; 
including HIV-specific characteristics for PLHIV. Overall the sample was predominantly female 
(75% of SNP and 50% of PLHIV). Both groups entirely comprised of participants self-identified 
as coloured. PLHIV were on average 8.56 years older and 7.71 kg heavier than SNP; while 
the groups were similar regarding leg length, height and BMI. Mean gait speed as measured 
by VICON tended to be slower in PLHIV than in SNP (1.17 ± 0.14 m/s in PLHIV versus 1.30 
± 0.11 m/s in SNP) – this difference was not statistically significant (p = 0.057) but may be 
considered clinically significant369 (mean difference 0.13 m/s). 
6.1.1. HIV-related characteristics 
The median (Q1 – Q3) CD4+ cell count amongst PLHIV was 505 (449 – 651) cells/µL, and 
only two (25%) PLHIV had an undetectable viral load (HIV-1 RNA <50 cp/mL). Half of PLHIV 
had an HIV-duration of less than two years and only one participant (12.5%) had an HIV 
duration of > 15 years. The majority (n = 6; 75%) of PLHIV were using HAART, all of which 
were NRTI/NNRTI-based first line regimes, with a median duration of 71.5 weeks (range: 16 
to 465 weeks) or 1.38 years.  
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 - 141 - | P a g e  
 
Table 6.1. Demographic, anthropometric and HIV-specific sample characteristics. 
Characteristic SNP (n = 8) PLHIV (n = 8) 
Demographic and anthropometric characteristics 
Age in years† 26.24 (23.51 – 31.38) 34.80 (30.73 – 45.14) 
Female gender 75% 50% 
Ethnicity/race   
Coloured 100% 100% 
Height (m) 1.59 ± 0.09 1.64 ± 0.08 
Weight (kg) 49.51 ± 11.24 57.22 ± 9.99 
BMI (kg/m2) 19.54 ± 3.03 21.19 ± 3.50 
Leg length (cm) 84.74 ± 5.53 85.88 ± 4.41 
Gait speed (m/s)# 1.30 ± 0.11 1.17 ± 0.14 
HIV-specific characteristics (n = 8) 
Most recent CD4+ T-cell count 
(cells/µL)# 
-- 505 (440 – 651 
Percent with detectable HIV-1 RNA 
(>50 cp/mL) 
-- 75% 
Time since HIV-1 diagnosis: --  
<2 years  -- 50% 
2 – 5 years  -- 25% 
>5<15 years  -- 12.5% 
>15 years  -- 12.5% 
Percent on HAART  -- 75% 
Median HAART duration (weeks)# -- 71.5 (16 – 465) 
Percent on first line HAART  -- 100% 
Percent on NRTI/NNRTI -- 100% 
†presented as median (first quartile to third quartile). 
All other values presented as mean ± standard deviation, or percentage. 
Abbreviations: HAART = highly active antiretroviral therapy; HIV-1 = human immunodeficiency 
virus 1; PLHIV = people living with HIV-1 infection; RNA, = ribonucleic acid; SNP = HIV-
seronegative participants. 
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6.2. Concurrent validity of the myoMOTION versus VICON 
in PLHIV and SNP 
6.2.1. Gait TSP parameters  
Table 6.2 presents the RMSE, absolute % error, bias and LoA between myoMOTION and 
VICON measurements for each TSP outcome and separately by HIV-serostatus. In addition, 
Figures 6.1 to 6.3 graphically present agreement between systems for the TSPs in the form 
of Bland Altman plots (PLHIV and SNP depicted on a single graph using blue and red colouring 
respectively).  
RMSE, bias and LoA between systems were close to zero for all temporal parameters as well 
as gait speed (especially once normalised for leg length), as well as for the spatial parameters 
that were normalised to leg length. This was the case for PLHIV as well as SNP. For spatial 
parameters, RMSE, bias and LoA values in PLHIV were within 1.2 cm or less of those 
observed in SNP. 
In both groups, the myoMOTION tended to underestimate absolute step and stride length 
compared to the reference, although the absolute percentage error was small: 1.66% and 
2.51% respectively for step and stride length in SNP and 1.07% and 2.28% for step and stride 
length in PLHIV. For temporal parameters, RMSE values, biases and % errors were close to 
identical in the two groups.  
Across all parameter outcomes, percentage differences were generally below 3%, except for 
double support time (both absolute and expressed as a percentage of the gait cycle). In both 
groups, these parameters had the largest discrepancies in percentage error. The actual 
double support duration had a small offset error (RMSE 0.03s in both groups) and good 
agreement (bias 0.01s in both groups, with similar and small LoA in both groups) but due to 
the short duration of each stride, when normalised to a percentage of the gait cycle, the double 
support percentage showed less agreement. The largest difference in measurement was a 
7.4% error in double support duration in SNP (also the highest percentage error for PLHIV, 
namely 5.79%), which, for both groups, equates to a 0.012s or 12ms time difference. The 
RMSE and bias associated with this outcome was however very small, as were the LoA – 
which suggested that the highest systematic error likely to be observed between systems in 
95% of individuals is a 0.07s difference  
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Table 6.2. Concurrent validity of myoMOTION-measured TSPs (direct output). Analyses 
were performed separately in people living with HIV-1 (PLHIV) and seronegative 
participants (SNP). 
 
 
 
 
 
Gait parameter SNP PLHIV 
Offset Agreement Offset Agreement 
RMSE 
(mean 
±SD) 
%D Bias 95% LoA 
RMSE 
(mean 
±SD) 
%D Bias 95% LoA 
Spatial parameters 
Step length (cm) 3.22 ± 1.63 1.66% -1.05  
-5.83; 
3.72  
4.38 ± 
2.01 1.07% -0.74 
-4.95; 
3.47 
Normalised step 
length 
0.04 ± 
0.02 1.66% -0.01 
-0.07; 
0.04 
0.05 ± 
0.02 1.07% -0.01 
-0.05; 
0.04 
Stride length (cm) 4.46 ± 3.51 2.51% -3.26 
-11.45; 
4.92 
4.46 ± 
2.62 2.28% -2.95 
-10.68; 
4.78 
Normalised stride 
length 
0.05 ± 
0.04 2.51% -0.04 
-0.13; 
0.05 
0.05 ± 
0.03 2.28% -0.03 
-0.11; 
0.05 
Temporal parameters 
Stance time (sec) 0.02 ± 0.01 1.22% 0.01 
-0.03; 
0.04 
0.03 ± 
0.02 1.06% 0.01 
-0.04; 
0.05 
Step time (sec) 0.03 ± 0.02 0.12% <0.00 
-0.03; 
0.03 
0.03 ± 
0.02 0.17% <0.00 
-0.02; 
0.02 
Single support 
time (sec) 
0.02 ± 
0.01 1.21% -0.01 
-
0.03;0.
02 
0.02 ± 
0.01 1.43% -0.01 
-0.02; 
0.01 
Double support 
time (sec) 
0.03 ± 
0.01 7.40% 0.01 
-0.04; 
0.06 
0.03 ± 
0.03 5.79% 0.01 
-0.05; 
0.07 
Temporophasic parameters 
Stance time 
(%GC) 
1.72 ± 
0.39 0.98% 0.57 
-1.37; 
2.51 
1.97 ± 
1.23 1.13% 0.69 
-2.00; 
3.43 
Single support 
time (%GC) 
2.44 ± 
1.35 1.37% -0.57 
-3.53; 
2.39 
2.31 ± 
1.40 1.26% -0.50 
-3.24; 
2.24 
Double support 
time (%GC) 
3.01 ± 
1.14 6.96% 1.14 
-3.58; 
5.86 
2.68 ± 
2.29 5.69% 1.18 
-4.14; 
6.51 
Temporospatial parameters 
Gait speed (m/s) 0.04 ± 0.03 2.68% -0.03 
-0.11; 
0.04 
0.04 ± 
0.03 2.13% -0.03 
-0.10; 
0.05 
Normalised gait 
speed 
0.01 ± 
0.01 2.68% -0.01 
-0.04; 
0.01 
0.01 ± 
0.01 2.13% -0.01 
-0.03; 
0.02 
Abbreviations: %D = percentage difference; cm = centimetres; GC = gait cycle; LoA = limits of 
agreement; m/s = meters per second; PLHIV = people living with HIV-1 infection; RMSE = root-
mean-square error; sec = seconds; SNP = HIV-seronegative participants.  
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Figure 6.1. Bland Altman plots showing bias (solid lines) and Limits of Agreement (dashed 
lines) between systems for TSPs in PLHIV and SNP (Study Two). These data are direct 
myoMOTION output, since modelling differences did not affect TSPs. Blue colouring 
indicates results for PLHIV and red colouring indicates results for SNP. 
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Figure 6.2. Bland Altman plots showing bias (solid lines) and Limits of Agreement (dashed 
lines) between systems for TSPs in PLHIV and SNP (Study Two). These data are direct 
myoMOTION output, since modelling differences did not affect TSPs. Blue colouring indicates 
results for PLHIV and red colouring indicates results for SNP. 
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6.2.2. Gait kinematics 
For kinematic measurements, RMSEs and results from Bland Altman analyses between the 
myoMOTION and VICON systems are reported in Tables 6.2 (direct output) and 6.3 
(calibration-offset adjusted output). Results are presented separately for PLHIV and SNP. 
Agreement between systems regarding kinematic angles is graphically presented using gait 
graphs in Figures 6.4 to 6.6. Bland Altman plots are not included in this dissertation due to the 
large number of outcomes and subsequent space requirements.  
6.2.2.1. Direct output comparison 
In PLHIV as well as in SNP, good agreement existed between the ranges of motion (ROM) 
measured by the myoMOTION and VICON systems (visualised in Figure 6.2). Generally, 
RMSEs, biases and LoA were larger in PLHIV versus SNP (although remaining within 2° from 
those observed in SNP). Comparing direct myoMOTION output to VICON revealed between-
system differences that were more apparent regarding discrete angles (i.e. angular values at 
specific time points of the gait cycle), and less so in joint/segment ROM (i.e. the motion range 
[difference] between minimum and maximum angle). Considering ROM, in both groups 
(PLHIV and SNP), differences between the systems were mostly below 5°; except for hip 
flexion ROM (during entire gait cycle and during pre-swing to initial swing). Regarding discrete 
angles, between-system differences exceeded 5° for fewer outcomes measured in SNP; 
Figure 6.3. Bland Altman plots showing bias (solid lines) and Limits of Agreement 
(dashed lines) between systems for TSPs (normalised stride speed) in PLHIV and SNP 
(Study Two). These data are direct myoMOTION output, since modelling differences did 
not affect TSPs. Blue colouring indicates results for PLHIV and red colouring indicates 
results for SNP. 
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differences were most likely to exceed 5° for discrete knee flexion/extension angles. As 
expected, due to the different model definitions and calibration procedures, discrete joint and 
segment angles in the sagittal plane were mostly underestimated by the myoMOTION relative 
to VICON (indicated by negative biases). 
For the pelvis, RMSEs were smaller than 5° for all ROMs and only exceeded 5° for the two 
discrete segment angles under investigation (i.e. pelvis rotation angle at initial contact and 
peak pelvis anterior tilt). The latter demonstrated particularly large LoA in both groups (-24.2° 
and -24.4° in PLHIV and SNP respectively), also showing the highest RMSE (12.5° ± 5.9° and 
10.2° ± 7.1° in PLHIV and SNP respectively) and biases (-12.5° and -10.1°). For both PLHIV 
and SNP, peak anterior pelvis tilt during the gait cycle showed the largest offsets and poorest 
agreement between systems, and pelvis tilt ROM during the gait cycle the smallest.  
In both groups, trends in between-system differences were similar, hip flexion angle at initial 
contact, peak hip flexion during swing, and peak hip extension during stance showed the 
largest RMSEs, biases and LoA; and hip flexion ROM from stance to swing the lowest. 
However, between-system differences were larger in PLHIV and often exceeded 5° even for 
ROM measurements, with only hip flexion ROM during LR (sagittal plane), hip abduction ROM 
during mid-stance and hip adduction ROM during loading response showing RMSEs below 5° 
in this group.  
For knee ROM measurements, between-system differences were below 5° in PLHIV as well 
as SNP, although some LoA exceeded 5° in both groups. Discrete knee angles showed larger 
differences and mostly exceeded 5°; except for knee flexion at initial contact in PLHIV. In 
contrast to observations for ROM measurements, between-system differences in discrete 
knee angles in the sagittal plane (angles often reported to be sensitive to gait speed 
differences) were larger in SNP than in PLHIV. Peak knee flexion angle during stance (loading 
response) showed the largest offsets (RMSE 15.3° ± 7.5° and 11° ± 7.5° in SNP and PLHIV 
respectively) and poorest agreement (biases of 14.2° and 9.8° in SNP and PLHIV respectively) 
between systems, with large LoA.  
Ankle ROM measurements showed RMSEs, biases and LoA to be smaller than 5° in both 
groups. Discrete ankle angles also showed differences of below 5° in SNP; in contrast, 
differences for these discrete outcomes somewhat exceeded 5° in PLHIV. Specifically, in 
ascending order, peak angle plantarflexion, ankle plantarflexion angle at toe-off and ankle 
dorsiflexion angle at initial contact showed the largest RMSEs, biases and LoA. This trend 
was mirrored in SNP, although between-system differences remained below 5° in SNP.  
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  Figure 6.4. Comparative gait traces between PLHIV (blue) and SNP (red), showing pelvis kinematics over one gait 
cycle as measured by VICON-PiG (left column) and myoMOTION (right column) respectively. The graphs illustrate 
the mean (solid lines) ± standard deviation (shaded areas bounded by dashed lines) estimated by each system for 
each group. 
 
    VICON-PiG: PLHIV vs SNP 
 
 
 
myoMOTION: PLHIV vs SNP 
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myoMOTION: PLHIV vs SNP 
 
    VICON-PiG: PLHIV vs SNP 
 
 
 
myoMOTION: PLHIV vs SNP 
 
  
myoMOTION: PLHIV vs SNP VICON-PiG: PLHIV vs SNP 
Figure 6.5. Comparative gait traces between PLHIV (blue) and SNP (red), showing hip kinematics over one 
gait cycle as measured by VICON-PiG (left column) and myoMOTION (right column) respectively. The 
graphs illustrate the mean (solid lines) ± standard deviation (shaded areas bounded by dashed lines) 
estimated by each system for each group. 
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myoMOTION: PLHIV vs SNP VICON-PiG: PLHIV vs SNP 
 
    VICON-PiG: PLHIV vs SNP 
 
 
 
myoMOTION: PLHIV vs SNP 
Figure 6.6. Comparative gait traces between PLHIV (blue) and SNP (red), showing sagittal plane knee and ankle 
kinematics over one gait cycle as measured by VICON-PiG (left column) and myoMOTION (right column) 
respectively. The graphs illustrate the mean (solid lines) ± standard deviation (shaded areas bounded by dashed 
lines) estimated by each system for each group 
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Table 6.3. Concurrent validity of myoMOTION-measured gait kinematics (direct output). 
Analyses were performed separately in people living with HIV (PLHIV) and seronegative 
participants (SNP).  
Kinematic angle 
SNP PLHIV 
Offset Agreement Offset Agreement 
RMSE 
(mean ± 
SD) 
Bias 95% 
LoA 
RMSE 
(mean ± 
SD) 
Bias 95% LoA 
Pelvis 
Pelvis tilt ROM during 
GC (°) 
2.1 ± 1.1 
 
2.0 -0.1; 4.1 2.9 ± 1.8 2.2 -2.2; 6.5 
Peak pelvis anterior 
tilt during GC (°) 
10.2 ± 7.1 -10.1 -24.4; 
4.2 
12.5 ± 5.9 -12.5 -24.2; -0.8 
Pelvis obliquity ROM 
during GC (°) 
2.4 ± 1.7 -0.6 -6.2; 5.0 4.7 ± 3.3 1.7 -9.3; 12.7 
Pelvis rotation ROM 
during GC (°) 
3.3 ± 1.7 3.0 -0.6; 6.6 4.1 ± 2.4 3.7 -1.2; 8.6 
Pelvis rotation at IC 
(°) 
5.5 ± 2.0 1.2 -1.0; 3.5 5.7 ± 4.5 2.2 -1.0; 5.5 
Hip 
Hip flexion ROM 
during GC (°) 
3.5 ± 1.1 -3.1 -6.0; -
0.2 
5.5 ± 2.1 -5.0 -9.1; -1.0 
Hip flexion ROM 
during LR (°) 
1.9 ± 1.5 0.5 -1.3; 2.3 2.3 ± 1.3 1.3 -2.0; 4.6 
Hip flexion ROM, PS 
to IS (H3) (°)  
3.1 ± 1.4 <0.0 -5.2; 5.1 5.1 ± 4.4 -1.6 -10.4; 7.2 
Hip flexion angle at IC 
(°) 
8.7 ± 5.1 -5.4 -22.0; 
11.3 
10.6 ± 4.5 -9.4 -22.1; 3.4 
Peak hip flexion 
during swing (°) 
7.8 ± 4.8 -3.7 -20.1; 
12.7 
10.0 ± 4.4 -9.0 -21.0; 3.0 
Peak hip extension 
during stance (°) 
7.3 ± 3.9 0.6 -16.0; 
17.1 
6.7 ± 3.7 4.0 -8.8; 16.7 
Hip abduction ROM 
during mid-stance (°) 
 
3.2 ± 1.7 <0.0 -5.3; 5.4 4.5 ± 3.1 3.3 -3.1; 9.6 
Hip adduction ROM 
during loading 
response (°) 
3.2 ± 1.4 2.8 -0.1; 5.6 2.9 ± 1.9 2.5 -1.4; 6.3 
Hip internal rotation 
ROM during GC (°) 
5.2 ± 1.4 1.7 -6.0; 9.5 5.7 ± 3.3 2.7 -6.7; 12.1 
Knee 
Knee flexion ROM 
during GC (°) 
2.2 ± 0.9 0.4 -3.1; 3.9 3.0 ± 1.5 1.4 -3.3; 6.0 
Knee flexion ROM 
during stance (K1) (°) 
2.8 ± 1.3 1.6 -1.9; 5.1 1.9 ± 1.7 0.7 -2.0; 3.4 
Knee flexion ROM 
from stance to swing 
(K3) (°) 
2.5 ± 1.3 -1.7 -5.1; 1.6 2.6 ± 1.3 -1.5 -5.5; 2.5 
Knee extension ROM, 
MSt to TSt (K2) (°) 
2.5 ± 1.3 -2.1 -4.9; 0.7 3.4 ± 1.8 -3.0 -6.7; 0.6 
Stellenbosch University  https://scholar.sun.ac.za
 - 152 - | P a g e  
 
Knee flexion at IC (°) 7.8 ± 1.9 5.8 -2.2; 
13.7 
4.8 ± 3.3 2.2 -6.3; 10.7 
Peak knee flexion 
during stance, LR (°) 
15.3 ± 7.5 14.2 -0.4; 
28.8 
11.0 ± 7.5 9.8 -5.5; 25.0 
Peak knee extension 
during stance (°) 
 
9.3 ± 2.8 -8.3 -1.1; -
15.5 
5.3 ± 4.0 -4.0 -12.5; 4.6 
Peak knee flexion 
during swing (°) 
8.5 ± 2.5 7.6 1.2; 
14.1 
5.4 ± 3.6 4.1 -4.1; 12.3 
Ankle 
Ankle dorsiflexion 
ROM during stance 
(A1) (°) 
2.7 ± 1.1 2.0 -1,1; 5.2 2.7 ± 0.7 1.7 -1.5; 4.9 
Ankle dorsiflexion 
ROM during swing (°) 
2.3 ± 1.8 1.1 -3.3; 5.4 2.4 ± 1.0 1.1 -2.3; 4.6 
Ankle plantarflexion 
ROM during push off 
(A2) (°) 
2.6 ± 1.7 0.5 -4.8; 5.8 3.4 ± 1.6 2.2 -2.7; 7.1 
Ankle dorsiflexion 
angle at IC (°) 
3.6 ± 1.7 -2.8 -7.3; 1.7 5.5 ± 1.8 -4.6 -10.8; 1.6 
Ankle plantarflexion 
angle at TO (°) 
4.1 ± 1.3 1.9 -4.1; 7.9 6.1 ± 3.3 5.1 -1.7; 11.8 
Peak ankle 
plantarflexion during 
GC (°) 
4.3 ± 2.1 1.1 -6.9; 9.2 5.4 ± 2.9 4.6 -2.7; 11.9 
Abbreviations: A1 = corresponding to A1 power phase of ankle; A2 = corresponding to A2 power 
phase of ankle; GC = gait cycle; H3 = corresponding to H3 power phase of hip; HR = heel rise; IC = 
initial contact;K1= corresponding to K1 power phase of knee; K2 = corresponding to K2 power phase 
of knee; K3 = corresponding to K3 power phase of knee; LoA = limits of agreement; LR = loading 
response; MSt = mid-stance; PLHIV = people living with HIV-1-infection; RMSE = root-mean-square 
error; ROM = range of motion; SD = standard deviation; SNP = HIV-seronegative participants; TO = 
toe-off; TSt = terminal stance. 
 
6.2.2.2. Calibration-adjusted output comparison 
Removing the calibration-offset between the kinematic waveforms of the systems/models 
resulted in improved consistency between systems/models regarding discrete angles, while 
ROM values were not affected. These results are presented in Table 6.3 
In PLHIV, the biggest discrepancies between systems were noted for peak knee flexion during 
stance (loading response) (RMSE 7.4° ± 4.5°; bias 6.1°), hip internal rotation ROM during the 
gait cycle (RMSE 5.7° ± 3.3°) and hip flexion ROM during the gait cycle (RMSE 5.5° ± 2.1°). 
In SNP, the biggest differences were similarly observed for peak knee flexion during stance 
(loading response) (RMSE 8.8° ± 5.1°; bias 6.8°) and hip internal rotation ROM during the gait 
cycle (RMSE 5.2° ± 1.4°). Offset removal rendered all other differences below 5°, although 
most LoA for most differences exceeded 5° for at least one of the limits. 
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Table 6.4. Concurrent validity of myoMOTION-measured kinematic gait angles 
(calibration-adjusted). Analyses were performed separately in people living with HIV 
(PLHIV) and seronegative participants (SNP). 
Kinematic angle SNP PLHIV 
Offset Agreement Offset Agreement 
RMSE 
(mean ± SD 
Bia
s 
95% 
LoA 
RMSE 
(mean ± SD) 
Bia
s 
95% LoA 
Pelvis 
Pelvis tilt ROM 
during GC (°) 
2.1 ± 1.1 2.0 -0.1; 4.1 2.9 ± 1.8 2.2 -2.2; 6.5 
Peak pelvis 
anterior tilt during 
GC (°) 
1.2 ± 0.5 -0.7 -2.6; 1.3 1.8 ± 1.4 -0.4 -4.8: 4.0 
Pelvis obliquity 
ROM during GC (°) 
2.4 ± 1.7 -0.6 -6.2; 5.0 4.7 ± 3.3 1.7 -9.3; 12.7 
Pelvis rotation 
ROM during GC (°) 
3.3 ± 1.7 3.0 -0.6; 6.6 4.1 ± 2.4 3.7 -1.2; 8.6 
Pelvis rotation at 
IC (°) 
2.2 ± 1.0 0.6 -0.7; 1.8 1.8 ± 1.1 0.8 -0.9; 2.4 
Hip 
Hip flexion ROM 
during GC (°) 
3.5 ± 1.1 -3.1 -6.0; -0.2 5.0 ± 2.1 -5.0 -9.1; -1.0 
Hip flexion ROM 
during LR (°) 
1.9 ± 1.5 0.5 -1.3; 2.3 2.3 ± 1.3 1.3 -2.0; 4.6 
Hip flexion ROM, 
PS to IS (H3) (°) 
3.1 ± 1.4 <0.0 -5.2; 5.1 5.1 ± 4.4 -1.6 -10.4; 7.2 
Hip flexion angle 
at IC (°) 
4.1 ± 1.5 -3.7 -6.7; -0.6 4.9 ± 2.6 -3.9 -10.6; 2.8 
Peak hip flexion 
during swing (°) 
2.4 ± 1.7 -2.0 -5.4; 1.3 4.7 ± 1.9 -3.5 -9.7; 2.8 
Peak hip extension 
during stance (°) 
2.4 ± 0.7 -1.0 -4.7; 2.4 3.3 ± 3.0 -1.5 -9.1; 6.0 
Hip abduction 
ROM during mid-
stance (°) 
3.2 ± 1.7 <0.0 -5.3; 5.4 4.5 ± 3.1 3.3 -3.1; 9.6 
Hip adduction 
ROM during 
loading response 
(°) 
3.2 ± 1.4 2.8 -0.1; 5.6 2.9 ± 1.9 2.5 -1.4; 6.3 
Hip internal 
rotation ROM 
during GC (°) 
5.2 ± 1.4 1.7 -6.0; 9.5 5.7 ± 3.3 2.7 -6.7; 12.1 
Knee 
Knee flexion ROM 
during GC (°) 
2.2 ± 0.9 0.4 -3.1; 3.9 3.0 ± 1.5 1.4 -3.3; 6.0 
Knee flexion ROM 
during stance (K1) 
(°) 
2.8 ± 1.3 1.6 -1.9; 5.1 1.9 ± 1.7 0.7 -2.0; 3.4 
Knee flexion ROM 
from stance to 
swing (K3) (°) 
2.5 ± 1.3 -1.7 -5.1; 1.6 2.6 ± 1.3 -1.5 -5.5; 2.5 
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Knee extension 
ROM, MSt to TSt 
(K2) (°) 
2.5 ± 1.3 -2.1 -4.9; 0.7 3.4 ± 1.8 -3.0 -6.7; 0.6 
Knee flexion at IC 
(°) 
4.2 ± 1.7 -1.6 -7.8; 4.6 3.9 ± 1.9 -1.5 -7.2; 4.2 
Peak knee flexion 
during stance, LR 
(°) 
8.8 ± 5.1 6.8 -2.8; 
16.3 
7.4 ± 4.5 6.1 -3.4; 15.5 
Peak knee 
extension during 
stance (°) 
3.2 ± 1.2 -0.9 -4.2; 2.4 3.9 ± 2.1 -0.3 -7.1; 6.5 
Peak knee flexion 
during swing (°) 
2.4 ± 1.1 0.2 -3.7; 4.2 2.6 ± 2.2 0.4 -5.5; 6.3 
Ankle 
Ankle dorsiflexion 
ROM during 
stance (A1) (°) 
2.7 ± 1.1 2.0 -1.1; 5.2 2.7 ± 0.7 1.7 -1.5; 4.9 
Ankle dorsiflexion 
ROM during swing 
(°) 
2.3 ± 1.8 1.1 -3.3; 5.4 2.4 ± 1.0 1.1 -2.3; 4.6 
Ankle 
plantarflexion 
ROM during push 
off (A2) (°) 
2.6 ± 1.7 0.5 -4.8; 5.8 3.4 ± 1.6 2.2 -2.7; 7.1 
Ankle dorsiflexion 
angle at IC (°) 
3.4 ± 1.3 -1.6 -5.9;2.8 2.8 ± 1.8 -1.3 -4.2; 1.7 
Ankle 
plantarflexion 
angle at TO (°) 
2.8 ± 1.4 0.7 -3.7; 5.1 3.7 ± 1.9 1.7 -2.7; 6.0 
Peak ankle 
plantarflexion 
during GC (°) 
3.2 ± 1.6 -0.1 -5.5; 5.4 2.5 ± 1.9 1.2 -3.7; 6.1 
Abbreviations: A1 = corresponding to A1 power phase of ankle; A2 = corresponding to A2 power 
phase of ankle; GC = gait cycle; H3 = corresponding to H3 power phase of hip; HR = heel rise; IC = 
initial contact;K1= corresponding to K1 power phase of knee; K2 = corresponding to K2 power 
phase of knee; K3 = corresponding to K3 power phase of knee; LoA = limits of agreement; LR = 
loading response; MSt = mid-stance; PLHIV = people living with HIV-1-infection; RMSE = root-
mean-square error; ROM = range of motion; SD = standard deviation; SNP = HIV-seronegative 
participants; TO = toe-off; TSt = terminal stance. 
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6.3. MyoMOTION reliability  
6.3.1. Temporal, spatial, temporophasic and temporospatial 
parameters (TSPs) 
Table 6.5 presents reliability results for myoMOTION-measured TSPs in terms of SEM, %SEM 
and the upper 95% CL of the SEM. For spatial parameters, measurements in SNP 
demonstrated better reliability relative to PLHIV (lower SEM, %SEM and upper 95% CL), 
although %SEM observed in the two respective groups were within 1.78% of each other. In 
both groups, step length (both absolute and normalised) showed good reliability (5% £ %SEM 
< 10.00%),364 while stride length (both absolute and normalised) showed excellent reliability 
(%SEM < 5%).364 
In contrast, to the trend observed for spatial parameters, temporal and temporophasic 
parameters showed better reliability in PLHIV than in SNP, especially for stance time in 
seconds. Based on %SEM, this outcome demonstrated good reliability in SNP, but excellent 
reliability in PLHIV. Step time in seconds and single support time in seconds showed good 
reliability in both groups, while double support time in seconds demonstrated sufficient 
reliability (10.00% £ %SEM < 20.00%).364 The largest error in double support time likely to be 
observed in 95% of cases for both groups was still only 0.04 seconds. 
Stance time as a percentage of the gait cycle showed excellent reliability in both groups, single 
support percentage showed good reliability in both groups and double support percentage 
showed sufficient reliability.  
Temporospatial parameters were more repeatable in SNP, although differences in %SEM 
were within ~1% between groups. Gait (stride) speed demonstrated excellent reliability in both 
groups, but once normalised to leg length, reliability was good in SNP and just above the limit 
for sufficient in PLHIV. The largest error likely to be observed in 95% of cases for PLHIV was 
still only 0.05 m/s – this remains below 0.1 m/s, which is considered as a clinically significant 
threshold in various populations.369 
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Table 6.5. Within-session reliability of myoMOTION-measured TSPs. Reliability was 
assessed using direct myoMOTION model output.  
Parameter SNP PLHIV 
SEM %SEM Upper 
95% CL 
SEM %SEM Upper 
95% CL 
Spatial parameters 
Step length (cm) 4.01 6.09% 4.81 4.33 6.82% 5.20 
Normalised step 
length 
0.04 5.20% 0.05 0.05 6.98% 0.06 
Stride length (cm) 3.20 2.46% 3.84 4.03 3.23% 4.84 
Normalised stride 
length 
0.04 2.65% 0.05 0.05 3.56% 0.06 
Temporal parameters 
Cadence 
(steps/min) 
8.31 7.08% 9.97 9.67 8.82% 11.60 
Normalised 
cadence 
2.45 7.04% 2.94 2.83 8.57 3.40 
Stance time (sec) 0.06 9.78% 0.07 0.03 4.48% 0.04 
Step time (sec) 0.04 7.70% 0.05 0.04 7.22% 0.05 
Single support time 
(sec) 
0.03 7.14% 0.04 0.03 6.91% 0.04 
Double support 
time (sec) 
0.03 15.23% 0.04 0.03 12.77% 0.04 
Temporophasic parameters 
Stance time (%GC) 1.97 3.31% 2.36 1.60 2.63% 1.92 
Single support time 
(%GC) 
2.56 6.34% 3.07 2.49 6.32% 2.99 
Double support 
time (%GC) 
2.18 11.42% 2.62 2.30 10.71% 2.76 
Temporospatial parameters 
Gait speed (m/s) 0.02 1.58% 0.02 0.02 1.75% 0.02 
Normalised gait 
speed 
0.04 9.20% 0.05 0.04 10.34% 0.05 
Abbreviations: %SEM = absolute percentage SEM; 95%CL = 95% confidence limits of SEM; GC = 
gait cycle; PLHIV = people living with HIV-1 infection; SEM = standard error of measurement; SNP = 
HIV-seronegative participants. 
Bold print indicates clinically significant values. 
SEM 95% confidence limits were calculated using a sample-and-trial-specific multiplying factor of 
1.2.362 
Stellenbosch University  https://scholar.sun.ac.za
 - 157 - | P a g e  
 
6.3.2. Kinematic angles 
Table 6.6 presents reliability results for myoMOTION-measured kinematic angles during gait. 
SEM values were generally very similar between both groups. In SNP, pelvis rotation at initial 
contact and ankle plantarflexion angle at toe-off were the only angles with reliability exceeding 
5°, while in PLHIV, peak knee flexion in stance (i.e. during loading response) showed an SEM 
of 5.8°, with an upper 95% CL of 7.0°. Additionally, ankle plantarflexion angle at toe-off and 
peak ankle plantarflexion during the gait cycle both demonstrated an upper 95% CL of 5.3° in 
PLHIV (although SEM values were below 5.0°). 
Table 6.6. Within-session reliability of myoMOTION-measured gait kinematics. 
Reliability was assessed using direct myoMOTION model output. 
Anatomical angle SNP PLHIV 
SEM Upper 95% 
CL 
SEM Upper 95% 
CL 
Pelvis 
Pelvis tilt ROM during GC 0.7 0.8 0.8 1.0 
Peak pelvis anterior tilt 
during GC 
1.1 1.3 1.2 1.4 
Pelvis obliquity ROM during 
GC 
0.9 1.1 1.1 1.3 
Pelvis rotation ROM during 
GC 
2.1 2.5 1.8 2.2 
Pelvis rotation at IC 5.2 6.2 3.7 4.4 
Hip 
Hip flexion ROM during GC 
(°) 
2.4 2.9 2.1 2.5 
Hip flexion ROM during LR 
(°) 
1.7 2.0 2.6 3.1 
Hip flexion ROM, PS to IS 
(H3) (°) 
2.3 2.8 2.0 2.4 
Hip flexion angle at IC (°) 2.4 2.9 2.1 2.5 
Peak hip flexion during 
swing (°) 
2.2 2.6 2.1 2.5 
Peak hip extension during 
stance (°) 
1.8 2.2 2.4 2.9 
Hip abduction ROM during 
mid-stance (°) 
2.6 3.1 2.0 2.4 
Hip adduction ROM during 
loading response (°) 
1.4 1.7 1.5 1.8 
Hip internal rotation ROM 
during GC (°) 
2.6 3.1 2.8 3.4 
Knee 
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Knee flexion ROM during 
GC (°) 
1.4 1.7 2.2 2.6 
Knee flexion ROM during 
stance (K1) (°) 
2.9 3.5 2.5 3.0 
Knee flexion ROM from 
stance to swing (K3) (°) 
3.0 3.6 2.8 3.4 
Knee extension ROM, MSt 
to TSt (K2) (°) 
1.9 2.3 2.4 2.9 
Knee flexion at IC (°) 3.0 3.6 3.2 3.8 
Peak knee flexion during 
stance, LR (°) 
3.9 4.7 5.8 7.0 
Peak knee extension during 
stance (°) 
2.9 3.5 3.1 3.7 
Peak knee flexion during 
swing (°) 
2.0 2.4 2.9 3.5 
Ankle 
Ankle dorsiflexion ROM 
during stance (A1) (°) 
2.0 2.4 1.9 2.3 
Ankle dorsiflexion ROM 
during swing (°) 
2.9 3.5 3.3 4.0 
Ankle plantarflexion ROM 
during push off (A2) (°) 
2.2 2.6 3.7 4.4 
Ankle dorsiflexion angle at 
IC (°) 
2.0 2.4 2.1 2.5 
Ankle plantarflexion angle 
at TO (°) 
5.2 6.2 4.4 5.3 
Peak ankle plantarflexion 
during GC (°) 
4.1 4.9 4.4 5.3 
Abbreviations: %SEM = absolute percentage SEM; 95%CI = 95% Confidence Interval; A1 = 
corresponding to A1 power phase of ankle; A2 = corresponding to A2 power phase of ankle; GC = 
gait cycle; H3 = corresponding to H3 power phase of hip; HR = heel rise; IC = initial contact; K1= 
corresponding to K1 power phase of knee; K2 = corresponding to K2 power phase of knee; K3 = 
corresponding to K3 power phase of knee; LoA = limits of agreement; LR = loading response; MSt = 
mid-stance; PLHIV = people living with HIV-1-infection; RMSE = root-mean-square error; ROM = 
range of motion; SD = standard deviation; SEM = standard error of measurement; SNP = HIV-
seronegative participants; TO = toe-off; TSt = terminal stance. 
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6.4. Chapter summary 
This chapter concludes the validity and reliability testing of the myoMOTION system. 
Results confirm that the validity of myoMOTION measurements was not compromised 
in PLHIV and community-matched SNP, and that findings (trends) were similar in both 
participant groups. Biomechanical modelling offsets between systems only affected 
discrete kinematic angles (pelvis, hip, knee and ankle), while TSPs and kinematic ROMs 
(with the exception of hip internal rotation ROM) were not affected and demonstrated 
values corresponding to good validity and reliability for direct myoMOTION modelling 
output. In addition, SEM values were similar to those obtained using the myoMOTION 
in healthy student volunteers  (Study One) and similar to or smaller than published 
values for OMC systems.318,326 All kinematic outcomes and TSPs showed clinically 
acceptable (kinematic differences < 5°) or acceptable-to-excellent (TSP percentage 
differences generally below 3%, and all below 20%) within-session reliability. For 
kinematic angles, total ROM in a given movement plane was generally more reliable 
than discrete angles. Apart from four discrete angles (pelvis rotation at initial contact, 
ankle plantarflexion at toe-off, peak ankle plantarflexion during the gait cycle and peak 
knee flexion during stance), reliability was clinically acceptable for all gait outcomes.  
In summary, the myoMOTION proved a valid system for measuring the gait outcomes 
of interest in a South African rural cohort including PLHIV and SNP. In addition, because 
absolute reliability statistics such as the SEM provides results in the original unit of 
measurement, the measurement error for each of the outcomes to be analysed in the 
cross-sectional field study is now known and will aid data interpretation in the cross-
sectional field study, presented in the next two chapters. 
 
.  
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  PART III 
DESCRIBING GAIT, BALANCE AND PHYSICAL 
PERFORMANCE IN SOUTH AFRICAN ADULTS 
LIVING WITH HIV-1 INFECTION 
Preface 
Part III of the dissertation reports the methodology and results of an observational cross-
sectional study (with an analytical component) to address the main aim of the dissertation: the 
comparison of gait kinematics and postural balance of PLHIV to those of community-matched 
SNP to ascertain key biomechanical differences, and the determination of correlations 
between clinical physical performance tests and a gait summary score (based on valid 
quantitative outcomes), fall-related outcomes and self-reported function. Significant 
correlations with the gait score will validate the tests as being able to screen for quantitative, 
early changes locomotor impairments, while associations with self-reported function and fall-
related outcomes will additionally indicate the potential to screen for consequences such as 
an increased fall risk. This third primary study is spread over two chapters (Chapters 6 and 7, 
see Figure below). Chapter 7 presents the study methodology, while Chapter 8 presents the 
results of both the descriptive comparison and correlation components of the study.   
Figure Part III. Schematic layout of the structure of Part III of the dissertation. IMC = 
inertial motion capture; PLHIV = people lving with HIV-1 infection; TSPs = temporal 
and spatial parameters. 
 
 
PART IIi 
Field-based research – 3DGA 
in PLHIV and correlations with 
clinical test(s) 
 
 
 
Towards better understanding 
of locomotor impairments in 
PLHIV and identifying the 
most valid test for early 
screening in PLHIV.  
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  PART III 
 
METHODOLOGY: CROSS-SECTIONAL FIELD 
STUDY 
7.1. Aims and objectives 
7.1.1. Aim 
The aim of this study was to describe gait and balance impairments existing among PLHIV 
residing in the Cape Winelands District of the Western Cape, South Africa, using state-of-the-
art three-dimensional gait analysis (3DGA) technology. It further aimed to identify whether 
relationships exist between selected physical performance tests (which may be considered in 
clinical practice to screen for early functional decline in PLHIV) and the findings of 3D gait 
analysis (summarised using a quantitative gait score), self-reported function and history and 
fear of falling. 
7.1.2. Objectives 
PRIMARY: 
1. To describe the difference in gait biomechanics between PLHIV and SNP as determined 
by pelvis, hip, knee and ankle joint/segment angles and angular motion during pre-
specified key events and sub-phases and of the gait cycle under usual-paced, fast-
paced and dual task conditions; 
2. To describe the difference between PLHIV and SNP regarding static postural stability as 
determined by centre of pressure (COP) excursion and velocity during single leg stance; 
3. To ascertain the correlations between clinical physical function test performance and a 
quantitative gait measure (i.e. a summary score of gait based on valid 3D-analysis gait 
outcomes), self-perceived functional ability, and fall-related outcomes (fall history, 
number of falls over the past year and fear of falling) within PLHIV. 
SECONDARY:  
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1. To describe the difference in clinical physical function test performance between PLHIV 
and SNP as determined by scoring the Health ABC Physical Performance Battery (PPB), 
six-metre walk tests, single leg stance tests and chair rise tests. 
7.2. Ethical considerations 
The study was conducted in accordance with the Declaration of Helsinki. Ethical approval for 
this project as a sub-study to the EndoAfrica studyvi was obtained from the Health Research 
Ethics Committee (HREC) of the Stellenbosch University (SU), South Africa (N15/05/043) 
(Appendix A). Permission to conduct the study at both the selected healthcare facilities of the 
Provincial Government of the Western Cape was provided by the Western Cape Provincial 
Research Health Committee (WC_2016RP10_878) (Appendices B and C). All eligible 
participants were required to read and sign an informed consent document prior to 
participating in the study (in their preferred language, English, Afrikaans or Xhosa). To ensure 
anonymity, a unique study identification code (e.g. HIVP2_001, HIVP2_002, etc.) was 
allocated to each participant on recruitment.  
7.3. Study design 
The research design was that of an observational, descriptive cross-sectional study, with 
correlation analysis incorporated as an analytical component. The project was a sub-study to 
the ongoing larger longitudinal EndoAfrica cohort (described previously in Chapter 4, Section 
4.7.2). 
7.4. Study setting 
This study was conducted in Worcester and Paarl; two of the largest towns in the Cape 
Winelands district, Western Cape, South Africa (Figure 7.1). In each town, a public community 
health centre (CHC) was the research base: in Worcester, data collection was conducted in a 
dedicated, private room on a satellite SU medical campus (Ukwanda) directly adjacent to the 
Worcester CHC (due to restricted space in the CHC itself); in Paarl, data collection was 
conducted in a dedicated, private room in the rehabilitation wing of the TC Newman CHC.  
                                               
vi Cape Winelands HAART to HEART (Prevalence)/EndoAfrica study, Department of Physiological 
Sciences, Stellenbosch University/Division of Medical Physiology, Faculty of Medicine and Health 
Sciences, Stellenbosch University (N12/12/086). 
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Figure 7.1. The Cape Winelands District (shaded red on the small and green on the 
larger map) of the Western Cape, South Africa. The current study was conducted in 
the towns of Worcester and Paarl, two of the largest towns in this municipal district. 
7.5. Study population 
Participants were recruited from the same population described for the overhead EndoAfrica 
study, as presented in Chapter 4, Section 4.7.2. For this sub-study, participants were 
additionally recruited from a former primary care site utilised by the overhead study, based in 
Paarl, to result in an additional but similar recruitment population. The study population 
primarily consisted of male and female adults (patients and their family or friends) residing in 
and around the Cape Winelands towns of Worcester and Paarl, Western Cape, South Africa, 
and visiting two public primary care CHCs in these regions. Both these sites represent primary 
care HIV clinics situated in two of the largest towns in the Cape Winelands District municipal 
area.  
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7.6. Sampling method 
7.6.1. Sample size 
Sample size was based on the study objective of testing the null hypothesis of equality of 
means in kinematic angles in two independent groups (PLHIV and SNP). A sample size 
calculation was performed based on preliminary data collected from the first 30 study 
participants (15 PLHIV and 15 SNP) in the field study, as no literature exists regarding 
expected effect sizes and variances of lower limb kinematics in PLHIV. A biostatistician was 
advised and recommended this pragmatic approach, which was stated as such in the study 
protocol. The following parameters were of interest for sample size calculation: absolute 
allowable error (minimum clinically important difference, MCID) in the estimation, the pooled 
standard deviation of the variable of interest (kinematic angles), statistical significance and 
statistical power.370 MCID guidelines for lower limb kinematic parameters have been 
suggested in the literature with a threshold of 5° generally being deemed acceptable for 
instrumented gait analysis.318,327,371 Results from the methods comparison studies (Part II of 
the dissertation) confirmed this value for IMC-measured gait when using the myoMOTION 
system in PLHIV. Preliminary kinematic results were examined to determine the outcome with 
the highest SD (inter-subject variability), which was identified as ankle dorsiflexion at initial 
contact. This allowed for a conservative estimate; consequently, the calculated sample size 
should be large enough to detect differences of 5° in lower limb gait kinematics. The pooled 
SD (x) was calculated as: 
x = 	g(:, − 1)(A,C) +	(:C − 1)(ACC)(:, +	:C − 2)  
=	g(15 − 1)(8.046C) + 	(15	 − 1)(8.693	C)(15 + 	15 − 2)  
= 8.376 
where x is the pooled SD, :,	and :C are the sample sizes in the groups being compared, and A, and AC are the respective sample SDs.  
Statistical level of significance was set at α = 0.05 (5% chance of finding a Type 1 error), and 
power (1-β) = 0.80 (20% chance of finding a Type 2 error). Sample size was subsequently 
calculated as:   
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 ≥	2xCÅÇ,ÉÑ/C +	Ç,ÉÜáCSC  
≥	2	(8.376)C(1.96 + 	0.84)C5C  ≥ 44.003 
where  is the minimun sample size per group, x is the pooled SD, Ç,ÉÑ/C		 is the value from 
the standard normal distribution holding 1 − j/2 below it (i.e. corresponding to significance of 
0.05), Ç,ÉÜ is the value from the standard normal distribution holding 1 − à below it (i.e. 
corresponding to 0.80 power) and S is the MCID.  
A total sample of at least 45 participants per group was thus proposed to detect a difference 
of 5° in joint angles. An additional 10% of participants were considered to allow for potential 
missing data points, resulting in a sample size of 50 participants per study group.  
A post hoc power analysis was performed to ascertain the power of the sample size of 50 
PLHIV to detect a moderate correlation (r = 0.4) between clinical performance tests and 
enhanced Gait Variability Index (EGVI) scores (the main criterion for validating the 
performance tests). Power was determined as 83%, which is deemed sufficient (>80%).  
7.6.2. Eligibility criteria 
Apart from the specific criteria related to HIV-serostatus (see Sections 7.6.2.2 and 7.6.2.3 
below), participants were selected on the basis of similar eligibility criteria: 
7.6.2.1. General criteria 
General eligibility criteria were similar to those listed for the second validity and reliability study, 
as listed and motivated in Section 4.8.1. Briefly, participants were eligible for the cross-
sectional field study if they were: 
1. Adults (aged 18 to 65 years).  
2. Had a body mass index (BMI) < 25kg/m2.  
3. Were independently ambulant (without any walking aids). 
4. Were able to consent and participate in all study procedures. 
Participants were excluded if they: 
1. Were pregnant (if female). 
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2. Had a current acute opportunistic infection or illness. 
3. Suffered from distal sensory peripheral neuropathy (data from folder and/or self-report; 
confirmed via a brief neurological conduction examination performed by the 
researcher). 
4. Had a history of seizures, mental retardation, head injury, stroke, epilepsy, cerebral 
palsy or other major neurological conditions. 
5. Suffered from any other neuromusculoskeletal impairments or injury that might affect 
their usual gait.  
6. Were visually impaired (not correctable with spectacles or contact lenses). 
7. Had ingested alcohol on the day of testing. 
7.6.2.2. Criteria for the HIV-seropositive group 
1. For the HIV-1 seropositive group (PLHIV), participants had to have a confirmed 
diagnosis of HIV-1 infection via blood test, either as an already-enrolled participant in 
the EndoAfrica study or as a participant independently recruited for the biomechanical 
sub-study. Once screened for the present study by the research nurse or health 
practitioner, and after agreeing to having their blood tested, those individuals who did 
not already have their status confirmed as part of the EndoAfrica study, were 
counselled by the research nurse (Worcester) or HIV-counselor (Paarl) and a rapid 
HIV test was performed at the relevant CHC to confirm their status.  
2. PLHIV were included regardless of HAART use. The systematic review62 presented in 
Chapter 3 found that gait and balance impairments in PLHIV is not likely associated 
with HAART use.  
7.6.2.3. Criteria for the HIV-seronegative group 
1. For the HIV-seronegative comparison group (SNP), participants had to be HIV-
seronegative adults from the same community as the HIV-1 seropositive group (either 
EndoAfrica participants or not). Once screened by the research nurse or health 
practitioner, and after agreeing to having their blood tested, those individuals who did 
not already have their status confirmed as part of the EndoAfrica study, were 
counselled and a rapid HIV test was performed at the CHC to confirm their status. 
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7.6.3. Sampling procedure 
All participants fulfilling eligibility criteria were recruited consecutively until the required sample 
size for this study was achieved. Although it may not be assumed that this method of sampling 
results in a fully representative sample of the entire target population, consecutive sampling 
was deemed the most appropriate option within the time- and financial constraints of the 
project. This method is also considered the best option among nonprobability techniques, as 
all available participants fulfilling inclusion criteria are studied, resulting in a fairly good 
representation of the overall population in a reasonable time frame.  
The sample of 100 adults (50 PLHIV and 50 SNP) was recruited from Worcester and Paarl 
between June 2016 and December 2017. Figure 7.2 illustrates the eligibility criteria and 
recruitment of study groups. Participants were enrolled from a local CHC in each respective 
town, making use of Health Professions Council of South Africa (HPCSA)-registered nurses 
(Worcester and Paarl) and accredited HIV-counsellors (Paarl). At the Worcester site, 
participation was proposed consecutively to individuals already enrolled in the EndoAfrica 
study or patients and their friends and family attending the CHC, identified by the nurse as 
potential participants (in the same manner as recruiting participants for the EndoAfrica study). 
At the Paarl site, PLHIV receiving primary outpatient care at TC Newman CHC and who were 
potentially eligible, were consecutively referred for study participation by the attending medical 
practitioner or nursing sister. Potentially eligible SNP were referred by the accredited HIV 
counsellors (who are also responsible for HIV testing) at the Paarl clinic. This ensured that 
these participants already had supporting blood results, fulfilling one of the criteria to 
participate as a control.  
At both sites, the relevant health professionals explained study procedures to potential 
participants, including the need for HIV-testing as part of the eligibility criteria. At the Worcester 
site, the research nurse also performed eligibility screening. Upon attending their scheduled 
session for data collection, participants had the chance to further discuss any questions or 
concerns with the researcher and still had the opportunity to decline participation. At the Paarl 
site, the researcher performed eligibility screening (referred participants had their HIV-
serostatuses already confirmed). Data collection sessions, either at the SU Ukwanda campus 
(Worcester) or in a dedicated room in TC Newman (Paarl), were scheduled on the same day 
of recruitment if participants indicated that they had time available (participants often had 
taken the entire day off from work to allow for visiting the CHC). For participants awaiting 
medication from the clinic pharmacy, arrangements were made to have these medications 
prepared for collection by the participant directly after their study participation. Alternatively, if 
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participants had other commitments, a suitable date and time was scheduled for data 
collection at the participant’s convenience and written on an appointment card. For those with 
mobile phones, a reminder text message was sent the day before participation, or the research 
nurse contacted their home phones. In Worcester participants were transported between the 
CHC and the SU Ukwanda campus, located directly next to Worcester CDC, by the research 
team (either the PhD candidate or a research assistant). All participants who still needed their 
serostatuses confirmed had to specifically provide signed informed consent for (and prior to) 
HIV screening – either as part of EndoAfrica consent or on the specific consent form for this 
study. Informed consent forms for this study were separate from the EndoAfrica forms and 
specific to each clinic (Appendices F and G). At both research sites, all participants received 
compensation for inconvenience and their time spent on research activities at a rate as 
recommended by the National Health Research Ethics Council (NHREC),334 provided in the 
form of local supermarket food vouchers.  
 
Figure 7.2. Flow chart demonstrating sample recruitment for the cross-sectional 
field study. 
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7.7. Measurement instruments and outcomes 
7.7.1. Three-dimensional gait analysis 
The myoMOTION inertial motion capture (IMC) system was used to capture walking gait 
biomechanics of the participants. The system was described in detail in Chapter 4, Section 
4.10. The 28 pelvic, hip, knee and ankle kinematics and 15 TSPs that were evaluated in the 
validity and reliability studies (described in Tables 4.5 and 4.6) were measured. Most of these 
outcomes demonstrated clinically acceptable reliability in the laboratory-based studies 
reported in Chapters 5 and 6. However, four discrete kinematic angles (ankle plantarflexion at 
toe-off, peak ankle plantarflexion during the gait cycle, peak knee flexion during stance and 
pelvis rotation at initial contact) demonstrated clinically unacceptable absolute reliability (Table 
6.6). Although these angles were retained in the analyses to aid visualisation of the overall 
gait pattern, they were flagged as outcomes that cannot be considered to represent a true 
between-group difference or true descriptors of gait in PLHIV. These four angles were thus 
not interpreted as contributors to the gait pattern.  
7.7.2. Composite score for quantifying gait variability (the 
enhanced Gait Variability Index, EGVI) 
The enhanced Gait Variability Index (EGVI) is a single-score summary measure used to 
quantify gait variability and is linked to mobility function.372,373 Specifically, it quantifies the 
distance between the magnitude of variability in a normative reference group, and that in a 
patient group.372 The index is based on five TSPs which are associated with functional 
outcomes (such as fall risk).238,372,374,375 When used in older adults (³ 65 years old) and across 
a range of mobility limitations and functional abilities (including high functioning individuals 
who may have had similar variability to the healthy reference population),372 the EGVI could 
discriminate elders with increased as well as decreased gait variability. The EGVI 
demonstrated significant (p<0.05) and moderate to strong correlations (r between 0.5 and 0.7) 
with all clinical tests of balance and mobility used in the study, and demonstrated a significant 
but weak correlation with history of falls (r = 0.35; p < 0.05). In addition, the index has been 
recommended372 as a more appropriate alternative to its predecessor (the original Gait 
Variability Index, GVI375) (A. Gouelle 2018, personal communication, 12 July).  
In this study, the validity and reliability of the individual parameters used to calculate the EGVI 
(step length [cm], step time [s], stance time [s], single support time [s], and stride velocity 
Stellenbosch University  https://scholar.sun.ac.za
 - 170 - | P a g e  
 
[cm/s]) was confirmed in PLHIV and SNP (Chapter 6). Therefore, although properties such as 
minimum clinically important difference (MCID) and discriminant validity of the EGVI in PLHIV 
remains unknown at this stage, the index was deemed justifiable as a valid summary measure 
of gait in this study.  
An EGVI score of 100 is considered “normal”, as it represents the mean score for the reference 
group. Obtaining a score of 100 would thus indicate that the relevant individual has an amount 
of variability that is similar to the norm, with each 10-point difference indicating a one standard 
deviation (SD) removal from the norm. A score greater than 100 indicates increased gait 
variability (e.g. a more unstable gait), and a score below 100 indicates reduced variability 
relative to the norm (e.g. a more rigid gait).372 Although existing control group values are 
embedded in the EGVI and is available for use, these data were obtained from French adults 
and would not be suited as reference data for this study cohort of younger-to-middle-aged 
adults from a rural South African community. The EGVI allows for replacing the embedded 
reference values with custom norms, and therefore data from the SNP (usual-paced walking) 
in this study were used to determine the normative EGVI values. 
7.7.3. Static balance 
Instrumented analysis of static standing balance was conducted using a high-resolution 
dynamic pressure mapping device, the MatScan Versatek (sensor model 3150E, Tekscan, 
Boston, Massachusetts) (Figure 7.3) at a frequency of 400 Hz. The MatScan is a low profile 
floor mat (thickness of 0.6 cm) comprising 2288 resistive sensors (1.4 sensors/cm2) with a 
sampling frequency of up to 440 Hz.376 Measures of anteroposterior (AP) and mediolateral 
(ML) sway can be provided by the device, including area and direction, elliptical pattern, 
distance and direction travelled by the centre of force (COF), variability in distance travelled 
by the COF, weight-bearing percentage and pressure distribution profiles.377 For this study, 
six COP-based measures were analysed378 (see Table 7.1 for descriptions and equations). 
The MatScan is portable and easy to operate, and is routinely used in clinical and research 
settings,379 including middle-aged HIV-1 seropositive populations.323,324 The validity of the 
MatScan for measuring COP parameters has been reported in healthy individuals as well as 
in various patient populations. Specifically relating to single leg standing, the MatScan has 
proven to provide valid COP measurements relative to force plate data during eyes open (EO) 
and eyes closed (EC) conditions in healthy adults (r > 0.92, p < 0.001).320 Measurement error 
for COP measures using the MatScan has only been reported in elderly rheumatoid arthritis 
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patients, with values of 1.29 mm to 1.33 mm being reported for ML displacements, and 1.79 
mm to 2.35 mm for AP displacements.379  
 
Table 7.1. Centre of pressure (COP) parameters assessed in the cross-sectional field 
study. 
Parameter Description Equation378 
Mean COP velocity 
(mm/s) 
Total COP excursion (distance 
travelled) for the specified time 
period, divided by the time period. 
1âIaä = KäKIr ÷ K 
Mean COP velocity in 
AP direction (mm/s) 
Average velocity of the COP in 
the AP direction 1âIaäåo = KäKIråo ÷ K 
Mean COP velocity in 
ML direction (mm/s) 
Average velocity of the COP in 
the ML direction. 1âIaädç = KäKIrdç ÷ K 
Mean COP distance 
(mm) 
Average distance from the mean 
COP (mean of the RD time 
series). 
1S2HK = 1 ÷LGS[:] 
Mean COP distance in 
the AP direction 
Average AP distance from the 
mean COP (mean absolute value 
of the AP time series) 
1S2HKåo= 1 ÷ L|èê[:]| 
Mean COP distance in 
the ML direction 
Average ML distance from the 
mean COP (mean absolute value 
of the ML time series) 
1S2HKdç= 1 ÷ L|1a[:]| 
Abbreviations: AP = anteroposterior (forwards/backwards); COP = centre of pressure; ML = 
mediolateral (sideways); mm = millimetres; mm/s = millimetres per second; MVELO = mean COP 
velocity; N = number of data points in analysis; n = time series (1,…,N); RD = resultant distance 
time series, referring to the vector distance from the mean COP to each pair of points in the APo 
and MLo time series, where the APo and MLo time series defines the COP path relative to the origin 
of the pressure mat coordinate system; T = period of time selected for analysis (30 seconds); 
TOTEX = total excursion of COP (total length of COP path).  
Figure 7.3. The MatScan pressure mat. 
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7.7.4. Physical performance tests 
Table 7.2 summarises the functional components assessed in this study by the various 
physical performance tests as well as the self-reported questionnaire. 
Table 7.2. Aspects of functional impairment and activity limitations assessed by the 
physical performance tests and the self-reported outcome measures. 
Physical performance test Aspect assessed 
The Health ABC Physical Performance 
Battery (PPB) 
Static balance, mobility and dynamic 
balance at a higher level of the functional 
spectrum compared to the SPPB. 
The Single Leg Stance Test Static postural balance and ability to shift weight into single support. 
The Six-metre Walk Test Gait speed (usual-paced) over a short distance. 
The 5STS test 
Lower limb muscle strength, speed and 
power, dynamic balance and functional 
mobility. 
The 30sSTS test Lower limb muscle strength and endurance. 
Eyes closed conditions 
Sensory reweighting; ability of vestibular 
and somatosensory systems to 
compensate lack of vision. 
Dual task activities Executive function; in particular related to divided attention (capacity to multi-task).380 
Self-reported questionnaire Domain assessed 
The EQ-5D-5L mobility function domain Self-perceived walking ability. 
The EQ-5D-5L self-care function domain  Self-perceived ability to wash and dress one-self. 
The EQ-5D-5L usual activities domain 
Self-perceived ability to perform usual 
activities such as work, study, housework, 
family or leisure activities. 
Abbreviations: 30sSTS = 30-seconds Sit-To-Stand; 5STS = Five-Times Sit-To-Stand; EQ-5D-5L = 
EuroQol 5-Dimensions 5-Levels questionnaire; PPB = Health ABC Physical Performance Battery; 
SLS = single leg stance; SPPB = Short Physical Performance Battery. 
7.7.4.1. The Health ABC Physical Performance Battery (PPB) 
Functional movement and balance in PLHIV and SNP were assessed using an expanded 
version of the traditional Short Physical Performance Battery (SPPB), namely the Health ABC 
Physical Performance Battery (PPB) (Appendix H). The original version of the SPPB381 have 
previously been shown to be both adversely affected and associated with falls in 
PLHIV.2,53,54,60,62 However, since the SPPB is an instrument established in the elderly, it may 
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be limited by a ceiling effect in younger people with higher functional performance levels.53 
Given that this study would include a relatively younger cohort, an expanded version of the 
SPPB was implemented to improve discrimination of physical function at the higher end of the 
functional spectrum, as proposed by Simonsick et al.382 The PPB has been validated for 
repeated measures of physical performance in elders who are high-functioning.382–384 The 
battery is scored according to standing balance (30-second positions held in a semi-tandem, 
tandem and SLS test), chair rise tests (the time taken to rise five times without assistance 
from sitting), gait speed (calculated in metres per second from the time taken to walk six 
metres at a usual pace) and a narrow walk test of dynamic balance (time to walk along a six-
metre-long, 20-cm wide walkway).  
PPB total score ranges continuously from zero to four. Higher scores indicate better 
performance. The first step in the scoring process is to convert test times to rates (speed) for 
the repeated chair stands (chair stands per second) and the two walk times (metres per 
second), and to assign a score of zero when a test was not done successfully. For standing 
balance, the time each of the three stands was held is summed, to create a maximum time of 
90 seconds. Each test performance is then divided by a standard divisor representing the 
maximal performance possible on that specific test, to derive a ratio score ranging from zero 
to one.382 For the chair stands, the divisor was 1x chair stand/second; for both the usual and 
narrow walks, the divisor was 2m/s; and for standing balance, the divisor was 90 seconds.382 
Finally, the ratio scores from the four individual tests are summed to generate a continuous 
scape ranging from zero to four. Simonsick et al.382 designed this approach specifically to 
minimise ceiling effects and maximise overall dispersion on each measure. A change of 0.12 
points on the PPB is considered to be a “small meaningful” change, while a difference of 0.22 
is regarded as a “substantial” change.385 The instructions for the PPB is presented in Appendix 
H. For the SLS component, the same instructions as in Section 7.7.4.2 below were used. 
7.7.4.2. The Single Leg Stance (SLS) Test (eyes open, closed and 
dual task) 
The single leg stance (SLS) test is commonly used to assess balance impairments and risk of 
falling across age groups.386–389 The test is associated with fall risk, particularly injurious falls 
and it has been demonstrated that adults who are unable to hold the test for five seconds have 
2.1 times the risk of sustaining an injurious fall.279 It was one of the first clinical tests to be 
assessed objectively in PLHIV, although it is difficult to draw definite conclusions regarding 
impairment of this activity due to heterogeneous reporting of methodology and results.62 
Nonetheless, and despite some criticism of the test as having learning effects, it may be an 
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appropriate activity for challenging and evaluating equilibrium since SLS may be involved in 
various motor tasks (walking, dressing, turning, stair climbing stair climbing) which require a 
transition from bipedal to single-leg conditions.390 Good test-retest reliability has been reported 
for the SLS in healthy women aged 55 to 77 years: intraclass correlation coefficients (ICC) 
ranged from 0.90 to 0.91 for eyes open (EO) and 0.74 to 0.75 for eyes closed (EC) 
conditions.391 A higher score on the test (longer time held) indicates better function.  
Although SLS with eyes open (EO) was assessed as part of the PPB, it was also performed 
separately on the pressure mat to enable capturing of centre of pressure (COP) data. In 
addition, trials were performed with EC and whilst performing a dual task. Participants were 
instructed to stand with both feet comfortably apart and facing forward on the pressure mat, 
with their arms crossed. Leg dominance does not seem to affect one-legged balancing 
ability392 and participants were thus allowed to choose a preferred stance leg. On verbal 
command, they were to stand on one (the preferred) leg by lifting the opposite foot so that the 
foot is ankle-height off the ground, but not touching the other leg. Participants were instructed 
to look straight ahead and focus on a point in front of them on the wall (an image of a large 
cross was fixated at eye-level on a wall about three metres in front of the participant). The 
instruction was to hold the SLS position as still and for as long as possible without the lifted 
leg touching down, and without shuffling or hopping (weight-bearing foot to remain fixed on 
mat) and until the verbal command was given to stop (i.e. after 30 seconds).  
Instructions for the SLS eyes closed (EC) condition were the same as for the EO condition, 
except that participants’ eyes had to be closed as soon as they had lifted the foot and gotten 
in position, and to keep their eyes closed for the duration of the trial. The third SLS condition 
involved the addition of a dual task (DT) activity (see Section 7.7.4.5). The instructions were 
to start counting backwards on a verbal command, and then to lift the foot upon the second 
verbal command.  
Participants were allowed a practice trial for all conditions, where after three test trials of 30 
seconds each were conducted in a random sequence (including the walk trials for 
instrumented gait analysis) to account for potential fatigue or learning effects towards the end 
of the trials. The trials were timed with a stopwatch and the best time out of three performances 
was recorded. The reported MCID for the timed SLS varies widely, from 10.8 seconds393 to 
24.1 seconds.394 
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7.7.4.3. The Six-metre Walk Test (6mWT) 
Gait speed is widely cited as a valid and reliable metric and predictor for functional status and 
overall health.50 It is strongly associated with quality of life and has been called the “functional 
vital sign”.395 A meaningful change in gait speed has been established at 0.1 m/s (at usual 
pace over a short course) across various populations, including elderly, hip fracture, and 
others.369 For the assessment of usual gait speed over a short distance, participants had to 
position themselves standing behind a starting line marked with masking tape on the floor; 
toes just touching the tape. The instruction was to start walking in a straight line upon the 
command “GO”, and to perform this walk at their usual walking pace along the six-metre long 
walkway. Participants were instructed to keep walking for a few steps once crossing the line 
marking the end of the course. In addition to a single practice trial, two trials were performed 
and the faster of the two attempts was used for analysis in this study (the time taken to walk 
the six-metre course was converted to speed in metres per second).396 This test formed part 
of the PPB, but an additional task condition was also performed, which involved a dual task 
activity (see Section 7.7.4.5). For this, participants were instructed to assume a standing 
position behind the starting line (as for the usual Six-metre Walk Test), to start counting (while 
still standing still) on a verbal command, and then to start walking whilst keeping on counting 
on the second verbal command. Participants were asked to count as accurately, not as fast, 
as possible without stopping their walk.  
7.7.4.4. Chair rise tests: the Five-Times Sit-To-Stand (5STS) Test and 
the 30-second Sit-To-Stand (30sSTS) Test 
Chair rise tests are measures of mobility-related function.397 These tests are usually employed 
to evaluate older adults; however, it has also proven to be valid as a measurement of physical 
performance in healthy younger adults.398 A systematic review399 found that the Five-Times 
Sit-To-Stand (5STS) Test demonstrated good to high test-retest reliability (ICCs 0.64 to 0.96) 
in most populations, including younger and older community-dwelling adults. The 5STS test 
has been recommended for use in PLHIV, as performance in this patient group was observed 
to be significantly slower (worse) relative to normative results.2,59 
STS was implemented both as a 5STS and a 30-second Sit-To-Stand (30ssts) Test. The two 
tests require execution of the same motion, but differ with regard to what they measure. The 
5STS test assesses the time required to complete five rapid STS actions, while the 30sSTS 
test records the number of repeated STS actions that can be completed within a period of 30 
seconds.400 The two tests are not considered interchangeable as the 5STS test is an indication 
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of lower limb power and speed, whereas the 30sSTS test is a proxy measure of lower limb 
endurance.400 MCIDs of two seconds have been reported for the 5STS test3,401 and of two to 
2.6 repetitions for the 30STS test.402 
The 5STS test was conducted by measuring the time taken for the participant to stand up from 
a seated position, with arms folded across the chest, five times as fast as possible. The 
30sSTS test, on the other hand, was conducted by asking the participant to perform as many 
as possible sit-to-stand manoeuvres for 30 seconds.403 Both tests started with the participant 
seated with feet comfortably placed (knees close to 90°) and ended in a standing position.404 
A standard chair (seat height of 44.5 cm, Figure 7.4) with a stable backrest and solid seat was 
used for the test, according to the standard STS test protocol.404,405 The tests were timed to a 
hundredth of a second using a stopwatch. Prior to the STS tests, two practice STS repetitions 
were allowed. The 5STS test was performed twice and the best result (fastest time) were used 
in this study for analysis397 whilst the 30sSTS test was performed once considering the fatigue 
it may inflict. Standardised instructions for the 5STS is provided  in Appendix H as part of the 
PPB.  
7.7.4.5. Dual tasking 
In order to investigate functional performance under more challenging conditions, participants 
additionally performed gait and balance tasks under dual task conditions. Dual tasking 
methodology is based thereon that performance of a more difficult, conscious activity 
interferes with a simultaneously performed primary task.406 It is proposed that the performance 
difference between single- and dual tasks represent the demands on the processing system 
when attention is divided between two tasks simultaneously, and thus may be used as an 
Figure 7.4. The standard-height chair used for the chair rise tests, and layout of the 
narrow walkway. 
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indication of the attention demands (cognitive compensation) required by the primary task.187  
In PLHIV, this might reveal more subtle movement impairments in higher functioning 
individuals.62,186  
The cognitive task was fully explained to each participant, i.e. counting backwards aloud in a 
suitable numerical unit. Subsequently, the appropriate level of difficulty was determined during 
a seated practice round.187 Participants were asked to count aloud backwards from a randomly 
selected number in units of three (practice started with this level), seven (if threes were 
deemed too easy), two (if threes were deemed too difficult) or one (if twos were deemed too 
difficult). The highest level of difficulty that the participant was able to perform as a single task 
was selected.187 This methodology was deemed appropriated due to the expected variation in 
level of education in the population (from tertiary education to no schooling). Subsequently, 
participants performed the relevant clinical tests (as described above) with the addition of the 
cognitive task. The number of mistakes during each trial was noted and a Cognitive Difficulty 
Score (CDS)187 was assigned (CDS data were not analysed for the purposes of this 
dissertation). The dual task performance sheet is attached as Appendix I. 
7.7.5. Self-reported function (via the EuroQol Five-Dimension 
Five-Level questionnaire) 
Participants were required to complete the entire five-level version of the European Quality of 
Life Five-Dimension questionnaire (EQ-5D-5L) (Appendix J), a standardised and extensively 
validated and tested instrument.407 Three domains were analysed to represent self-reported 
function (see paragraph below), while the domains related to current pain and 
anxiety/depression were presented separately (the depression/anxiety domain was analysed 
as representing self-reported anxio-depressive symptoms; the acute pain domain was 
analysed as an indicator of pain on the day of testing). The health-related quality of life 
(HRQOL) visual analogue scale (VAS) data from the EQ-5D-5L were not analysed for the 
purposes of the current dissertation, but will be reported at a later stage. 
The EQ-5D-5L was used to measure dimensions of subjective function as domains of HRQOL: 
specifically, the domains of mobility (walking), self-care (washing or dressing) and usual 
activities (e.g. work, study, housework, family or leisure activities). The EQ-5D-5L is available 
in English for South Africa, Afrikaans and isiXhosa and although not specifically designed for 
HIV-1 infection, has been validated, tested for reliability and successfully applied in PLHIV,408–
410 including in South African adult HIV-seropositive populations,407,411,412 according to 
standards set by the EuroQol Group.413 Delate and Coons409 provide evidence for the 
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construct validity of the EQ-5D in PLHIV and report that the EQ-5D (p < 0.05) was able to 
discriminate between groups of participants stratified by disease severity on the basis of either 
CD4+ cell counts or HIV-1 RNA copies. The EQ-5D was introduced by the EuroQol Group in 
2009 to improve the sensitivity and to reduce ceiling effects of the previous three-level 
instrument (the EQ-5D-3L). The EQ-5D-5L essentially consists of two pages: the EQ-5D-5L 
descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system 
defines health in terms of five dimensions or domains: mobility function, self-care function, 
usual activities function, pain and anxiety/depression. Each of the five dimensions comprising 
the EQ-5D descriptive system is divided into five levels of perceived problems: no problems, 
slight problems, moderate problems, severe problems and extreme problems. The participant 
is requested to indicate their current health state by ticking the box next to the most appropriate 
statement in each of the five dimensions, resulting in a one-digit number (between one and 
five) that expresses the level selected for that dimension. For analysis in this study, the EQ-
5D-5L levels were dichotomised into “no problems” (i.e. level 1) and “problems” (i.e. level 2 to 
5), in order to change the profile into frequencies of reported problems.414  
7.7.6. Fall history and fear of falling 
For this study, a fall was defined according to the definition posed by the Prevention of Falls 
Network Europe (ProFaNE) as “an unexpected event in which the participant comes to rest 
on the ground, floor, or lower level”,415 which has also been used in previous fall studies in 
PLHIV (see Table 2.1). The assessment of fall history (over the past 12 months) and fear of 
falling formed part of the self-administered questionnaire (Appendix K) and comprised of 
questions previously used in a South African Western Cape population.416 The history of any, 
as well as the number of, fall(s) in the past year was assessed by using the questions, “Have 
you had a fall in the last year (by that, I mean did you fall to the ground, or to a lower level)?” 
and “If YES, about how many times did you fall in the last year?”, respectively. Further inquiry 
was also made about the circumstance leading to the fall, since only falls not resulting from a 
major external event (such as pedestrian accident or having a stroke) were included in the 
study analysis. Additionally, all participants were asked about fear of falling (“Are you ever 
afraid of falling when walking or standing?” with a “yes” or “no” answer, and an inquiry into the 
reason for the fear of falling.  
Although not yet investigated specifically in PLHIV, a review by Ganz et al.417 found that simple 
retrospective recall of falls over the past year demonstrates similar specificity (specificity 91% 
to 95%) but less sensitivity (sensitivity 80% to 89%) than ongoing prospective weekly and 
monthly fall calendars or diaries. It remains uncertain as to what the optimal time period is to 
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assess using simple recall questions,156 although it has been shown that falls recall in a one-
year timeframe was better than shorter three- or six-month recall periods.418 It has been 
suggested that for studies where intensive and prospective ascertainment of falls is not 
feasible, 12-month falls recall questions with fewer responses may be an acceptable 
alternative.419 Falls were dichotomised as any (“yes”) or none (“no”) in the prior 12 months,55,158 
and the number of falls over this period was dichotomised as having had a single fall versus 
two or more falls. 
7.7.7. Other questionnaire data and clinical measures 
All participants completed a custom-designed baseline questionnaire (Appendix K). Before 
data collection, the questionnaire (and also the EQ-5D-5L questionnaire) was piloted on five 
PLHIV and five SNP from the same community and recruited in the same manner as other 
participants (these individuals participated in the validation study, for which questionnaire data 
were not relevant, and their data were thus also not analysed as part of the cross-sectional 
study). This was done to confirm sufficient understanding (face validity), i.e. to evaluate the 
appropriateness of questions and to allow correction of unclear items.  
 
Apart from sociodemographic information, the questionnaires included questions pertaining to 
co-morbidities to augment folder information extracted from the EndoAfrica study. Participants 
who were not enrolled in the EndoAfrica study, were asked to complete an additional brief 
questionnaire (extracted from the formal EndoAfrica questionnaire – Appendix L).  
7.7.7.1. Peripheral neuropathy and lower limb joint ROM screening 
Although also included in the verbal screening, functional lower limb joint ROM and the 
absence of sensory peripheral neuropathy was confirmed via a brief screening. A goniometer 
was used to assess for any gross joint restrictions (as in Chapter 4, Section 4.11.2.1) while a 
brief neurological examination (ankle reflex and light touch) was performed to check for 
neuropathy. No additional participants had to be excluded following these confirmatory tests. 
7.7.7.2. Clinical and anthropometric characteristics 
Height was measured with the participant barefoot and in light clothes, by having the 
participant stand straight on the floor with their heels, back and head against a wall and arms 
hanging freely by their sides. A flat, rigid measuring ruler was placed horisontally on the 
participant's head and the point where it touched the wall was marked. The vertical distance 
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from the mark to the floor was then measured with a tape measure, and recorded in 
centimetres to the nearest 0.5 centimetre.416 The use of a stadiometer was preferable to 
measure standing height, but due to budgetary constraints, was not feasible for the 
study.  Weight was measured using an electronic scale as described in Chapter 4, Section 
4.11.2.2. 
7.7.7.3. Muscle strength 
Hand-held dynamometry (HHD) offers an affordable, portable, and easy-to-use alternative to 
laboratory-based dynamometry for the assessment of isometric muscle strength, and has 
previously demonstrated excellent results for use as a clinically-feasible tool.420–422 Lower limb 
muscle testing was performed using a Lafayette Manual Muscle Testing System Model-01165 
(Lafayette Instrument Company, Lafayette IN, USA). This particular model has demonstrated 
good to excellent reliability for most measures of isometric lower limb strength in a healthy 
population, with intra-rater reliability proving good to excellent (ICC ³ 0.75) (highest values 
having been obtained for proximal muscles).420 Concurrent validity (criterion-reference: Kin-
Com dynamometer) was good to excellent for the hip and knee (ICCs ³ 0.75), with mostly 
moderate results shown for the ankle muscles (ICCs ³ 0.51).420 In addition, in a South African 
population of PLHIV, intra- and interrater reliability of HHD was demonstrated as good, with r-
values for hip flexors ranging between 0.94 to 0.97, for knee extensors between 0.83 to 0.90 
and for ankle dorsiflexors between 0.76 to 0.89.422 Having used a hand-held dynamometer 
(HHD) before (e.g. undergraduate class demonstrations) the researcher (PhD candidate) was 
familiar with the device and its operation.  
In this study, the maximal isometric strength of the hip flexors, extensors and abductors; knee 
flexors and extensors; and ankle dorsi- and plantarflexors was assessed using a make test. 
Make tests are reported to be more reliable, comfortable and safe than break tests423 and 
require the examiner to hold the HHD stationary while the subject exerts a sustained maximal 
force against it. In contrast, a break test is performed when the participant’s maximal muscular 
effort is overcome by the examiner and the tested joint gives way.423 The testing positions for 
each participant were standardised to ensure that gravity eliminated positions were used for 
each muscle group. In order to avoid participant fatigue due to frequent position changes, the 
sequence of testing positions was consistent; starting with a supine position and progressing 
to sitting. However, the testing sequence in each testing position was randomised for each 
participant.423 The movement to be tested was demonstrated to the participant, after which 
they were asked to perform the movement to confirm understanding and to ensure that 
stabilisations were adequate. Standard verbal encouragement was provided by the researcher 
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during each maximal contraction. Participants were instructed to avoid explosive contraction 
and to rather increase effort gradually over about two seconds to maximum once they heard 
the instruction “ready, GO”. Participants were instructed to then hold the maximum contraction 
for a further five seconds and cease contraction once the researcher gives the instruction to 
relax.421,423 Two trials were completed for each muscle group, and the mean was used for final 
analysis. In the event that more than 10% difference was noted between the two trials, a third 
trial was performed, and the mean of the two best trials used. Testing was done bilaterally and 
strength values were averaged for the two sides. Results were recorded in Newton and 
rounded to one decimal. The HHD’s piston and force pad was always held perpendicular to 
the limb segment to which it was being applied to. The specific test position for each muscle 
group is provided as part of the data collection form in Appendix K. 
7.7.7.4. Bone mineral density 
Bone status was evaluated by means of calcaneal quantitative ultrasound (QUS), using the 
SONOST 3000 Ultrasound Bone Densitometer (OsteoSys, Korea). Compared to dual energy 
X-ray absorptiometry (DEXA), QUS is relatively inexpensive, radiation-free, and portable; and 
has been recently been confirmed as a useful screening tool for monitoring BMD in PLHIV.424–
427 Although its use in clinical practice remains an area of research and is device-specific, 
QUS offers an appropriate tool for comparing BMD between different groups and identifying 
factors associated with variation in BMD, especially in resource-limited settings where DEXA 
is not available.426,428,429 The SONOST QUS device has been used in South African coloured, 
black and white populations.429,430 The QUS device was calibrated once daily, prior to 
measurements, using a phantom object.431 Measurements were conducted with the participant 
sitting comfortably facing the device and with the non-dominant foot432–434 (calcaneus) placed 
on the support platform for measurement. Three re-positioned trials were conducted per foot 
to obtain an average measure. Bone status was expressed as the T-score (standard deviation 
from the mean in healthy young adults of the same gender), Z-score (standard deviation in 
persons of the same age and gender) and bone quality index (BQI), which is calculated by the 
QUS device from speed of sound (SOS in m/s – marker of bone density and elasticity) and 
broadband ultrasound attenuation (BUA in dB/MHz – indicator of bone structure429) and has a 
lower precision error than either of these variables alone.431 
7.7.7.5. Level of physical activity  
Engaging in physical activity for less than 60 minutes per week (or less than two days a week) 
was regarded as low physical activity, whilst engaging in mild to moderate exercise for more 
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than 60 minutes per week or participating in at least 30 minutes of moderate (or higher 
intensity) exercise for at least five days a week (or at least 150 minutes per week) were 
grouped together and considered as moderate-to-high levels of physical activity.435 
Participants who responded “none” to the question, were considered as participating in no 
exercise. For further analyses, participants were dichotomised into “low” (i.e. including “none”) 
and moderate-to-high levels of physical activity. 
7.7.7.6. Chronic pain and cognitive function  
Information on chronic pain and cognitive function was recorded as part of the self-
administered questionnaire (Appendix K) using, respectively, the bodily pain scale and the 
cognition scale from the HIV Medical Outcomes Survey (MOS-HIV). The MOS-HIV has been 
derived from the MOS-Short-Form-20436,437  by adding constructs that are pertinent 
to PLHIV, including cognitive functioning, energy/fatigue, health distress, and quality of 
life.437   
MOS-HIV subscales are scored on a scale ranging from 0 to 100, with higher 
scores indicating better perceived health. The reliability, construct validity, and 
responsiveness of the MOS-HIV scale and summary scores are widely reported and the 
instrument is one of the most widely used among those employed in studies of PLHIV.409,436 
The subscales of the MOS-HIV can be included as individual sections within a longer interview 
or questionnaire.437  
 Chronic pain was defined according to six levels of responses ranging from “none” to “very 
severe” to the question “How much bodily pain have you generally had during the past four 
weeks?” along with a five-level response (“Not at all” to “extremely”) to the question “During 
the past four weeks, how much did pain interfere with your normal work (or your normal 
activities, including work outside the home and housework)?”.54 The four-week recall may be 
questioned as a true measure of chronic pain; however, at the time of study no validated 
chronic pain questionnaire was available for PLHIV in South Africa. Raw pain scores for both 
these questions were recoded as per MOS-HIV instructions so that a lower score 
represented a worse outcome,437 and the raw recoded scores of individual items in the MOS-
HIV pain domain were summed (resulting in a score range of two to 11). These 
raw scores were then transformed according to the instruction manual437 (to obtain a score 
ranging from zero to 100, with a higher score indicating better functioning) using the equation:  
E?6:Qëíì&îïël = 100÷ (11 − 2) × (E?6:ëíñ − 2) 
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Cognitive functioning was assessed using the six-item HIV-MOS cognitive dimension, which 
measures the degree of cognitive difficulties that participants have experienced over the past 
four weeks. Participants were asked to indicate how much of the time they have had difficulty 
to reason or solve problems, been forgetful, had difficulty with paying attention and with 
concentrating on activities. Raw scores were summed to a maximum score of 24 and 
transformed to obtain a score out of 100 (no recoding was necessary since the lowest level 
already corresponded to the worst outcome): 
ó=7:696ò5Qëíì&îïëlôT = 100÷ (24− 4) × (ó=7:696ò5ëíñ − 4) 
The MOS-HIV cognitive domain measures functional status owing to neuropsychological 
impairment. Evidence supports the clinical utility of this brief self-report measure related to 
cognitive abilities in early HIV-1 infection for the screening of HIV-1-associated cognitive-
motor disorders.  The MOS-HIV cognitive domain has demonstrated significant associations 
with objective neuropsychological test performance overall and in specific domains, and 
seems particularly sensitive to changes in neuropsychological test performance (especially 
behaviours that involve neurocognitive or psychomotor speed) in early HIV-1.438,439 
7.7.7.7. Substance use and HAART adherence 
Alcohol and substance abuse information was based on self-report of current or prior abuse, 
according to quantity consumed per week54 – these questions were contained in the 
EndoAfrica questionnaire. HAART adherence was based on self-reported categories: 
“prescribed HAART but refused”; “started HAART but now stopped”; “prescribed HAART but 
currently taking less than prescribed dose”; “started HAART but currently nonadherent”; or 
“started HAART and adherent”. PLHIV on HAART were deemed adherent if they indicated 
that they took their medication all or most of the time, i.e. missed no more than two doses per 
week (if on a twice-daily regimen) or no more than one dosage per week (if on a once-daily 
regimen.440 Responses to the adherence questioning were afterwards dichotomised into 
“adherent” and “non-adherent”.440 
7.7.7.8. Additional data extracted from the EndoAfrica study or its 
questionnaire  
Sociodemographic and lifestyle data (age, gender, ethnicity/race, home language, educational 
level, employment status, monthly income, alcohol use over the past 12 months and current 
smoking status), medical history (polypharmacy, multimorbidity, hypertension, cardiovascular 
disease, diabetes, chronic fatigue, and chronic pulmonary disease) were extracted from the 
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EndoAfrica database, or recorded by the relevant research nurse/healthcare worker using 
selected pages from the EndoAfrica questionnaire (Appendix L). In addition, for PLHIV, the 
following were extracted: HIV duration in years, most recent CD4+ cell count, viral load 
(dichotomised as detectable or not), HAART history, including regimen and duration in weeks, 
C-reactive protein (CRP) levels in mg/L, haemoglobin (Hb) in g/dL, and creatinine in μmol/L. 
When these data were not available as part of the EndoAfrica dataset, the research nurse 
(Worcester) or the researcher (as registered physiotherapist) (Paarl) obtained the results (if 
available) confidentially from the relevant patient folder. Confidential access to medical folders 
were discussed and cleared with the clinic manager at the Paarl site; and was also included 
as part of the written informed consent provided by all participants.  
7.7.8. Covariables 
Although confounding was not considered in this study (in an effort to describe PLHIV in a 
way that they would “typically” present to clinicians), selected important covariables were 
considered which may feasibly influence locomotor performance in PLHIV. Increased BMI and 
the presence of peripheral neuropathy were controlled for as per exclusion criteria. Other 
covariables that could contribute to kinematic or clinical test outcomes were age (continuous 
data: years), gender (binary data: male/female), leg-length-normalised gait speed (continuous 
data: dimensionless) or leg length (continuous data: cm), anxio-depressive symptoms (binary 
data: defined as reporting problems on the EQ-5D-5L depression/anxiety domain, versus no 
problems), current smoking status (binary data: yes/no) and level of physical activity (binary 
data: none/low versus moderate-to-high). 
Lower limb performance is known to be affected by advancing age in the general population 
as well as PLHIV,154,287 and gender may influence kinematics in the coronal plane (due to 
biomechanical differences such as the larger quadriceps angle [Q-angle] in women) - although 
consistent correlations between gender and sagittal or transverse plane kinematics during gait 
are more controversial.314,441 Leg length has been used as a surrogate measure for height442 
and both measures are often used to normalise gait speed and other temporal and spatial 
parameters in comparative biomechanical studies. Height and leg length both influence gait 
speed, with taller individuals usually walking faster than their shorter peers.255 Co-morbid 
psychiatric disorders such as depression and anxiety have been suggested to have a 
detrimental effect on the degree of physical disability in PLHIV.53 In the general population, 
depression-associated “sad walking” has been characterised by slowed gait speed, reduced 
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lower extremity joint ROM, and increased postural flexion.443,444 Low physical activity has been 
associated with decreased gait speed445 due to eventual loss of strength and aerobic capacity.  
Physical performance tests were adjusted for all listed covariables except gait speed, 
considering that gait speed forms an inherent part of some of the performance tests, and is a 
performance test itself.32 COP data were adjusted for gender only (which may also serve as a 
proxy for foot size) and due to a lack of consistent evidence of relevant covariables to COP 
parameters. In the case of gait biomechanics, data were adjusted for leg-normalised gait 
speed, age and gender. Slower gait speed in patient groups relative to healthy groups is a 
major contributor to differences in gait angles and parameters, limiting characterisation of the 
potential gait pathophysiology.245,446 Gait speed is reported to have a significant influence on 
joint/segment angles in the sagittal, coronal and transverse planes, as well as on TSPs.447,448 
Slower gait speeds generally impose decreased joint angle excursions and increased TSPs 
(particularly temporal or temporophasic parameters such as the stance and double support 
phases of the gait cycle) – although certain variables such as cadence, decreased ankle 
plantarflexion ROM and hip sagittal kinematics seem relatively robust to gait speed 
changes.234,449 Sagittal knee joint kinematics and coupling motion of the knee joint and ankle 
plantarflexion, on the other hand, seem particularly susceptible to gait speed changes.245 As 
a universal biologic phenomenon, reduced gait speed may serve as a proxy measure for 
various other conditions (for example depression, which may manifest via a slowed gait), and 
has been suggested as a reflection of the integrated performance of numerous organ systems 
as well as age-related changes.450  
Additional potential covariables which did not significantly differ between PLHIV and SNP 
(such as pain) were not considered in statistical models. 
7.8. Study procedures 
Figure 7.6 outlines the data collection procedures. The entire data collection procedure lasted 
approximately 90 minutes per participant. This time included the collection of some additional 
data variables which are not reported in this dissertation, but will provide valuable information 
for additional analysis to be conducted at a later stage. 
7.8.1. Preparation of the venue for gait and balance evaluation 
The test venues in Worcester and Paarl were both private, well-lit rooms with sufficient space 
(minimum of about 10 metres of straight walking space) for gait analysis and clinical tests. The 
researcher obtained the keys for the respective venues on the day of testing and no other 
persons had unsupervised access to the venues on these days. A research assistant assisted 
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in setting up the test space. At both test sites, the rooms were equipped with air conditioning 
systems which were set at a comfortable room temperature. Masking tape was used to lay out 
a straight walkway for gait analysis (about eight metres, with one metre marked before and 
after). Within this course, a six-metre distance was marked for the six-metre walk tests; and 
two six-metre-long strips of masking tape were placed 20cm apart for the narrow walk 
component of the PPB. A standard-height (44.5 cm) chair was positioned against one of the 
walls for the chair rise tests. 
The myoMOTION system was set up by placing the recording laptop and receiver module on 
a table positioned perpendicular to the gait walkway, and setting up a tripod web camera in 
front of the table and facing the walkway. The MatScan system was also connected to the 
laptop, and the pressure mat placed next to the walkway. The mat was always positioned in 
a similar orientation, perpendicular to the laptop station, so that participants’ feet were 
orientated in the same direction with regards to the pressure mat. A black cross, printed full-
size on an A4 sheet, was positioned against a wall at eye-level ahead of the pressure mat. A 
30-cm wooden step was placed in an area of open floor space next to the walkway (facing the 
same direction as the walkway, i.e. parallel) and away from metal objects or electrical cable, 
to serve as a calibration station for the myoMOTION. Although the myoMOTION system does 
not require calibration of the test volume, participant calibration is required before and in-
between trials. Participant calibration of the myoMOTION was described in detail in Section 
4.10.2. 
A quiet corner of the test venue was set up with a portable plinth for clinical evaluation of 
participants (joint ROM screening, muscle testing, QUS) as well as for questionnaire 
completion (a chair and table was provided). The QUS device was set up as per the 
manufacturer’s instructions, with the power cable directly connected to the wall socket and the 
device at least 20cm away from the wall. At the start of each day of data collection, a once-off 
calibration of the QUS device was performed using a phantom object. Figure 7.5 shows the 
set-up of the myoMOTION system in the testing venues. 
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7.8.2. Questionnaire completion 
All self-reported questionnaires were completed by the participant at the start of the testing 
session, prior to any other data collection procedures (i.e. before they became aware of their 
performance abilities), with either the researcher or a research assistant standing by for any 
questions. 
The quality of self-reported data – as opposed to objective clinical or laboratory collected data 
– partly depends on setting an appropriate context for the study participant, ensuring that they 
are aware of the importance and relevance (within the context of the study) of their 
response.437 This may elicit more appropriate responses from participants that 
more accurately reflect their self-perceived state.437 Therefore, the following procedures were 
implemented during administration of the questionnaires:   
• The relevant questionnaire was introduced and explained (including its purpose within 
the context of the study).  
• The participant was alerted to the fact that the questionnaires contained no identifying 
particulars (e.g. name or ID number) except for an anonymous study code. 
• Upon handing the questionnaire to the participant, it was paged through and explained 
how it was to be completed.  
• The participant was allowed to ask questions prior to and during completion of the 
questionnaire. 
Figure 7.5. The set-up of the motion analysis systems in the test venues. 
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• For a few participants, the questionnaires were administered by means of face-to-face 
interviews.437 Since reading ability and comprehension vary among individuals, 
participants may vary in the extent to which self-completed responses to 
questionnaires are consistent and valid reflections of their subjective experience.437 
Participants who were functionally illiterate or had a reading ability below primary 
school level were thus provided with interview administration.437 
7.8.3. Physical assessment 
Following questionnaire completion and prior to further test procedures, height, weight and 
leg length were measured by the research assistant and screening of lower limb joint ROM as 
well as distal peripheral neuropathy was performed by the researcher, as previously described 
(measurement of joint widths was not necessary for the field study).  
Sociodemographic information and medical history were recorded for each participant 
(Appendix L) by the research assistant, if not already done so by the research nurse. For 
EndoAfrica participants, these data were extracted from the overhead study, along with 
laboratory results confirming HIV status.  
7.8.4. Participant preparation 
Participants were orientated to the testing venue and the logistics of the subsequent testing 
procedures were explained. Each participant was scheduled for a single test visit and a 
maximum of four participants were tested per day. Participants were requested to wear shorts 
and a tight-fitting shirt (or no shirt, if male) so as to enable efficient placement of IMUs 
(appropriate clothing were provided if the participant did not have their own). Participants 
remained barefooted during physical evaluation and all subsequent motion analysis and 
clinical tests.  
7.8.4.1. IMU placement 
IMUs were placed on seven lower limb segments as described in Chapter 4, Section 4.11.3. 
Participants were instructed not to touch or move any of the IMUs, particularly after calibration 
of the system. 
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7.8.4.2. Practice trials  
Participants were allowed practice trials prior to each physical performance test, as mentioned 
for each relevant test above. Prior to any of these, the dual task familiarisation (described in 
Section 7.7.4.5) was performed in a seated position.  
Practice trials for 3DGA were performed after the IMUs were fixated to their various body 
segments, but before the myoMOTION was calibrated. As in the validation and reliability 
studies (Chapter 4), these trials were performed along the marked walkway to familiarise 
participants to the feeling of walking with the IMUs placed on them. Participants were explicitly 
instructed to walk “as normal as possible” once the IMUs were attached.  
7.8.5. MyoMOTION model calibration 
The myoMOTION system was calibrated by having the participant stand stationary in a neutral 
reference posture (N-pose) on a 30-cm wooden block. Refer to Chapter 4, Section 4.11.5.2 
for a detailed description of the calibration procedure, including the standardised instructions. 
This procedure was proven to demonstrate good intra-rater repeatability in Phase II of the 
project (see Chapter 5). The system was calibrated before the first gait trial, and subsequently 
in-between each gait trial. 
7.8.6. Clinical test performance 
Clinical tests were performed according to standardised instructions and according to the 
procedures explained in the relevant sections above and Appendix H. The performance 
sequence was randomised by drawing cards with test allocation from a box (although the order 
of testing within the PPB was adhered to; i.e. the balance component, then the chair rise 
component, followed by the short walk tests). This methodology attempted to mitigate the 
effects of fatigue or learning on test performance. 
7.8.7. Instrumented gait analysis 
Participants started walking approximately one metre before the taped line on the floor and 
ended after crossing the second line. MyoMOTION recordings were manually started and 
stopped as soon as the participant crossed each of these lines, respectively. Each participant 
performed three recalibrated gait trials per gait condition, namely usual-paced, fast-paced and 
dual task. Gait trials immediately followed myoMOTION calibrations and the conditions 
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(condition and also task) were randomised to limit the effects of familiarisation and fatigue on 
gait, as well as balance, tasks. Participants walked barefoot for all trials.  
For the gait recordings, participants were instructed to look ahead and walk comfortably in a 
straight line, and not to focus on the masking tape lines on the floor. Additionally, participants 
were instructed to perform each of the three subsequent trials per condition (usual-paced, 
fast-paced and dual task) as they did the previous trial (i.e. not to speed up as they become 
more familiar with the procedures). Participants were also requested to notify the researcher 
immediately should any of the IMUs become loose. For the fast-paced task, participants were 
instructed to walk as fast as they could without running, as if they were late for a departing 
bus or taxi.451 For the dual task condition, participants were instructed to count backwards in 
the units determined during the seated practice trial (see Section 7.7.4.5) without prioritising 
either task. Refer to Appendix I for the specific instructions for each task condition. 
A gait trial was deemed successful if the participant did not target any lines on the floor by 
looking down at it or by noticeably changing their stride length, and if the researcher noted 
three strides per limb. The intercepted gait trials were performed in alternating directions and 
after each trial, the participant performed a balance trial, where after they returned immediately 
to the wooden platform for the next pre-walk calibration.  
7.8.8. Instrumented postural balance assessment 
In addition to a verbal instruction, the SLS procedure to be performed on the pressure mat 
was demonstrated to each participant and one practice trial was permitted. Participants were 
instructed not to hop, shuffle or shift their feet relative to the mat surface, and to maintain the 
SLS position with arms crossed for as long and as still as possible, or until the verbal stop 
command was given. Data capture started with the foot-off event. The task was performed 
three times and up to a maximum of 30 seconds. Participants were allowed to choose a 
preferred stance leg.392 The instructions for this test is provided in Appendix M.  
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Data collection form: self-completion section (Worcester & Paarl) and additional data 
collection form (Paarl only). 
EQ-5D-5L questionnaire. 
 
Physical assessment (weight, height, leg length, lower limb joint ROM, peripheral 
neuropathy, muscle strength). 
 
Dual tasking (DT) à familiarisation task (seated, prior to tests). 
Physical performance tests: 
PPB (including SLS eyes open (EO), 6mWT and 5STS tests). 
30sSTS test. 
SLS eyes closed (EC). 
SLS DT. 
6mWT DT. 
6mWT fast. 
 
Bone mineral density testing (allowing period of rest between movement testing). 
IMU placement. 
 
MyoMOTION calibration on wooden block. 
 
3D capture of SLS test. 
(3x EO*, 3x EC* and 3x DT)  
3D gait analysis  
(3x usual-paced, 3x fast and 3x DT) 
Figure 7.6. Schematic representation of the data collection procedures in the cross-
sectional field study. Rounded arrows indicate that the individual tasks and conditions 
were executed in a random order for each participant. 
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7.9. Data reduction and processing 
Performance test scores were calculated as previously explained in the relevant sections. Raw 
study data on the outcomes listed above were extracted and entered into a custom MS Office 
Excel spreadsheet. The MS Excel file was imported into SPSS as well as STATA for statistical 
analyses.  
7.9.1. MyoMOTION 
MyoMOTION and MatScan data processing was performed by a qualified neuromechanics 
laboratory analyst, in continuous close consultation with the PhD candidate. Gait data 
recorded by the myoMOTION and Noraxon’s myoResearch (MR3) software were exported to 
single .csv files (for each trial). Data were then imported into MATLAB (2017a) for processing 
and analysis. The raw myoMOTION data were filtered using a 4th order zero-lag low pass 
Butterworth filter with a cut-off frequency of 6 Hz, to attenuate any noise within the signals. 
MyoMOTION data were not pre-processed, but were corrected for magnetic drift (distortion) 
post-recording on the foot, shank and thigh segments. Gait events were determined within the 
software (using a built-in algorithm). The cyclical gait events, defined by the foot contact and 
foot off events (and other custom key events), were then used to segment the data into gait 
cycles (starting and ending with subsequent foot contacts). Once the data were segmented, 
and prior to determining myoMOTION outcomes, the data were negated (“flipped”) according 
the positive definitions of each joint/segment motion. The relevant TSPs and kinematic angular 
outcomes were then determined and the outcomes were subsequently exported to an Excel 
workbook, which was imported into the relevant statistical software.  
7.9.2. MatScan 
Raw COP data recorded by the MatScan were filtered using a 4th order Butterworth filter with 
a 10Hz cut-off frequency. These data were exported to MATLAB for processing and 
calculation of the relevant COP outcomes. Custom algorithms were developed according to 
definitions by Prieto et al.378 for calculation of mean COP excursions and velocities for a task 
duration of 30 seconds. Given that participants’ feet were aligned parallel to the pressure mat 
area with the same orientation for all participant throughout the study, the ML and AP 
directions of movement respectively were assumed as orthogonal and parallel to the MatScan 
area.  
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Invalid trials were considered those where foot shuffling or hopping occurred, or if the lifted 
leg touched down on the mat prior to 30 seconds. COP measurement outcomes suffer from 
error if shuffling of the feet (horisontal translation or rotation relative to the mat surface) occurs. 
The researcher therefore manually inspected plantar pressure videos (recorded by the 
MatScan software) of all participants to identify periods of foot shifting, or trials where the lifted 
foot touched down prior to 30 seconds. In the cases where such movements were noted, trials 
were discarded. For the remaining trials, the 30-second time periods containing the valid COP 
data, defined by start (foot off) and end (foot contact, or at 30 seconds) events, were analysed. 
Three attempts were allowed per task, and thus three recordings of the relevant task were 
available for each participant. The first successful trial for each participant was selected for 
processing. These data were exported from the MatScan software in the form of ASCII files. 
7.9.3. The enhanced Gait Variability Index (EGVI) 
EGVI calculations were based on the five specified TSPs, which were generated within MR3 
software. Raw myoMOTION data were custom formatted by a motion laboratory technician 
for use within the MS Excel EGVI macro that was provided by the original author (A Gouelle) 
and EGVI calculations were performed in consultation with the author. For each participant, 
an EGVI score was calculated if a minimum of five absolute differences (at least 13 
consecutive steps) were available. The raw data were obtained from the three short gait trials 
performed by each participant, and within each trial, a minimum of three consecutive values 
for each alternative parameter was required to enable EGVI calculation.452 Gait variability is 
known to differ depending on whether data are collected from continuous walking or multiple 
short trials,453 therefore the EGVI (which is designed to assess intra-trial variability) 
compensates for the inter-trial variability induced by such methodology by separating values 
obtained from different trials and standardising each using the mean of the series (leg and 
trial) to which it belongs.375  
As a first step in EGVI calculation, and to compensate for inter-trial variability, ten (two values 
for each original raw TSP) alternative variables (Eì) need to be calculated for each lower limb. 
This was done as follows: the trial mean TSPij (for any given TSP “i” within any given trial “j”) 
was ascribed a dimensionless value of 100%. For left and right legs separately, the within-trial 
TSPij foot falls were then expressed as percentages of the trial mean. Next, the differences in 
percentages between within-trial foot falls were determined over all trials. A mean and SD 
absolute difference of TSPi foot falls was obtained in this manner, and provided the two 
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alternative parameters for each raw TSP (Eì). The mean represents the magnitude of the 
parameter’s variability while the SD evaluates the consistency of the fluactuation.375 
These alternative parameters were adjusted in relation to pre-specified weighting coefficients 
(óì) determined by Gouelle et al.375 through a principal component analysis. For each 
participant (j), the products were summed as: 
AÑ =L(Eì × óì),*,  
The distance between the sum score of a PLHIV (j), and those of the SNP was calculated, 
and +1 was added to the computed distance372: 
DÑ,böo = |AÑ − Aböo| + 1 
A raw index score was obtained by calculating the natural logarithm of this difference: 
Iõâ2ëíñÑ = ln(DÑ,böo) 
The z-score was calculated: 
ûIõâ2ëíñÑ = Iõâ2ëíñÑ − @5?:(Iõâ2ëíñböo)HS(Iõâ2ëíñböo)  
The EGVI score is determined from the z-score as follows: 
Iõâ2Ñ = 100 − 10 × ûIõâ2ëíñÑ  
Each limb is considered independently, and an overall EGVI score is provided as well as the 
mean of left and right limbs. The overall EGVI score was used in this study. 
7.10. Statistical analysis   
All data were entered into a custom-built MS Excel worksheet (master dataset for the cross-
sectional field study), and exported to statistical software for analysis. All statistical analyses 
were performed using the IBM Statistical Package for Social Sciences (SPSS Statistics) for 
Macintosh, Version 25.0 (International Business Machines Corporation, Armonk, NY) and 
STATA Version 14.2 (StataCorp. 2015. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP). All p-values were two-tailed and the statistical significance level 
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was set at ɑ = 0.05. Normal distribution of data was assessed statistically using Shapiro-Wilk 
tests, and visually using histograms, box-and-whisker plots and Q-Q plots.  
7.10.1. Descriptive statistics 
Participant characteristics (demographic, anthropometric, lifestyle, medical and clinical), self-
reported function, fall-related outcomes, clinical test performance as well as 3D gait and 
balance outcomes were summarised using mean and standard deviation (SD) for normally 
distributed continuous variables, median and interquartile range (IQR) for skewed continuous 
variables, and percentages for categorical outcomes. For physical performance tests and 
biomechanical data, the range was also described. Additionally, for physical performance tests 
with maximum and minimum cut-off scores, score distributions were examined for floor and 
ceiling effects. The percentage of participants respectively scoring the minimum (floor) and 
maximum (ceiling) possible scores were reported. Such effects indicate the limited ability of a 
clinical test to discriminate between participants due to the test either being too difficult or too 
easy.454  Floor and ceiling effects >15% were deemed significant.455 
7.10.2. Differences between people living with HIV-1-infection 
(PLHIV) and HIV-seronegative participants (SNP) 
Differences in continuous data between PLHIV and SNP were determined by using parametric 
analysis (independent Student’s t-tests) for normally distributed data and non-parametric 
analysis (Mann-Whitney U tests) for skewed data. Percentages between groups were 
compared using chi-squared tests or, in the case of small sample sizes, Fisher’s exact tests. 
To illustrate absolute differences in the relevant measurement units (e.g. scores or degrees), 
mean differences or Hodges-Lehmann's median differences456 and the respective 95% 
confidence intervals (CI) were calculated for clinical tests and biomechanical outcomes. The 
95% CI for Hodges-Lehmann's median differences are robust to the possibility that the two 
population distributions differ in ways other than location, such as having unequal variances. 
Bonferroni correction for multiple comparisons were not made, given that the number of 
outcomes for comparison were defined a priori, and considering the correlated nature of many 
gait outcomes.457 Comparisons were therefore assessed as planned at the 5% level of 
significance.  
A second set of statistical analyses was conducted to compare physical performance tests 
and biomechanical data between PLHIV and SNP whilst statistically controlling for selected 
covariables. Candid covariables were selected based on their potential important influence on 
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the relevant outcomes as previously reported in the literature. For physical performance tests, 
covariables entered into the model included age (continuous data), gender (binary data), leg 
length (continuous data), depression/anxiety symptoms (binary data), current smoking status 
(binary data) and level of physical activity (binary data). For biomechanical gait outcomes, 
covariables included dimensionless gait speed (to also account for leg length differences), 
age and gender (gait speed was considered a proxy for the effects of smoking, depression 
and level of physical activity). For COP parameters, covariables included gender. 
Based on the aim of describing between-group differences (as opposed to ascertaining risk 
prediction), factorial analyses of covariance (ANCOVA) were used to test for group differences 
while adjusting for the various covariables. HIV status constituted the independent variable 
and separate ANCOVA models were created for each dependent variable. Normality of the 
distribution of model residuals were confirmed for all dependent variables.458 Treating clinical 
performance tests as continuous variables in all analyses,459 for each dependent outcome 
(e.g. kinematic angle, test result, etc.) potential interactions between HIV-serostatus and the 
factors and covariables included in the ANCOVA were examined for significance. Where 
significant interactions were noted, an HIV x covariable term was included in the final model.460 
If any interaction term was not statistically significant, it was removed from the model and the 
analysis rerun without the interaction term.460 Strictly speaking, this no longer constitutes a 
traditional ANCOVA; but still suffices as a linear model and is appropriate for observational 
(as opposed to experimental) designs. By including the interaction, the assumption of 
homogeneity of slopes is relaxed and therefore a universal assessment of the effect of HIV 
can no longer be made, as these differences depend on the value of the covariable. Although 
it is possible to describe the effect of HIV-serostatus at selected values of the covariable (e.g. 
at the quartiles) such analyses were beyond the scope of the research question of this study. 
Homogeneity of variance was confirmed by checking for a non-significant Levene’s test (p > 
0.05). In the case of a significant Levene’s test, estimated parameters with robust 
heteroskedasticity-consistent (HC3) standard errors were calculated.461 
7.10.3. Correlations between physical performance tests, 
EGVI, self-reported function and fall-related outcomes 
Correlations (strength and direction of relationships) between ordinal physical performance 
test results and EGVI scores, self-reported function and fall number and history were 
evaluated using non-parametric Spearman’s rank (rs) correlation coefficients. Pearson 
product-moment (r) coefficients were calculated between normally distributed variables. 
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Correlations of 0.2 ≤ 0.39 were deemed weak; 0.4 ≤ 0.59 were considered moderate; 0.6 ≤ 
0.79 were considered strong; and 0.8 ≤ 1.0 very strong.462  Associations between the selected 
clinical tests and the binary variables (yes/no) of having experienced any fall over the past 
year, as well as having a fear of falling, were assessed using independent Student’s t-test or 
Mann-Whitney U tests, depending on the data distribution.  
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  PART III 
 
RESULTS: CROSS-SECTIONAL FIELD STUDY 
8.1. Descriptive profile of the HIV-seropositive and HIV-
seronegative groups  
8.1.1. Sample composition 
The study population consisted mainly of patients visiting primary health care clinics in 
Worcester and Paarl. Between May 2016 and December 2017, 186 potentially eligible 
participants were assessed by the research nurses or HIV-counsellors for eligibility (including 
counselling and rapid HIV screening for those with an unknown serostatus). One-hundred-
and-six participants were confirmed eligible and participated in the study (PLHIV = 54 and 
SNP = 52).  
The primary reasons for non-participation were unavailability for further testing following 
EndoAfricavii participation (people living with HIV-1 infection [PLHIV], 7%), refusal (PLHIV, 
14% and seronegative participants [SNP], 24%), participants not arriving for participation after 
being screened (PLHIV, 5% and SNP, 38%), having a body mass index (BMI) > 25kg/m2 
(PLHIV, 13% and SNP, 18%), and, amongst SNP, refusal to undergo HIV testing (SNP 18%). 
Other reasons for non-participation included active pulmonary tuberculosis (TB), age >65 
years or feeling unwell (PLHIV, 7%) and alcohol intoxication (SNP, 3%). 
Two SNP who passed the verbal screening were later found to have used alcohol on the 
morning of data collection. Their data sets were excluded from analysis in accordance with 
the study exclusion criteria. Due to technical failure of the myoMOTION system resulting in 
corrupted 3D data (not able to turn the virtual floor in MR3 software), data sets from the first 
four PLHIV were also excluded from analysis. Consecutive sampling continued until a final 
sample of 50 PLHIV and 50 SNP data sets were available for analysis.  
                                               
vii The overhead EndoAfrica study is described in Chapter 4, Section 4.7. 
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The study protocol evolved during the early stages of data collection and subsequently bone 
mineral density (BMD) testing was only included from the thirteenth participant onwards (after 
the Stellenbosch University [SU] Health Research Ethics Committee [HREC] approved the 
protocol amendment); resulting in bone status data being available for n = 92 (92%) of 
participants (44 PLHIV and 48 SNP). Similarly, dual tasking was only introduced from the 
seventeenth participant, resulting in dual task data being available for n = 88 (88%) of 
participants (41 PLHIV and 47 SNP). Other reasons for missing data were inability to perform 
single leg stance (SLS) with eyes closed (EC) (n = 4 PLHIV) or during dual tasking (n = 2 
PLHIV), missing laboratory results from patient folders (some non-EndoAfrica participants) 
and failure to fill in the EQ-5D-5L questionnaire correctly. Figure 8.1 illustrates the inclusion 
and exclusion process of study participants and their data. 
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Figure 8.1. Flow diagram of participant and data inclusion and exclusion for the 
cross-sectional field study. 
 
HIV seronegative volunteers 
from the same communities 
as specified for HIV 
seropositive patients 
(Worcester & Paarl)
HIV seropositive and 
seronegative participants in 
Heart to HAART/EndoAfrica
study (Worcester only)
Current HIV seropositive 
patients attending standard 
care treatment at the Paarl and 
Worcester Hospital Infectious 
Diseases Unit/HIV clinic
Potential HIV seropositive participants Potential HIV seronegative participants
Approached for participation by research nurse / HIV counsellor
Assessed for eligibility by research nurse / HIV counsellor (including, for 
unknown status, counselling and rapid HIV screening) 
(n = 186; PLHIV = 100, SNP = 86)
PLHIV excluded (Total = 46):
• Unavailable (n = 7)
• Refused participation (n = 
14)
• DNA (n = 5)
• BMI>25 (n = 13)
• Active TB (n = 3)
• Age>65 (n = 2)
• Unwell on test day (n = 2)
SNP excluded (Total = 34)
• Refused participation (n = 8)
• DNA (n = 13)
• BMI>25 (n = 6)
• Refused HIV testing (n = 6)
• Alcohol intoxication on day 
(n = 1)
PLHIV datasets excluded:
• Technical failure (n = 4)
SNP datasets excluded:
• Alcohol intoxication (n = 2)
Analysed 
(PLHIV = 50 , SNP = 50)
PLHIV data not available for analysis:
• BMD (n =  6)
• Dual task activities (n = 9)
• Single leg stance DT on pressure mat (n = 6)
• Self-reported function from EQ-5D-5L (n = 1)
• Depression/anxiety from EQ-5D-5L (n = 2)
• Viral load (n = 4)
• HAART duration (n = 1)
• Haemoglobin (n = 10)
• Creatinine (n = 6)
• Kinematic data: insufficient gait cycles (fast-
paced, n = 5; dual task, n = 2)
SNP data not available for analysis:
• BMD (n =  2)
• Dual task activities (n = 3)
• Single leg stance DT on pressure mat (n = 8)
• Kinematic data: insufficient gait cycles 
(usual-paced, n = 2; fast-paced, n = 5)
Participated / 
continued consecutive 
sampling
(PLHIV = 54, SNP = 52)
Abbreviations: BMD = bone mineral density; 
BMI = body mass index; DNA = did not arrive; 
DT = dual task; EC = eyes closed; HAART = 
highly active anti-retroviral therapy; n = 
number of participants; PLHIV = people living 
with HIV-1 infection; SNP = HIV-seronegative 
participants; TB = tuberculosis. 
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8.1.2. Sociodemographic characteristics 
Sociodemographic characteristics of the participants in the PLHIV and SNP groups are 
presented in Table 8.1. Relative to SNP, PLHIV were 5.51 years older. Both groups had a 
higher distribution of younger versus older age groups. Both groups were predominantly 
female, but SNP included significantly more women than the PLHIV group. Ethnicity/race 
distribution differed significantly between groups, although both groups predominantly 
comprised of coloured participants. PLHIV were more likely to be employed (either part time 
or full time).  
Table 8.1. Sociodemographic characteristics of PLHIV and SNP in the cross-sectional 
study. 
Characteristics PLHIV (n = 50) SNP (n = 50) p-value 
Age (years) 36.61  
(31.96; 45.59) 
31.10  
(23.22; 45.07) 
0.017§ 
Age younger than 50 years 80% 86% 0.424† 
Female gender 58% 80% 0.017† 
Ethnicity/race   0.012‡ 
Coloured  84% 98%  
Black  14% 0%  
White  2% 2%  
Home language   0.007‡ 
Afrikaans  88% 94%  
English  0% 6%  
isiXhosa  12% 0%  
Education lower than Grade 12 58% 56% 0.840† 
Employed  58% 40% 0.072† 
Total household income per month   0.645‡ 
<R1,000 p/m 32% 24%  
R1,000 – R4,999   44% 48%  
R5,000 – R9,999   16% 14%  
R10,000 – R20,000   8% 10%  
>R20,000   0% 4%  
Abbreviations: n = number of participants; PLHIV = people living with HIV-1 infection; Q1 = first 
quartile; Q3 = third quartile; SNP = HIV-seronegative participants. 
Data are presented as median (Q1; Q3) or percentage. § Mann Whitney U test; †Chi-square test of 
homogeneity; ‡Fisher’s exact test (r x 2). p-values in bold print indicate statistical significance at p < 
0.05. 
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8.1.3. Anthropometrics and clinical measurements 
PLHIV on average had longer leg lengths than SNP. Bone mineral density measures were 
significantly lower in PLHIV. Relative to SNP, the percentage of osteopaenia and osteoporosis 
cases in PLHIV was larger, although these differences did not reach statistical significance. 
Lower limb muscle testing revealed that PLHIV had significantly weaker maximum isometric 
knee extensor (mean difference of -14.73 Newton (N), p = 0.045) and knee flexor strength 
(mean difference of -14.06 N, p = 0.020) than SNP; no other investigated lower limb muscle 
groups demonstrated significant differences (Table 8.2). 
Table 8.2. Clinical measurements and anthropometric characteristics of PLHIV and SNP 
in the cross-sectional study. 
Characteristic PLHIV  (n = 50) 
SNP  
(n = 50) p-value 
Height (m) 1.63 ± 0.09 1.60 ± 0.08 0.061$ 
BMI (kg/m2) 21.49 ± 4.80 20.40 ± 4.95 0.677$ 
Leg length (cm) 86.84 ± 5.45 84.45 ± 4.12 0.016$ 
Bone status (based on T-
score)a,b 
n(PLHIV) = 44; n(SNP) = 
48 
  0.095‡ 
Osteopaenia  56.82% 41.67%  
Osteoporosis  4.55% 0.00%  
Normal 38.64% 58.33%  
T-score# -1.15  
(-1.43; -0.85) 
-0.82  
(-1.32; -0.10) 0.016
§ 
Z-score# -1.13  
(-1.43; -0.67) 
-0.73  
(-1.27; -0.03) 0.024
§ 
BQI 81.30  
(77.05; 87.43) 
88.70  
(79.17;102.80) 0.010
§ 
Muscle strength 
Plantarflexors (N) 169.16 ± 36.15 181.91 ± 30.28 0.059$ 
Dorsiflexors (N) 133.03 ± 23.94 131.81 ± 23.62 0.798$ 
Knee extensors (N) 189.10 ± 38.03 203.83 ± 34.34 0.045$ 
Knee flexors (N) 147.06 ± 32.57 161.12 ± 26.57 0.020$ 
Hip extensors (N) 216.87 ± 38.97 212.16 ± 34.25 0.523$ 
Hip flexors (N) 205.54 ± 37.28 193.78 ± 28.18 0.078$ 
Hip abductors (N) 103.64 (86.38; 
126.36) 
109.19 (100.14; 
125.82) 0.082
§ 
Abbreviations: BMI = body mass index; BQI = bone quality index; cm = centimetres; m = metres; n = number 
of participants; N = Newton; PLHIV = people living with HIV-1-infection; Q1 = first quartile; Q3 = third quartile; 
SD = standard deviation; SNP = HIV-seronegative participants. 
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Data are presented as mean ± SD or median (Q1; Q3). $Independent Student’s t-test; ‡Fisher’s exact test 
(rx2); § Mann Whitney U test. p-values in bold print indicate statistical significance at p < 0.05. 
aBone mineral density data not collected for n = 6 PLHIV and n = 2 SNP, as QUS was only added to the 
study protocol after the first eight participants. 
8.1.4. Lifestyle characteristics 
Lifestyle characteristics (Table 8.3) were similar between PLHIV and SNP, except for level of 
physical activity and smoking status. Relative to SNP, PLHIV were less likely to be current 
smokers and more likely to report moderate to high levels of physical activity, while SNP were 
more likely to report low or no physical activity.  
Table 8.3. Lifestyle characteristics of PLHIV and SNP in the cross-sectional study. 
Characteristic PLHIV  (n = 50) 
SNP 
 (n= 50) p-value 
Physical activity   0.033† 
None  12% 30%  
Low  44% 46%  
Moderate to high  44% 24%  
Alcohol use over past 12 months   0.334‡ 
None  48% 38%  
Light  36% 54%  
Moderate   12% 6%  
Heavy  4% 2%  
Current smoker 52% 72% 0.039† 
Injection drug use, ever 2% 0% 0.500† 
Abbreviations: n = number of participants; PLHIV = people living with HIV-1-infection; SNP = HIV-
seronegative participants. 
†Chi-square test of homogeneity; ‡Fisher’s exact test (r x 2). p-values in bold print indicate 
statistical significance at p < 0.05. 
8.1.5. Medical history 
PLHIV did not differ significantly from SNP regarding medical history (Table 8.4), with the 
exception of more PLHIV reporting symptoms of depression/anxiety, as measured by the 
relevant EQ-5D-5L domain and more PLHIV being subject to nonantiretroviral polypharmacy. 
The most common non-ART medications in descending order for PLHIV were vitamin 
supplements (especially Vitamin C), hypertension diuretics, ACE inhibitors, analgesics 
(antipyretics), beta-blockers, statins, calcium channel blockers, bronchodilators, aspirin, anti-
inflammatories, analgesics (opioids) and tricyclic antidepressants. For SNP, the most common 
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medications in descending order were ACE inhibitors, hypertension diuretics, beta-blockers, 
corticosteroids, statins, aspirin, analgesics (opioids) and biguanides. 
Table 8.4. Medical history in PLHIV and SNP in the cross-sectional study. 
Characteristic PLHIV  (n = 50) 
SNP  
(n = 50) p-value 
Nonantiretroviral polypharmacy (two or 
more non-HAART medications) 32% 10% <0.001
† 
Multimorbidity (two or more 
comorbidities) 8% 4% 0.678
‡ 
Hypertension 20% 14% 0.424† 
Cardiovascular disease 2% 2% 1.000‡ 
Diabetes Type 1 or 2 0% 2% 1.000‡ 
Chronic fatigue  6% 0% 0.242‡ 
Chronic pulmonary disease 8% 6% 1.000‡ 
Depression/anxietya 
n(PLHIV) = 48; n(SNP) = 50 25% 4% 0.003
† 
Current (acute) pain  
n(PLHIV) = 49; n(SNP) = 50 34.7% 18% 0.059
† 
Chronic pain (MOS-HIV score) 77.78 (55.56; 
88.89) 
88.89 (77.78; 
100.00) 0.127
§ 
Cognitive function, (MOS-HIV score) 80.00 (60.00; 
95.00) 
87.50 (75.00; 
95.00) 0.076
§ 
Abbreviations: ART = antiretroviral therapy; n = number of participants; PLHIV, people living with 
HIV-1 infection; Q1 = first quartile; Q3 = third quartile; SNP = HIV-seronegative participants.  
Results presented as percentage or median (Q1; Q3). †Chi-square test; § Mann Whitney U test; 
‡Fisher’s exact test. p-values in bold print indicate statistical significance at p < 0.05. 
aDepression/anxiety: missing data for n = 2 PLHIV - one participant omitted the anxiety/depression 
question; another filled out the entire questionnaire (all domains) incorrectly. 
bCurrent pain: missing data for n = 1 PLHIV who filled out the entire EQ-5D-5L questionnaire 
wrong. 
8.2. HIV-related characteristics 
Table 8.5 presents disease-related characteristics of PLHIV. Most PLHIV (44%) had an HIV 
duration of five to 15 years. The average CD4+ count was below 500 cells/µL and less than 
half of PLHIV had undetectable viral loads. Almost all PLHIV (90%) were using HAART, with 
a median duration of about 2.3 years. The most common current HAART regimen was NNRTI-
based (efavirenz/emtricitabine/tenofovir, n = 80%). Non-adherence (defined as missing more 
than two prescribed HAART dosages per week) was reported by 22.22% of HAART-users. 
Investigated laboratory results mostly fell within normal ranges reported for the general 
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population, although 48% of PLHIV had C-reactive protein (CRP) levels exceeding 3mg/L 
(normal value in the general population <3 mg/dL).   
Table 8.5. HIV-related characteristics in the cross-sectional study (n = 50). 
Variable Estimate 
Time since HIV diagnosis (years) 
<2 years  18% 
2 – 5 years  32% 
5<15 years  44% 
>15 years  6% 
Current CD4+ T-cell count  
(cells/µL) 
448.78 ± 232.99 
Detectable HIV-1 RNA (³50 cp/mL) 
n = 46a 
54.30% 
On HAART  90% 
On first line HAART  84.44% 
On second line HAART  15.56% 
HAART duration (weeks) 
n = 44b 
119 (62; 312) 
Current HAART regime  
PI-based  20% 
NNRTI-based  80% 
INI-based  0% 
NRTI in the regimen: 
None  2.22% 
3TC only 2.22% 
TDF only 2.22% 
ABC/AZT + 3TC  13.33% 
TDF + FTC 80% 
HAART adherent  77.78% 
CRP (mg/L) 
n = 33c 
3.60 (1.45; 13.45) 
Haemoglobin (g/dL) 
n = 40c 
14.01 ± 1.90 
Creatinine (μmol/L) 
n = 44c 
64.50 (54.00; 72.00) 
Abbreviations: 3TC = lamivudine/epivir; ABC = abacavir; AZT = azidothymidine/zidovudine/retrovir; 
cells/µL = cells per microlitre; cp/mL = copies per millilitre; FTC = emtricitabine; g/dL = grams per 
decilitre; HAART = highly active antiretroviral therapy; HIV-1 RNA = viral load; INI = integrase 
inhibitor; mg/L = milligrams per litre; n = number of participants; NNRTI = non-nucleoside reverse-
transcriptase inhibitor; NRTI = nucleoside reverse-transcriptase inhibitors; PI = protease inhibitor; 
PLHIV = people living with HIV-1 infection; Q1 = first quartile’ Q3 = third quartile; SD = standard 
deviation; SNP = seronegative participants; TDF = tenofovir; μmol/L = micromole per litre. 
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Data are mean ± SD, median (Q1; Q3) or percentage. 
aViral loads missing for n = 4 participants who were not enrolled in the EndoAfrica (EA) study and 
had no values recorded in clinic folders. 
bART duration unknown for n = 1 participant as these data were not recorded in the clinic folder 
and the participant also did not know the duration. 
cLaboratory results were obtained from the EA database for shared participants (n = 33); all other 
values were as the most recent results from clinic folders or coded as missing (n = 10 for 
Haemoglobin and n=6 for Creatinine) if not reported in folder. 
8.3. Differences in self-reported function and fall history  
8.3.1. Self-reported function 
Self-reported function (Figure 8.2) was assessed in terms of three function-related domains 
from the EQ-5D-5L descriptive system. Responses to each of these domains were captured 
on a five-point Likert scale (“no problems” to “unable”) and were then dichotomised into 
“problems” and “no problems”.414 Relative to SNP, a significantly larger percentage of PLHIV 
reported problems with mobility (walking) (22.4% versus 8%, p = 0.046) and self-care activities 
(washing and dressing) (12.2% versus 2%, p = 0.047), while the percentage of PLHIV 
reporting problems with usual activities (e.g. work, study, housework, family or leisure 
activities) did not differ significantly from SNP (20.4% versus 8%, p = 0.077). Data were 
missing for one PLHIV who completed the entire questionnaire incorrectly, affecting all three 
domains.  
Figure 8.2. Self-reported function in PLHIV (blue) and SNP (dark red), reported in terms of 
three function-related domains from the EQ-5D-5L descriptive system. The asterisks 
indicate the domains that differed significantly (p < 0.05).  
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Figure 8.2. Self-reported functio  in PLHIV (blue) a   (dark red), reported in terms 
of three function-related domains from the EQ-5D-5L descriptive system. The asterisks 
indicate the domains that differed significantly. 
8.3.2. Falls and fear of falling 
The percentage of PLHIV who experienced any number of falls during the previous 12 months 
was significantly higher compared to SNP. The most common reasons reported for falling 
were accidentally tripping over objects (SNP and PLHIV) or legs giving way for no apparent 
reason (PLHIV). No significant differences were evident regarding the actual number of falls 
experienced, although trends were higher in PLHIV. More PLHIV reported having a fear of 
falling, although the difference was not statistically significant (Table 8.6).  
 
 
 
* 
22.40% 
8.00% 
12.20% 
2.00 % 
20.40% 
8.00% 
* 
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8.3.2. Falls and fear of falling 
The percentage of PLHIV who experienced any number of falls during the previous 12 months 
was significantly higher compared to SNP. The most common reasons reported for falling 
were accidentally tripping over objects (SNP and PLHIV) or legs giving way for no apparent 
reason (PLHIV). No significant differences were evident regarding the actual number of falls 
experienced, although trends were higher in PLHIV. More PLHIV reported having a fear of 
falling, although the difference was not statistically significant (Table 8.6).  
Table 8.6. Fall history in PLHIV and SNP in the cross-sectional study. 
Fall history PLHIV  (n = 50) 
SNP  
( n= 50) p-value 
Any fall during the past 12 months   34% 16% 0.038† 
Number of falls during the past 12 months   0.114† 
Single fall 20% 10%  
Recurrent falls (two or more) 14% 6%  
Fear of falling 20% 14% 0.425† 
Abbreviations: PLHIV = people living with HIV-1 infection; SNP = seronegative participants. 
†Chi-square test of homogeneity. Bold print indicates values of statistical significance (p < 0.05). 
 
8.4. Differences in clinical functional test performance  
8.4.1. Health ABC Physical Performance Battery (PPB) 
Unadjusted comparisons of the Health ABC Physical Performance Battery (PPB) (Table 8.7) 
revealed significantly lower scores (worse performance) for PLHIV versus SNP on total score 
as well as for all but the static balance test components. Minimum clinically important 
differences (MCID) for the PPB (total score) have been suggested as 0.12 points (small 
difference) to 0.22 points (substantial difference) across various conditions385; according to 
these criteria (albeit established in non-HIV populations), the difference in total PPB score 
(0.37 points) may correspond to a substantial clinically meaningful difference between PLHIV 
and SNP.  
After controlling for age, gender, leg length, depression/anxiety symptoms, current smoking 
status and level of physical activity, the significant between-group differences remained for 
total-, gait- and chair rise scores. Adjusted analyses also revealed significant interactions 
between HIV-serostatus and depression/anxiety symptoms for both of the gait speed sub 
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scores (F = 6.16, p = 0.015 and F= 4.91, p = 0.029 for the usual and narrow tests, respectively), 
indicating that the effect of HIV-1 infection on gait speed scores depended on the presence or 
absence of depressive symptoms. These interactions are illustrated in Figure 8.3.   
The PPB and its components demonstrated no floor or ceiling effects in either group, except 
for the balance score domain (highest level assessed = 30 seconds single leg stance [SLS] 
with eyes open): 70% of PLHIV and 90% of SNP respectively reached ceiling effects in this 
test component.  
 
 
 
 
Figure 8.3. Profile plots demonstrating the interaction between HIV-serostatus and the 
presence or absence of depressive symptoms on gait speed scores. The left plot 
represents the usual six-metre gait sub score, and the right plot the narrow gait sub 
score. For both tests, the presence of HIV has a larger detrimental effect in the presence 
of depressive/anxiety symptoms. 
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 Table 8.7. H
ealth A
B
C
 Physical Perform
ance B
attery (PPB
) perform
ance in PLH
IV and SNP. Blue arrow
s indicate the directional trend of the 
difference in PLH
IV relative to SNP. Unadjusted 
A
djusted 
C
linical test 
com
ponents 
Estim
ate 
[%
 floor / %
 ceiling] 
M
ean or 
m
edian 
difference 
(95%
 C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
M
ean 
difference ± 
SE (95%
 CI) 
p-value 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
H
ealth A
B
C
 Physical Perform
ance B
attery (PPB
): score range 0 – 4 
PPB
 total score 
(m
edian [IQ
R
] 
[range]) 
2.44 (0.51) 
(1.25; 3.01) 
[0%
; 0%
] 
2.78 (0.29) 
(2.20; 3.32) 
[0%
, 0%
] 
-0.37 
(-0.47; -0.24) 
<0.001
Ô 
2.36 ± 0.06 
(2.25; 2.472) 
2.67 ± 0.07 
(2.53; 2.82) 
-0.32 ± 0.09 
(-0.48; -0.15) 
<0.001
Ô 
PPB
 balance score 
(m
edian [IQ
R
] 
[range]) 
1.0 (0.004) 
(-0.25; 1.00) 
[0%
; 76%
] 
1.0 (0.0) 
(0.76; 1.00) 
[0%
; 90%
] 
0.00 
(0.00; 0.00) 
0.057
= 
0.95 ± 0.02 
(0.91 ± 0.99) 
0.98 ±0.04 
(0.90; 1.06) 
-0.95 ± 0.50 
(-1.94; 0.04) 
0.060
Ô 
PPB
 usual gait 
speed score (m
ean 
± SD
 [range]) 
0.51 ± 0.12 
(0.24; 0.76) 
[0%
; 0%
] 
0.61 ± 0.09 
(0.41; 0.81) 
[0%
; 0%
] 
-0.10 ± 0.02
b 
(-1.14; -0.06) 
<0.001
Ô 
0.52 ± 0.02 
(0.49; 0.55) 
0.61 ± 0.02 
(0.58; 0.65) 
-0.09 ± 0.02 
(-0.14; -0.05) 
<0.001
Ô 
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 PPB
 narrow
 w
alk 
gait speed score 
(m
ean ± SD
 [range]) 
0.50 ± 0.14 
(0.22; 0.75) 
[0%
; 0%
] 
0.60 ± 0.11 
(0.41; 0.94) 
[0%
; 0%
] 
-0.10 ± 0.03
b 
(-0.15; -0.05) 
<0.001
Ô 
0.48 ± 0.02 
(0.44; 0.52) 
0.64 ± 0.04 
(0.55; 0.73) 
-0.16 ± 0.47  
(-0.26; -0.07) 
0.001
Ô 
PPB
 chair rise 
score (m
ean ± SD
 
[range]) 
 
0.46 ± 0.12 
(0.28; 0.75) 
[0%
; 0%
] 
0.60 ± 0.15 
(0.41; 1.00) 
[0%
; 2%
] 
-0.14 ± 0.02
b  
(-0.19; -0.10) 
<0.001
Ô 
0.46 ± 0.02 
(0.42; 0.50) 
0.55 ± 0.03 
(0.50; 0.60) 
-0.09 ± 0.03 
(-0.14; -0.04) 
<0.001
Ô 
A
bbreviations: C
I = confidence interval; IQ
R
 = interquartile range; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; P
P
B = H
ealth A
B
C
 
P
hysical P
erform
ance B
attery; S
D
= standard deviation; S
E
 = standard error; S
N
P
 = seronegative participants. 
C
ovariables included age, gender, leg length, depression/anxiety sym
ptom
s, current sm
oking status and level of physical activity.  
U
nadjusted p-values w
ere obtained via M
ann-W
hitney U
 tests or independent sam
ple t-tests. A
djusted p-values w
ere obtained via F-test in G
eneral Linear M
odel 
(A
N
C
O
V
A
).  
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8.4.2. Single leg stance tests (eyes closed and dual task) 
Since SLS with EO (SLS EO) did not differ between groups as part of the PPB sub score, and given 
the high ceiling effects observed, this test was not analysed further as a lone-standing measure of 
clinical function performance. The SLS test was however assessed under two more challenging 
conditions, namely SLS with eyes closed (SLS EC), and SLS whilst performing a dual task (SLS 
DT). (Table 8.8) presents the unadjusted and adjusted results for these tests, assessed in terms of 
maximum time held in seconds (limit of 30 seconds). 
Inspection of minimum and maximum scores showed that for the SLS EC test, 12% of PLHIV and 
30% of SNP respectively reached a ceiling effect. In addition, 12% of PLHIV showed a floor effect 
(i.e. unable to hold the stance for at least one second463). SLS DT had high ceiling effects in both 
groups (63.4% and 91.4% in PLHIV and SNP respectively) – showing that most PLHIV, and almost 
all SNP, were able to perform the test up to the maximum time of 30 seconds. 
For unadjusted analyses, Mann-Whitney U tests were run to determine if there were differences in 
SLS EC and SLS DT outcomes (maximum time held) between PLHIV and SNP. For both SLS EC 
and SLS DT, distributions of the maximum time held for PLHIV and SNP were not similar (p < 0.001). 
The median difference in maximum time held was significant for the eyes-closed condition (shorter 
time in PLHIV) but not for the dual task condition, as indicated by the 95% confidence intervals (CIs). 
After adjustment, PLHIV still had a significantly lower adjusted mean SLS EC time compared to SNP. 
Adjustment for covariables rendered between-group differences in SLS DT insignificant.  
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 Table 8.8. Single leg stance (SLS) test perform
ance in PLH
IV and SN
P. B
lue arrow
s indicate the directional trend of the difference in 
PLH
IV relative to SN
P. 
U
nadjusted 
A
djusted 
C
linical test 
com
ponents 
M
edian (IQ
R
) (range)  
[%
 floor; %
 ceiling] 
M
edian 
difference 
(95%
 C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
M
ean 
difference ± 
SE (95%
 CI) 
p-value 
PLH
IV 
SN
P 
PLH
IV 
SN
P 
 
Single leg stance (SLS) test (m
axim
um
 tim
e 30 sec) 
Eyes 
closed, 
seconds 
7.93 (9.70) 
(0.00; 30.00) 
[12%
; 12%
] 
15.04 (20.78) 
(4.00; 30.00) 
[0%
; 30%
] 
-6.13 
(3.00; 10.46) 
<0.001
Ô 
11.27 ± 1.55 
(8.19; 14.35) 
17.30 ± 1.94 
(13.45; 
21.14) 
-6.02 ± 1.96 
(-9.92; -2.13) 
0.003
Ô 
D
ual task, 
seconds 
n(P
LH
IV
) = 
41; n(S
N
P
) = 
47
a 
30.00 (9.85) 
(2.00; 30.00) 
[0%
; 
 63%
] 
30.00 (0.00) 
(11.92; 
30.00) 
[0%
; 92%
] 
0.00 
(0.00; 0.00) 
0.002* = 
24.39 ± 1.35 
(21.72; 
27.07) 
29.11 ± 1.59 
(25.95; 
32.27) 
-4.72 ± 2.54 
(-9.79; 0.35) 
0.063
Ô 
A
bbreviations: C
I = confidence interval; IQ
R
 = interquartile range; P
LH
IV
 = people living w
ith H
IV
-1 infection; SE
 = standard error; S
N
P = seronegative 
participants. 
C
ovariables included age, gender, leg length, depression/anxiety sym
ptom
s, current sm
oking status and level of physical activity. 
* indicates a M
ann-W
hitney U
 p-value that represents a difference in score distributions betw
een groups, as opposed to a difference in m
edians – the 
reader is advised to refer to the m
edian difference and 95%
 C
I for a m
ore clinically relevant interpretation.. 
aD
ual task (D
T) activities w
ere only included later in data collection protocol; thus no D
T data w
ere collected for n (S
N
P
) = 3 and n (P
LH
IV
) = 9. 
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8.4.3. Six-metre gait speed test (usual-paced and dual task) 
Gait speed over six metres (Table 8.9) was significantly slower in PLHIV relative to SNP in 
both task conditions but more so under the more challenging circumstance of performing a 
dual task. Mean ± SE differences between PLHIV and SNP were -0.20 ± 0.04 (95% CI = -0.29 
m/s to 0.12 m/s) for the usual-paced condition and -0.25 m/s ± 0.05 (95% CI = -0.36 m/s to 
0.15 m/s) for the dual task condition. For both tasks the differences between PLHIV and SNP 
exceed the MCID of 0.1 m/s generally reported across various populations for gait speed.464 
After adjustment, the mean difference remained larger than 0.1 m/s and significant (p < 0.001) 
for both usual-paced and dual task gait. Adjusted analysis showed a statistically significant 
interaction between HIV-serostatus and depression/anxiety on usual-paced (but not dual task) 
gait speed over a six-metre course (F = 5.48, p = 0.021). This interaction showed a similar 
pattern to what was observed for the gait speed sub scores of the PPB as was presented 
previously in Figure 8.3.  
8.4.4. Chair rise tests 
Table 8.10 presents the results for chair rise performance in PLHIV relative to SNP. 
Unadjusted comparisons revealed that PLHIV performed the Five-Times Sit-To-Stand (5STS) 
Test significantly slower (longer time required) than SNP (mean ± SE difference = -2.99 
seconds, 95% CI = 2.07 seconds to 3.90 seconds,  p < 0.001); exceeding the MCID of ~2 
seconds reported for this test in various other populations401 and suggested in PLHIV.3 The 
difference was just under two seconds after adjustment and remained significant (p < 0.001). 
Adjusted analysis revealed a statistically significant interaction between HIV-serostatus and 
age on the time it took to complete five repeated chair rises (F= 6.06, p = 0.016). The 
interaction is depicted in Figure 8.4.  
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Figure 8.4. Grouped scatter plot demonstrating the interaction effect between HIV-
serostatus and age on Five-Times Sit-To-Stand time, showing that the detrimental 
effect of HIV-serostatus increases with age.  
 
Unadjusted comparisons for the 30-second STS (30sSTS) test revealed that PLHIV performed 
an average of 3.72 less repetitions than SNP (p < 0.001), exceeding the MCID of 2 to 2.60 
repetitions previously applied in an HIV population.402 After adjustment, simple main effects 
for HIV-serostatus demonstrated a significant mean difference of -4.81 repetitions ± 1.91 
repetitions (p = 0.013). 
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 Table 8.9. Six-m
etre W
alk Test (6m
W
T) perform
ance in PLH
IV and SN
P. B
lue arrow
s indicate the directional trend of the difference in PLHIV 
relative to SNP. 
U
nadjusted 
A
djusted 
C
linical test 
M
ean ± SD
 (range) 
 
M
ean 
difference 
(95%
 C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
M
ean 
difference ± 
SE (95%
 CI) 
p-value 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
 
Six-m
etre W
alk Tests (6m
W
T) (speed in m
/s) 
U
sual-paced, 
m
/s  
0.99 ± 0.24 
(0.47; 1.51) 
1.22 ± 0.18 
(0.81; 1.62) 
-0.20 ± 0.04 
(-0.29; 0.12) 
<0.001
Ô 
0.97 ± 0.04 
(0.89; 1.04) 
1.30 ± 0.08 
(1.14; 1.45) 
-0.33 ± 0.08 
(-0.50; -0.17) 
<0.001
Ô 
D
ual task, 
m
/s  
n(P
LH
IV
) = 
41; n(S
N
P
) = 
47
a 
0.75 ± 0.27 
(0.12; 1.21) 
1.00 ± 0.23 
(0.50; 1.76) 
-0.25 ± 0.05 
(-0.36; 0.15) 
<0.001
Ô 
0.74 ± 0.05 
(0.65; 0.84) 
0.96 ± 0.06 
(0.84; 1.069) 
-0.22 ± 0.06 
(-0.33; -0.10) 
0.001
Ô 
A
bbreviations: C
I = confidence interval; m
/s = m
etres per second; n = num
ber of participants; P
LH
IV
 = people living w
ith H
IV
-1 infection; S
E
 = standard error; 
S
N
P
 = seronegative participants. 
C
ovariables included age, gender, leg length, depression/anxiety sym
ptom
s, current sm
oking status and level of physical activity. 
U
nadjusted p-values w
ere obtained via independent sam
ple t-tests. A
djusted p-values w
ere obtained via F-test in G
eneral Linear M
odel (A
N
C
O
V
A
). B
old print 
indicates statistical significance at p < 0.05.  
aD
ual task (D
T) activities w
ere only included later in data collection protocol; thus, no D
T data w
ere collected for n (S
N
P
) = 3 and n (P
LH
IV
) = 9. 
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 Table 8.10. C
hair rise test perform
ance in PLH
IV and SN
P. B
lue arrow
s indicate the directional trend of the difference in PLH
IV relative 
to SN
P. 
U
nadjusted 
A
djusted 
C
linical 
test 
M
ean ± SD
 (range) 
 
M
ean 
difference 
(95%
 C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
M
ean 
difference ± 
SE (95%
 CI) 
p-value 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
PLH
IV  
(n = 50) 
SN
P  
(n= 50) 
 
C
hair rise tests 
5STS, 
seconds 
 
11.59 ± 2.83 
(6.70; 18.00) 
8.60 ± 1.63 
(5.00; 12.23) 
2.99 ± 0.46
a 
(2.07; 3.90) 
<0.001
Ó 
11.45 ± 0.38 
(10.69; 
12.21) 
9.53 ± 0.48 
(8.58; 10.47) 
1.92 ± 0.47 
(0.99; 2.85) 
<0.001
Ó 
30sSTS, 
repetitions 
15.94 ± 5.01 
(8; 30) 
19.66 ± 4.94 
(11; 32) 
-3.72 ± 0.99
a 
(-5.59; -1.75) 
<0.001
Ô 
16.19 ± 0.86 
(14.49; 
17.89) 
21.00 ± 1.78 
(17.47; 
24.53) 
-4.81 ± 1.91 
(-8.60; -1.02) 
0.013
Ô 
A
bbreviations: 30sS
TS = 30-second S
it-To-S
tand Test; 5S
TS = 5-Tim
es S
it-To-S
tand Test; C
I = confidence interval; n = num
ber of participants; P
LH
IV = 
people living w
ith H
IV
-1 infection; S
E = standard error; S
N
P
 = seronegative participants. 
C
ovariables in the adjusted m
odel w
ere age, gender, leg length, depression/anxiety sym
ptom
s, current sm
oking status and level of physical activity. 
U
nadjusted p-values w
ere obtained via independent sam
ple t-tests. A
djusted p-values w
ere obtained via F-test in G
eneral Linear M
odel (A
N
C
O
V
A
). B
old 
print indicates statistical significance at p < 0.05. 465 
 
Stellenbosch University  https://scholar.sun.ac.za
 - 217 - | P a g e  
 
8.5. Differences in biomechanical gait outcomes 
As shown in Figure 8.1, selected participant datasets were excluded from kinematic outcomes 
due to not having enough valid gait cycles available (i.e. at least six cycles). Specifically, n = 
2 SNP datasets (4%) were excluded from the usual-paced outcomes, n = 5 SNP (10%) and n 
= 5 PLHIV (10%) datasets were excluded from the fast outcomes, and n = 2 PLHIV trials (n = 
4) were excluded from the dual task outcomes. 
8.5.1. Temporal, spatial, temporophasic and temporospatial 
parameters (TSPs) 
8.5.1.1. Usual-paced gait 
Full data for unadjusted and adjusted TSP comparisons for usual-paced gait are presented in 
Table 8.11. Unadjusted comparisons demonstrated that at a usual pace, all TSPs differed 
significantly between PLHIV and SNP, except single support time as percentage of the gait 
cycle. The usual-paced gait speed of PLHIV was significantly slower than that of SNP. The 
slower speed in PLHIV resulted from both a shorter mean step length (resulting in a shorter 
mean stride length) and a lower mean cadence. The trends and significance of the differences 
for all said outcomes remained similar once normalised to leg length. PLHIV spent a longer 
percentage of the gait cycle in stance and double support. In accordance, PLHIV also 
demonstrated a shorter single support time, although this difference did not reach statistical 
significance.  
After adjusting for age, gender and normalised gait speed, only stance time, step time, gait 
speedviii and normalised gait speedix remained significantly different between groups. The 
direction of the differences remained the same. Relative to SNP, PLHIV thus demonstrated a 
slower gait speed with an increased stance and step time. However, HIV-serostatus only 
demonstrated a significant main effect for gait speed (F = 15.79, p < 0.001) and normalised 
gait speed (F = 16.59, p < 0.001). For stance and step time, significant interactions were noted 
between HIV-serostatus and gender (F = 4.93, p = 0.29 and F = 4.95, p = 0.29 for stance and 
step time respectively), as well as HIV-serostatus and speed (F = 14.87, p < 0.001 and F = 
                                               
viii Gait speed was only adjusted for age and gender. 
ix Normalised gait speed was only adjusted for age and gender. 
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12.33, p = 0.001 for stance and step time respectively). The effect of HIV on these outcomes 
thus depended on the gender of the participant. Figure 8.5 demonstrates these interactions. 
 
Figure 8.5. Interaction effects noted between HIV-serostatus and gender, and HIV-serostatus 
and gait speed for stance and step time during usual-paced gait. For both outcomes, the 
effects of HIV seem larger in men; in addition, the effects of HIV seem more apparent at 
slower gait speeds.  
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 Table 8.11.Tem
poral, spatial, tem
porophasic and tem
porospatial param
eters during usual-paced gait in PLH
IV and SN
P. B
lue arrow
s indicate 
the directional trend of the difference in PLH
IV relative to SNP. 
G
roup 
n 
Unadjusted 
Adjusted 
M
ean ± SD (95%
 
CI) 
Difference (95%
 CI) 
p-value 
M
ean ± SE (95%
 
CI) 
Difference (95%
 CI) 
p-value 
Step length (cm
) 
PLHIV 
50 
57.52 ± 7.66 
(55.35; 59.70) 
-3.65 ± 1.41 
(-6.44; -0.90) 
0.011
Ô 
60.55 ± 0.56 
(59.44; 61.65) 
1.30 ± 
0.85 
(-0.38; 3.00) 
0.127
Ó 
SNP 
48 
61.17 ± 6.14 
(59.38; 62.95) 
59. 24 ± 0.61 
(58.03; 60.45) 
Norm
alised step length
‡ 
PLHIV 
50 
0.73 ± 0.08 
(0.71; 0.75) 
-0.06 ± 0.02 
(-0.09; -0.03) 
0.001
Ô 
0.76 ± 0.006 
(0.75; 0.77) 
0.01 ± 
0.01 (-0.01; 
0.03) 
0.297
Ó 
SNP 
48 
0.79 ± 0.08 
(0.76; 0.81) 
0.75 ± 0.007 
(0.74; 0.76) 
Stride length (cm
) 
PLHIV 
50 
113.21 ± 15.96 
(108.67; 117.74) 
-7.79 ± 2.86 
( -13.47; -2.11) 
0.008
Ô 
119.36 ± 1.11 
(117.15; 121.58) 
2.41 ± 1.70 
(-0.96; 5.77) 
0.159
Ó 
SNP 
48 
121.0 ± 12.03 
(117.50; 124.49) 
116.96 ± 1.22 
(114.54; 119.38) 
Norm
alised stride length 
PLHIV 
50 
1.44 ± 0.18 
(1.39; 1.49) 
-0.12 ± 0.03 
(-0.18; 0.05) 
<0.001
Ô 
1.50 ± 0.01 
(1.48; 1.53) 
0.03 ± 0.02 
(-0.01; 
0.07) 
0.122
Ó 
SNP 
48 
1.56 ± 0.15 
(1.51; 1.60) 
1.47 ± 0.02 
(1.44; 1.50) 
Cadence (steps/m
in) 
PLHIV 
50 
104.48 ± 12.64 
(100.89; 108.07) 
-11.86 ± 2.31  
(-16.44; 7.28) 
<0.001
Ô 
109.69 ± 0.85 
(108.01; 111.37) 
-2.06 ± 1.26 
(-4.57; 0.45) 
0.106
Ô 
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SNP 
48 
116.34 ± 9.99 
(113.44; 119.24) 
111.75 ± 0.86 
(110.04; 113.46) 
Norm
alised cadence 
PLHIV 
50 
29.61 ± 3.74 
(28.55; 30.68) 
-3.15 ± 0.68 
(-4.51; 1.80) 
<0.001
Ô 
31.05 ± 0.24 
(30.57; 31.52) 
-0.51 ± 0.36 
(-1.21; 0.20) 
0.155
Ô 
SNP 
48 
32.77 ± 2.98 
(31.91; 33.63) 
31.55 ± 0.24 
(31.07; 32.03) 
Stance tim
e (sec) 
PLHIV 
50 
0.73 ± 0.10 
(0.71; 0.76) 
0.09 ± 0.02 
(0.05; 0.12) 
<0.001
Ó 
0.69 ± 0.01 
(0.68; 0.71) 
0.02 ± 0.01 
(0.001; 0.03) 
0.038
Ó 
SNP 
48 
0.65 ± 0.06 
(0.63; 0.67) 
0.67 ± 0.01 
(0.66; 0.68) 
Step tim
e (sec) 
PLHIV 
50 
0.59 ± 0.07 
(0.56; 0.61) 
0.06 ± 0.01 
(0.04; 0.09) 
<0.001
Ó 
0.55 ± 0.004 
(0.55; 0.56) 
0.02 ± 0.01 
(0.002; 0.03) 
0.023
Ó 
SNP 
48 
0.52 ± 0.04 
(0.51; 0.53) 
0.54 ± 
0.01 (0.53; 
0.55) 
Single support tim
e (sec) 
PLHIV 
50 
0.44 ± 0.05 
(0.42; 0.45) 
0.04 ± 0.01  
(0.03; 0.06) 
<0.001
Ó 
0.42 ± 0.004 
(0.41; 0.43) 
0.01 ± 
0.01 
(-0.001; 0.03) 
0.077
Ó 
SNP 
48 
0.39 ± 0.03 
(0.38; 0.40) 
0.41 ± 0.01 
(0.40; 0.42) 
Double support tim
e (sec) 
PLHIV 
50 
0.29 (0.09) 
(0.25; 0.34) # 
0.05 ± 0.01 
(0.02; 0.07) 
<0.001
Ó 
0.28 ± 
0.01 
(0.27; 0.29) 
0.003 ± 0.01 
(-0.01; 0.02) 
0.667
Ó 
SNP 
48 
0.24 (0.06) 
(0.22; 0.27) # 
0.27 ± 
0.01 
(0.26; 
0.28) 
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Stance tim
e (%
G
C) 
PLHIV 
50 
62.64 (2.36) 
(61.50; 63.86) # 
0.65 ± 0.34    
(-0.03; 1.33) 
0.031
Ó 
62.21 
± 0.21 
(61.79; 62.62) 
-0.11 ± 0.32 
(-0.74; 0.53) 
0.733
Ô
= 
SNP 
48 
61.67 (2.39) 
(60.82; 63.20) 
62.32 ± 0.23 
(61.86; 62.77) 
Single support tim
e (%
G
C) 
PLHIV 
50 
37.37 ± 1.72 
(36.88; 37.85) 
-0.55 ± 0.38 
(-1.31; 0.21) 
0.153
Ô 
37.87 ± 0.24 
(37.39; 38.35) 
0.22 ± 0.37 
(-0.52; 
0.95) 
0.562
Ó 
SNP 
48 
37.92 ± 2.04 
(37.32; 38.51) 
37.66 ± 0.27 
(37.13; 38.19) 
Double support tim
e (%
G
C) 
PLHIV 
50 
25.26 (3.76) 
(23.24; 27.00) # 
1.20 ± 0.69 
(-0.18; 2.58) 
0.042
Ó 
24.33 ± 0.43 
(23.49; 25.18) 
0.32 ± 0.72 
(-1.11; 
1.76) 
0.655
Ô 
SNP 
48 
23.48 (4.72) 
(21.80; 26.53) # 
24.66 ± 0.47 
(23.73; 25.59) 
G
ait speed (m
/s) † 
PLHIV 
50 
0.99 ± 0.22 
(0.93; 1.06) 
-0.18 ± 0.04 
(-0.30; -0.10) 
<0.001
Ô 
1.01 ± 0.03 
(0.95; 1.07 
-0.17 ± 0.04 
(-0.26; 
-0.08) 
<0.001
Ô 
SNP 
48 
1.18 ± 0.19 
(1.12; 1.23) 
1.18 ± 0.03 
(1.12; 1.24) 
Norm
alised gait speed
† 
PLHIV 
50 
0.36 ± 0.08 
(0.33; 0.38) 
-0.07 ± 0.01 
(-0.10; -0.04) 
<0.001
Ô 
0.36 ± 0.01 
(0.34; 0.38) 
-0.06 ± 0.02 
(-0.09;  -0.03) 
0.001
Ô 
SNP 
48 
0.43 ± 0.07 
(0.41; 0.45) 
0.42 ± 
0.01 
(0.40; 0.45) 
A
bbreviations: C
I = confidence interval; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; S
D
 = standard deviation; S
E
 = standard 
error; sec = seconds; S
N
P
 = H
IV
-seronegative participants. 
C
ovariables in the adjusted m
odel w
ere gender, age and leg-length norm
alised gait speed. 
#presented as m
edian (IQ
R
) (Q
1 – Q
3); p-value obtained via M
ann-W
hitney U
 test. 
‡S
ince norm
alised step and stride length w
ere already scaled to leg length, the m
odels for these outcom
es included unadjusted gait speed as covariable. 
†G
ait speed and norm
alised gait speed w
ere only adjusted for gender and age. 
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8.5.1.2. Fast-paced gait  
Unadjusted comparisons showed that differences in unadjusted gait speed were no longer 
significant in fast-paced gait (p = 0.050), although normalised gait speed remained significantly 
slower in PLHIV (p = 0.032). Spatial parameters and temporophasic parameters no longer 
differed significantly between PLHIV and SNP, but temporal and temporospatial parameters 
including cadence, normalised cadence (both decreased in PLHIV), stance time, step time, 
single support time and double support time in seconds (all increased in PLHIV) differed 
significantly between PLHIV and SNP (p < 0.05).    
Adjusted analysis rendered all TSP differences non-significant between groups, except for 
step time, which was increased in PLHIV relative to SNP Full results are presented in Table 
8.12. 
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 Table 8.12. Tem
poral, spatial, tem
porophasic and tem
porospatial param
eters during fast-paced gait in PLHIV and SNP. Blue arrow
s indicate 
the directional trend of the difference in PLH
IV relative to SNP.  
G
roup 
n 
U
nadjusted 
A
djusted 
M
ean ± SD
 (95%
 C
I) 
D
ifference (95%
 CI) 
p-value 
M
ean ± SE (95%
 
C
I) 
D
ifference (95%
 CI) 
p-value 
Step length (cm
) 
PLH
IV 
45 
69.36 ± 10.08 
(66.33; 72.39) 
-1.62 ± 1.78 
(-5.15; 1.91)    
0.365
Ô 
71.42 ± 0.62 
(70.19; 72.64) 
1.10 ± 0.88 
(-0.65; 2.85) 
0.216
Ó 
SN
P 
45 
70.98 ± 6.37 
(69.06; 72.89) 
70.32 ± 0.65 
(69.02; 71.62) 
N
orm
alised step length
‡ 
PLH
IV 
45 
0.88 ± 0.10 
(0.85; 0.91) 
-0.03 ± 0.02 
(-0.07; 0.01)    
0.172
Ô 
0.90 ± 0.01 
(0.88; 
0.92) 
0.01 ± 0.01 
(-0.02; 0.03) 
0.583
Ó 
SN
P 
45 
0.91 ± 0.08 
(0.89; 0.94) 
0.89 ± 0.01 
(0.87; 0.91) 
Stride length (cm
) 
PLH
IV 
45 
137.18 ± 20.73 
(130.95; 143.40) 
-3.24 ± 3.60 
(-10.39; 3.91)       
0.370
Ô 
141.37 ± 1.27 
(138.85; 143.89) 
2.08 ± 1.81 
(-1.52; 5.69) 
0.253
Ó 
SN
P 
45 
140.42 ± 12.37 
(136.70; 144.13) 
139.29 ± 1.34 
(136.62; 142.0) 
N
orm
alised stride length 
PLH
IV 
45 
1.75 ± 0.21 
(1.68; 
1.81) 
-0.06 ± 0.04 
(-0.13; 0.02)             
0.169
Ô 
1.78 ± 0.02 
(1.75; 
1.81) 
0.01 ± 0.02 
(0.04; 0.06) 
0.611
Ó 
SN
P 
45 
1.80 ± 0.16 
(1.75; 
1.85) 
1.77 ± 0.02 
(1.73; 
1.80) 
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C
adence (steps/m
in) 
PLH
IV 
45 
132.24 ± 14.57 
(127.86; 136.61) 
-8.47 ± 2.82 
(-14.07; -2.86)  
0.004
Ô 
134.43 ± 1.08 
(132.282; 136.58) 
-2.73 ± 1.54 
(-5.80; 0.34) 
0.080
Ô 
SN
P 
45 
140.70 ± 12.08 
(137.07; 144.33) 
137.16 ± 1.14 
(134.90; 139.43) 
N
orm
alised cadence 
PLH
IV 
45 
37.39 ± 4.42 
(36.06; 38.71) 
-2.27 ± 0.82 
(-3.89; 0.64)   
0.007
Ô 
38.07 ± 0.30 
(37.48; 38.66) 
-0.76 ± 0.43 
(-1.60; 0.09) 
0.067
Ô 
SN
P 
45 
39.65 ± 3.23 
(38.68; 40.62) 
38.82 ± 0.32 
(38.20; 39.45) 
Stance tim
e (sec) 
PLH
IV 
45 
0.55 ± 0.08 
(0.53; 
0.58) 
0.04 ± 0.01 
(0.01; 0.07) 
0.004
Ó 
0.54 ± 0.01 
(0.53; 
0.55) 
0.01 ± 0.01 
(-0.001; 0.03) 
0.076
Ó
 
SN
P 
45 
0.51 ± 0.05 
(0.50; 0.53) 
0.53 ± 0.01 
(0.52; 
0.54) 
Step tim
e (sec) 
PLH
IV 
45 
0.46 ± 0.05 
(0.45; 
0.48) 
0.03 ± 0.01 
(0.01; 0.05)                 0.002
Ó 
0.46 ± 0.004 
(0.45; 
0.46) 
0.01 ± 0.01 
(0.001; 0.02) 
0.039
Ó 
SN
P 
45 
0.43 ± 0.04 
(0.42; 
0.44) 
0.44 ± 0.004 
(0.43; 
0.45) 
Single support tim
e (sec) 
PLH
IV 
45 
0.37 ± 0.03 
(0.36; 0.38) 
0.02 ± 0.01 
(0.006; 0.03)                0.003
Ó 
0.37 ± 0.003 
(0.36; 
0.37) 
0.01 ± 0.01 
(0.00; 0.02) 
0.065
Ó 
SN
P 
45 
0.34 ± 0.02 
(0.34; 0.36) 
0.36 ± 0.004 
(0.35; 
0.36) 
D
ouble support tim
e (sec) 
PLH
IV 
45 
0.19 ± 0.05 
(0.17; 0.20)  
0.02 ± 0.01 
(0.003; 0.04) 
0.026
Ó 
0.18 ± 0.004 
(0.17; 0.19) 
0.01 ± 0.01 
(-0.01; 0.02) 
0.413
Ó 
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SN
P 
45 
0.16 ± 0.04 
(0.15; 
0.18)  
0.17 ± 0.004 
(0.17; 
0.18) 
Stance tim
e (%
G
C
) 
PLH
IV 
45 
60.03 ± 1.99 
(59.43; 60.63)  
0.58 ± 0.40 
(-0.21; 1.37) 
0.147
Ó 
59.65 ± 0.18 
(59.30; 60.00) 
-0.05 ± 0.25 
(-0.56; 0.45) 
0.834
Ô 
SN
P 
45 
59.45 ± 1.76 
(58.92; 59.98) 
59.70 ± 0.19 
(59.33; 60.10) 
Single support tim
e (%
G
C
) 
PLH
IV 
45 
40.04 ± 2.08 
(39.41; 40.66) 
-0.59 ± 0.42 
(-1.44; 0.25)              
0.166
Ô 
40.37 ± 0.22 
(39.94; 40.80) 
0.05 ± 0.31 
(-0.58; 0.67) 
0.885
Ó 
SN
P 
45 
40.63 ± 1.95 
(40.05; 41.22) 
40.33 ± 0.23 
(39.87; 40.79) 
D
ouble support tim
e (%
G
C
) 
PLH
IV 
45 
20.00 ± 4.00 
(18.79; 21.20) 
-1.17 ± 0.80 
(-2.75; 0.41)               
0.144
Ó 
19.28 ± 0.37 
(18.55; 20.01) 
-0.10 ± 0.52 
(-1.14; 0.94) 
0.852
Ô 
SN
P 
45 
18.82 ± 3.53 
(17.76; 19.88)  
19.38 ± 0.39 
(18.60; 20.15) 
G
ait speed (m
/s) † 
PLH
IV 
45 
1.52 ± 0.35 
(1.42;1.63) 
-0.12 ± 0.06 
(-0.24; 0.00)                 0.050
Ô 
1.55 ± 0.04 
(1.47; 
1.64) 
-0.10 ± 0.06 
(-0.22; 0.03) 
0.120
Ô 
SN
P 
45 
1.64 ± 0.22 
(1.58; 1.71) 
1.65 ± 0.05 
(1.56; 
1.74) 
N
orm
alised gait speed
† 
PLH
IV 
45 
0.55 ± 0.12 
(0.51; 0.58) 
-0.05 ± 0.02 
(-0.09; - 0.004)              0.032
Ô 
0.56 ± 0.02 
(0.53; 
0.59) 
-0.04 ± 0.02 
(-0.08; 0.01) 
0.099
Ô 
SN
P 
45 
0.59 ± 0.08 
(0.57; 
0.62) 
0.59 ± 0.02 
(0.56; 
0.63) 
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A
bbreviations: C
I = confidence interval; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; S
D
 = standard deviation; S
E
 = standard error; sec 
= seconds; S
N
P = H
IV
-seronegative participants. 
C
ovariables in the adjusted m
odel w
ere gender, age and leg-length norm
alised gait speed. 
‡S
ince norm
alised step and stride length w
ere already scaled to leg length, the m
odels for these outcom
es included unadjusted gait speed as covariable. 
†G
ait speed and norm
alised gait speed w
ere only adjusted for gender and age. 
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8.5.1.3. Dual task gait  
Table 8.13 presents results for TSPs measured under dual task conditions. As expected, gait 
speed was slower in both groups compared to usual-paced gait. Unadjusted comparisons 
demonstrated a similar pattern in TSP differences as described for usual-paced gait, namely 
significantly reduced gait speed in PLHIV relative to SNP, with decreased spatial parameters 
and cadence in PLHIV, and generally increased temporal and temporophasic parameters. 
Whereas single support time as a percentage of the gait cycle was the only non-significant 
between-group difference for usual-paced gait, dual task conditions led to stance time as a 
percentage of the gait cycle being the only non-significant difference. Adjusted analysis 
rendered all TSP differences non-significant, except for gait speed, normalised gait speed and 
stride length - which were increased in PLHIV along with a significantly increased step time 
(p-value for analysis with robust HC3 SE = 0.022). A significant interaction was noted for HIV-
serostatus and gait speed (F = 22.10, p < 0.001) on step time, as illustrated in Figure 8.6. 
 
Figure 8.6. Grouped scatter plot demonstrating the interaction effect between HIV-
serostatus and gait speed on step time during dual task conditions, showing that the 
detrimental effect of HIV-serostatus is particularly apparent at slow speeds. 
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 Table 8.13. Tem
poral, spatial, tem
porophasic and tem
porospatial param
eters during dual task gait in PLH
IV and SN
P. Blue arrow
s 
indicate the directional trend of the difference in PLH
IV relative to SN
P. 
G
roup 
n 
U
nadjusted 
A
djusted 
M
ean ± SD
 (95%
 
C
I) 
D
ifference (95%
 
C
I) 
p-value 
M
ean ± SE (95%
 
C
I) 
D
ifference (95%
 
C
I) 
p-value 
Step length (cm
) 
PLH
IV 
39 
56.03 ± 7.46 
(53.61; 58.45) 
-4.19 ± 1.56 
(-7.30; 1.08) 
0.009
Ô 
59.81 ± 0.74 
(58.34; 61.28) 
2.00 ± 1.05 
(-0.10; 4.10) 
0.061
Ó 
SN
P 
47 
60.22 ± 7.00 
(58.16; 62.27) 
57.81 ± 0.72 
(56.38; 59.23) 
N
orm
alised step length
‡ 
PLH
IV 
39 
0.72 ± 0.09 
(0.69; 0.75) 
-0.06 ± 0.02  
(-0.10; -0.02) 
0.003
Ô 
0.76 ± 0.01 
(0.74; 0.78) 
0.02 ± 0.01 
(-0.01; 0.05) 
0.122
Ó 
SN
P 
47 
0.78 ± 0.09 
(0.75; 0.80) 
0.74 ± 0.010 
(0.72; 0.76) 
Stride length (cm
) 
PLH
IV 
39 
109.96 ± 15.99 
(104.78; 115.14) 
-8.45 ± 3.24 
(-14.89; -2.00) 
0.011
Ô 
117.99 ± 1.50 
(115.00; 120.97) 
4.50 ± 2.14 
(0.25; 8.76) 
0.038
Ó 
SN
P 
47 
118.41 ± 14.06 
(114.28; 122.54) 
113.48 ± 1.46 
(110.59; 116.38) 
N
orm
alised stride length 
PLH
IV 
39 
1.41 ± 0.19 
(1.35; 
1.47) 
-0.12 ± 0.04 
(-0.20; 0.04) 
0.005
Ô 
1.50 ± 0.02 
(1.46; 1.54) 
0.05 ± 0.03 
(-0.01; 0.10) 
0.088
Ó 
SN
P 
47 
1.53 ± 0.19 
(1.47; 
1.58) 
1.45 ± 0.02 
(1.41; 
1.49) 
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C
adence (steps/m
in) 
PLH
IV 
39 
97.37 ± 15.43 
(92.37; 102.37) 
-16.07 ± 2.96 
(-21.95; -10.19) 
<0.001
Ô 
106.11 ± 1.32 
(103.48; 108.74) 
-3.76 ± 1.90 
(-7.56; 0.04) 
0.052
Ô 
SN
P 
47 
113.44 ± 11.99 
(109.92; 116.96) 
109.87 ± 1.38 
(107.13; 112.62) 
N
orm
alised cadence 
PLH
IV 
39 
27.52 ± 4.60 
(26.02; 29.01) 
-4.38 ± 0.86 
(-6.09; -2.67) 
<0.001
Ô 
30.18 ±
 
0.40 
(29.39; 30.97) 
-1.06 ± 0.58 
(-2.20 ±0.09) 
0.071
Ô 
SN
P 
47 
31.90 ± 3.34 
(30.92; 32.88) 
31.24 ± 0.42 
(30.41; 32.06) 
Stance tim
e (sec) 
PLH
IV 
39 
0.80 ± 0.15 
(0.76; 
0.85) 
0.14 ± 0.02 
(0.09; 0.19) 
<0.001
Ó 
0.72 ± 0.01 
(0.70; 
0.74) 
0.02 ± 0.01 
(0.00; 05) 
0.100
Ó 
SN
P 
47 
0.67 ± 0.08 
(0.64; 
0.69) 
0.70 ± 0.01 
(0.68; 
0.72) 
Step tim
e (sec) 
PLH
IV 
39 
0.61 (0.16) 
(0.54; 0.70) 
0.10 ± 0.02 
(0.06; 0.14) 
<0.001
Ó 
0.57 ± 0.01 
(0.56; 
0.59) 
-0.19 ± 0.08
$ 
(-0.35; -0.33) 
0.022
$Ó 
SN
P 
47 
0.54 (0.08) 
(0.50; 0.58) 
0.56 ± 0.01 
(0.54; 
0.57) 
Single support tim
e (sec) 
PLH
IV 
39 
0.45 (0.09) 
(0.42; 0.51) 
0.06 ± 0.01 
(0.04; 0.09) 
<0.001
Ó 
0.44 ± 0.01 
(0.43; 0.46) 
0.02 ± 0.01 
(0.00; 0.04) 
0.098
Ó 
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SN
P 
47 
0.41 (0.04) 
(0.38; 0.43) 
0.43 ± 0.01 
(0.41; 0.44) 
D
ouble support tim
e (sec) 
PLH
IV 
39 
0.33 ± 0.08 
(0.31; 
0.36)  
0.07 ± 0.01 
(0.04; 0.10) 
<0.001
Ó 
0.29 ± 0.01 
(0.27; 0.30) 
0.01 ± 0.01 
(0.01; 0.03) 
0.371
Ó 
SN
P 
47 
0.26 ± 0.06 
(0.25; 
0.28)  
0.28 ± 0.01 
(0.27; 
0.29) 
Stance tim
e (%
G
C
) 
PLH
IV 
39 
62.95 ± 1.81 
(62.37; 63.54)  
0.66 ± 0.41 
(0.15; 1.46) 
0.108
Ó 
62.27 ± 0.29 
(61.71; 62.84) 
-0.30 ± 0.41 
(-1.11; 0.51) 
0.467
Ô 
SN
P 
47 
62.29 ± 1.92 
(61.73; 62.86) 
62.57 ± 0.28 
(62.02; 63.12) 
Single support tim
e (%
G
C
) 
PLH
IV 
39 
37.02 ± 1.72 
(36.46; 37.58) 
-0.99 ± 0.39 
(-1.78; -0.20) 
0.014
Ô 
37.60 ± 0.27 
(37.06; 38.14) 
-0.05 ± 0.39 
(0.82; 0.73) 
0.904
Ô 
SN
P 
47 
38.00 ± 1.90 
(37.45; 38.56) 
37.65 ± 0.26 
(37.12; 38.17) 
D
ouble support tim
e (%
G
C
) 
PLH
IV 
39 
25.93 ± 3.21 
(24.89; 26.97) 
1.64 ± 0.75 
(0.14; 3.14) 
0.032
Ó 
24.67 ± 0.52 
(23.63; 25.71) 
-0.25 ± 0.74 
(-1.73; 1.23) 
0.738
Ô 
SN
P 
47 
24.29 ± 3.69 
(23.21; 25.37)  
24.92 ± 0.51 
(23.91; 25.93) 
G
ait speed (m
/s) † 
PLH
IV 
39 
0.90 ± 0.22 
(0.83; 
0.97) 
-0.23 ± 0.05 
(-0.32; -0.13) 
<0.001
Ô 
0.92 ± 0.04 
(0.84 ± 0.99) 
-0.19 ± 0.05 
(0.29; -0.09) 
<0.001
Ô 
SN
P 
47 
1.13 ± 0.22 
(1.06; 
1.19) 
1.11 ± 0.04 
(1.03; 
1.18) 
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N
orm
alised gait speed
† 
PLH
IV 
39 
0.32 ± 0.08 
(0.30; 
0.35) 
-0.08 ± 0.02 
(-0.12; -0.05) 
<0.001
Ô 
0.33 ± 0.01 
(0.30; 
0.36) 
-0.07 ± 0.02 
(-0.11; -0.03) 
<0.001
Ô 
SN
P 
47 
0.41 ± 0.08 
(0.39; 0.43) 
0.40 ± 0.01 
(0.37; 
0.43) 
A
bbreviations: C
I = confidence interval; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; S
D
 = standard deviation; S
E
 = standard 
error; sec = seconds; S
N
P
 = H
IV
-seronegative participants. 
C
ovariables in the adjusted m
odel w
ere gender, age and leg-length norm
alised gait speed. 
‡S
ince norm
alised step and stride length w
ere already scaled to leg length, the m
odels for these outcom
es included unadjusted gait speed as covariable. 
†G
ait speed and norm
alised gait speed w
ere only adjusted for gender and age. 
 $E
stim
ated param
eters w
ith robust H
C
3 S
E
s due to a significant Levene’s test (p = 0.020).  
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8.5.2. The enhanced Gait Variability Index (EGVI) 
EGVI scores were calculated in 42 PLHIV and 37 SNP for the usual-paced condition, and in 
40 PLHIV and 33 SNP for the dual task condition. EGVI calculation requires a minimum of five 
absolute differences (at least 13 consecutive steps per trial),372,375 which necessitated the 
exclusion of some participant datasets. This was mainly the consequence of the myoMOTION 
system failing to detect consecutive gait events under very slow gait speeds. The EGVI was 
not calculated for fast-paced gait, due to problems with many participants not having enough 
valid consecutive strides per limb within a trial (e.g. many cycles demonstrated flight times, 
i.e. no period of double support). Calculating the EGVI for this condition would thus not have 
yielded a valid outcome in terms of gait variability for comparison. 
When calculated under usual-paced conditions, mean ± SD EGVI scores in PLHIV (94.21 ± 
9.55) were significantly lower (mean difference of -5.91 ± 1.94, 95% CI = -9.77 to -2.03, p = 
0.003) compared to EGVI scores in SNP (which constituted the norm, i.e. 100.11 ± 7.73); 
indicating lower variability in PLHIV relative to what may be considered the norm in the sample. 
When calculated under dual task conditions for both groups (retaining the same norm values 
as for the usual-paced condition), both groups demonstrated lower EGVI scores (less 
variability than what is considered the norm), with significantly lower scores (mean difference 
= -7.96 ± 2.29, 95% CI = -12.52 to -3.39, p = 0.001) for PLHIV (mean EGVI score = 89.67 ± 
8.79) relative to SNP (mean EGVI score = 97.63 ± 10.46).  
Usual-pace and dual task EGVI mean scores remained significantly lower in PLHIV after 
adjusting for age and gender (adjusted mean difference = -4.89 ± 2.39, p = 0.045, 95% CI = -
9.66; -0.12 for usual pace and -8.86 ± 2.82, p = 0.003, 95% CI = -14.493; -3.234 for dual task).  
8.5.3. Kinematic angles 
8.5.3.1. Usual-paced gait  
Unadjusted comparisons of joint/segment angles showed no significant differences between 
PLHIV and SNP for the pelvis, except for a significantly decreased range of pelvic obliquity in 
PLHIV. At the hip, PLHIV demonstrated significantly reduced flexion range during the gait 
cycle, peak flexion during swing, abduction range during midstance and adduction range 
during loading response.  
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At the knee, PLHIV also demonstrated smaller angles relative to SNP, with significantly 
decreased knee flexion range during the gait cycle and from stance to swing, as well as 
reduced peak knee flexion during swing. 
The ankle joint demonstrated the largest between-group difference, namely 4.1°, this was the 
amount by which ankle plantarflexion during push-off was decreased in PLHIV relative to SNP. 
Other significant differences (decreased angles in PLHIV) included ankle dorsiflexion range 
during swing, ankle plantarflexion angle at toe-off and peak angle plantarflexion angle during 
the gait cycle. 
Adjusting for age, gender and normalised gait speed revealed non-significant differences for 
all angles, although directional trends mostly remained the same. Nine out of the total of 28 
measured angles showed a directional change: pelvic rotation ROM during the gait cycle, 
pelvic rotation at initial contact, hip flexion ROM during the gait cycle, hip flexion at initial 
contact, knee flexion ROM from stance to swing, knee flexion at initial contact, peak knee 
flexion during stance and during swing (all decreased in PLHIV relative to SNP prior to 
adjustment, and increased in PLHIV after adjustment), and peak hip flexion during swing 
(decreased in PLHIV relative to SNP prior to adjustment, and similar in both groups after 
adjustment). The largest difference between PLHIV and SNP was again observed for ankle 
plantarflexion ROM during push-off, which remained decreased in PLHIV, but not significantly 
so (mean difference = -2°, p < 0.081. Table 8.14 shows the full results for unadjusted and 
adjusted comparisons under usual-paced gait conditions. 
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 Table 8.14. K
inem
atic low
er lim
b angles and RO
M
 during usual-paced gait in PLH
IV and SNP. B
lue arrow
s indicate the directional trend of 
the difference in PLH
IV relative to SN
P. 
G
roup 
n 
U
nadjusted 
A
djusted 
M
ean ± SD
 (95%
 
C
I) 
D
ifference (95%
 
C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
D
ifference (95%
 
C
I) 
p-value 
Pelvis tilt R
O
M
 during G
C
 ( °) 
PLH
IV 
50 
4.3 (3.2) # 
(3.4; 6.5) 
-0.7  
(-0.1; 1.5) 
0.084
Ô 
5.3 ± 0.4 
(4.5; 6.0) 
-0.3 ± 0.5 
(-1.4; 0.7) 
0.544
Ô 
SN
P 
48 
5.2 (3.9)  # 
(3.9; 7.8) 
5.6 ± 0.4 
(4.8; 6.4) 
Peak pelvis anterior tilt during G
C
 ( °) 
PLH
IV 
50 
0.7 (5.1)  # 
(-2.1; 3.0) 
-0.8  
(-0.6; 2.4) 
0.286
Ô 
0.2 ± 0.6 
(-0.9; 1.3) 
-0.2 ± 0.9 
(-2.0; 1.7) 
0.858
Ô 
)SN
P 
48 
1.4 (4.3) # 
(-0.3; 4.0) 
0.4 ± 0.7 
(-1.0; 1.7) 
Pelvis obliquity R
O
M
 during G
C
 ( °) 
PLH
IV 
50 
10.1 ± 2.5 
(9.4; 10.8) 
-1.7 ± 0.6  
(-2.8; 0.6) 
0.002
Ô 
10.4 ± 0.4 
(9.6; 11.2) 
-0.8 ± 0.6 
(-1.9; 0.3) 
0.151
Ô 
SN
P 
48 
11.9 ± 3.0 
(11.0; 12.7) 
11.2 ± 0.4 
(10.4; 12.1) 
Pelvis rotation RO
M
 during G
C
 ( °) 
PLH
IV 
50 
13.2 ± 3.5 
(12.2; 14.2) 
-0.9 ± 0.8  
(-2.5; 0.7) 
0.271
Ô 
13.6 ± 0.6 
(12.5; 14.7) 
0.5 ± 0.9 
(-1.2; 2.3) 
0.566
Ó 
SN
P 
48 
14.1 ± 4.4 
(12.8; 15.3) 
13.1 ± 0.7 
(11.8; 14.4) 
Pelvis rotation angle at initial contact ( °) 
PLH
IV 
50 
4.2 (4.0)  # 
(2.7; 6.7) 
-0.1 
(-1.2; 1.1) 
0.921
Ô 
4.6 ± 0.4 
(3.8; 5.5) 
0.2 ± 0.7 
(-1.2; 1.5) 
0.815
Ó 
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SN
P 
48 
4.9 (3.6)  # 
(2.6; 6.2) 
4.5 ± 0.5  
(3.5; 5.5) 
H
ip flexion R
O
M
 during G
C ( °) 
PLH
IV 
50 
38.8 ± 4.0 
(37.6; 39.9) 
-2.3 ± 0.8 
(-4.0; 0.7) 
0.006
Ô 
40.0 ± 0.5 
(39.1; 40.9) 
0.9 ± 0.7 
(0.6; 2.3) 
0.236
Ó 
SN
P 
48 
41.1 ± 4.1 
(39.9; 42.3) 
39.1 ± 0.5 
(38.0; 40.2) 
H
ip flexion R
O
M
 during loading response ( °) 
PLH
IV 
50 
7.7 ± 2.4 
(7.0; 8.4) 
0.3 ± 0.5 
(-0.7; 1.3) 
0.529
Ó 
7.3 ± 0.4 
(6.6; 8.0) 
0.2 ± 0.6 
(-0.9; 1.4) 
0.706
Ó 
SN
P 
48 
7.4 ± 2.7 
(6.6; 8.1) 
7.1 ± 0.4 
(6.2; 8.0) 
H
ip flexion R
O
M
 pre-sw
ing to initial sw
ing ( °) 
PLH
IV 
50 
8.0 ± 2.3 
(7.4; 8.7) 
0.4 ± 0.5 
(-0.6; 1.4) 
0.401
Ó 
7.8 ± 0.4 
(7.1; 8.5) 
0.2 ± 0.6 
(-1.0; 1.4) 
0.765
Ó 
SN
P 
48 
7.6 ± 2.5 
(6.9; 8.4) 
7.6 ± 0.4 
(6.8; 8.5) 
H
ip flexion angle at initial contact ( °) 
PLH
IV 
50 
24.1 ± 5.3 
(22.5; 25.6) 
-2.0 ± 1.1 
(-4.2; 0.2) 
0.075
Ô 
24.2 ± 0.7 
(22.8; 25.5) 
0.6 ± 1.0 
(-1.5; 2.7) 
0.561
Ó 
SN
P 
48 
26.1 ± 5.6 
(24.4; 27.7) 
23.6 ± 0.8 
(22.1; 25.1) 
Peak hip flexion during sw
ing ( °) 
PLH
IV 
50 
27.1 ± 5.1 
(25.6; 28.5) 
-2.7 ± 1.0  
 (-4.7; 0.7) 
0.009
Ô 
27.2 ± 0.6 
(26.1; 28.4) 
0.00 
1.000
= 
SN
P 
48 
29.8 ± 4.8 
(28.4; 31.2) 
27.2 ± 0.6 
(26.0; 28.6) 
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Peak hip extension during stance ( °) 
PLH
IV 
50 
11.5 ± 5.0 
(10.0; 12.9)   
0.3 ± 0.9 
(-1.5; 2.1) 
0.725
Ó 
12.6 ± 0.5 
(11.6; 13.7) 
1.1 ± 0.9 
(-0.6; 2.9) 
0.201
Ó
 
SN
P 
48 
11.1 ± 3.9 
(10.0; 12.3)   
11.5 ± 0.7 
(10.2; 12.8) 
 
H
ip abduction R
O
M
 during m
id-stance ( °) 
PLH
IV 
50 
3.9 ± 1.6 
(3.5; 4.4)   
-1.2 ± 0.4 
(-2.0; 0.4) 
0.002
Ô 
4.4 ± 0.2 
(3.9; 4.9) 
-0.2 ± 0.4 
(-1.0; 0.6) 
0.610
Ô 
SN
P 
48 
5.1 ± 2.1 
(4.5; 5.8)   
4.6 ± 0.3 
(4.0; 5.1) 
H
ip adduction R
O
M
 during loading response ( °) 
PLH
IV 
50 
6.2 ± 2.2 
(5.6; 6.8)   
-1.5 ± 0.5 
(-2.5; 0.6) 
0.001
Ô 
6.4 0.3 
(5.8; 7.0) 
-0.5 ± 0.5 
(-1.4; 0.4) 
0.282
Ô 
SN
P 
48 
7.7 ± 2.4 
(7.0; 8.4)   
6.9 ± 0.3 
(6.2; 7.5) 
H
ip internal rotation R
O
M
 during G
C ( °) 
PLH
IV 
50 
16.1 ± 4.0 
(15.0; 17.3)   
-1.0 ± 0.8  
(-2.7; 0.6) 
0.232
Ô 
16.6 ± 0.6 
(15.4; 17.8) 
-0.7 ± 0.9 
(-2.5; 1.2) 
0.486
Ô 
SN
P 
48 
17.2 ± 4.3 
(15.9; 18.4)   
17.3 ± 0.7 
(16.0; 18.6) 
K
nee flexion R
O
M
 during G
C
 ( °) 
PLH
IV 
50 
61.1(5.6) 
(57.7; 63.4)  # 
-2.6  
(-4.3; 0.8) 
0.004
Ô 
61.4 ± 0.6 
(60.1; 62.6) 
-0.6 ± 0.9 
(2.4; 1.2) 
0.498
Ô 
SN
P 
48 
63.6 (5.8) 
(60.0; 65.8)  # 
62.0 ± 0.7 
(60.6; 63.4) 
K
nee flexion R
O
M
 during stance ( °) 
PLH
IV 
50 
10.1 ± 4.1 
(8.9; 11.2)   
-1.5 ± 0.8  
(-3.1; 0.2) 
0.078
Ô 
11.1 ± 0.5 
(10.0; 12.1) 
-0.3 ± 0.8 
(-2.0; 1.3) 
0.689
Ô 
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SN
P 
48 
11.5 ± 4.1  
(10.4; 12.7)   
11.4 ± 0.6 
(10.2; 12.6) 
K
nee flexion R
O
M
 from
 stance to sw
ing ( °) 
PLH
IV 
50 
56.9 ± 4.9 
(55.5; 58.3)   
-2.5 ± 1.0  
(-4.4; 0.6) 
0.012
Ô 
57.6 ± 0.6 
(56.4; 58.8) 
0.24 ± 0.9 
(-1.6; 2.1) 
0.801
Ó 
SN
P 
48 
59.4 ± 4.6 
(58.1; 60.8)   
57.4 ± 0.7 
(56.0; 58.8) 
K
nee extension R
O
M
 from
 m
id-stance to term
inal stance ( °) 
PLH
IV 
50 
8.9 ± 4.6 
(7.6; 10.2)   
-1.1 ± 1.0 
(-3.1; 0.8) 
0.250
Ô 
10.0 ± 0.6 
(8.7; 11.2) 
0.9 ± 0.9 
(-0.9; 2.7) 
0.315
Ó 
SN
P 
48 
10.0 ± 5.1 
(8.6; 11.5)   
9.0 ± 0.7 
(7.6; 10.4) 
K
nee flexion at initial contact ( °) 
PLH
IV 
50 
4.8 ± 6.3 
(3.0; 6.6)   
-0.1 ± 1.1 
(-2.3; 2.2) 
0.961
Ô 
5.1 ± 0.8 
(3.5; 6.7) 
1.5 ± 1.2 
(-0.9; 4.0) 
0.219
Ó 
SN
P 
48 
4.9 ± 4.6 
(3.5; 6.2)   
3.6 ± 0.9 
(1.8; 5.3) 
Peak knee flexion during stance ( °) 
PLH
IV 
50 
43.1 ± 7.0 
(41.2; 45.1)   
-2.2 ± 1.2 
(-4.6; 0.2) 
0.069
Ô 
43.6 ± 0.8 
(42.0; 45.2) 
0.2 ± 1.2 
(-2.2; 2.7) 
0.849
Ó 
SN
P 
48 
45.3 ± 4.7 
(44.0; 46.7)   
43.4 ± 0.9 
(41.6; 45.2) 
Peak knee extension during stance ( °) 
PLH
IV 
50 
-3.4 ± 5.5 
(-5.0; -1.9) 
0.1 ± 0.9 
(-1.7; 2.0) 
0.899
Ó 
-3.5 ± 0.7 
(-4.9; -2.2) 
-1.2 ± 1.0 
(-3.2; 0.9) 
0.250
Ó 
SN
P 
48 
-3.3 ± 3.4 
(-4.3; -2.3)   
-2.3 ± 0.7 
(-3.8; -0.9) 
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Peak knee flexion during sw
ing ( °) 
PLH
IV 
50 
62.4 ± 7.2 
(60.3; 64.4)   
-3.1 ± 1.3 
(-5.7; 0.5) 
0.018
Ô 
63.7 ± 0.8 
(62.2; 65.3) 
0.4 ± 1.2 
(-1.9; 2.7) 
0.713
Ó 
SN
P 
48 
65.5 ± 5.5 
(64.0; 67.1)   
63.3 ± 0.9 
(61.5; 65.0) 
A
nkle dorsiflexion R
O
M
 during stance ( °) 
PLH
IV 
50 
21.0 ± 3.2 
(20.1; 22.0)   
-0.3 ± 0.7 
(-1.6; 1.0) 
0.691
Ô 
20.6 ± 0.5 
(19.7; 21.5) 
-0.9 ± 0.7 
(-2.3; 0.5) 
0.222
Ô 
SN
P 
48 
21.3 ± 3.3 
(20.3; 22.3)   
21.5 ± 0.5 
(20.5; 22.5) 
A
nkle dorsiflexion R
O
M
 during sw
ing ( °) 
PLH
IV 
50 
16.9 ± 4.9 
(15.5; 18.3)   
-3.1 ± 1.0    
(-5.1; 1.1) 
0.003
Ô 
18.0 ± 0.7 
(16.5; 19.4) 
-1.5 ± 1.1 
(-3.7; 0.6) 
0.159
Ô 
SN
P 
48 
20.0 ± 5.1 
(18.6; 21.5)   
19.5 ± 0.8 
(17.9; 21.2) 
A
nkle plantarflexion RO
M
, heel rise to toe-off (push off) ( °) 
PLH
IV 
50 
28.4 ± 5.2 
(26.9; 29.9)   
-4.1 ± 1.1 
(-6.2; 2.0) 
0.001
Ô 
29.8 ± 0.7 
(28.3; 31.2) 
-2.0 ± 1.1 
(-4.2; 0.2) 
0.081
Ô 
SN
P 
48 
32.5 ± 5.4 
(30.9; 34.0)   
31.7 ± 0.8 
(30.0; 33.4) 
A
nkle dorsiflexion angle at initial contact ( °) 
PLH
IV 
50 
-8.6 (5.6) 
(-11.7; -6.1)  # 
0.8 
(0.6; 2.2) 
0.235
Ó 
-8.7 ± 0.5 
(-9.7; -7.8) 
-0.1 ± 0.7 
(-1.5; 1.2) 
0.831
Ó 
SN
P 
48 
-8.2 (3.9) 
(-10.1; -6.2)  # 
-8.6 ± 0.5 
(-9.6; -7.6) 
A
nkle plantarflexion angle at toe-off ( °) 
PLH
IV 
50 
16.0 ± 6.0 
(14.3; 17.7)   
-3.0 ± 1.2 
(-5.4; 0.7) 
0.012
Ô 
16.8 ± 0.8 
(15.2; 18.5) 
-0.9 ± 1.2 
(-3.4; 1.6) 
0.462
Ô 
SN
P 
48 
19.0 ± 5.6 
(17.4; 20.7)   
17.8 ± 0.9 
(16.0; 19.6) 
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Peak ankle plantarflexion during G
C
 ( °) 
PLH
IV 
50 
18.9 ± 5.6 
(17.3; 20.5)   
-3.1 ± 1.2 
(-5.3; 0.8) 
0.010
Ô 
19.5 ± 0.8 
(17.9; 21.1) 
-1.5 ± 1.3 
(-4.0; 1.0) 
0.224
Ô 
SN
P 
48 
21.9 ± 5.8 
(20.2; 23.6)   
21.0 ± 0.9 
(19.2; 22.8) 
A
bbreviations: C
I = confidence interval; G
C
 = gait cycle; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; R
O
M
 = range of m
otion; S
D
 = 
standard deviation; S
E
 = standard error; S
N
P
 = H
IV
-seronegative participants. 
C
ovariables included gender (m
ale/fem
ale), age (in years) and norm
alised gait speed. 
#presented as m
edian (IQ
R
) (Q
1; Q
3). 
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8.5.3.2. Fast-paced gait  
At fast-paced gait (Table 8.15) no differences were apparent at the pelvis between PLHIV and SNP, 
while PLHIV demonstrated significantly decreased hip flexion range during the swing phase. At the 
knee, PLHIV achieved a smaller peak knee flexion angle during stance (i.e. during loading response) 
as well as a decreased peak knee flexion angle during swing. The only significant difference evident 
at the ankle was decreased dorsiflexion range during swing. The largest differences occurred at the 
ankle (dorsiflexion during swing, mean difference = -3°) and knee (peak flexion during swing, mean 
difference -3°). Adjusted analyses rendered all differences between PLHIV and SNP non-significant; 
the largest differences occurring at the knee (peak flexion during stance, decreased in PLHIV, mean 
difference = -1.5°, p = 0.169) and pelvis (rotation range during the gait cycle, increased in PLHIV, 
mean difference = 1.6°, p =0.088).
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 Table 8.15. K
inem
atic low
er lim
b angles and RO
M
 during fast-paced gait in PLH
IV and SN
P. B
lue arrow
s indicate the directional trend of the 
difference in PLH
IV relative to SNP. 
G
roup 
n 
U
nadjusted 
A
djusted 
M
ean ± SD
 
(95%
 C
I) 
D
ifference (95%
 
C
I) 
p-value 
M
ean ± SE (95%
 C
I) 
D
ifference (95%
 
C
I) 
p-value 
Pelvis tilt R
O
M
 during G
C
 ( °) 
PLH
IV 
45 
6.2 (4.0)  # 
(4.8; 8.8)   
-0.3 
(-0.7; 1.4) 
0.506
Ô 
7.2 ± 0.4 
(6.4; 8.0) 
0.3 ± 0.6 
(-0.8; 1.5) 
0.553
Ó 
SN
P 
45 
6.8 (3.7)  # 
(5.2; 8.9) 
6.8 ± 0.4 
(6.0; 7.7) 
Peak pelvis anterior tilt during G
C
 ( °) 
PLH
IV 
45 
1.8 ± 4.1 
(0.7; 3.2) 
-0.9 ± 0.9 
(-2.7; 0.9) 
0.343
Ô 
1.8 ± 0.6 
(0.6; 3.1) 
0.0 ± 0.9 
(-1.7; 1.8) 
0.964
= 
SN
P 
45 
2.8 ± 4.5 
(1.5; 4.2) 
1.8 ± 0.7 
(0.5; 3.1) 
Pelvis obliquity R
O
M
 during G
C
 ( °) 
PLH
IV 
45 
13.3 ± 3.4 
(12.3; 14.3) 
-0.8 ± 0.7 
(-2.2; 0.6) 
0.279
Ô 
13.7 ± 0.5 
(12.8; 14.6) 
0.4 ± 0.6 
(-0.9; 1.6) 
0.584
Ó 
SN
P 
45 
14.1 ± 3.3 
(13.1; 15.1) 
13.3 ± 0.5 
(12.4; 14.3) 
Pelvis rotation RO
M
 during G
C
 ( °) 
PLH
IV 
45 
16.3 (4.9)  # 
(14.4; 19.2) 
-0.4  
(-2.4; 1.8) 
0.678
Ô 
17.04 ± 0.6 
(15.8; 18.3) 
1.6 ± 1.0 
(-0.2; 3.4) 
0.088
Ó 
SN
P 
45 
16.4 (7.8) 
(12.7; 20.4) 
15.4 ± 0.7 
(14.1; 16.8) 
Pelvis rotation angle at initial contact ( °) 
PLH
IV 
45 
5.5 (2.9)  # 
(3.8; 6.7) 
0.4  
(-1.6; 0.7) 
0.446
Ó 
5.7 ± 0.6 
(4.7; 6.7) 
0.8 ± 0.8 
(-0.7; 2.4) 
0.289
Ó 
SN
P 
45 
5.3 (4.3)  # 
(2.7; 7.0) 
4.9 ± 0.6 
(3.7; 6.0) 
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H
ip flexion R
O
M
 during G
C ( °) 
PLH
IV 
45 
45.3 ± 4.9 
(43.9; 46.8) 
-1.2 ± 1.0 
(-3.2; 0.7) 
0.219
Ô 
45.9 ± 0.5 
(44.8; 46.9) 
0.4 ± 0.7 
(-1.1; 1.9) 
0.585
Ó 
SN
P 
45 
46.6 ± 4.4 
(45.2; 47.9) 
45.5 ± 0.5 
(44.4; 46.5) 
H
ip flexion R
O
M
 during loading response ( °) 
PLH
IV 
45 
6.1 (3.2)  # 
(4.6; 7.8) 
0.68 
(-0.3; 1.6) 
0.179
Ó 
5.7 ± 0.3 
(5.1; 6.4) 
0.4 ± 0.5 
(-0.5; 1.4) 
0.373
Ó 
SN
P 
45 
5.4 (3.2)  # 
(3.7; 6.9) 
5.3 ± 0.4 
(4.6; 6.0) 
H
ip flexion R
O
M
 pre-sw
ing to initial sw
ing ( °) 
PLH
IV 
45 
6.5 ± 2.5 
(5.7; 7.2) 
-0.2 ± 0.5 
(-1.2; 0.8) 
0.677
Ô 
6.1 ± 0.3 
(5.4; 6.8) 
-0.4 ± 0.5 
(-1.4; 0.6) 
0.387
Ô 
SN
P 
45 
6.7 ± 2.3 
(6.0; 7.4) 
6.6 ± 0.4 
(5.8; 7.3) 
H
ip flexion angle at initial contact ( °) 
PLH
IV 
45 
28.6 ± 5.9 
(26.9; 30.4) 
-1.8 ± 1.2 
(-4.2; 0.5) 
0.123
Ô 
28.6 ± 0.7 
(27.2; 30.0) 
0.1 ± 1.0 
(-1.9; 2.1) 
0.934
= 
SN
P 
45 
30.5 ± 5.3 
(28.9; 32.1) 
28.5 ± 0.8 
(27.0; 30.0) 
Peak hip flexion during sw
ing ( °) 
PLH
IV 
45 
31.0 ± 5.6 
(29.3; 32.7) 
-2.7 ± 1.2 
(-5.1; 0.3) 
0.028
Ô 
30.8 ± 0.7 
(29.5; 32.1) 
-0.4 ± 0.9 
(-2.3; 1.5) 
0.650
Ô 
SN
P 
45 
33.7 ± 5.7 
(32.0; 35.4) 
31.2 ± 0.7 
(29.8; 32.6) 
Peak hip extension during stance ( °) 
PLH
IV 
45 
13.5 (8.9)  # 
(10.0; 18.9) 
1.3 
(-0.8; 3.4) 
0.228
Ó 
14.6 ± 0.9 
(12.8; 16.4) 
1.1 ± 1.2 
(-1.4; 3.6) 
0.431
Ó 
SN
P 
45 
11.9 (5.6)  # 
(9.6; 15.2) 
13.5 ± 0.9 
(11.8; 15.3) 
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H
ip abduction R
O
M
 during m
id-stance ( °) 
PLH
IV 
45 
6.8 ± 2.3 
(6.1; 7.5) 
-0.9 ± 0.5 
  (-1.9; 0.2) 
 
0.096
Ô 
7.1 ± 0.3 
(6.4; 7.8) 
-0.2 ± 0.5 
(-1.1; 0.8) 
0.733
Ô 
SN
P 
45 
7.7 ± 2.7 
(6.9; 8.5) 
7.3 ± 0.4 
(6.6; 8.0) 
H
ip adduction R
O
M
 during loading response ( °) 
PLH
IV 
45 
6.7 ± 2.2 
(6.0; 7.3) 
-0.4 ± 0.5 
(-1.3; 0.5) 
0.352
Ô 
6.6 ± 0.3 
(6.0; 7.3) 
-0.3 ± 0.5 
(-1.2; 0.6) 
0.533
Ô 
SN
P 
45 
7.1 ± 2.1 
(6.5; 7.7) 
6.9 ± 0.3 
(6.2; 7.6) 
H
ip internal rotation R
O
M
 during G
C ( °) 
PLH
IV 
45 
18.3 ± 3.9 
(17.1; 19.5) 
-0.1 ± 0.9 
(-1.8; 1.6) 
0.901
= 
18.5 ± 0.6 
(17.3; 19.8) 
0.1 ± 0.9 
(-1.7; 1.9) 
0.926
= 
SN
P 
45 
18.4 ± 4.4 
(17.1; 16.7) 
18.5 ± 0.7 
(17.1; 19.8) 
K
nee flexion R
O
M
 during G
C
 ( °) 
PLH
IV 
45 
62.9 ± 4.5 
(61.5; 64.2) 
-1.3 ± 0.9 
(-3.2; 0.6) 
0.164
Ô 
63.2 ± 0.6 
(62.0; 64.3) 
0.4 ± 0.8 
(-1.3; 2.0) 
0.655
Ó 
SN
P 
45 
64.2 ± 4.6 
(62.8; 65.6) 
62.8 ± 0.6 
(61.6; 64,0) 
K
nee flexion R
O
M
 during stance ( °) 
PLH
IV 
45 
13.1 ± 4.22 
(11.8; 14.4) 
-0.5 ± 0.8 
(-2.1; 1.2) 
0.590
Ô 
13.9 ± 0.5 
(12.8; 14.9) 
-0.7 ± 0.8 
(-2.3; 0 .8) 
0.334
Ô 
SN
P 
45 
13.6 ± 3.8 
(12.4; 14.7) 
14.6 ± 0.6 
(13.5; 15.7) 
K
nee flexion R
O
M
 from
 stance to sw
ing ( °) 
PLH
IV 
45 
61.3 ± 5.1 
(59.7; 62.8) 
-1.6 ± 1.1 
(-3.8; 0.5) 
0.135
Ô 
61.5 ± 0.6 
(60.3; 62.7) 
0.4 ± 0.9 
(-1.3; 2.2) 
0.613
Ó 
SN
P 
45 
62.9 ± 5.1 
(61.4; 64.5) 
61.1 ± 0.6 
(59.8; 62.4) 
Stellenbosch University  https://scholar.sun.ac.za
 - 244 - | P
a
g
e
 
 
K
nee extension R
O
M
 from
 m
id-stance to term
inal stance ( °) 
PLH
IV 
45 
16.7 ± 5.8 
(15.0; 18.4) 
-0.6 ± 1.1 
(-2.8; 1.7) 
0.618
Ô 
17.8 ± 0.7 
(16.5; 19.1) 
0.3 ± 0.9 
(1.6; 2.2) 
0.737
Ó 
SN
P 
45 
17.27 ± 4.9 
(15.8; 18 .7) 
17.5 ± 0.7 
(16.1; 18.9) 
K
nee flexion at initial contact ( °) 
PLH
IV 
45 
7.5 ± 6.8 
(5.5; 9.5) 
-1.5 ± 1.3 
(-4.5; 1.0) 
0.235
Ô 
7.5 ± 0.9 
(5.8; 9.2) 
-0.1 ± 1.3 
(-2.6; 2.4) 
 
0.941
Ô 
SN
P 
45 
9.0 ± 5.0 
(7.5; 10.5) 
7.6 ± 09 
(5.7; 9.4) 
Peak knee flexion during stance ( °) 
PLH
IV 
45 
41.9 ± 6.4 
(40.0; 43.8) 
-2.4 ± 1.2 
(-4.8; 0.1) 
0.041
Ô 
41.3 ± 0.8 
(39.8; 42.8) 
-1.5 ± 1.1 
(-3.7; 0 .7) 
0.169
Ô 
SN
P 
45 
44.3 ± 4.6 
(42.9; 45.7) 
42.8 ± 0.8 
(41.2; 44.5) 
Peak knee extension during stance ( °) 
PLH
IV 
45 
-2.7 (7.0) # 
(-6.5; 0.5) 
1.4 
(-0.5; 3.3) 
0.141
Ô 
-2.9 ± 0.6 
(-4.2; -1.7) 
0.8 ± 0.9 
(-0.9; 2.6) 
0.357
Ô 
SN
P 
45 
-3.9 (3.7)  # 
(-6.0; -2.2) 
-3.8 ± 0.7 
(-5.1; -2.5) 
Peak knee flexion during sw
ing ( °) 
PLH
IV 
45 
65.1 ± 6.7 
(63.1; 67.1) 
-3.0 ± 1.3     
(-5.5; 0.5)  
0.020
Ô 
65.2 ± 0.7 
(63.7; 66.6) 
-0.8 ± 1.0 
(-2.9; 1.2) 
0.426
Ô 
SN
P 
45 
68.1 ± 5.3 
(66.5; 69.7) 
66.0 ± 0.8 
(64.5; 67.6) 
A
nkle dorsiflexion R
O
M
 during stance ( °) 
PLH
IV 
45 
16.9 ± 3.6 
(15.8; 18.0) 
0.5 ± 0.8 
(-1.0; 2.0)         
0.533
Ó 
16.6 ± 0.5 
(15.6; 17.5) 
-0.30 ± 0.7 
(-1.7; 1.1) 
0.664
Ô 
SN
P 
45 
16.4 ± 3.5 
(15.3; 17.5) 
16.9 ± 0.5 
(15.8; 17.9) 
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A
nkle dorsiflexion R
O
M
 during sw
ing ( °) 
PLH
IV 
45 
20.7 ± 6.3 
(18.9; 22.6) 
-3.0 ± 1.2 
(-5.4; 0.5) 
0.019
Ô 
21.4 ± 0.8 
(19.9; 23.0) 
-1.4 ± 1.1 
(-3.6; 0.9) 
0.238
Ô 
SN
P 
45 
23.7 ± 5.5 
(22.0; 25.3) 
22.8 ± 0.9 
(21.1; 24.5) 
A
nkle plantarflexion RO
M
, heel rise to toe-off (push off) ( °) 
PLH
IV 
45 
29.3 ± 5.3 
(27.7; 30.9) 
-2.0 ± 1.1 
(-4.2; 0.1)     
0.063
Ô 
29.7 ± 0.7 
(28.2; 31.2) 
-1.3 ± 1.1  
(-3.5; 0.8) 
0.219
Ô 
SN
P 
45 
31.3 ± 5.0 
(29.8; 32.8) 
31.1 ± 0.8 
(29.5; 32.7) 
A
nkle dorsiflexion angle at initial contact ( °) 
PLH
IV 
45 
-7.4 ± 3.3 
(-8.4; -6.4) 
-1.1 ± 0.7 
(-2.4; 0.2) 
0.103
Ó 
-7.3 ± 0.5 
(-8.3; -6.4) 
-0.4 ± 0.7  
(-1.7; 1.0) 
0.569
Ó 
SN
P 
45 
-6.3 ± 3.0 
(-7.2; -5.4) 
-6.9 ± 0.5 
(-7.9; -5.9) 
A
nkle plantarflexion angle at toe-off ( °) 
PLH
IV 
45 
20.0 ± 6.7 
(18.0; 22.0) 
-1.5 ± 1.3 
(-4.0; 1.1) 
0.255
Ô 
20.7 ± 0.9 
(18.9; 22.5) 
-0.2 ± 1.3 
(-2.7; 2.3) 
0.874
Ô 
SN
P 
45 
21.5 ± 5.5 
(19.9; 23.2) 
20.9 ± 1.0 
(19.0; 22.8) 
Peak ankle plantarflexion during G
C
 ( °) 
PLH
IV 
45 
22.0 ± 6.5 
(20.0; 24.0) 
-1.5 ± 1.3 
(-4.0; 1.1) 
0.251
Ô 
22.6 ± 0.9 
(20.8; 24.4) 
-0.4 ± 1.3 
(-3.0; 2.2) 
0.748
Ô 
SN
P 
45 
23.5 ± 5.7 
(21.7; 25.2) 
23.1 ± 0.1 
(21.1; 25.0) 
A
bbreviations: C
I = confidence interval; G
C
 = gait cycle; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; R
O
M
 = range of m
otion; S
D
 = 
standard deviation; S
E
 = standard error; S
N
P
 = H
IV
-seronegative participants. 
C
ovariables included gender (m
ale/fem
ale), age (in years) and norm
alised gait speed. 
#presented as m
edian (IQ
R
) (Q
1; Q
3). 
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8.5.3.3. Dual task gait  
Figure 8.7 illustrates the kinematic curves (unadjusted data) for PLHIV and SNP. Unadjusted 
comparisons of kinematic angles for dual task gait showed decreased pelvis obliquity and 
rotation ranges during the gait cycle. Hip adduction range during loading response was also 
significantly decreased in PLHIV. At the knee, flexion range during the gait cycle and from 
stance to swing was significantly lower in PLHIV relative to SNP. Peak knee flexion during 
stance and during swing was also decreased in PLHIV. Ankle dorsiflexion range during swing 
was significantly reduced in PLHIV, as was ankle plantarflexion during push-off, ankle 
plantarflexion angle at toe-off and peak ankle plantarflexion during the gait cycle. The largest 
differences were noted for peak knee flexion during swing (mean difference = -4.6°), knee 
flexion range from stance to swing (mean difference = 4.8°) and knee flexion range during the 
gait cycle (mean difference is -4.6°). 
Adjusted analyses showed PLHIV to have significantly higher pelvis rotation angles at initial 
contact. At the hip, an increase in both hip flexion ROM over the gait cycle and flexion angle 
at initial contact was noted. Total knee flexion range during the gait cycle was decreased, but 
knee flexion at initial contact was increased while knee extension range from mid-stance to 
terminal stance was increased, and peak knee extension in stance was also increased in 
PLHIV.  No significant differences were noted at the ankle after adjustments were made. The 
largest difference observed was knee flexion angle at initial contact (increased in PLHIV, mean 
difference = 3.7°). Figure 8.7 shows the unadjusted gait curves and Table 8.16 the full 
unadjusted and adjusted comparison results. A significant interaction was noted between HIV-
serostatus and gait speed on knee flexion range during the gait cycle; this interaction is 
demonstrated in Figure 8.8. 
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Figure 8.7. Kinematic gait curves for PLHIV (blue) and SNP (red) under dual task conditions. 
Solid curve lines indicate mean angular values and shaded areas bound by dashed lines indicate 
the respective standard deviations. vertical lines indicate toe-off. note that these graphs depict 
data that have not been adjusted for speed or other covariables. 
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 Table 8.16. K
inem
atic low
er lim
b angles and RO
M
 during dual task gait in PLH
IV and SN
P. B
lue arrow
s indicate the directional trend of the 
difference in PLH
IV relative to SNP. 
G
roup 
n 
U
nadjusted 
A
djusted 
M
ean ± SD
 
(95%
 C
I) 
D
ifference (95%
 
C
I) 
U
nadjusted p-value 
M
ean ± SE (95%
 C
I) 
D
ifference (95%
 
C
I) 
p-value 
 
Pelvis tilt R
O
M
 during G
C
 ( °) 
PLH
IV 
39 
4.4 (2.0)  # 
(3.5; 5.5) 
-0.6 
(-1.4; 0.1) 
0.124
Ô 
5.2 ± 0.4 
(4.5; 5.0) 
0.1 ± 0.5 
(-0.9; 1.1) 
0.819
= 
SN
P 
47 
4.8 (3.3)  # 
(3.8; 7.2) 
5.09 ± 0.4 
(4.4; 5.8) 
 
Peak pelvis anterior tilt during G
C
 ( °) 
PLH
IV 
39 
0.9 ± 3.5 
(-0.2; 2.0) 
-0.6 ± 0.8 (-2.3; 
1.1) 
0.469
Ô 
0.9 ± 0.6 
(-0.4; 2.1) 
0.7 ± 0.9 
(-1.1; 2.5) 
0.462
Ó 
SN
P 
47 
1.5 ± 4.1 
(0.3; 2.7) 
0.2 ± 0.6 
(-1.0; 1.5) 
 
Pelvis obliquity R
O
M
 during G
C
 ( °) 
PLH
IV 
39 
9.3 ± 2.7 
(8.4; 10.1) 
-2.3 ± 0.6 
(-3.5; 1.2) 
<0.001
Ô 
10.0 ± 0.4 
(9.2; 10.9) 
-0.5 ± 0.6 
(-1.7; 0 .7) 
0.399
Ô 
SN
P 
47 
11.6 ± 2.8 
(10.8; 12.5) 
10.6 ± 0.4 
(9.7; 11.4) 
 
Pelvis rotation RO
M
 during G
C
 ( °) 
PLH
IV 
39 
12.7(5.4)  # 
(10.5; 15.9) 
-0.9 
(-2.8; 1.0) 
0.001
Ô 
14.5 ± 0.8 
(12.9; 16.1) 
1.3 ± 1.2 
(-1.1; 3.6) 
0.280
Ó 
SN
P 
47 
13.9(6.9)  # 
(10.9; 17.8) 
13.2 ± 0.8 
(11.7; 14.8) 
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Pelvis rotation angle at initial contact ( °) 
PLH
IV 
39 
5.3 ± 2.7 
(4.4; 6.2) 
0.8 ± 0.7 
(-0.5; 2.2) 
0.225
Ó 
5.5 ± 0.5 
(4.4; 6.6) 
1.8 ± 0.8 
(0.3; 3.3) 
0.022
Ó 
SN
P 
47 
4.5 ± 3.5 
(3.4; 5.5) 
3.7 ± 0.5 
(2.7; 4.7) 
 
H
ip flexion R
O
M
 during G
C ( °) 
PLH
IV 
39 
38.7 ± 5.3 
(37,0; 40.5) 
-1.7 ± 1.1 
(-3.9; 0.5) 
0.120
Ô 
40.4 ± 0.7 
(39.0; 41.7) 
2.4 ± 1.0 
(0.5; 4.4) 
0.016
Ó 
SN
P 
47 
40.5 ± 4.9 
(39.0; 41.9) 
37.9 ± 0.7 
(36.5; 39.3) 
 
H
ip flexion R
O
M
 during loading response ( °) 
PLH
IV 
39 
7.9 ± 2.7 
(7.0; 8.8) 
0.8 ± 0.6 
(-0.3; 1.9) 
0.169
Ó 
6.9 ± 0.4 
(6.0; 7.7) 
-0.4 ± 0.6 
(-1.6; 0.8) 
0.470
Ô 
SN
P 
47 
7.1 ± 2.6 
(6.3; 7.9) 
7.3 ± 0.4 
(6.4; 8.1) 
 
H
ip flexion R
O
M
 pre-sw
ing to initial sw
ing ( °) 
PLH
IV 
39 
8.0 ± 2.1 
(7.4; 8.7) 
-0.1 ± 0.5 
(-1.1; 0.9) 
0.793
Ô 
8.0 ± 0.4 
(7.2; 8.9) 
-0.0 ± 0.6 
(-1.2; 1.1) 
0.964
= 
SN
P 
47 
8.2 ± 2.4 
(7.5; 8.9) 
8.1 ± 0.4 
(7.3; 8.9) 
 
H
ip flexion angle at initial contact ( °) 
PLH
IV 
39 
24.6 ± 5.8 
(22.7; 26.5) 
-0.7 ± 1.3 
(-1.8; 3.3) 
0.341
Ô 
25.5 ± 0.8 
(24.0; 27.0) 
2.8 ± 1.1 
(0.6; 4.9) 
0.012
Ó 
SN
P 
47 
25.8 ± 5.7 
(24.1; 27.5) 
22.7 ± 0.7 
(21.3; 24.2) 
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Peak hip flexion during sw
ing ( °) 
PLH
IV 
39 
27.5 ± 6.0 
(25.5; 29.4) 
-2.1 ± 1.2 
(-4.4; 0.3) 
0.083
Ô 
28.5 ± 0.8 
(27.0; 30.0) 
 
0.057
Ó 
SN
P 
47 
30.0 ± 5.0 
(28.1; 31.0)  
26.5 ± 0.7 
(25.1; 28.0) 
 
Peak hip extension during stance ( °) 
PLH
IV 
39 
11.1 ± 4.6 
(9.6; 12.6) 
0.4 ± 1.0 
(-1.5; 2.4) 
0.670
Ó 
12.1 ± 0.7 
(10.6; 13.5) 
0.6 ± 1.0 
(-1.5; 2.7) 
0.568
Ó 
SN
P 
47 
10.7 ± 4.4 
(9.4; 12.0) 
11.5 ± 0.7 
(10.0; 12.9) 
 
H
ip abduction R
O
M
 during m
id-stance ( °) 
PLH
IV 
39 
4.2 ± 2.0 
(3.5; 4.8) 
-0.6 ± 0.4     
(-1.5; 0.2) 
0.148
Ô 
4.9 ± 0.3 
(4.3; 5.5) 
0.7 ± 0.4 
(-0.1; 1.5) 
0.104
Ó 
SN
P 
47 
4.8 ± 2.1 
(4.2; 5.4) 
4.2 ± 0.3 
(3.6; 4.8) 
 
H
ip adduction R
O
M
 during loading response ( °) 
PLH
IV 
39 
6.1 ± 2.2 
(5.4; 6.8) 
-1.42 ± 0.5 
(-2.4; 0.4) 
0.005
Ô 
6.3 ± 0.4 
(5.6; 7.0) 
-0.4 ± 0.5 
(-1.4; 0 .7) 
0.460
Ô 
SN
P 
47 
7.5 ± 2.4 
(6.8; 8.2) 
6.7 ± 0.4 
(6.0; 7.4) 
 
H
ip internal rotation R
O
M
 during G
C ( °) 
PLH
IV 
39 
16.1 ± 4.3 
(14.7; 17.5) 
0.9 ± 1.0 
(-2.9; 1.1) 
0.371
Ô 
16.8 ± 0.8 
(15.2; 18.4) 
-0.0 ± 1.2 
(-2.3; 2.3) 
0.979
= 
SN
P 
47 
17.0 ± 4.9 
(15.6; 18.4) 
16.8 ± 0.8 
(15.2;18.4) 
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K
nee flexion R
O
M
 during G
C
 ( °) 
PLH
IV 
39 
59.0(6.4)  # 
(55.3; 61.7) 
-4.6 
(-6.5; 2.7) 
<0.001
Ô 
60.1 ± 0.9 
(58.4; 61.8) 
-2.9 ± 1.1 
(-5.1; -0.6) 
0.013
Ô 
SN
P 
47 
63.2 (6.1)  # 
(60.8; 66.9) 
63.0 ± 0.8 
(61.4; 64.6) 
 
K
nee flexion R
O
M
 during stance ( °) 
PLH
IV 
39 
10.1 (5.9)  # 
(6.3; 12.2) 
-1.6 
(-3.3; 0.4) 
0.130
Ô 
11.7 ± 0.6 
(10.5; 13.0) 
0.8 ± .9 
(1.1; 2.6) 
0.411
Ó 
SN
P 
47 
11.0 (5.1)  # 
(8.8; 13.9) 
11.0 ± 0.6 
(9.7; 12.2) 
 
K
nee flexion R
O
M
 from
 stance to sw
ing ( °) 
PLH
IV 
39 
54.8 (7.0)  # 
(52.5; 59.5) 
-4.8  
(-6.6; 2.9) 
<0.001
Ô 
56.7 ± 0.9 
(55.0; 58.5) 
-2.3 ± 1.2 
(-4.6; 0.0) 
0.052
Ô 
SN
P 
47 
59.5 (5.4)  # 
(57.5; 62.9) 
59.0 ± 0.8 
(57.4; 60.2) 
 
K
nee extension R
O
M
 from
 m
id-stance to term
inal stance ( °) 
PLH
IV 
39 
9.0 ± 5.1 
(7.4; 10.7) 
-1.2 ± 1.2 
(-3.5; 1.2) 
0.318
Ô 
11.4 ± 0.7 
(9.9; 12.8) 
2.3 ± 1.0 
(0.3; 4.4) 
0.027
Ó 
SN
P 
47 
10.2 ± 5.7 
(8.5; 11.9) 
9.1 ± 0.7 
(7.7; 10.4) 
 
K
nee flexion at initial contact ( °) 
PLH
IV 
39 
5.2 (10.5)  # 
(0.8; 11.3) 
0.8 
(-2.0; 3.7) 
0.529
Ó 
6.4 ± 1.0 
(4.5; 8.3) 
3.7 ± 1.4 
(1.0; .6.5) 
0.008
Ó 
SN
P 
47 
4.3 (6.5)  # 
(1.4; 7.8) 
2.7 ± 0.9 
(0.8; 4.6) 
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Peak knee flexion during stance ( °) 
PLH
IV 
38 
42.1 ± 8.1 
(39.5; 44.7) 
-3.7 ± 1.4 
(-6.5; 0.9) 
0.010
Ô 
44.3 ± 1.1 
(42.1; 46.5) 
0.1 ± 1.4 
(-2.8; 3.0) 
0.944
= 
SN
P 
47 
45.8 ± 4.8 
(44.4; 47.3) 
44.2 ± 1.0 
(42.2; 46.3) 
 
Peak knee extension during stance ( °) 
PLH
IV 
38 
-3.2 (7.9)  # 
(-7.9; 0.0) 
-0.7 
(-3.3; 1.8) 
0.490
Ó 
-4.5 ± 0.8 
(-6.2; -2.9) 
-3.2 ± 1.2 
(-5.5; -0.9) 
0.007
Ó 
SN
P 
47 
-3.1 (5.0)  # 
(-4.9; 0.0) 
-1.3 ± 0.8 
(-2.9; 0.3) 
 
Peak knee flexion during sw
ing ( °) 
PLH
IV 
38 
60.9 ± 5.1 
(58.1; 67.7) 
-4.6 ± 1.5 
(-7.6; -1.7) 
0.002
Ô 
63.5 ± 1.1 
(61.4; 65.6) 
0.1 ± 1.4 
(-2.7; 2.9) 
0.939
= 
SN
P 
47 
65.6 ± 5.1 
(64.1; 67.0) 
63.3 ± 1.0 
(61.4; 65.3) 
 
A
nkle dorsiflexion R
O
M
 during stance ( °) 
PLH
IV 
38 
21.9 ± 3.6 
(20.7; 23.1) 
0.2 ± 0.8 
(-1.3; 1.8) 
0.756
Ô 
20.9 ± 0.6 
(19.8; 22.1) 
-1.1 ± 0.8  
(-2.8; 0.50) 
0.171
Ô 
SN
P 
47 
21.6 ± 3.5 
(20.6; 22.7) 
22.1 ± 0.6 
(21.0; 23.2) 
 
A
nkle dorsiflexion R
O
M
 during sw
ing ( °) 
PLH
IV 
38 
16.7 ± 4.8 
(15.1; 18.2) 
-3.2 ± 1.2 
(-5.6; 0.8) 
0.008
Ô 
17.5 ± 1.0 
(15.6; 19.4) 
-1.4 ± 1.4 
(-4.1; 1.4) 
0.321
Ô 
SN
P 
47 
19.9 ± 6.0 
(18.1; 21.6) 
18.9 ± 0.9 
(17.0; 20.8) 
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A
nkle plantarflexion RO
M
, heel rise to toe-off (push off) ( °) 
PLH
IV 
38 
27.4 (8.2)  # 
(24.7; 32.9) 
-3.9 
(-6.5; 1.3) 
0.003
Ô 
29.2 ± 1.0 
(27.2; 31.1) 
-1.9 ± 1.4 
(-4.6; 0.9) 
0.182
Ô 
SN
P 
47 
31.7 (9.2)  # 
(27.4; 36.6) 
31.0 ± 0.9 
(29.2; 32.9) 
 
 
A
nkle dorsiflexion angle at initial contact ( °) 
PLH
IV 
38 
-9.3 (6.3)  # 
(-12.2; -5.9) 
-0.8 
(-2.3; 0.8) 
0.296
Ó 
-9.1 ± 0.6 
(-10.2; -7.0) 
0.8 ± 0.8 
(-0.8; 2.5) 
0.307
Ô 
SN
P 
47 
-8.3 (3.6) 
(-10.6; -7.0) 
-10.0 ± 0.6 
(-11.1; -8.9) 
 
A
nkle plantarflexion angle at toe-off ( °) 
PLH
IV 
38 
15.5 ± 6.3 
(13.4; 20.5) 
-3.1 ± 1.4 
(-5.8; 0.4) 
0.025
Ô 
16.8 ± 1.1 
(14.7; 19.0) 
-0.8 ± 1.6 
(-3.9; 2.2) 
0.585
Ô 
SN
P 
47 
18.6 ± 6.3 
(16.8; 20.5) 
17.7 ± 1.1 
(15.6; 19.8) 
 
 
Peak ankle plantarflexion during G
C
 ( °) 
PLH
IV 
38 
18.8 (6.8)  # 
(14.1; 20.9) 
-3.3 
(-6.2; 0.3) 
0.035
Ô 
19.5 ± 1.1 
(17.3; 21.7) 
-1.9 ± 1.6 
(-5.0; 1.2) 
0.233
Ô 
SN
P 
47 
21.8 (10.6)  # 
(16.8; 27.4) 
21.3 ± 1.1 
(19.2; 23.5) 
A
bbreviations: C
I = confidence interval; G
C
 = gait cycle; n = num
ber of participants; P
LH
IV = people living w
ith H
IV
-1 infection; R
O
M
 = range of m
otion; S
D
 = 
standard deviation; S
E
 = standard error; S
N
P
 = H
IV
-seronegative participants. 
C
ovariables w
ere gender (m
ale/fem
ale), age (in years) and norm
alised gait speed. 
#presented as m
edian (IQ
R
) (Q
1; Q
3). 
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Figure 8.8. The interaction noted between HIV-serostatus and gait speed on knee flexion 
range during the gait cycle. Under dual task conditions, the effect of HIV on reducing 
knee flexion range during the gait cycle depends on the walking speed and appears 
larger at slower speeds.  
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8.6. Differences in biomechanical standing balance 
outcomes 
8.6.1. Centre of pressure (COP) parameters during dual task 
single leg stance  
COP data were only analysed for the dual task condition for the purposes of this thesis, given 
that only 22 SNP and seven PLHIV were able to complete the full 30-second trial with eyes 
closed. Shorter time intervals from this condition will be analysed at a later stage, but for the 
purposes of this dissertation it was decided to present the zero to 30 second time interval (full 
trial data) as this would provide the most reliable data for COP outcomes390,466 and would 
enable comparison to previous studies performed in PLHIV.62,323  
SLS DT data were available for 45 SNP and 40 PLHIV (i.e. 85% of the total sample). Since DT 
activities were only introduced later in the protocol, no such data were collected for 12 study 
participants (n = 3 SNP and n = 6 PLHIV). In addition, one SNP had invalid SLS DT trials due 
to constant foot shuffling, two PLHIV had invalid trials due to shuffling and one PLHIV was 
unable to perform SLS under the dual task condition (unsafe). A single best trial per participant 
was selected for analysis since few participants had two or three successful full-length trials 
(this is also how the SLS test is often used in clinical practice).467 
Table 8.17 presents the COP results (unadjusted and adjusted for gender differences). The 
data for mean COP velocity in the ML direction (p = 0.031) and mean COP excursion in the 
ML direction (p = 0.08) whilst performing a dual task demonstrated significant differences 
between PLHIV and SNP. Mean velocity was increased in PLHIV, indicating that this group 
displayed faster COP movement in the ML direction, or needed more postural adjustments to 
maintain stability compared to SNP. Significantly larger excursion in the ML direction was also 
evident for PLHIV. No significant differences in COP AP or combined parameters were found 
between the groups. 
After adjusting for gender, differences in mean COP excursion in ML direction remained 
significant, but the difference noted for mean  ML velocity became non-significant and mean 
COP combined instead became significant (p = 0.027). 
When performing adjusted analyses, mean COP excursion demonstrated a significant 
Levene’s test (p = 0.038) and further checking of assumptions demonstrated skewed 
distribution of the residuals (Shapiro Wilk test = 0,025 and 0.035 for SNP and PLHIV 
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respectively). After inspecting the stabilogram and video data, the participant was deemed to 
be a true outlier, who demonstrated large movements whilst maintaining SLS. Sensitivity 
analyses were performed to assess the impact of removing the outlier. Removal of the outlier 
led to an insignificant Levene’s test (p = 620) and normal distribution of the residuals (Shapiro 
Wilk = 0.232 and 0.320 for SNP and PLHIV respectively); however, the conclusions drawn 
from the adjusted analysis did not change as the difference between groups remained non-
significant (mean difference = 0.71 mm ± 0.54 mm, p = 0.197, 95% CI = -0.38 mm to 1.79 mm. 
Therefore, the outlier was retained in the analysis. 
Table 8.17. Centre of pressure (COP) outcomes for dual task single leg standing in 
PLHIV and SNP.  
Group n 
Unadjusted Adjusted 
Estimate Difference (95% CI) 
p-
value 
mean ± SE 
(95% CI) 
Difference 
(95% CI) 
p-
value+ 
Mean COP velocity (mm/s) (0 –30s) 
PLHIV 34 
44.55 
(23.98) 
(36.46; 
60.44) 5.41 
(-0.76; 
12.36) 
0.071#Ó 
51.17 ± 2.85 
(45.48;
 56.8
5) 7.68 ± 4.48 
(-
1.25;16.61) 
0.091Ó 
SNP 38 
39.23 
(16.70) 
(33.65; 
50.33) 
43.49 ± 3.45 
(36.60; 
50.38) 
Mean COP velocity (mm/s) in AP direction (0 – 30s) 
PLHIV 34 
25.09 
(12.30) 
() 2.35 
(-1.38; 
6.36) 
0.180#Ó 
29.22 ± 1.89 
(25.44; 
32.99) 4.61 ± 2.97 
(-1.32; 
10.54) 
0.126Ó 
SNP 38 
22.77 
(9.28) 
(19.58; 
28.86) 
24.61 ± 2.29 
(20.03; 
29.18) 
Mean COP velocity (mm/s) in ML direction (0 – 30s) 
PLHIV 34 
30.99 
(17.43) 
(26.95; 
44.38) 4.91 
(0.32; 
9.55) 
0.031#Ó 
35.97 ± 1.85 
(32.28;
 39.6
7) 5.13 ± 2.91 
(-0.67; 
10.93) 
0.082Ó 
SNP 38 
27.75 
(12.62) 
(22.60; 
35.22) 
30.84 ± 2.24 
(26.37;
 35.3
2) 
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Mean COP excursion (mm) (0-30 s) 
PLHIV 34 
9.63 ± 2.39 
(8.79; 
10.46) 1.01 ± 0.51 
(0.00; 
2.02) 
0.050Ó 
9.71 ± 0.36 
1.29 ± 0.57 
(0.16; 2.43) 0.027
Ó 
SNP 38 
8.62 ± 1.89 
(7.99; 
9.24) 
8.42 ± 0.44 
Mean COP distance (mm) in AP direction (0 – 30s) 
PLHIV 34 
6.23 ± 1.90 
(5.57; 
6.89) 0.42 ± 0.41 
(-0.40; 
1.25) 
0.312$Ó 
6.28 ± 0.30 
(5.68; 6.89) 
0.66 ± 0.47 
(-0.29; 1.60) 0.169
Ó 
SNP 38 
5.81 ± 1.62 
(5.27; 
6.34) 
5.63 ± 0.37 
(4.90 6.35) 
Mean COP distance (mm) in ML direction (0 – 30s) 
PLHIV 34 
6.06 ± 1.54 
(5.52; 
6.59) 0.85 ± 0.31 
(0.23; 
1.47) 
0.008$Ó 
6.11 ± 0.22 
(5.67; 6.56) 
0.95 ± 0.35 
(0.25; 1.65) 0.008
Ó 
SNP 38 
5.21 ± 1.07 
(4.85; 
5.56) 
5.16 ± 0.27 
(4.62; 5.70) 
Abbreviations: AP = anterior-posterior direction; CI = confidence interval; COP = centre of pressure; 
GC = gait cycle; n = number of participants; ML = medial-lateral direction; PLHIV = people living 
with HIV-1 infection; ROM = range of motion; SD = standard deviation; SE = standard error; SNP = 
HIV-seronegative participants. 
The adjusted model included gender. 
apresented as median (IQR) (Q1 – Q3) or mean ± SD (95% CI). 
#Mann-Whitney U test. 
$Independent student’s t-test. 
+F-test from 2x2 ANOVA (HIV-serostatus x gender). 
8.7. Correlations of clinical tests with a complex and 
quantitative composite gait score, self-reported 
function and fall-related outcomes in PLHIV 
Table 8.18 below presents (for PLHIV only) the correlation matrix of the selected clinical tests 
with a quantitative summary measure of gait (the EGVI), self-reported function and fall history, 
with associations being reported as either Pearson product-moment (r) or Spearman’s rank 
(rs) correlation coefficients. Cells with significant correlations (ρ < 0.05) are highlighted in 
orange (darker orange denotes the corresponding r-value of the significant correlation, with 
the p-value highlighted in lighter orange). Refer to Section 7.10.3 for interpretation of strength 
of correlation coefficients.  
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Table 8.18. Pearson product moment (indicated with §) and Spearman’s rank correlation 
coefficients showing relationships between the EGVI, self-reported function and fall 
number with clinical measures of mobility. Highlighted cells indicate significant 
correlations (dark and light orange for correlation coefficient and p-value respectively).  
PLHIV (58% female; 
median age 36.61 years) 
EGVI. 
usual-
paced 
EGVI. 
dual 
task 
Self-
reported 
function: 
Mobility 
Self-
reported 
function: 
Self-care 
Self-
reported 
function: 
Usual 
activities 
Number 
of falls 
over 
past 
year 
PPB total 
ratio score 
(0 - 4) 
Correlation 
Coefficient 0.30 0.37 -0.46 -0.44 -0.41 0.02 
Sig. (2-
tailed) 0.058 0.032 0.001 0.002 0.003 0.888 
n 42 33 49 49 49 50 
PPB balance 
ratio score 
Correlation 
Coefficient 0.05 -0.28 -0.34 -0.30 -0.14 -0.45 
Sig. (2-
tailed) 0.746 0.112 0.018 0.037 0.356 0.001 
n 42 33 49 49 49 50 
PPB usual 
walk ratio 
score 
Correlation 
Coefficient 0.17
§ 0.25§ -0.51 -0.41 -0.39 0.11 
Sig. (2-
tailed) 0.276 0.167 0.000 0.003 0.006 0.432 
n 42 33 49 49 49 50 
PPB narrow 
walk ratio 
score 
Correlation 
Coefficient 0.22
§ 0.10§ -0.39 -0.37 -0.41 0.20 
Sig. (2-
tailed) 0.155 0.583 0.005 0.008 0.004 0.155 
n 42 33 49 49 49 50 
PPB chair 
rise ratio 
score 
Correlation 
Coefficient 0.36
§ 0.42§ -0.44 -0.48 -0.29 -0.16 
Sig. (2-
tailed) 0.021 0.016 0.001 <0.001 0.042 0.270 
n 42 33 49 49 49 50 
Six-metre 
Walk Test 
(time in 
seconds 
converted to 
speed) 
Correlation 
Coefficient 0.17
§ 0.25§ -0.51 -0.41 -0.39 0.11 
Sig. (2-
tailed) 0.276 0.167 <0.001 0.003 0.006 0.432 
n 42 33 49 49 49 50 
Six-metre 
Walk Test, 
dual task 
(time in 
seconds 
converted to 
speed) 
Correlation 
Coefficient 0.25
§ 0.30§ -0.36 -0.14 -0.23 -0.11 
Sig. (2-
tailed) 0.160 0.090 0.024 0.386 0.161 0.514 
n 
33 33 40 40 40 41 
Five-Times 
STS test 
Correlation 
Coefficient -0.36
§ -0.42§ 0.44 0.48 0.29 0.16 
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(time in 
seconds) 
Sig. (2-
tailed) 0.019 0.016 0.001 <0.001 0.042 0.270 
n 42 33 49 49 49 50 
30-second 
STS test 
(repetitions 
completed) 
Correlation 
Coefficient 0.35
§ 0.37§ -0.36 -0.46 -0.38 -0.13 
Sig. (2-
tailed) 0.021 0.033 0.010 0.001 0.008 0.364 
n 42 33 49 49 49 50 
Single Leg 
Stance Test, 
eyes closed 
(time in 
seconds) 
Correlation 
Coefficient 0.22 -0.06 -0.46 -0.46 -0.30 -0.19 
Sig. (2-
tailed) 0.169 0.732 0.001 0.001 0.039 0.184 
n 42 33 49 49 49 50 
Single Leg 
Stance Test, 
dual task 
(time in 
seconds) 
Correlation 
Coefficient -0.06 -0.26 0.00 -0.11 -0.30 -0.24 
Sig. (2-
tailed) 0.752 0.150 0.985 0.509 0.064 0.133 
n 33 33 40 40 40 41 
Abbreviations: n = number of participants; PLHIV = people living with HIV-1 infection; PPB = Health 
ABC Physical Performance Battery; Sig. = Statistical significance; STS = Sit-To-Stand.  
Bold print indicates statistically significant correlations (p < 0.05) regardless of strength of 
correlation.. 
Correlations of 0.2 ≤ 0.39 = weak; 0.4 ≤ 0.59 = moderate; 0.6 ≤ 0.79 = strong; 0.8 ≤ 1.0 = very 
strong.462  
 
Figures 8.9 to 8.13 are scatterplot graphs of selected significant correlations as reported in 
Table 8.18 above. Associations between clinical tests and the EGVI and fall history are shown, 
as well as the test showing the best correlation with self-reported function (since most clinical 
tests demonstrated significant correlations with self-reported function). All correlations were 
moderate to weak. 
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Figure 8.9. The positive correlation between PPB total score and the EGVI calculated for 
the dual task condition in PLHIV (rs = 0.37). 
 
Figure 8.9 above shows that PLHIV who achieved higher (better) total scores on the PPB also 
demonstrated higher EGVI scores under the dual task condition (i.e. gait pattern variability 
closer to the norm, represented by a score of 100).  
 
Figure 8.10. The negative correlation between the Five-Times Sit-To-Stand Test (time in 
seconds) and the EGVI calculated for usual-paced gait in PLHIV (r = -0.36). 
PPB total ratio score (0-4) 
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The 5STS test (time in seconds) correlated the best with EGVI scores, although the 
correlations were weak for EGVI scores calculated for usual-paced gait, and only moderate for 
scores calculated for dual task gait. Figure 8.10 (previous page) and Figure 8.11 above show 
that PLHIV took a longer time to complete five repeated sit-to-stand actions and also 
demonstrated lower EGVI scores for usual-paced gait as well as dual task gait (i.e. lower gait 
variability than the norm). 
Figure 8.11. The negative correlation between the Five-Times Sit-To-Stand Test (time in 
seconds) and the EGVI calculated for dual task gait in PLHIV (r = -0.42). 
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Figure 8.12. The negative correlation between the PPB balance ratio score (maximum 
score of 1) and number of falls during the past 12 months (rS = -0.45). Note that a jitter 
function was applied to the nominal data in the plot to enhance graphic representation 
of the correlation. 
Figure 8.12 above shows that PLHIV achieving maximum scores on the balance sub score of 
the PPB (maximum ratio score of 1, based on semi-tandem, full-tandem and single leg stance 
tests of 30 seconds each) were most likely not to have reported any falls over the past 12 
months. However, some of those achieving maximum scores also reported one or more falls 
– this is explained by the fact that this test demonstrated a very high ceiling effect in PLHIV 
(Table 8.7) and is thus likely too easy a test to discriminate fallers from non-fallers. 
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Figure 8.13. The negative correlation between six-metre walk test performance 
(time in seconds converted to walking speed) and self-reported mobility 
function, where a lower EQ-5D-5L score indicates better function (rS = -0.51). 
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Figure 8.13. The negative correlation between Six-metre Walk Test performance (time in 
seconds converted to walking speed) and self-reported mobility function, where a lower EQ-
5D-5L score indicates better function (rS = -0.51). 
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Figure 8.13 above shows that PLHIV who were faster in completing the 6mWT tended to report 
higher mobility function (i.e. a lower EQ-5D-5L score, or less problems with walking).  
Associations between the selected clinical tests and the binary variables (yes/no) of having 
experienced any fall over the past year, as well as having a fear of falling, were assessed using 
independent Student’s t-test or Mann-Whitney U tests, depending on the data distribution. 
PLHIV reporting a fear of falling achieved significantly worse scores in the total PPB, the PPB 
narrow walk sub score and the PPB chair rise sub score. Those with a fear of falling also 
performed significantly worse in the SLS EC, required a significantly longer time to complete 
5STS actions, and completed significantly less STS repetitions within 30-seconds (Table 8.19). 
Table 8.19. Comparisons of clinical test performance in PLHIV with and without fear of 
falling. Orange cells (dark or light) indicate significant p-values. 
PLHIV (58% female; 
median age 36.61 years) Fear of falling (n = 10) 
No fear of falling 
(n = 40) p-value 
PPB total ratio score (0 - 
4) 2.28 (1.53; 2.37) 2.49 (2.34; 2.75) 0.008 
PPB balance ratio score 
0.99 (0.68; 1.00) 1.00 (1.00; 1.00) 0.092 
PPB usual walk ratio 
score 0.47 ± 0.15 0.52 ± 0.11 0.248 
PPB narrow walk ratio 
score 0.42 ± 0.16 0.52 ± 0.13 0.048 
PPB chair rise ratio score 0.37 ± 0.07 
 
0.48 ± 0.12 
 
0.008 
Six-metre Walk Test (time 
in seconds converted to 
speed) 
0.93 ± 0.30 1.03 ± 0.23 0.248 
Six-metre Walk Test, dual 
task (time in seconds 
converted to speed) 
0.67 ± 0.23 0.78 ± 0.28 0.278 
Five-Times STS test (time 
in seconds) 13.93 ± 2.69 11.00 ± 2.57 0.003 
30-second STS Test 
(repetitions completed) 12.70 ± 4.40 16.75 ± 4.87 0.021 
Single Leg Stance Test, 
eyes closed (time in 
seconds) 
4.18 (0.00; 7.94) 9.14 (5.64; 17.90) 0.004 
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Single Leg Stance Test, 
dual task (time in 
seconds) 
 23.50 (13.38; 30.00) 30.00 (25.30; 30.00) 0.112 
Abbreviations: n = number of participants; PLHIV = people living with HIV-1 infection; PPB = Health 
ABC Physical Performance Battery; Q1 = first quartile; Q3 = third quartile; SD = standard deviation; 
STS = Sit-To-Stand;  
Results are presented as median (Q1; Q3) or mean ± SD. p-values obtained from independent 
Student’s t-tests or Mann-Whitney U tests. 
Bold print (in orange cells) indicates statistical significance, p < 0.05. 
 
The PPB balance sub score was the only clinical test to show a significant difference 
between PLHIV with a retrospective self-report of experiencing any falls during the past year 
and those with no fall history. Those reporting previous falls achieved a significantly lower 
ratio score in this domain of the PPB (Table 8.20).  
Table 8.20. Comparisons of clinical test performance in PLHIV with and without any 
falls during the past year. Orange cells indicate significant p-values. 
PLHIV (58% female; 
median age 36.61 
years) 
Any fall during 
past year (n = 
17) 
No falls during 
past year (n = 33) p-value 
PPB total ratio score 
(0 - 4) 2.40 (1.73; 2.68) 2.45 (2.21; 2.74) 0.927 
PPB balance ratio 
score 0.96 (0.76; 1.00) 1.00 (1.00; 1.00) <0.001 
PPB usual walk ratio 
score 0.53 ± 0.15 0.50 ± 0.11 0.434 
PPB narrow walk ratio 
score 0.53 ± 0.16 0.42 ± 0.12 0.299 
PPB chair rise ratio 
score 0.44 ± 0.12 0.47 ± 0.12 0.340 
Six-metre Walk Test 
(time in seconds 
converted to speed) 
1.05 ± 0.29 0.99 ± 0.22 0.434 
Six-metre Walk Test, 
dual task (time in 
seconds converted to 
speed) 
0.71 ± 0.28 0.77 ± 0.27 0.494 
Five-Times STS Test 
(time in seconds) 12.28 ± 3.23 11.24 ± 2.58 0.222 
30-second STS Test 
(repetitions 
completed) 
15.35 ± 6.16 16.24 ± 4.37 0.557 
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Single Leg Stance 
Test, eyes closed 
(time in seconds) 
5.45 (0.25; 8.75) 9.1 (4.92; 17.45) 0.091 
Single Leg Stance 
Test, dual task (time 
in seconds) 
25.00 (17.15; 30.00) 30.00 (26.65; 30.00) 0.094 
Abbreviations: n = number of participants; PLHIV = people living with HIV-1 infection; PPB = 
Health ABC Physical Performance Battery; Q1 = first quartile; Q3 = third quartile; SD = standard 
deviation; STS = Sit-To-Stand;  
Results are presented as median (Q1; Q3) or mean ± SD. p-values obtained from independent 
Student’s t-tests or Mann-Whitney U tests. 
Bold print (orange cells) indicates statistical significance, p < 0.05. 
 
 
8.8. Chapter summary 
This chapter presented the results of the cross-sectional field study. The two participant groups 
(PLHIV and SNP) differed with regards to median age (although both groups were on average 
in their thirties) and gender composition (both groups were predominantly female, but SNP 
included a significantly higher percentage of women).  
Instrumented gait analysis showed that PLHIV walked significantly slower than SNP under all 
task conditions (although for fast-paced gait, this difference disappeared in adjusted analysis). 
Unadjusted comparisons of TSPs showed differences typically associated with a slow gait 
speed. After adjusting for covariables including speed, differences were less and mostly 
remained for temporal and temporospatial parameters, but not spatial or temporophasic 
parameters. Kinematic angles during gait were mostly reduced in PLHIV, as would be 
expected from the TSP results. After adjusting for covariables, dual task gait showed the most 
differences, with increased proximal angles (hip and knee), except for knee flexion range 
during the gait cycle, which was significantly decreased in PLHIV. No significant differences 
were evident at the ankle, although all ankle angles and ranges demonstrated trends towards 
being decreased in PLHIV. EGVI scores revealed significantly lower scores in PLHIV for usual-
paced as well as dual task gait. These results remained after adjusted analyses and 
demonstrate lower gait variability in PLHIV relative to what is consider the norm (in SNP). 
PLHIV demonstrated increased COP balance measures in the ML direction, and, after 
adjustment for gender, for total COP excursion.  
Relative to SNP, PLHIV reported significantly lower mobility and selfcare function. Clinical test 
performance revealed that PLHIV were significantly impaired on clinical tests relative to their 
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seronegative peers, even after adjusting for covariables, although some ceiling effects were 
noted especially for static balance tests. 
All clinical tests (except SLS DT) showed moderate to weak correlations with the domains of 
self-reported function. Only the balance sub score of the PPB correlated significantly with fall 
history, but this test component may be of limited utility in PLHIV. The chair rise tests, and in 
particular the 5STS test, correlated the best with quantitative EGVI scores and also with self-
reported function (albeit still all moderate to weak correlations). This test also demonstrated a 
significant association with fear of falling in PLHIV.  
These findings, in the context of Parts I and II of the dissertation, and relevant implications, 
will subsequently be discussed in Chapter 9, the general Discussion of the dissertation. 
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DISCUSSION 
9.1. Introduction 
This project provided novel quantitative information about locomotor impairments found among 
people living with HIV-1 infection (PLHIV) residing in the Cape Winelands District of the 
Western Cape, South Africa, using state-of-the-art three-dimensional (3D) movement analysis 
technology. The study further correlated the findings of 3D gait analysis (3DGA), as well as 
self-reported function and history and fear of falling, to selected physical performance tests 
which may be considered in clinical settings to screen for early functional decline in PLHIV.  
9.1.1. Overview of the research presented in the dissertation 
The dissertation was divided into three parts to present a systematic review and three primary 
studies, viz: 
• Part I reviewed the chronic nature of HIV-1 and its consequences related to various 
body systems, including a published systematic review62 of the current evidence related 
to objective locomotor impairments in PLHIV. Review results provided the theoretical 
groundwork for the study conceptualisation and aided in selecting clinically relevant 
gait and balance outcomes and clinical tests.  
• Part II of the dissertation involved two related observational laboratory-based studies 
to test the validity and reliability of gait outcomes measured by a newly-acquired 
portable 3DGA system. Results from these studies informed the interpretation of gait 
differences noted between PLHIV and HIV-seronegative participants (SNP) in the 
cross-sectional field study. 
• Part III presented the third and main observational study and incorporated the 
theoretical hypotheses derived from Part I along with the technical insights gained from 
Part II. The outcome of Part III was not only the description of key biomechanical 
differences in the gait and balance of PLHIV relative to SNP, but also the proposal of 
a valid physical performance test for early clinical screening which can be used in 
clinical practice. 
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Presented within a framework of the general effects of ageing on locomotor function, this 
chapter will provide an integrated discussion of the key findings from the various studies 
and contributions towards the understanding of gait and balance impairments in PLHIV, 
the rigour of such findings, the participant profile and potential implications for 
rehabilitation, and the use of a simple, standardised, valid clinical performance test in 
PLHIV.  
9.2. Evidence for walking gait and balance impairments 
among South African adults living with HIV-1 infection 
Chapter 3 presented a systematic overview of evidence supporting increased postural sway 
and velocity in PLHIV under challenging conditions, as quantitatively determined by static 
posturography. The review highlights that little quantitative data is available about walking gait 
in PLHIV. Furthermore, methodological differences complicate comparisons between studies 
or to data from HIV-seronegative cohorts, and the evidence is mostly of fair to low quality. 
However, the limited information (mostly described in high-income countries) suggested that 
gait and balance impairments exist in middle-aged PLHIV, resembling fall-associated metrics 
in the elderly.62  
9.2.1. Gait speed 
The cross-sectional data from this PhD provide new knowledge by showing that the gait of 
PLHIV is primarily characterised by a significant slowing of movement. This observation is 
based on comparisons to community-matched SNP, and was evident when walking at a usual 
pace or when counting backwards while walking (performing a dual task), even after adjusting 
for covariables. Comparing these results to findings from Chapter 3,30,32,49,59,121,261 this study 
provides new information about the way walking speed impairments manifest in PLHIV. The 
systematic review (Chapter 3) established that PLHIV demonstrate slowed walking when 
having to produce a fast gait, but not when walking at a usual pace.62 Notably, the 
methodologies of included studies assessing gait speed varied substantially, and most of the 
evidence was derived from studies measuring tests such as six-minute walking distance 
(6MWD).2,3,55,59,121,260,261 Although proven to correlate well with gait speed,299 6MWD measures 
different aspects of walking function than short distance walking tests, since it is actually an 
indicator of functional aerobic capacity.468 Furthermore, most of the studies reporting 
differences in 6MWD used predicted norms from the literature for comparison. This is of 
concern, as gait patterns strongly relate to – and is influenced by –  the community or culture 
that a person hails from.209 Therefore larger between-group differences may be apparent when 
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comparing data collected in patients from a certain population or community and a comparison 
group from another; for example when healthy people (and not just patients) from the same 
underlying  population would tend to walk slower than healthy people in a different “normative” 
reference dataset (e.g. data from the general population, which may have been readily 
available from population-based studies, routine health information systems and registries).  
The pitfalls of deriving inferences from inappropriate reference groups in HIV research are 
reported.469 Conclusions regarding accelerated or accentuated ageing in PLHIV may for 
example merely reflect the underlying age distribution in the two cohorts being compared in 
studies failing to use appropriately matched comparison groups.152 However, recruiting a 
matched comparison group in HIV research is by no means a trivial task,152,469 as was evident 
during data collection for this study by failed efforts to recruit a sample matched on age and 
gender, despite the help of a research nurse. This issue was addressed by statistically 
adjusting comparisons of main outcomes for age, gender and selected important covariables 
associated with locomotor outcomes (e.g. gait speed) in this community-matched cohort to 
ascertain true between-group differences in locomotor characteristics.469 
When trying to explain the slow gait speed noted among PLHIV in this study, various 
hypotheses may be considered. This study excluded people with peripheral neuropathy and 
therefore neuropathy or associated pain was not likely a reason for walking slower. After 
controlling for the effects of age, gender and speed, PLHIV walked with increased temporal 
parameters (absolute time spent in stance and producing steps), confirming the general 
slowness of movement and explaining the significantly slowed usual-paced gait speed. More 
insight was gained by considering adjusted analysis of dual task gait. This analysis adds 
additional insight because it shows biomechanical adaptations elicited under cognitive load 
and which are primarily attributable to disease physiology, without the confounding effects of 
speed, age or gender. PLHIV namely walked with an increased step time and had difficulty in 
generating sufficient stride lengths, resulting in the slower speed. These changes resemble a 
commonly-reported strategy in older adults to increase stability and reduce variability, 
specifically in the presence of fear of falling.238,470 In this study, one-fifth of PLHIV reported 
suffering from a fear of falling (Table 8.6). It is feasible that this fear may have contributed in 
adopting an overly-controlled pattern in an effort to achieve a “safe” gait.  
Even more relevant perhaps, is considering the three gait domains proposed by Verghese et 
al.471 as being characteristic of gait performance in older adults at risk of cognitive decline and 
dementia. According to this theory, (i) changes in the rhythm domain (characterised by 
cadence, swing time and stance time) are associated with declines in memory, (ii) changes in 
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the pace domain (characterised by speed and stride length) relate to reduced executive 
function and (iii) changes in the variability domain (characterised by stride length variability) 
are associated with mild cognitive decline.471 The changes noted under dual task conditions in 
PLHIV in this study thus fit the domains related to executive function and mild cognitive 
impairment. This is concurrent with reports that executive function is affected by HIV-1 
infection298 and that neurocognitive decline of varying severity occur in HIV293,294,296,472 and has 
been associated with slow timed gait tests in this population.473 Furthermore, as noted in 
Chapter 2, volumetric changes in the cerebellar white matter and subcortical grey matter of 
PLHIV – both of which are brain regions involved in motor control and cognition - may be 
associated with the development of mobility disability despite well-controlled viral load. Hinken 
et al.186 previously used a dual task paradigm (using auditory reaction time and visual choice 
tasks) in PLHIV and demonstrated that HIV-1 infection is associated with impairments in 
divided attention and the simultaneous processing of competing stimuli, even in asymptomatic 
PLHIV. Such deficits have been associated with disruption of the anterior attentional system.186 
Gait speed is particularly sensitive to white matter alterations. The involvement of central motor 
and sensory systems similar to that seen with ageing may therefore be implicated in PLHIV, 
as has also been suggested by prior studies.474  
Whether this slowing in speed and shortening of stride length successfully produced a safer 
gait is uncertain, considering that a third of PLHIV in this study experienced one or more falls 
during the past year (Table 8.6). Given the lower enhanced Gait Variability Index (EGVI) scores 
achieved in PLHIV versus SNP, which indicate reduced gait variability,372 it seems that PLHIV 
succeeded in their efforts to implement a less variable gait. Walking with shorter steps 
maintains the centre of mass (COM) closer to the moving base of support (BOS) and should 
thus be more stable.475 However, step length shortening may also be maladaptive,476 and an 
over-controlled gait may thus be vulnerable to unexpected perturbations. It may thus be 
questioned whether the less variable gait pattern was truly the safer option – this is discussed 
further in Section 9.2.3. 
9.2.2. Kinematic patterns  
A key finding of this research project is that PLHIV showed changes in joint range of motion 
(ROM), especially at the hip and knee and in a distal-to-proximal pattern-shift in joint excursion. 
PLHIV had significantly increased hip ROM (similar finding to elderly gait)232 and reduced knee 
ROM (similar finding to elderly gait, although this is an inconsistent observation in older 
adults)232 whilst ankle plantarflexion was not significantly reduced during push-off (different to 
elderly gait).232 The expectation that PLHIV might demonstrate a kinematic gait pattern similar 
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to that observed in elderly gait was thus partly confirmed under dual task conditions and 
independent of gait speed.  
Albeit statistically significant, the magnitudes of these angular differences between PLHIV and 
SNP were not large (all smaller than 5° in Table 8.16, which is considered a general threshold 
for clinical significance in various adult populations).318 On the other hand, the differences all 
exceeded 2°, the threshold generally considered in kinematic literature to distinguish artefacts 
of measurement error.327,477 These angles also all exceeded the relevant measurement errors 
determined for each outcome using the myoMOTION system/model in Chapter 6 (except for 
the 2.3° increase in knee extension ROM noted for PLHIV; versus a standard error of 
measurement [SEM] of 2.4°). This implies that the differences were valid. Whether they were 
large enough to be of clinical (functional) importance, specifically in PLHIV, remains uncertain 
and is an area for future research. Follow-up studies to assess change over time would be 
useful for quantifying meaningful differences in PLHIV. 
The kinematic patterns described above is similar to the age-related biomechanical plasticity 
of gait232 often seen in older adults. This walking strategy involves a distal-to-proximal shift in 
muscle function and thus joint ROM232 (in this study, elicited during dual task walking). The 
phenomenon of biomechanical plasticity is thought to most likely be related to changes in 
neural and musculoskeletal function.478 The underlying mechanism in PLHIV may be similar, 
given the potential involvement of central neuromotor control hypothesised in the previous 
section. Specifically relating to muscle function, Scott et al.121 found that PLHIV had difficulty 
in activating their knee extensor muscles (but not necessarily other muscles) and that this 
reduced central activation was associated with weakness and decreased specific force. 
Although these authors did not assess consequences for gait, perhaps a similar impaired 
activation could explain the reduced knee ROM, as well as the weaker knee extensors, noted 
in this cohort of PLHIV. 
 An interesting finding from the 3DGA was that when faced with the physical challenge of 
walking at a maximum speed, PLHIV had the capacity to increase their speed and overcome 
the impairments (kinematic as well as TSPs) noted for usual-paced or dual task gait. This may 
have implications for rehabilitation, as it seems that PLHIV may have the potential to improve 
their preferred gait pattern. However, whether the observed biomechanical impairments are 
reversible is not known and may need to be addressed in future research. It has been shown 
in older adults (including very fit individuals such as runners) that the age-related distal-to-
proximal shift is resistant to exercise interventions, as such interventions failed to alter 
mechanical joint output.232 However, exercise was still able to mitigate the effects of 
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neuromuscular impairment by improving leg strength478 and is thus worth investigating in 
PLHIV – especially given the generally positive effects ascribed to aerobic as well as 
progressive resistive exercise in PLHIV.479,480 
Maximal isometric lower limb muscle strength did not show many differences between PLHIV 
and SNP in this study (Table 8.2), with significantly lower strength (for PLHIV) only noted for 
knee extensors and flexors. Reduced knee extensor strength, in particular, has been cited as 
an independent risk factor for hip fracture and a predictor for mortality after fragility fracture in 
older adults.481,482 This raises concern when considering the fall-related statistics and gait and 
balance impairments described in this study cohort. Although the minimum clinically important 
difference (MCID) for muscle strength changes in PLHIV is unknown, differences in thigh 
muscle strength of about 4% have been reported as clinically meaningful in patients with knee 
osteoarthiritis483 in terms of resulting in better patient-reported outcomes. Whether these 
differences are large enough to impact on functional performance may be questioned; as 
increases of more than 20% still seemingly result in relatively small increases in gait 
speed.232,484  
Considering the observed kinematic patterns described above, it is plausible that muscle 
activation and power, more so than strength, were responsible for the observed changes in 
PLHIV. This suggests that PLHIV may benefit more from exercise regimes that focus on 
improving the dynamic function of muscle, as opposed to isometric strength. The benefits of 
aerobic and progressive resistive exercise have already been reported in two Cochrane-
method systematic reviews479,480 but it may be worth investigating which exercises specifically 
result in meaningful improvements in gait function. Longitudinal research is warranted. 
A cross-sectional study44 conducted in Zimbabwe demonstrated that lower limb weakness, 
particularly of the proximal (hip) muscles, impacts on self-perceived function in PLHIV. In 
contrast to the current study, however, these authors found that knee flexor and extensor 
strength did not differ significantly between PLHIV and SNP, while ankle muscles (plantar- and 
dorsiflexors) and hip muscles (flexors, extensors, abductors and adductors) were significantly 
weaker in PLHIV.44 The reason behind the discrepancy in observations is not clear, but may 
in part be attributed to the fact the PLHIV participating in the Zimbabwean study were on 
average significantly older than the current study group (70% of those participants being in an 
age range between 40 and 69 years), while the relatively smaller control group was mostly 
aged below 40 years (although the authors did adjust their analyses for demographic factors). 
Furthermore, although not significantly different from SNP, findings from the current study 
show a directional trend for hip muscles to be stronger in PLHIV compared to SNP, while 
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plantarflexors trended towards being weaker. This pattern would be in accordance with the 
age-related biomechanical plasticity of ageing gait as mentioned above. However, as 
comparing muscle strength differences between PLHIV and SNP was not a primary objective 
of this study, muscle strength results were not adjusted for age, gender or any other 
covariables; whilst Mhariwa et al.44 performed regression analyses and adjusted for 
demographic factors. It was noted in Chapter 2 that evidence regarding muscle strength 
differences between PLHIV and SNP is contradictory. Further research regarding muscle 
strength as a primary outcome and using multivariable analyses is thus warranted to be able 
to draw more robust conclusions regarding strength differences, and whether such differences 
are of importance regarding gait function.  
9.2.3. Composite score of gait variability  
Variability defines the normal fluctuations that occur across multiple steps or strides 485 and 
increasing evidence supports the use of gait variability as a means of quantifying 
locomotion.237,372,373,375 EGVI scores in this study revealed significantly lower variability in 
PLHIV relative to what is considered the norm in the reference population during usual and 
dual task gait. This finding was contrary to the expected increased gait variability in PLHIV, 
based on the U-shaped variation of gait variability, which implies that people who walk very 
slowly often have increased variability.446 However, a real trend does seem to exist in these 
data, given that both gait speed and EGVI scores decreased in PLHIV under the dual task 
condition. Of importance, data from SNP in this study were used to construct a normative 
dataset for comparison – therefore, it can be said with confidence that the variability noted in 
PLHIV was significantly decreased relative to what would be considered normal in this 
population for usual-paced as well as dual task gait. These results remained after adjusted 
analyses (age and gender) and therefore appear valid. 
The relationship between gait variability and fall risk has been suggested to be non-linear486,487 
– with those at either end of the spectrum (either having too much or too little variability) being 
at greater risk of falls. An “ideal” state of variability has been proposed for optimal functioning 
(in gait as well as in other biological systems), with the hypothesis that a large enough deviation 
from this state would be associated with pathology.488 A decrease from the ideal state of 
variability renders the system too rigid and unchanging (e.g. a rigid gait pattern), while an 
increase makes the system unstable and chaotic.488 Excessively decreased gait variability has 
been noted in various studies including those performed in older adults,238,372,486,489,490 multiple 
sclerosis,485 and Parkinson’s Disease.372,491 The lower variability noted for PLHIV thus may 
indicate over-control of gait: a more rigid and less adaptable gait relative to SNP. Although 
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only an assumption, this may indicate that steps are carefully regulated in an attempt to 
increase stability.238 This approach may be maladaptive and represent an inflexible system 
with fewer available degrees of freedom485; a state that has been associated with impaired 
capacity to adapt and adjust gait patterns485 and which may thus potentially add to an increased 
fall risk in PLHIV when exposed to unexpected perturbations. 
As established in Chapter 3, PLHIV are reported to have prolonged automated postural 
response latencies, with abnormal postural reflex regulation under unpredictable, but not 
predictable, perturbations.62,262 Due to these response latencies, PLHIV may require more 
regularity of movement to avoid large or unexpected perturbations during walking.485 It has 
been noted that gait speed should be considered when interpreting variability measures, as 
elders who walk slowly (speeds of less than 1 m/s) regardless of their fall status, have 
previously demonstrated lower variability than those who walk faster than 1 m/s.487 The mean 
adjusted gait speed achieved for dual task walking by PLHIV in this study was 0.92 m/s (versus 
1.11 m/s in SNP) and therefore may be associated with the low variability. Either way, since 
both slowed gait and decreased variability may pose fall risks, it remains evident that the gait 
of PLHIV is impaired in domains probably related to falls. 
The choice of dual-task-related parameters also need consideration when interpreting findings 
from data collected under such conditions. It has been proposed that by combining the two 
rhythmic tasks of walking and backwards counting (which constitutes an attention as well as a 
rhythmic task), gait regularity may actually be emphasised.492 This may explain why SNP also 
somewhat reduced their gait variability when performing a dual task. The effect was probably 
larger in PLHIV, as backwards counting has been proposed to have a particularly regulating 
effect in individuals with an inherently unstable gait and high fall risk492 as may be the case for 
PLHIV participating in this study. 
9.2.4. Static standing balance 
This study revealed significant increases in mean centre of pressure (COP) excursion (ROM) 
in a mediolateral (ML) direction, as well as mean overall COP excursion in PLHIV under a dual 
task condition (Table 8.17). Increased COP excursion is a directional trend widely interpreted 
as indicative of poor postural balance control, as such a strategy may reflect the inability to 
recover from small postural perturbations.493 The concerns regarding the interpretation of 
increased postural sway as “poor” balance were mentioned in Chapter 3. Nevertheless, 
increased COP excursions have been noted to relatively consistently predict falls in older 
adults (especially in a ML direction, when compensatory sideways-stepping fails).494 The 
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findings of this study are also in agreement with the systematic review (Chapter 3), which found 
increased postural parameters in PLHIV, which were mostly elicited under challenging 
conditions (although these conditions were related to visual and sensorimotor input, while 
cognitive load was not investigated).  
What these findings add, is that impaired postural control in PLHIV is evident in conditions 
where the visual and vestibular systems are left intact, leaving the somatosensory system and 
cognitive processing as potential mechanisms. The systematic review in Chapter 3 indicated 
that impaired postural balance in PLHIV was mostly elicited under conditions where visual 
input was reduced (eyes closed), while eyes open conditions did not reveal impairments in 
asymptomatic PLHIV.62 Other studies have since been identified which report similar findings 
in asymptomatic PLHIV323 with evidence to suggest that not only the visual but also the 
vestibular and proprioceptive systems are responsible for increased COP parameters in 
PLHIV.322 However, none of these studies investigated dual task conditions. The findings from 
the current study suggest cognitive function as yet another contributor to impaired postural 
stability. 
It was noted in Chapter 2 that PLHIV may use hyperactivation of adjacent brain areas to 
maintain a certain level of performance (the “brain reserve theory”), and that this strategy may 
fail under more challenging conditions.101 Given the dual task condition employed in the current 
study, it may be deduced that deficits in cognitive processing largely contributed to the 
increased COP excursion noted in this cohort. Postural control has generally been considered 
an automated response to vestibular, somatosensory/proprioceptive and visual inputs, but 
evidence has since shown that postural regulation involves cognitive processes as well.495–497 
Dual task performance may reliably differentiate elderly fallers and non-fallers498 and it has also 
been shown that postural sway increases when a dual task is applied in healthy younger adults 
(18 to 30 years old).497 Although single leg stance (SLS) under dual task conditions has not 
previously been investigated in PLHIV, it seems likely to elicit differences given the cognitive 
domains commonly affected by HIV-1 infection.298,323 Several neuropsychological theories on 
human information processing have been developed to attempt to explain the difficulties in the 
concurrent performance of dual tasks.499 The capacity-sharing theory, for example, refers to a 
situation where a limited capacity in attention resources exists, so that the performance of two 
tasks that require attention causes a deterioration of at least one or both of the tasks.497,499 
This seems a feasible situation in this cohort of PLHIV, given that they tended to score lower 
on the cognition domain of the MOS-HIV (not a statistically significant, but a clinically significant 
difference), along with the observation that they made more mistakes in counting backwards 
whilst performing the SLS than they did in the seated practice session (although these 
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Cognitive Difficulty Scores [CDS] were not formally analysed or presented for the purposes of 
this dissertation).  
Static standing tests measure but the simplest form of balance control, and considering the 
complexities of dynamic balance involved in gait, it is difficult to directly relate the current 
findings to gait impairments. What does seem clear, is that both gait and static balance 
deteriorated when PLHIV were subjected to a dual task, and both these motor tasks thus 
indicate impaired cognitive processing in PLHIV as a contributor to motor impairment. The 
subtle COP deviations may potentially indicate an early alteration in the postural balance 
system occurring before manifestation of gross balance impairment in clinical tests, as 
previously proposed in PLHIV.323 However, PLHIV likely need more complex assessments of 
balance than single leg stance (also given the limited utility of clinical timed single leg stance 
tests noted for this cohort [Table 8.8]) to produce robust results. Tests involving dynamic 
balance or fatigued muscle states may be better suited. 
Together, the findings from static posturography in this study suggest that subtle balance 
impairments occur in PLHIV under cognitively challenging conditions, which may precede 
gross manifestation of such impairments in simple clinical tests. The findings also align the 
widely proposed impaired cognitive processing related to divided attention in PLHIV. Given the 
prevalence of fallers in this sample of PLHIV, that impaired balance in PLHIV has been 
identified as a risk factor for falls55 and that increases in COP excursion have commonly been 
associated with falls (albeit not yet proven in PLHIV), it may be that the increases in COP 
parameters in this sample had contributed to an increased fall risk. The implications are that 
balance training may be of value in PLHIV. However, more complex and dynamic balance 
testing or fatigued muscle states – both for use during posturography and as clinical tests – 
are needed to elicit meaningful results. Future laboratory studies could for example further 
investigate cortical and biomechanical factors that come into play during complex or 
unanticipated tasks in PLHIV by adding electroencephalography (EEG). Such studies may 
provide more insight into the motor planning capacity of PLHIV and its predictive value for 
adverse outcomes. 
The impairments noted in this study are subtle (as noted with ageing adults) and manifested 
under challenging cognitive-motor conditions. The use of motion analysis technology enabled 
the identification of subtleties that would remain unnoticed during clinical observation alone. 
However, the use of technology demands a thorough understanding of its associated 
measurement errors and artefacts. Whilst the validity and reliability of the established gold 
standard in motion analysis (laboratory-based optical systems) have been proven; this study 
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demanded the collection of data at the respective clinical sites in a community setting. 
Therefore, the preliminary studies (Chapters 4 to 6) were aimed at assessing the rigour (validity 
and reliability) regarding the key outcomes (gait) using a newly acquired, portable motion 
analysis system. The next section discusses the key findings related to the validity and 
reliability of the biomechanical gait outcomes selected for analysis in this study. 
9.3. Towards establishing robust three-dimensional gait 
analysis evidence in people living with HIV-1 
infection: rigour of outcomes 
9.3.1. Concurrent validity  
At the start of this project, the myoMOTION inertial motion capture (IMC) system was newly 
acquired by the Stellenbosch University (SU) Movement Laboratory. The system needed to be 
assessed in terms of its validity and limitations regarding clinical gait assessment in a South 
African population and especially regarding custom-specified outcomes (as defined in Tables 
4.5 and 4.6). It is particularly important for individual gait laboratories to establish reliability of 
its own operators and the technical limitations of the specific technology being used, along with 
the ability of the instrument to reliably measure the specific gait outcomes of interest for the 
clinical assessment at hand.326 
The main finding from Study One (Chapter 5) was that the myoMOTION highly compares to 
the VICON-Plug-in-Gait (PiG) model output after accounting for biomechanical modelling 
offsets between systems. Confirming and expanding these findings in a rural South African 
population, Study Two (Chapter 6) confirmed that the validity of myoMOTION measurements 
was not compromised in participants from a rural setting, including PLHIV and SNP. However, 
because of an inherent and consistent offset between the systems/models (largely stemming 
from the myoMOTION model’s calibration procedure, which differs from VICON-PiG as 
explained in Chapter 5), the myoMOTION and other systems such as VICON-PiG cannot be 
used interchangeably. However, these modelling offsets only affected average and discrete 
kinematic angles, and not TSPs and joint/segment ROM. Since only the myoMOTION was 
used for 3DGA in the cross-sectional field study, the kinematic offset errors for the discrete 
angles do not have serious implications for the study data in terms of comparing participants 
measured using the same system. However, it must be kept in mind that the field study data 
(particularly in terms of discrete outcomes) cannot readily be compared to data from studies 
where gait angles were measured by other systems. The implication is that follow up gait 
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analysis studies in PLHIV should carefully consider the measurement system and 
biomechanical model selected for 3DGA. The data from this study may prove useful for 
comparison to datasets obtained with the myoMOTION system, but cannot be compared to 
data from other systems when referring to absolute angles. Trends in ROM and TSPs, which 
are often better indicators of overall gait pattern, may however be comparable to other 
systems. 
9.3.2. Absolute reliability  
Schwartz et al.313 proposed two potential sources of error which may affect variability in gait 
data: intrinsic and extrinsic. In this study, potential sources of variability may have included the 
reliability of the custom-defined gait outcomes (relating to methodology and measurement), 
the new myoMOTION system itself (instrumentation) and the individual (the PhD candidate in 
this case) setting up the calibration poses (rater). 
All kinematic outcomes and TSPs showed clinically acceptable (kinematics) or 
acceptable/excellent (TSPs) within-session reliability. Because absolute reliability statistics 
such as the SEM provide results in the original unit of measurement, knowledge was also 
gained regarding the interpretation of gait outcomes in the cross-sectional field study. As 
expected, for kinematic angles, total ROM in a given movement plane was generally more 
reliable than discrete angles – this makes sense considering that the modelling differences 
dictate a different “starting” point and peak angles for each respective system, while there 
should be no reason for relative measures between these discrete angles to differ between 
systems designed to measure human motion.  
The absolute reliability noted for the myoMOTION agrees with published reports for OMC-
measured kinematic angles in the various movement planes in healthy adults.318,327 In the 
cohort of PLHIV and SNP, the myoMOTION demonstrated good reliability for all angles except 
four, namely pelvis rotation at initial contact, peak knee flexion during stance, ankle 
plantarflexion at toe-off and peak ankle plantarflexion during the gait cycle. These findings may 
indicate that some key events of the gait cycle are inherently more variable, or that the 
myoMOTION and VICON systems were both more susceptible to (and potentially affected in 
different ways by) soft tissue movement at these events. For the field study, these outcomes 
were kept in the analysis to help establish a comprehensive picture of the gait pattern. 
However, the high measurement error likely significantly affected (in clinical terms) the group 
mean values observed for each of these listed outcomes. Therefore, these angles were 
flagged as outcomes that may not represent a true between-group difference, and were 
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considered not to be true descriptors of the gait deviations noted in PLHIV. Together, results 
indicated that accepting a MCID of 5° is generally reasonable for lower limb angles (except for 
hip rotation and the four discrete variables mentioned above) when using the myoMOTION for 
3DGA.  
9.3.3. The N-pose calibration as a source of error 
The setup of the calibration N-pose for the myoMOTION was assessed as an important source 
of extrinsic error. This calibration needs to be performed multiple times within an analysis 
session with the system. It was determined that a trained rater can accurately and repeatably 
implement these N-poses. Although previous studies have assessed the repeatability of similar 
and different (i.e. functional) calibration poses,309,500 repeatability has not been investigated for 
the myoMOTION, and not many have evaluated setup accuracy. Robert-Lachaine et al.309 was 
one of the few which also assessed accuracy by defining a “perfect” pose-execution using 0°-
criteria, as was done in this study. These authors demonstrated similar sagittal plane offsets 
(especially for the pelvis) to the present study. The observed values for pelvis offset agree with 
clinically reported anterior pelvic tilt values during normal stance in able-bodied adults,501 
confirming that the biomechanical constraints of normal human posture inherently affect the 
pose, but consistently (small standard deviations) and in an anatomically feasible manner.  
This study further demonstrated clinically acceptable intra-rater repeatability for setting up all 
angles. Proper comparisons to the literature are hampered by heterogeneous published 
protocols and outcomes, but good intra-rater repeatability has generally been reported for 
setting up calibration poses, trending towards transverse angles being less so.189,309 In this 
study, N-pose setup was determined to be the major contributor in offsets noted between 
myoMOTION and VICON. Throughout the field study, the researcher (PhD candidate) was the 
only operator responsible for setting up the N-pose, which decreased the risk of inconsistency 
in N-pose setup and its effect on subsequent gait measures. Overall, the good intra-rater 
repeatability noted for the N-pose setup, and the good within-session reliability of the 
myoMOTION support the use of this system across multiple participants or sessions. The gait 
impairments noted in PLHIV using this system, including parameters included in EGVI 
calculation, may be considered to be of scientific rigour.  
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9.4. Towards understanding potential implications: 
public burden and rehabilitation considerations 
9.4.1. Burden implied by the participant profile 
Despite to some extent reflecting the profile of South African PLHIV (for example in terms of 
age, gender and employment rates),36 many factors hinder the generalisability of findings from 
this study to clinical settings in the larger South African context. On the other hand, some such 
factors may render the study findings more representative to the Cape Winelands or Western 
Cape, which is beneficial for drawing context-specific conclusions. Nevertheless, the profile of 
PLHIV who participated in this study does shed light on the complexity of chronic HIV and its 
potential consequences in a cohort where motor impairments persist, despite HAART. 
9.4.1.1. Economic implications 
This study revealed rigorously-measured locomotor impairments in a relatively young, 
economically-active group of PLHIV – of which almost half were unemployed. A young age 
group presenting with impairments represents a potential increase in economic burden on 
households and at community level. A recent study by Jakubowski et al.502 indicated that 
PLHIV in Sub-Saharan Africa were more likely to have lost time from work due to illness and 
have incurred additional healthcare expenditures – these effects were linked to CD4+ count. 
The addition of movement impairments to systems already weakened by HIV disease factors 
may compound these effects.   
The fact that more woman in South Africa are affected by HIV-1 infection36 (being both 
physiologically and socially vulnerable to the effects of the disease) may also hold true in this 
study, as more than half of PLHIV were women (Table 8.1) (although this may also reflect the 
fact that women are more likely than men to attend clinics). Nevertheless, this phenomenon 
further shifts the burden of HIV-1 in terms of household dynamics, and children may also be 
affected. When women (being the main cares or even the head of household) suffer ill health 
and eventually become physically impaired, children may have to leave school prematurely to 
care for ill parents. At the same time, these households have to deal with the economic impact 
of a loss of income from the parent, or increased costs of healthcare utilisation (e.g. transport 
costs).36 
Addressing morbidity by early targeting of the gait and balance impairments existing in PLHIV 
can ultimately yield substantial economic gains to the community and perhaps South Africa, 
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due to reduced healthcare utilisation and improved economic outcomes for vulnerable 
populations. Further studies need to confirm the potential of rehabilitation to reduce the 
economic impact and improve the well-being of all PLHIV in South Africa by including larger, 
more diverse samples, which may also allow for subgroup analyses. 
9.4.1.2. Health resource implications: 
The participant profile noted in this study illustrates the complex nature of chronic HIV. 
Participants suffered from many comorbidities such as depression/anxiety, chronic pain and 
potentially cognitive dysfunction. Many of these comorbidities have been associated with 
adverse outcomes such as functional decline – this escalates the effect that movement 
impairments may have on mobility function in PLHIV.   
Young-to-middle-aged people suffering from movement impairments, comorbid to chronic 
conditions such as HIV-1 infection, may potentially decline even further in function as they live 
and age with these impairments. The implication is that long-term chronic health and 
rehabilitation care will be needed. Chronic care models have not yet been fully developed in 
South Africa.63 This highlights the need to identify and effectively address movement 
impairments and confirms the need for research such as the current study. 
9.4.2. Rehabilitation considerations 
9.4.2.1. Health promotion 
A healthy lifestyle should be promoted among PLHIV by physiotherapists and other health care 
workers, but this may go beyond the obvious. Adherence to HAART is vital for the treatment 
to effectively suppress viraemia, and should thus be improved. Research regarding HAART 
adherence has indicated that predictors and risk factors are region-dependent, behoving 
context-specific development of non-adherence profiles.503,504 In resource-limited settings 
including South Africa, functional limitations, physical inactivity, chronic pain and reduced 
quality of life are amongst the factors associated with non-adherence to HAART,7,505 
emphasising the importance of addressing such risk factors in South African PLHIV and that 
physiotherapists may be very well suited to promote HAART adherence and prevent further 
secondary complications – given that these risk factors may at least in part be modifiable by 
rehabilitation.506  
The sample in this (field) study had a relatively low CD4+ T-cell count (below 500 cells/µL, 
Table 8.5). Although almost all PLHIV were using HAART for at least six months or more, less 
than half had viral loads below the limits of detection. This observation may partly be due to 
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the fact that about a fifth of PLHIV in this sample reported non-adherence to HAART (Table 
8.5) (which may even have been an underestimation, since these data are based on self-
report). Together, increased chronic pain levels, lower cognitive function, more anxio-
depression symptoms and more self-reported mobility problems may explain these non-
adherence statistics. In the general population, it is known that chronic pain can lead to a 
vicious cycle in those affected, where avoidance of physical activity may lead to increased 
disability due to immobility and atrophy.507 Interestingly though, it has been shown in South 
African PLHIV that chronic pain did not lead to the expected impairments in activity, and that 
PLHIV may suppress the effects of pain on activity due to a fear of stigma as well as financial 
stresses.508 This would explain the observation that 44% of PLHIV in this study reported 
relatively high levels of physical activity despite also reporting chronic pain. However, almost 
90% of PLHIV did not meet requirements for moderate physical activity (Table 8.3). A 
concerning finding by Hanass-Hancock et al.40 was the observation of an association between 
HAART adherence and mobility. This finding suggested that people with mobility limitations 
may experience barriers when accessing healthcare or, alternatively, that poor adherence is 
associated with developing mobility problems. Physiotherapists need to be aware of the many 
risk factors for mobility disability which may co-exist in PLHIV and the importance of effective 
interventions aimed at promoting and improving physical activity and overall mobility in a 
complex population. 
9.4.2.2. Prevention 
In the general population, fall prevention (primary and secondary) is a critical health and 
prevention issue regarding the care of older adults.494,509 The risk factors for falls are manifold, 
and many may be modifiable (e.g. impaired balance, muscle weakness and polypharmacy). 
Evidence suggests that fall risk increases with the number of risk factors; therefore, 
multifactorial interventions are advocated as effective strategies to reduce functional decline 
and prevent the associated burden of complications such as falls.509 
Fall risk is usually not a concern in the average younger person – for example, a 36-year-old 
would not routinely be screened for fall risk. However, fall prevention may be of importance for 
younger individuals living with HIV. Not only are these people at a higher risk of falling (for 
example, a third of the young-to-middle-aged cohort of PLHIV in this study reported having at 
least one fall in the previous year, Table 8.6) but they may also be more likely to sustain a 
fracture when falling. This is due to the reduced bone mineral density commonly noted in 
PLHIV, as also demonstrated in this study (Tables 8.2 and 8.6). Fall prevention must become 
a priority among health care workers dealing with PLHIV. 
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Although the risk factors for falls amongst PLHIV are still being investigated, they do not 
necessarily seem unique to PLHIV or directly related to HIV disease markers (see Chapter 2, 
Section 2.5) – with common risk factors for falls in PLHIV including frailty, peripheral 
neuropathy, slowed gait, impaired balance, multimorbidity, and polypharmacy (Chapter 2, 
Section 2.5). The current sample demonstrated gait and balance impairments as already 
discussed, with a third of PLHIV also reporting nonantiretroviral polypharmacy and 8% 
reporting multimorbidity (Table 8.4). Falls pose a particular concern for PLHIV because of the 
prevalence of reduced BMD (almost 60% of PLHIV in this study suffered from either 
osteopaenia or osteoporosis).  
It may be worth extrapolating from the high-quality evidence existing for the elderly that has 
recommended multifactorial risk assessments and screening to identify those at risk of falling, 
and specifically target risk factors existing in PLHIV as part of a tailored falls prevention 
programme (see also Section 9.4.2.3 below regarding the potential value of early screening in 
PLHIV). A systematic review494 found strong evidence for the use of the Five-Times Sit-To-
Stand (5STS) Test and gait speed assessments to predict falls among community-dwelling 
older adults. The review also supported the predictive value of laboratory-based assessments 
of postural sway and gait variability. Further investigating and incorporating such evaluation 
tools into comprehensive assessments of PLHIV may contribute towards improved falls 
prevention in this population and interventions in this younger population may need to 
specifically target intrinsic risk factors, such as mobility, strength/power, gait, and sensory 
impairment. 
9.4.2.3. Early screening and rehabilitation 
Early screening for motor impairments in PLHIV will make prevention and treatment 
rehabilitation more effective. Based on the findings from this study, the 5STS test is 
recommended for identifying physical impairment in PLHIV. This test is useful but not yet 
definitive. It is thus recommended as a test worth investigating further.  
The recommendation of the 5STS test is based on the fact that this test (i) significantly correlated 
with quantitative, self-reported and fall-related outcomes in PLHIV and (ii) showed a high 
prevalence of impairment in PLHIV relative to SNP. It is especially important in a culturally-diverse 
country such as South Africa – with substantial inequalities and varying disease profiles between 
geographical regions510 – that low-cost and pragmatic rehabilitation measures should be validated 
in context. Such evidence-based measures have the potential to contribute to cost-effective 
optimisation of rehabilitation outcomes.60,510 It is important to note the limitations of the 5STS test 
at this early stage as a screening tool, and not a predictive measure or diagnostic tool. Screening 
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tests should be followed up by more targeted assessments and rehabilitation. As evident from 
the biomechanical findings and associated logical inferences discussed earlier in this chapter, 
interventions focusing on improving balance, lower limb muscle function and bone density may 
be most beneficial for PLHIV. However, we do not know at present whether the biomechanical 
impairments observed in PLHIV are reversible, and longitudinal follow up studies are needed 
to confirm this and make more conclusive recommendations.   
In recognition of the dearth of high-level evidence regarding rehabilitation interventions for 
PLHIV, O’Brien et al.170 recently compiled evidence-informed recommendations providing a 
guideline for rehabilitation with older adults living with HIV. More research is however required  
– and specifically for younger cohorts. The authors note that combining the areas of 
rehabilitation, HIV-infection and disability will enable further development of evidence-informed 
recommendations relevant to rehabilitation in the context of HIV-1 and contribute towards 
actionable recommendations to inform future practice. 
9.4.2.4. Education 
The International Classification of Function (ICF) is increasingly advocated as an overarching 
theme in the management of PLHIV.37,511 Understanding HIV-associated impairments, 
functional limitations and participation restrictions is vital for effective rehabilitation.23 While 
clinicians mostly manage the diagnosis and medical treatment of health conditions, functional 
ramifications and activity limitations have been reported to be a bigger priority to South African 
PLHIV in terms of participation and livelihood40 and can only be mitigated through rehabilitation 
strategies. Physiotherapists need to be aware of movement and gait impairments with 
potentially serious functional consequences in PLHIV, and need to expand their skill sets to 
assess and manage such patients. Current South African statistics imply that every eighth 
patient seen by physiotherapists (or by physiotherapy students) in South Africa may also be a 
person living with HIV-1 infection.36 In order to enable therapists to maximise functional 
outcomes in these patients, physiotherapeutic education programs (undergraduate as well as 
postgraduate) therefore need to shift the focus from a mostly biomedical approach (for 
example focusing on the pathology of HIV-1 infection) to a more rehabilitation-focused 
approach (for example the potential mobility problems associated with the condition, their 
consequences and potential treatment approaches – see also Figure 2.2 of how the ICF 
applies). The new knowledge regarding biomechanical impairments in PLHIV, as well as the 
risk of falls and the potential value of early screening, should be incorporated in undergraduate 
training, Continuous Professional Development (CPD) courses and other training workshops 
(potentially also including other healthcare workers).   
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LIMITATIONS  
The studies included in this dissertation have limitations that should be considered when 
interpreting the findings of the research. The limitations of the systematic review are included 
in Chapter 3 and thus not presented here.  
10.1. Limitations of the validity and reliability studies (Chapters 4 to 
6) 
• Although VICON-Plug-in-Gait (PiG) served as the reference standard, the system is 
susceptible to faulty marker placement.354,512 Nevertheless, marker placement was 
performed by the same laboratory-trained physiotherapist (the PhD candidate) throughout 
both laboratory-based studies, and participants with above-normal body mass index (BMI) 
were excluded from this project, which likely limited these effects.  
• The measurement of gait biomechanics by the myoMOTION was only assessed under 
usual-paced conditions, which may specifically limit interpretation of the fast-paced data 
collected in the field study. Due to some participants demonstrating very slow gait speeds 
in the laboratory studies, observations regarding anticipated difficulties could be made 
regarding performance at such slow speeds. Difficulties were mostly related to missed 
event detection resulting in invalid or missed gait cycles, due to the fact that gait cycle 
detection by the myoMOTION involves the definition of peak angular velocity events. This 
observation affected data analysis for the field study to some extent as some trials with 
missed events were identified (n = 2). Unfortunately, the system’s performance under fast-
paced gait conditions remains uncertain and would most likely be affected by inertial 
measurement unit (IMU) movement. However, all field-study participants were of normal 
BMI and care was taken to securely fixate IMUs to the various body segments. 
Considerations regarding the tasks assessed in the laboratory-based studies were also 
made in the light of what was deemed pragmatic and reasonable regarding the time that 
the participants, who were transported from Worcester, had to spend in the motion analysis 
laboratory. 
• Soft tissue artefact (STA) differences between systems were not specifically controlled 
(quantified). However, it may be argued that it is redundant to differentiate STA from 
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calibration errors for very small dynamic differences, as the combined STA- and calibration 
error was already below 5°.  
• Between-day test-retest or inter-rater reliability was not investigated. However, reliability in 
terms of repeated IMU-placement is probably at least as good as the reliability of OMC 
marker-placement, since IMUs require no accurate placements or anatomical landmark 
identification. In addition, only one operator was involved throughout the project, and each 
participant was measured on one occasion only. 
• A conservative approach was implemented to remove the average offset between 
waveforms estimated by the myoMOTION and VICON systems/models. Had a matrix 
approach been adopted, and segment rotations of the myoMOTION model been changed 
to adjust for modelling differences, more of the between-system error would have been 
compensated for. However, this is a complex and time-intensive method and was beyond 
the scope and pragmatic restraints of the current dissertation. The approach we adopted 
was considered sufficient for reliably illustrating the point that the differences in the system 
outputs are dominated by calibration offsets and not by IMU tracking, and that data 
provided by the system remains clinically usable. Removing the error even more strictly 
would in fact strengthen this point even more and is reserved for further analysis at a later 
stage.  
• Both validity and reliability studies included predominantly female participants. However, 
these distributions also reflect the situation in the cross-sectional field study, and the 
influence of gender on gait kinematics are not well established (most evidence existing for 
some differences in coronal plane kinematics).314,441  
• Estimates are limited by the small sample size, especially in the second study (Chapter 6). 
However, the magnitudes of measures of agreement, offset and reliability were similar 
within PLHIV and SNP groups, implying that the presence of HIV-1 did not affect the 
comparison between systems.  
10.2. Limitations of the cross-sectional field study (Chapters 7 to 8) 
• Findings of this study cannot be extrapolated to clinical settings in other provinces of South 
Africa. However, this limitation also reflects a strength as this sample is to a large extent 
representative of the HIV-seropositive population living in the Western Cape of South Africa 
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and thus provides context-specific evidence for use of the 5STS test in rural primary care 
clinics.  
• It was decided not to apply Bonferroni corrections due to the strong correlations existing 
between individual gait variables,457,513 and the fact that gait outcomes were pre-planned 
in this study. However, potential chance findings of statistical significance due to a Type I 
error cannot be excluded. To address the problem of a potential chance finding, 
relationships between gait outcomes that demonstrated to be statistically significantly 
different between groups were examined for clinical feasibility and described in the context 
of the other significant angles and TSPs. The rationale was that it would be unlikely for a 
chance finding of significance to be associated with significant differences in its contributing 
variables. 
• Despite inflating the calculated sample size to 50 per group, missing trials for various tasks 
still led to a smaller number of outcomes being available for some analyses. For example, 
the dual task paradigm was only introduced later during the data collection protocol, after 
noting the importance of cognitive factors in PLHIV, along with the realisation that verbally-
instructed fast walking may not be a reliable method.451 Therefore, dual task data was only 
available for 41 PLHIV and 47 SNP. The impact of the late introduction of the dual task 
condition was even more apparent for static posturography data. In addition to the 12 
participants for whom no such data were collected, one SNP had invalid dual task trials 
due to constant foot shuffling, two PLHIV had invalid trials due to shuffling and one PLHIV 
was unable to perform single leg standing under the dual task condition (unsafe). Dual task 
data were thus only available for 45 SNP and 40 PLHIV.  Similarly, enhanced Gait 
Variability Index (EGVI) scores were calculated in only 42 PLHIV and 37 SNP for the usual-
paced condition, and in 40 PLHIV and 33 SNP for the dual task condition. EGVI calculation 
requires a minimum of five absolute differences (at least 13 consecutive steps per 
trial),372,375 which necessitated the exclusion of some participant datasets. This was mainly 
the consequence of the myoMOTION system failing to detect consecutive gait events 
under very slow gait speeds. It was additionally decided not to calculate the EGVI for fast-
paced gait, due to problems with many participants not having enough valid consecutive 
(as opposed to total) strides per limb within a trial. Calculating the EGVI for this condition 
would thus not have yielded a valid outcome in terms of gait variability for comparison.  
• Verbal instructions were provided to participants to walk as fast as they could (as if trying 
to catch a bus or taxi) in order to assess fast (maximum) walking speed. Compared to using 
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a metronome, for example, it was hoped that this method would facilitate more natural gait 
patterns at each speed. The reliability of this verbal instruction may be questioned in terms 
of truly eliciting the participants’ maximum effort.451  
• Centre of pressure (COP) data were only analysed for the dual task condition for the 
purposes of the current thesis – based on the results from the systematic review in Chapter 
3 (that single leg stance differences only became apparent in more challenging conditions) 
and due to the fact that an eyes-closed single leg stance task may be too difficult and 
variable to reveal meaningful differences between groups.514 Indeed, only 22 SNP and 
seven PLHIV were able to complete the full 30-second trial with eyes closed without 
shuffling, despite being allowed a practice attempt. Shorter time intervals from this 
condition will be analysed at a later stage, but for the purposes of this dissertation it was 
decided to present the zero- to 30-second time interval (full trial data) as this would provide 
the most meaningful data for COP outcomes390 and would enable comparison to previous 
studies performed in PLHIV.3,33,113 Thus, the dual task condition, maintained for 30 
seconds, was deemed sufficient to elicit between-group differences in COP parameters 
and therefore to answer the research question. 
• The reliability of the MatScan pressure mat was not tested specifically in the sample 
participating in this study. Unlike the myoMOTION, the MatScan is a widely used tool in 
research which has been proven to be valid and reliable for assessing the task at hand 
(single leg stance) and well as the basic COP parameters assessed in this study. Although 
not assessed specifically in PLHIV, these previous findings were noted in healthy adults 
as well as older adults. The movement of PLHIV was not expected to be vastly different 
from these populations and there was no reason to suspect that the device would be 
unreliable for measuring a simple task of static balance in PLHIV, using traditional/standard 
outcomes. Furthermore, the MatScan has proven useful in PLHIV before.321–324 
Nevertheless, this limitation should be kept in mind when interpreting the results from the 
static posturography since the measurement errors for COP velocity and excursion were 
not determined for intrinsic variability existing in this specific sample.  
• Static balance was quantified simplistically, using basic traditional COP parameters, as has 
mostly been done in PLHIV. The ecological validity of these outcomes and the static 
posture is questionable, since single leg stance constitutes the simplest condition of 
postural control and the selected outcomes only address a small subset of the full balance 
repertoire. In addition, the fact that the single best effort trial out of three attempts was used 
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per participant may have led to some participants only achieving the successful trial in the 
third try, allowing a degree of habituation that does not occur when individuals suddenly 
lose their balance in daily life. Furthermore, the number of response strategies available to 
participants was restricted, i.e. by instructing participants to respond with foot-in-place (no 
shuffling or hopping allowed) and with arms crossed in front of the chest. The purpose of 
asking participants to cross their arms was to account for possible substitution efforts in 
maintaining balance with arm movements during testing.467  
• Given the relatively low levels of formal education in this sample, a backwards counting 
task using units of three proved to be appropriate for most, but not all participants. 
Therefore a methodology as proposed by Swanenburg et al.187 was adopted, to determine 
a suitable level of difficulty for each participant. However, it may have been that the task 
was still too difficult for some, resulting in performing the primary task (e.g. walking) whilst 
discarding the secondary task (i.e. counting) without any attempt to perform this second 
task accurately (e.g. careless and random counting). This was observed and addressed in 
a couple of participants; however, such cases may still have occurred without the 
researcher noticing and may have mitigated the effect of the dual task. 
• Fall outcomes were based on retrospective self-report of events by participants, which may 
have resulted in an underreporting of falls, especially in those with cognitive impairment 
(e.g. forgetfulness). However, within the limitations of the study timeframe, prospective 
data collection was not possible.  
• Despite initial attempts, it was not possible to match participant numbers on gender and 
age. The study was heavily dependent on the demographic of the participants that were 
also participating in the EndoAfrica study. Although it was initially envisioned to only use 
participants who were also enrolled in the EndoAfrica cohort, it became apparent that this 
methodology severely limited timely recruitment for the current study. In addition, many of 
the participants were already affected by a large appointment burden. The protocol was 
therefore amended to also include participants from the local community that were not 
participating in the EndoAfrica study, and the Paarl site was additionally added for data 
collection. However, these issues ultimately led to unequal age and gender distributions 
between PLHIV and SNP. These factors were controlled for statistically during data 
analysis of the biomechanical and clinical performance outcomes. 
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• Large numbers of steps are usually required for the accurate estimation of stride-to-stride 
variability.237 This study used a limited number of steps, i.e. the absolute minimum required 
for calculating the EGVI. Larger numbers of steps are likely to provide more reliable results. 
Despite the portability offered by the myoMOTION system, available private space for gait 
analysis was still constrained at the clinical venues. The number of steps used in this study 
was the maximum that could be performed within these limited spaces.   
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RECOMMENDATIONS 
The research contained in this dissertation provides novel findings and presents a good 
foundation for future research. Based on the findings of the various studies, the following 
recommendations are made: 
• To expand the use of the myoMOTION to populations with higher body mass indices (BMI), 
the effect that soft tissue artefacts (STA) may have on the measurement error of the 
myoMOTION needs to be established. Determining the psychometric properties of this 
system for higher BMIs would expand its usability among a wider population of people 
living with HIV-1 infection (PLHIV), who are also susceptible to obesity in the modern-day 
HAART era. 
• The individual contribution of error sources to the validity of the myoMOTION should be 
further investigated by using a matrix approach to control for the biomechanical model 
differences. For example, raw signals from the myoMOTION can be used to align the local 
coordinate systems of the myoMOTION and VICON-PiG systems based on angular 
velocities during a 3D motion.515  
• Due to the cross-sectional study design of the field study, no conclusions can be drawn 
regarding causality. Future high-quality prospective cohort studies are needed to establish 
whether HIV-1 leads to the development of biomechanical impairments at early ages, and 
whether the Five-Times-Sit-To-Stand (5STS) Test is a predictor of adverse outcomes 
including falls, which may either be addressed early in rehabilitation, or treated as 
preventative factors in at-risk PLHIV. 
• Future studies should determine whether the biomechanical impairments noted in PLHIV 
are reversible following rehabilitation, which may be targeted at improving cognitive-motor 
function (e.g. cognitive training) and/or restoring a flexible gait pattern and a faster gait 
speed. However, care should be taken when implementing the latter approach before the 
underlying contributing factors to the kinematic deviations have been determined, including 
how these may relate to fall risk. The fact that PLHIV were able to tap into resources and 
walk with a pattern similar to SNP at a fast pace may imply that the noted gait impairments 
may be reversible. On the other hand, if fast walking and longer strides place PLHIV at a 
higher risk for falling due to exceeding their maximal threshold for safe walking, simply 
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altering these potentially compensatory parameters without addressing factors such as 
dynamic balance or inflexibility may actually increase their fall risk. Future studies should 
ascertain whether assuming a more normal pattern kinematic pattern and walking at a 
faster pace requires more effort from PLHIV, whether fast walking can be maintained with 
a normal kinematic pattern for extended periods of time, and whether fast walking with 
larger stride lengths increases fall risk in PLHIV. 
• This study can only speculate about the neuromuscular patterns involved in the gait of 
PLHIV, such as impaired force and activation of lower limb muscles. An understanding of 
such patterns would be valuable and may guide the development of targeted rehabilitation 
strategies. Future studies should include comprehensive gait analysis protocols involving 
kinetics and electromyography (EMG) in PLHIV. 
• The HIV-related reasons underlying the observed biomechanical impairments and poor 
chair rise performance can only be theorised in this cross-sectional study. Future 
appropriately-powered analyses of association involving sub groups according to HIV-
specific and other clinical characteristics should be conducted to gain further insight. Such 
analyses would also reveal the ability of the 5STS to discriminate high-risk groups for poor 
performance within PLHIV, and the determination of relevant cut-off scores would yield the 
test more suited specifically to PLHIV, as opposed to basing interpretation on cut-offs 
determined in older adults. 
• The value of the 5STS to screen for self-reported problems related to quality of life domains 
may warrant its use as a measure of treatment outcomes in PLHIV, in terms of functional 
performance and quality of life. Future research should ascertain the ability of the 5STS to 
serve as a measure of monitoring treatment outcomes over time in PLHIV.  
• It would be of value to explore knowledge among South African physiotherapists and other 
first contact health care workers in primary care settings regarding the risk of specific gait 
and balance impairments in PLHIV, and the fact that fall risk may be increased. Data on 
referral patterns and utilisation of physiotherapy services, as well as the manner in which 
(if at all) the physiotherapeutic management of PLHIV are tailored towards high-risk 
patients would highlight areas that need to be addressed and incorporated in practice and 
policy. 
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• Relating to the previous point, awareness should be increased amongst South African 
physiotherapists and health professionals regarding the locomotor risks, including reduced 
bone mineral density and increased fall risks, which may occur in relatively young PLHIV. 
It may be of value to incorporate a quick, simple, no-cost tool such as the 5STS test as 
part of a standard assessment of PLHIV by first contact practitioners, with referral for 
rehabilitation and fall risk management (if the screening was not done by the 
physiotherapist themselves). Physiotherapists should also consider to screen PLHIV who 
consult them for other reasons (such as lower back pain) using the 5STS test. It must be 
emphasised that the test remains a screening tool to guide further intervention or testing, 
and should as such be followed up with appropriate methods such as manual muscle 
testing. Such assessment may suggest additional impairments that need further specific 
testing and treatment. This dual approach may restore or maintain normal function and 
prevent functional decline. 
• This study suggests that the 5STS assessment may be a more valid test than the full PPB 
for screening for locomotor impairment in PLHIV, due to the high ceiling effects noted for 
the balance component of the full battery. This is a valuable finding, because it supports 
the use of the 5STS test when time and space is limited in clinical settings. However, use 
of the full PPB or the Six-Minute Walk Test in particular may still be of value in 
understanding PLHIV’s experience of their mobility problem. It seems that these tests may 
also be more useful in older cohorts and should thus be assessed as such in future 
research. Clinically measured gait speed in particular may remain an important indicator of 
functional decline in PLHIV aged 50 years and older.58 
• Regarding postural stability, future studies should implement complex and dynamic 
balance testing or fatigued muscle states to elicit meaningful results. Future laboratory 
studies could also investigate cortical and biomechanical factors that come into play during 
complex or unanticipated tasks in PLHIV by adding electroencephalography (EEG) to the 
protocol. Such studies may provide more insight into the motor planning capacity of PLHIV 
and its predictive value for adverse outcomes. 
• The 5STS test as a stand-alone screening test revealed moderate correlations with 3D gait 
analysis and clinical outcomes. The search thus needs to continue for ways to render this 
test more sensitive to subtle gait and balance impairments in PLHIV. Adding a dual task to 
the testing protocol may be one option.      
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CONCLUSION 
HIV-1 is now a chronic condition. Not only is one in every eight South Africans living with the 
disease, but HIV-1 infection is also the number one cause of years lost to disability in the 
country. The virus itself, associated comorbidities and highly active antiretroviral therapy 
(HAART) (despite its success in prolonging life) are associated with impairments and declines 
in function that may develop into disability. South African rehabilitation professionals are faced 
with a larger, working-aged and evolving number of people living with HIV-1 infection (PLHIV) 
who are at risk of functional decline and need to consider the potential impact of HIV-1 on the 
rehabilitation system. Motor impairments have been noted in PLHIV since the virus was 
discovered, and remain a concern in the modern treatment era. Functional performance 
related to the lower limbs and walking ability is a particular concern in PLHIV. While the motor 
system is clearly affected by HIV-1, the literature regarding gait and balance impairments 
largely focuses on self-reported outcomes or clinical performance tests. Thus, a poor 
understanding of exactly why and how the motor system is affected, remained. This study 
found that PLHIV present with a slowed and less adaptable gait, and that biomechanical 
deviations exist in the presence of a dual task. These deviations resemble the biomechanical 
plasticity noted in elderly gait. In addition, PLHIV demonstrate postural stability deficits 
(increased centre of pressure excursion) whilst performing a dual task. The study further shows 
that the Five-Times Sit-To-Stand (5STS) Test is the most valid clinical test to screen for early 
gait deviations in a clinical setting. These findings were noted in a relatively young group of 
PLHIV, of which a third reported one or more falls during the past year. The findings not only 
improve understanding of the gait and balance of PLHIV, but also highlight the need to screen 
young-to-middle aged PLHIV for motor impairments by integrating standardised clinical tests. 
However, while the 5STS test is suggested as a potential screening tool for existing 
impairments, it remains unknown whether the test is predictive of falls, or whether the 
impairments screened for in PLHIV are reversible. In addition, whilst kinematics provide some 
insight into the basic gait pattern adopted, kinetic analyses will provide more information 
regarding the neuromuscular patterns. More research, especially clinical trials and follow-up 
studies, is needed to address these issues and to establish an empirical evidence base for 
recognising the importance of secondary prevention of motor impairments in PLHIV on a policy 
level. Identifying and addressing such impairments at an early stage can ultimately yield 
substantial economic gains due to reduced healthcare utilisation amongst PLHIV who will be 
living well into old age with this complex condition.  
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APPENDIX A: 
Ethics approval 
 
 
Approval Notice
Response to Modifications- (New Application)
04-Mar-2016
Berner, Karina K
Ethics Reference #: N15/05/043
Title: Biomechanical analysis of specific motor impairments contributing to functional decline in adults with HIV/AIDS.
Dear Mrs Karina Berner,
The Response to Modifications - (New Application) received on 11-Dec-2015, was reviewed by members of Health Research Ethics Committee 2
via Expedited review procedures on 04-Mar-2016 and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: 04-Mar-2016 -03-Mar-2017
Please remember to use your protocol number (N15/05/043) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
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APPENDIX D: 
Informed consent form (first validity and reliability study: 
Student and staff volunteers) 
 
TITLE OF THE RESEARCH PROJECT:  The validity and reliability of the 
myoMOTION inertial motion capture system when measuring walking gait in HIV-
seropositive as well as HIV-seronegative adults 
 
REFERENCE NUMBER: N15/05/043 
PRINCIPAL INVESTIGATOR: Karina Berner, Doctoral Candidate  
ADDRESS: Division of Physiotherapy, Department of Interdisciplinary Health Sciences, 
Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, Cape Town, 8000 
CONTACT NUMBER: 021 938 9667 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
The aim of this study is to determine the precision and accuracy (reliability and validity) of a 
new three-dimensional motion analysis system (myoMOTION inertial motion capture system) 
recently acquired by the SU Central Analytical Facilities (CAF) 3D Human Biomechanics Unit.  
The performance of this system will be tested against the current reference standard, namely 
the VICON camera system, using about 24 HIV-negative and 8 HIV-positive adults.  This study 
is the first phase of a bigger project, and the reason we are doing this study is to determine 
whether the myoMOTION system will be a suitable tool for use in the next study phase.   
This study will be conducted in the CAF 3D Human Biomechanics Unit, Tygerberg Medical 
Campus.  You will be responsible for your own transportation to and from the testing facility. 
 
You will be asked to perform six to 10 normal walks along a measured walkway in the motion 
laboratory, while the two systems record you simultaneously.  For this, you will need to change 
into shorts and a sleeveless sports top (females)/no shirt (males) and remove your shoes.  A 
physiotherapist will measure your weight and height beforehand, as well as the range of motion 
of your joints.  Before performing the walks, small reflective markers and motion sensors will 
be stuck to certain areas of your body using special double-sided tape.  These will be removed 
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after testing.  The expected duration of the entire testing session per participant (excluding 
transport to and from campus) will be about 90-120 minutes and will be scheduled at your 
convenience.  Four participants will be tested per day, over a course of eight days (a total of 
32 participants). 
Why have you been invited to participate? 
You have been invited to participate in this study because you responded to our advertisement 
and is an able-bodied adult that met the specific inclusion criteria.   
What will your responsibilities be? 
• You will be asked to go for confidential HIV-testing (available at Tygerberg Campus 
Health Services) at a time convenient for you (any time prior to the biomechanical 
analysis session), to confirm your status as HIV-negative. 
• You will be expected to be available on the agreed-upon testing time (only one testing 
session is required per participant). You will also be responsible for your own transport 
to and from the testing facility. 
• Woman will be asked to put on a sports top and shorts (that will be provided) and men 
will only wear shorts. We will then measure your weight and height, as well as the range 
of motion of your lower limb joints using a non-invasive measurement tool (goniometer).   
• Small sensors will be put on your skin by means of a double-sided sticker. You will then 
be asked to walk up and down an area of 10 metres. In-between you will be asked to 
hold a static standing posture while the two systems calibrate. Only you and two 
researchers will be in the measurement area while you are walking. After the walking 
measurements have been completed, the sensors will be removed and you can put 
your own clothes back on. 
 
HIV testing 
As part of this research study, you will be asked to undergo an HIV test. Before agreeing to 
participate, it is important that you read and understand the following explanation of the HIV 
testing.  You may not participate in the study if you decide not to go for the HIV test. However, 
the result of this test will not only determine whether you are suitable to continue with the 
research study, but could also have a profound influence on your health and lifestyle. 
• Purpose 
The purpose of the HIV test is to exclude any persons who are HIV-positive from this 
particular group of study participants, as HIV may influence the way that a person walks.  
• Procedure 
The HIV test will be done on a sample of blood drawn from your arm or obtained via a 
finger prick (rapid test). The test can detect antibodies that your immune system makes 
when HIV is present. The HIV antibody test is used to determine of you have been infected 
with HIV. An HIV test is extremely accurate if performed three months after exposure.  
 
A negative test means that it is extremely unlikely that you are infected with HIV.  If you 
had a recent expose (less than three months), an HIV test will need to be repeated to 
assure that you are not in the “window” period of HIV infection before the antibodies are 
present. 
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A confirmed positive test means that it is very likely that you have been infected with HIV. 
This test does not determine how advanced the illness is and is it not a test for AIDS. 
Medical care and additional testing will be needed to help plan treatment. If you test is 
positive, you may not continue as a participant in the study. You will be referred to an 
appropriate medical clinic for further testing and counseling.   
 
If you test positive, you will not have any recourse to the researchers or study site for 
compensation or treatment.    
 
• Advantages and disadvantages of HIV testing 
Advantages may include: 
- Making yourself available to healthcare and counseling for HIV which has many 
benefits 
- Preventing the transmission of HIV to your sexual partners 
- Informing your partner so he/she can also prevent the spread of HIV 
- Avoiding blood donations 
- Preventing mother to child HIV transmission 
 
Disadvantages may include: 
- Emotional stress, depression and despair 
- Stigmatisaion 
- Discrimination 
- Rejection by family, friends, sexual partners and/or spouse 
 
These advantages and disadvantages should be carefully considered before signing the 
consent form. 
Will you benefit from taking part in this research? 
Although there are no personal benefits from taking part in this study, it will help us determine 
the validity and reliability of the new technology, so that it may be used in the next study phase.  
This next phase will involve using the new system in clinics to analyse the movement of adults 
living with HIV/AIDS, so that any impairments may be identified and a suitable screening test 
be selected for this population.  Your participation in the current study will therefore benefit 
future patients. 
Are there in risks involved in your taking part in this research? 
Taking blood from your arm for the HIV test may cause bruising, infection, fainting, pain, or 
discomfort. All normal precautions will be taken to keep these side effects from happening. 
If you do not agree to take part, what alternatives do you have? 
Not applicable – no treatment is involved in this study. 
Who will have access to your medical records? 
Information gathered will be treated as confidential and shared only between the researchers 
involved. Any information of yours used in the thesis or subsequent publications will remain 
anonymous.  
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• Confidentiality of HIV testing 
 
Your HIV test results will be matched to your name by a unique participant code assigned to 
your blood specimen – in this way, your identity will be protected.  The test result will be kept 
confidential and only selected health-care providers will be informed on a need-to-know basis 
– this will include the principle investigator (KB) and any practitioners nominated by yourself. 
 
Your HIV testing information and test results cannot be released to anyone without your written 
consent. A general consent for health care and information release does not cover HIV-related 
information.  If you are found to be HIV-positive, you are not required to personally tell anyone 
about this diagnosis. However, it is very important to notify your sexual partners and those that 
might have been exposed to your blood. 
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
It is unlikely that any injury will occur as a result of taking part in this study. 
 
 Will you be paid to take part in this study and are there any costs involved? 
You will receive compensation valued at R100 (e.g. grocery shopping voucher) for your time 
and effort to undergo HIV-testing.  There will be no costs involved for you if you do take part in 
this study. In the event of a positive HIV test, you will be responsible the costs of any ongoing 
medical care and support. 
 
Is there anything else that you should know or do? 
Ø You can contact Ms Karina Berner at 021 938 9667 / (email address) if you have any 
further queries or encounter any problems. 
Ø You can contact the Health Research Ethics Committee at 021 938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your 
researcher. 
Ø You will receive a copy of this information and consent form for your own records. 
Ø  
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled “The validity and reliability of the myoMOTION inertial motion capture 
system when measuring walking gait in HIV-seropositive as well as HIV-seronegative 
adults”. 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I agree to have blood drawn in order to undergo an HIV test as described before in 
order to determine my suitability for participation in this clinical study.  I understand 
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that until my HIV status have been confirmed as being HIV-negative, my 
participation in the study is not guaranteed.  
• I do not consider myself to be in a high-risk group for contracting HIV and have no 
reason to believe that I have been previously exposed. 
• I understand I will be informed of the results of the test in confidence, and that I will 
be advised regarding further counseling and care, should the result be positive. 
• I understand that should I be tested and found to be HIV-positive during the 
screening period, I cannot hold the study researchers liable for my treatment or 
care. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
 ....................................................................  ............................................................. 
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
                            Signature of investigator              Signature of witness 
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APPENDIX E: 
Informed consent form (second validity and reliability 
study: Community sample) 
 
TITLE OF THE RESEARCH PROJECT:  The validity and reliability of the 
myoMOTION inertial motion capture system when measuring walking gait in HIV-
seropositive as well as HIV-seronegative adults 
 
REFERENCE NUMBER: N15/05/043 
PRINCIPAL INVESTIGATOR: Karina Berner, Doctoral Candidate  
ADDRESS:  
Division of Physiotherapy, Department of Health and Rehabilitation Sciences, Faculty of 
Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, 
Cape Town, 8000 
CONTACT NUMBER: 021 938 9667 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
The aim of this study is to determine the precision and accuracy (reliability and validity) of a 
new three-dimensional motion analysis system (myoMOTION inertial motion capture system) 
recently acquired by the SU Central Analytical Facilities (CAF) 3D Human Biomechanics Unit.  
The performance of this system will be tested against the current reference standard, namely 
the VICON camera system, using 16 HIV-seropositive and 16 HIV-seronegative participants.   
 
This study is the first part of a bigger project, which forms part of the HAART to HEART study 
being done in Worcester, and the reason we are doing this study is to determine whether the 
myoMOTION system will be a suitable tool for use in the next study phase.  Although this 
smaller study is thus part of the HAART to HEART study, it has a different goal and is 
concerned with human movement. We are enrolling people from both Worcester and Paarl. 
Whether you choose to participate, or not, in this smaller study will not affect your current 
participation in the bigger study (if you are from Worcester), nor will it mean that you have to 
participate in any further research such as the bigger study (for example if you are from Paarl 
and not already involved in the bigger study). 
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This study will be conducted in the CAF 3D Human Biomechanics Unit, Tygerberg Medical 
Campus.  Transport to and from the testing facility will be provided to you by the research 
team, as well as a light lunch on the day that you are tested, and you will be compensated for 
your time. 
 
You will be asked to perform a number of normal walks along a measured walkway in the 
motion laboratory, while the two systems record you simultaneously.  For this, you will need to 
change into shorts and a sleeveless sports top (females)/no shirt (males) and remove your 
shoes.  A physiotherapist will measure your weight and height beforehand, as well as the range 
of motion of your joints.  Before performing the walks, small reflective markers and motion 
sensors will be stuck to certain areas of your body using special double=sided tape.  These 
will be removed after testing.  The expected duration of the entire testing session per 
participant (excluding transport between Worcester/Paarl and Tygerberg) will be about one 
hour and will be scheduled at your convenience.  Four participants will be tested per day, over 
a course of eight days (32 participants in total). Taking into account driving time and the fact 
that three other people will also be tested on the same day, the entire trip should take about 
six hours out of your day (once off). 
Why have you been invited to participate? 
You have been invited to participate in this study because you are an adult living in the Cape 
Winelands area that met the specific inclusion criteria and agreed to participate. If you are from 
Worcester, you have also been invited because you are already part of the bigger Cape 
Winelands HAART to HEART study. 
What will your responsibilities be? 
• You will be expected to be available for a trip to Tygerberg Medical Campus (transport 
and lunch provided, as well as compensation for your time) on the agreed-upon testing 
day and time (only one testing session is required per participant).  
 
• Woman will be asked to put on a sports top and shorts (that will be provided) and men 
will only wear shorts. We will then measure your weight and height, as well as the range 
of motion of your lower limb joints using a non-invasive measurement tool (goniometer).   
 
• Small sensors will be put on your skin by means of a double-sided sticker. You will then 
be asked to walk twelve times up and down an area of 10 metres, and stand still on a 
wooden block in between six of these walks.  Only you and two researchers will be in 
the measurement area while you are walking. After the walking measurements have 
been completed, the sensors will be removed and you can put your own clothes back 
on. 
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Will you benefit from taking part in this research? 
If a movement problem is identified, a physiotherapist will provide you with information on how 
to correct such a problem.  Also, your participation will help us determine the validity and 
reliability of the new technology, so that it may be used in the next study phase.  This next 
phase will involve using the new system in clinics to analyse the movement of adults living with 
HIV/AIDS, so that any impairments may be identified and a suitable screening test be selected 
for this population.  Your participation in the current study will therefore also benefit future 
patients. 
Are there in risks involved in your taking part in this research? 
There are no risks involved in your taking part in this study. 
If you do not agree to take part, what alternatives do you have? 
You will not be denied any standard of treatment if you do not wish to take part in this research 
study.  For example, if you feel that you have problems with movement, you are still welcome 
to consult the physiotherapist at your local clinic.  Your participation in the main HAART to 
HEART study will also not be affected. 
Who will have access to your medical records? 
Only medical staff and the principal researcher will have access to your medical records.  All 
information will be treated with respect and utmost confidentiality.  Under no circumstances 
will your name or any form of identification be used. All information will also be treated as 
confidential and shared only between the researchers involved.  
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
It is unlikely that any injury will be suffered as a result of taking part in this study. 
  
Will you be paid to take part in this study and are there any costs involved? 
You will receive compensation (according to NHREC (2012) guidelines) for your time at a rate 
of R20 per hour, as well as R20 for the inconvenience of undergoing HIV testing and 
performing physical activities. This will be in the form of a food voucher. There will be no costs 
involved for you, if you do take part.  Transport between Worcester CDC and Tygerberg 
Medical Campus will be provided, as well as a light lunch, free of charge. 
 
Is there anything else that you should know or do? 
Ø You can contact Mrs Karina Berner at 021 938 9300 / (email address) if you have 
any further queries or encounter any problems. 
Ø You can contact the Health Research Ethics Committee at 021 938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your 
researcher. 
Ø You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled “The validity and reliability of the myoMOTION inertial motion capture 
system when measuring walking gait in HIV-seropositive as well as HIV-seronegative 
adults”. 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
• I have consumed no alcohol today. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
 ....................................................................  ............................................................. 
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
 ....................................................................  ............................................................. 
Signature of investigator Signature of witness 
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APPENDIX F:  
Informed consent form (cross-sectional field study: 
Worcester) 
 
TITLE OF THE RESEARCH PROJECT: Biomechanical analysis of specific 
movement impairments contributing to early functional decline in adults living 
with HIV/AIDS: Sub-study to the Cape Winelands HAART to HEART study  
 
REFERENCE NUMBER: N15/05/043 
 
PRINCIPAL INVESTIGATOR: Karina Berner, Doctoral Candidate  
ADDRESS: Division of Physiotherapy, Department of Health and Rehabilitation Sciences, 
Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, Cape Town, 8000 
CONTACT NUMBER: 021 938 9667 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
• This study forms part of a bigger project, namely the Cape Winelands HAART to 
HEART study, which you are also a part of.  The purpose of this smaller study is to look 
at the way you normally walk, as well as your balance, using a special portable 
movement analysis system, and to compare these findings with a short movement test, 
to see if they tell us similar things about your movement.  If the movement test agrees 
with the movement analysis system, physiotherapists may use this test in clinics to 
identify movement problems in patients and start treating them at an early stage.   
• We will also gather information about your own idea of your well-being, ability to do and 
remember things and whether you have ever fallen down in the last year, using short 
questionnaires, to see how this information compare to the way you move. 
• This study will be done in a private room at a Stellenbosch University’s Ukwanda 
campus, located next to Worcester CDC (transport will be provided to and from the 
clinic).  We will need two test groups of about 40 participants each – a group of is HIV-
seropositive and a group who is HIV-seronegative. 
Stellenbosch University  https://scholar.sun.ac.za
 341 | P a g e  
 
• You will be measured by a registered physiotherapist.  Your body weight and height 
will be collected, as well as nerve testing of your feet, strength testing of your leg 
muscles and the amount of movement in your leg joints.  The strength of your bones 
will also be measured. Measurements will not cause you any harm of discomfort.  
• You will be asked to walk 3 times at a normal speed, 3 times at a fast speed and 3 
times whilst counting aloud backwards, while the movement system records you.  You 
will also be asked to stand on one leg on a mat that measures movement (for 30 
seconds at a time) – 3 times with open eyes, 3 times with closed eyes and 3 times 
while you count backwards loudly.  For this, you will need to change into shorts and a 
sleeveless sports top (women)/no shirt (men) and remove your shoes.  
• Before performing the walks, small motion sensors will be stuck to certain areas of your 
body using special double-sided tape.  These will be removed after testing.  The 
expected duration of the entire testing session per person will be between 1 ½ hours 
and 2 hours.  About 3 to 4 participants will be tested per day. 
• We are selecting persons who are willing to participate in this sub-study from all 
persons who are also partaking in the main study. Everyone participating in the main 
study therefore has an equal chance of being selected for this study, and may 
participate should they match our study criteria.  
Why have you been invited to participate? 
You have been invited to participate in this study because you are part of the main HAART to 
HEART study and an adult living in the Cape Winelands that met the specific inclusion criteria. 
What will your responsibilities be? 
• You will be expected to be available on the agreed-upon testing time (only one testing 
session is required per person). We will transport 1 or 2 participants at a time to the 
nearby Ukwanda campus, where testing will be done. The entire time that you will be 
away, will be about 2 hours; we will also transport you back to Worcester CDC. 
• You will be expected to fill in two short questionnaires, to find out about your medical 
conditions, pain, whether you have ever fallen down in the past year or are afraid of 
falling, how you feel about your memory and concentration, and how you feel about 
doing daily activities. 
• Woman will be asked to put on a sports top and shorts (which will be provided) and 
men will only wear shorts. We will then measure your weight and height, as well as 
nerve symptoms in your feet.  We will also measure the range of motion of your leg 
joints using a simple measurement tool.  The strength of your muscles will also be 
tested with a hand-held device.   
• The strength of your bones will be tested by placing your foot in a machine for a few 
seconds. This will not hurt or be uncomfortable.  This test is not a diagnosis, but only a 
screening test. This means that it gives us an idea of how strong your bones are, and 
whether it might be necessary to investigate or manage this further. You will receive a 
copy of your results.  
• We will make some activities more difficult by asking you to count backwards out loud 
while you walk or while you stand on one leg. We will let you practice beforehand. The 
purpose is not to see how well you count, but rather to see if you move differently while 
your attention is focused on an additional activity. 
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• You will perform a short physical test which evaluates walking and balance – the 
activities (5 times sit-to-stand, some balance tests and a short walk) will be timed with 
a stopwatch.  
• Small sensors will be put on your skin by means of a “Velcro” strap or a double-sided 
sticker. You will then be asked to walk three times up and down an area of 10 metres 
as you normally walk, three times at a fast speed and three times while you count out 
loud. You will also be asked to stand on one leg on a special mat that measures 
movement, first with your eyes open, then with your eyes closed and then while you 
count.  You will do these three times for 30 seconds. After the movement 
measurements have been completed, the sensors will be removed and you can put 
your own clothes back on. 
Will you benefit from taking part in this research? 
If a movement problem is identified, a physiotherapist will provide you with information on how 
to correct such a problem.  Your participation in this study will also benefit future patients, as 
we will learn more about movement impairments in your population and which test would be 
best for physiotherapists to use for identifying such problems.  Appropriate treatment can then 
be started earlier for future patients. 
Are there in risks involved in your taking part in this research? 
There are no risks involved in taking part in this study. 
If you do not agree to take part, what alternatives do you have? 
You will not be denied any standard of treatment if you do not wish to take part in this research 
study.  For example, if you feel that you have problems with movement, you are still welcome 
to consult the physiotherapist at your local clinic. 
Who will have access to your medical records? 
Only medical staff and the principal researcher of the HAART to HEART study will have access 
to your medical records.  All information will be treated with respect and utmost confidentiality.  
Under no circumstances will your name or any form of identification be used.  The principle 
researcher of the smaller study will not have direct access to your medical file, but will receive 
relevant medical information from the principle researcher of the HAART to HEART study.  For 
example, it is important for this study that we know you HIV-status and medical history (e.g. 
whether you suffer from Diabetes).  This information will also be treated as confidential and 
anonymous, and shared only between the researchers involved.  
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
It is unlikely that any injury will occur as a result of taking part in this study. 
  
Will you be paid to take part in this study and are there any costs involved? 
You will receive compensation for your time at a rate of R10 per hour (according to NHREC 
(2012) guidelines) if you participate in this study. This will be in the form of a food voucher.  
There will be no costs involved for you, if you do take part. 
Is there anything else that you should know or do? 
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Ø You can contact Mrs Karina Berner at 021 938 9300 / (email address) if you have any 
further queries or encounter any problems. 
Ø You can contact the Health Research Ethics Committee at 021 938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your 
researcher. 
Ø You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled “Biomechanical analysis of specific movement impairments contributing 
to early functional decline in adults living with HIV/AIDS: Sub-study to the Cape 
Winelands HAART to HEART study”. 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 ....................................................................  ............................................................. 
Signature of participant Signature of witness 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. ... 
 ....................................................................  ............................................................. 
Signature of investigator Signature of witness  
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APPENDIX G: 
Informed consent form (cross-sectional field study: 
Paarl) 
 
TITLE OF THE RESEARCH PROJECT: Biomechanical analysis of specific 
movement impairments contributing to early functional decline in adults living 
with HIV/AIDS: Sub-study to the Cape Winelands HAART to HEART study  
 
REFERENCE NUMBER: N15/05/043 
PRINCIPAL INVESTIGATOR: Karina Berner, Doctoral Candidate  
ADDRESS: Division of Physiotherapy, Department of Health and Rehabilitation Sciences, 
Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, Cape Town, 8000 
CONTACT NUMBER: 021 938 9300 / 021 938 9896 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
• This study forms part of a bigger project, namely the Cape Winelands HAART to 
HEART study, which is currently being conducted in Worcester.  The purpose of this 
smaller study is to look at the way you normally walk, as well as your balance, using a 
special portable movement analysis system. We will then compare these findings to 
those of a short movement test, to see if they tell us similar things about your 
movement.  If the movement test agrees with the movement analysis system, 
physiotherapists may use this test in clinics to identify movement problems in patients 
and start treating them at an early stage.   
• We will also gather information about your own idea of your well-being, ability to do and 
remember things and whether you have ever fallen down in the last year, using short 
questionnaires, to see how this information compare to the way you move. 
• This study will be done in a private room in the TC Newman clinic in Paarl (we are also 
currently testing participants in Worcester).  We will need two test groups of about 40 
or more participants each – a group of is HIV-seropositive and a group who is HIV-
seronegative. 
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• You will be measured by a registered physiotherapist.  Your body weight and height 
will be collected, as well as nerve testing of your feet, strength testing of your leg 
muscles and the amount of movement in your leg joints.  The strength of your bones 
will also be measured. Measurements will not cause you any harm of discomfort.  
• You will be asked to walk 3 times at a normal speed, 3 times at a fast speed and 3 
times whilst counting aloud backwards, while the movement system records you.  You 
will also be asked to stand on one leg on a mat that measures movement (for 30 
seconds at a time) – 3 times with open eyes, 3 times with closed eyes and 3 times 
while you count backwards out loud.  For this, you will need to change into shorts and 
a sleeveless sports top (women)/no shirt (men) and remove your shoes.  
• Before performing the walks, small motion sensors will be stuck to certain areas of your 
body using special double-sided tape.  These will be removed after testing.  The 
expected duration of the entire testing session per person will be between 90 minutes 
and 2 hours.  About 3 to 4 participants will be tested per day. 
Why have you been invited to participate? 
You have been invited to participate in this study because you are an adult, attending the TC 
Newman clinic as an out-patient, you are living in the Cape Winelands district and meet the 
specific inclusion criteria. 
What will your responsibilities be? 
• You will be expected to be available on the agreed-upon testing time (only one testing 
session is required per person). Participation in the study will take about 2 hours of 
your time. 
• You will be expected to fill in two short anonymous questionnaires, to find out about 
your medical conditions, pain, whether you have ever fallen down in the past year or 
are afraid of falling, how you feel about your memory and concentration, and how you 
feel about doing daily activities. 
• You will also be asked questions about your medical history, exercise, lifestyle and 
habits – your answers will be kept anonymous. 
• Woman will be asked to put on a sports top and shorts (which will be provided) and 
men will only wear shorts. We will then measure your weight and height, as well as 
nerve symptoms in your feet.  We will also measure the range of motion of your leg 
joints using a simple measurement tool.  The strength of your muscles will also be 
tested with a hand-held device.   
• The strength of your bones will be tested by placing your foot in a machine for a few 
seconds. This will not hurt or be uncomfortable.  This test is not a diagnosis, but only a 
screening test.  This means that it gives us an idea of how strong your bones are, and 
whether it might be necessary to investigate or manage this further. You will receive a 
copy of your results.  
• We will make some activities more difficult by asking you to count backwards out loud 
while you walk or while you stand on one leg. We will let you practice beforehand. The 
purpose is not to see how well you count, but rather to see if you move differently while 
your attention is focused on an additional activity. 
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• You will perform a short physical test which evaluates walking and balance – the 
activities (5 times sit-to-stand, some balance tests and a short walk) will be timed with 
a stopwatch.  
• Small sensors will be put on your skin by means of a “Velcro” strap or a double-sided 
sticker. You will then be asked to walk three times up and down an area of 10 metres 
as you normally walk, and three times at a fast speed. You will also be asked to stand 
on one leg on a special mat that measures movement, first with your eyes open and 
then with your eyes closed.  You will do this three times for 30 seconds. After the 
movement measurements have been completed, the sensors will be removed and you 
can put your own clothes back on. 
Will you benefit from taking part in this research? 
If a movement problem is identified, a physiotherapist will provide you with information on how 
to correct such a problem.  Your participation in this study will also benefit future patients, as 
we will learn more about movement impairments in your population and which test would be 
best for physiotherapists to use for identifying such problems.  Appropriate treatment can then 
be started earlier for future patients. 
Are there in risks involved in your taking part in this research? 
There are no risks involved in taking part in this study. 
If you do not agree to take part, what alternatives do you have? 
You will not be denied any standard of treatment if you do not wish to take part in this research 
study.  For example, if you feel that you have problems with movement, you are still welcome 
to consult the physiotherapist at your local clinic. 
Who will have access to your medical records? 
Only the principal researcher of this study (Mrs. K Berner, a registered physiotherapist) will 
have access to your medical records.  For example, it is important for this study that we know 
your HIV-status and medical history (e.g. whether you suffer from Diabetes).  All information 
will be treated with respect and utmost confidentiality.  Under no circumstances will your name 
or any form of identification be used or linked to your medical information, or any of the 
questions that you answer during the study. 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
It is unlikely that any injury will occur as a result of taking part in this study. 
 
 Will you be paid to take part in this study and are there any costs involved? 
You will receive compensation for your time at a rate of R20 per hour (according to NHREC 
(2012) guidelines) if you participate in this study, as well as an additional R10 for the 
inconvenience of performing the physical activities. This will be in the form of a food voucher.  
There will be no costs involved for you, if you do take part. 
 
Is there anything else that you should know or do? 
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Ø You can contact Mrs Karina Berner at: 021 938 9300 / 021 938 9896 / (email address) 
if you have any further queries or encounter any problems. 
Ø You can contact the Health Research Ethics Committee at 021 938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your 
researcher. 
Ø You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled “Biomechanical analysis of specific movement impairments contributing 
to early functional decline in adults living with HIV/AIDS: Sub-study to the Cape 
Winelands HAART to HEART study”. 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
• I have not consumed any alcohol today. 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 ....................................................................  ............................................................. 
Signature of participant Signature of witness 
 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. ... 
 ....................................................................  ............................................................. 
Signature of investigator Signature of witness  
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APPENDIX H: 
Health ABC Physical Performance Battery (PPB) 
 
 
 
Patient Name: _________________  Date: _______ 
Health ABC Physical Performance Battery 
 
1. Repeated Chair Stands  
 
Instructions: Do you think it is safe for you to try and stand up from a chair five times without 
using your arms? Please stand up straight as quickly as you can five times, without stopping in 
between. After standing up each time, sit down and then stand up again. Keep your arms folded 
across your chest. Please watch while I demonstrate. I’ll be timing you with a stopwatch. Are you 
ready? Begin  
 
Grading: Begin stop watch when subject begins to stand up. Count aloud each time subject 
arises. Stop the stopwatch when subject has straightened up completely for the fifth time. Also 
stop if the subject uses arms, or after 1 minute, if subject has not completed rises, and if 
concerned about the subject’s safety.. Record the number of seconds and the presence of 
imbalance. Then complete ordinal scoring.  
 
Time: _____sec (if five stands are completed)  
 
 
 
 
2. Balance Testing  
Begin with a semi-tandem stand (heel of one foot placed by the big toe of the other foot). 
Individuals unable to hold this position should try the side-by-side position. Those able to stand in 
the semi-tandem position should be tested in the full tandem position. Once you have completed 
time measures, complete ordinal scoring.  
 
a. Semi-tandem Stand  
 
Instructions: Now I want you to try to stand with the side of the heel of one foot touching the big 
toe of the other foot for about 10 seconds. You may put either foot in front, whichever is more 
comfortable for you. Please watch while I demonstrate.  
 
TIME HELD: ____ seconds 
 
 
b. Tandem Stand  
 
Instructions: Now I want you to try to stand with the heel of one foot in front of and touching the 
toes of the other foot for 10 sec. You may put either foot in front, whichever is more comfortable 
for you. Please watch while I demonstrate.  
 
Grading: Stand next to the participant to help him or her into the side-by-side position. Allow 
participant to hold onto your arms to get balance. Begin timing when participant has feet together 
and lets go.  
 
TIME HELD: ____ seconds 
 
 
 
 
 
 
 
articip nt code: ___ __ 
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Patient Name: _________________  Date: _______ 
 
 
       c. Single Leg Stance:  
 
Instructions: Stand with your spine as vertical as possible, with your arms hanging 
down.  Lift you’re the leg of your choice and hold as long as possible. 
 
Grading: Stand next to the participant and help him or her to assume the single leg stance 
position.  Allow the participant to hold onto your arms to get balance.  Begin timing 
when the participant lets go.   
 
TIME HELD: _____ seconds 
 
Total Balance: semi-tandem+ full tandem + single leg stance: _____/90 sec 
 
 
 
 
3. 6 meter walk 
 
Instructions: This is our walking course. If you use a cane or other walking aid when walking 
outside your home, please use it for this test. I want you to walk at your usual pace to the other 
end of this course. Walk all the way past the other end of the tape before you stop. I will walk with 
you. Are you ready?  
 
Grading: Press the start button to start the stopwatch as the participant begins walking. Measure 
the time take to walk 6 meters. Then complete ordinal scoring.  
 
Time: _____ sec (Calculation: 6 meters/______ seconds = _____ m/sec)  
 
 
 
 
4. Narrow Corridor Test (6 meters) 
 
Instructions:  Walk at your usual pace but stay between the lines of tape. 
 
Grading:  If participant steps outside the tape 2/more times this constitutes a failure.  Up 
to 3 trials for two valid times are allowed.  The average of the two trials is taken.   
.   
Trial 1: ______ seconds   
Trial 2: ______ seconds 
Trial 3: ______ seconds Average time: ______ seconds 
 
 
 
Developed based on Simonsick EM et al.  Measuring higher level physical function in well-
functioning older adults: expanding familiar approaches in the Health ABC study.  J Gerontol A 
Biol Sci Med Sci.  2001; 56: M644-9.   
Participant code: ___ ___ 
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APPENDIX I: 
Dual tasking sheet 
 
FAMILIARISATION 
 
Participant sits comfortably.  Instruction: “Count aloud backwards, in counts of (7 / 3 / 2 / 
1), starting from (select random number between 80 - 99). Try to count as accurately as 
possible. You have 30 seconds.” (Examiner times 30 seconds with stopwatch.) 
To calculate Cognitive Difficulty Score (CDS), circle the relevant options below – this 
practice-round is used to confirm the appropriate difficulty level per participant à select 
the difficulty level where the participant makes the least mistakes:  
 
Cognitive difficulty score, taking into account task difficulty and mistakes made 
during tasking.187 
Difficulty counting 
backwards (units used) 
Mistakes made (Y/N) Cognitive difficulty score 
1 YES 1 
1 NO 2 
2 YES 3 
2 NO 4 
3 YES 5 
3 NO 6 
7 YES 7 
7 NO 8 
 
 
CLINICAL TESTS (timed with stopwatch) 
 
1) SIX-METRE WALK AT USUAL PACE, while counting down backwards in units of 
_________ (select 7 / 3 / 2 / 1), starting from _______________(select random number 
between 80 and 99). 
 
Time taken to complete walk (seconds):  
Number of mistakes:  
Calculated Cognitive Difficulty Score (refer 
to table): 
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2) SIX-METRE NARROW WALK at usual pace, while counting down backwards in units of 
_________ (select 7 / 3 / 2 / 1), starting from _______________(select random number 
between 80 and 99). 
 
Time taken to complete walk (seconds):  
Number of mistakes:  
Calculated Cognitive Difficulty Score (refer 
to table): 
 
 
3) SINGLE LEG STANCE WITH EYES OPEN, while counting down backwards in units of 
_________ (select 7 / 3 / 2 / 1), starting from _______________(select random number 
between 80 and 99). 
Time stance held (seconds; max 30):  
Number of mistakes:  
Calculated Cognitive Difficulty Score (refer 
to table): 
 
 
 
3D ANALYSIS (3 TRIALS EACH – RANDOMISE ORDER) 
 
1) SINGLE LEG STANCE on pressure mat with eyes open and arms crossed, while counting 
down backwards in units of _________ (select 7 / 3 / 2 / 1), starting from 
_______________(select random number between 80 and 99). 
 
 TRIAL 1 TRIAL 2 TRIAL 3 
Time stance held (seconds):    
Number of mistakes:    
Cognitive difficulty score (refer to 
table): 
   
 
 
2) WALKING AT USUAL PACE, while counting down backwards in units of _________ (select 
7 / 3 / 2 / 1), starting from _______________(select random number between 80 and 99). 
 
 TRIAL 1 TRIAL 2 TRIAL 3 
Gait speed: (*extract from 
software) 
   
Number of mistakes:    
Cognitive difficulty score (refer to 
table): 
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NOTES 
• Order of balance tasks (single, dual, with and without vision) to be changed randomly to 
control for effects of fatigue and learning. 
• Cognitive task: 
o Counting backwards using units of 7’s.  
o Ask participant to count backwards as accurate as possible in 30 seconds as an 
initial practice-round.  If units of 7 are too difficult – use units of 3’s, 2s or 1’s instead, 
as appropriate. 
o Starting-number selected at random from range between 80 – 99.187 
o Counting must be controlled throughout for accuracy and all mistakes should be 
noted.  
o No feedback on performance should be given during testing.  
o Evaluation of performance: Difficulty (7s, 3s, 2s or 1s) of subtraction-units, and 
number of mistakes made by participant 187 – dichotomized into “mistakes: yes” and 
“mistakes: no”. 
o Use the above to define six performance scores.187 The lowest score is designated 
a 1: when mistakes are made when counting backwards using 1’s.  The highest 
score (8) is given when counting down in 7’s without mistakes (refer to the 
“Cognitive Difficulty Score” table for scoring). 
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APPENDIX J: 
EuroQol Five-Dimensions Five-Levels questionnaire 
 
 
South Africa (English) © 1999 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health Questionnaire 
 
 
English version for South Africa 
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2 
 
South Africa (English) © 1999 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own state of health TODAY. 
  
Mobility  
I have no problems in walking about q 
I have some problems in walking about q 
I am confined to bed q 
  
Self-Care  
I have no problems with self-care q 
I have some problems washing or dressing myself q 
I am unable to wash or dress myself q 
  
Usual Activities (e.g. work, study, housework, family or leisure activities)  
I have no problems with performing my usual activities q 
I have some problems with performing my usual activities q 
I am unable to perform my usual activities q 
  
Pain / Discomfort  
I have no pain or discomfort q 
I have moderate pain or discomfort q 
I have extreme pain or discomfort q 
  
Anxiety / Depression  
I am not anxious or depressed q 
I am moderately anxious or depressed q 
I am extremely anxious or depressed q 
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3 
 
South Africa (English) © 1999 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
0 
 
 
 
To help people say how good or bad their state of health 
is, we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in your 
opinion, how good or bad your own health is today. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or bad 
your state of health is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Best imaginable 
state of health 
Worst imaginable 
state of health 
Your own state of 
health today 
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APPENDIX K: 
Field study data collection form 
 
Project title: Biomechanical analysis of specific movement impairments 
contributing to early functional decline in adults living with HIV/AIDS: Sub-study 
to the Cape Winelands HAART to HEART study 
Ethics approval nr: N15/05/043 
 
 
 
 
 
CONFIDENTIAL 
 
 
 
 
 
 
                                                    IDENTIFICATION CODE: HIVP2_     
Date and time:  
Assessment by:  
Research assistant:  
Age:  
Sex:  
HIV status SNP PLHIV 
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KOGNITIEWE FUNKSIE (vanuit die MOS-HIV vraelys)  
(English on next page) 	
Merk  asseblief ‘n blokkie by elke vraag: 
 Die 
heeltyd 
Meeste 
van die 
tyd 
Baie van 
die tyd 
Sommige 
van die 
tyd / 
somtyds 
‘n Klein 
bietjie 
van die 
tyd 
Nooit nie 
Hoe gereeld, tydens die laaste 
4 weke: 
      
a. Was dit moeilik om te 
redeneer en probleme op 
te los, byvoorbeeld, om 
planne te maak, om 
besluite te maak, of om 
nuwe dinge te leer? 
 
1 o 
 
2 o 
 
3 o 4 o 5 o 6 o 
b. Het jy dinge vergeet wat 
onlangs gebeur het, 
byvoorbeeld, waar jy iets 
neergesit het of wanneer jy 
afsprake gehad het?  
 
1 o 2 o 3 o 4 o 5 o 6 o 
c. Was dit moeilik om jou 
aandag vir lank op enige 
aktiwiteit te hou?  
 
1 o 2 o 3 o 4 o 5 o 6 o 
d. Was dit moeilik om dinge 
te doen waar jy moes 
konsentreer en dink?  
 
1 o 2 o 3 o 4 o 5 o 6 o 
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COGNITIVE FUNCTIONING (from MOS-HIV questionnaire) 	
 
Please tick a box for each question: 
								
 6
 
  All of 
the 
Time 
 
Most of 
the Time
 
A Good 
Bit of 
the Time
 
Some of 
the 
Time 
 
A Little 
of the 
Time 
 
None of 
the 
Time 
10. How much of the time, 
during the past 4 
weeks: 
      
  
a. 
Did you have 
difficulty reasoning 
and solving 
problems, for 
example, making 
plans, making 
decisions, learning 
new things? 
 
 
1  
 
 
 
 
 
2  
 
 
3  
 
 
4  
 
 
5  
 
 
6  
 
 
  
b. 
Did you forget 
things that 
happened recently, 
for example, where 
you put things and 
when you had 
appointments? 
 
 
1  
 
 
2  
 
 
3 
 
 
4  
 
 
5  
 
 
6  
  
c. 
Did you have 
trouble keeping 
your attention on 
any activity for 
long? 
 
1  
 
2  
 
3  
 
4  
 
5  
 
6 
  
d. 
Did you have 
difficulty doing 
activities involving 
concentration and 
thinking? 
 
1  
 
2  
 
3  
 
4  
 
5  
 
6  
 
 
 
11. Please check the box that best describes whether each of the following statements is true or false 
   for you.                 (Check one box on each line) 
 
 Definitely 
True 
Mostly 
True 
Not 
Sure 
Mostly 
False 
Definitely
False 
a. I am somewhat ill. 1  2  3  4  5  
b. I am as healthy as anybody I 
know. 
1  2  3  4  5  
c. My health is excellent. 1  2  3  4  5  
d. I have been feeling bad lately. 1  2  3  4  5 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PYN  (vanuit die MOS-HIV vraelys) 
 (English on next page) 
 
 
 
1. Hoeveel liggaamlike pyn het jy gedurende die afgelope 4 weke ervaar?  
(Merk ‘n blokkie) 
 
 
Geen 
 
 
Net effens 
 
Matig 
 
Redelik 
 
Ernstig 
 
Baie ernstig 
 
1o 
 
 
2o 
 
3o 
 
4o 
 
5o 
 
6o 
 
 
 
 
 
 
2. Gedurende die afgelope 4 weke, hoeveel het pyn ingemeng met jou normale 
werk (insluitend werk buite die huis en huiswerk)?  
(Merk ‘n blokkie) 
 
 
Glad nie 
 
 
Effens 
 
Redelik 
 
Heelwat 
 
Vreeslik baie 
 
1o 
 
 
2o 
 
3o 
 
4o 
 
5o 
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PAIN  (from MOS-HIV questionnaire) 		
 
1. How much bodily pain have you generally had during the past 4 weeks?  
(Check one) 
 
None 
 
 
Very mild 
 
Mild 
 
Moderate 
 
Severe 
 
Very 
severe 
 
1o 
 
 
2o 
 
3o 
 
4o 
 
5o 
 
6o 
 
 
 
 
 
2. During the past 4 weeks, how much did pain interfere with your normal work 
(or your normal activities, including work outside the home and housework)? 
(Check one) 
 
Not at all 
 
 
A little bit 
 
Moderately 
 
Quite a bit 
 
Extremely 
 
1o 
 
 
2o 
 
3o 
 
4o 
 
5o 
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@ Antwoord ook asseblief die volgende vrae so eerlik as moontlik, tot op die bladsy waar 
die navorser vir u gewys het om te stop. Onthou, u is welkom om ‘n vraag te vra as u iets 
nie verstaan nie!  
@ Please also answer the following questions as honestly as possible, up to where the 
researcher has shown you where to stop. Remember, you are welcome to ask a question 
if you don’t understand some of the questions! 	
AFDELING A: DOMINANTE HAND & VORIGE FRAKTURE / SECTION B: HAND 
DOMINANCE & PREVIOUS FRACTURES 
1. Is u links- of regs-handig? / Are you left- or right handed? LINKS / LEFT 
REGS / 
RIGHT 
2. Het u al ooit ‘n been in u liggaam gebreek? / Have you ever 
broken a bone in your body?  JA /YES  NO /NEE 
>> Indien NEE – beweeg asb aan na Afdeling B / If NO – please move on to Section B. 
3. Indien JA – watter been, en hoe lank terug was dit? / If YES - which bone and how long 
ago did it happen? 
______________________________________________________________ 
 
3.1 Beskryf asseblief hoe dit gebeur het dat u die been gebreek het (baie kortliks) / Please 
describe how this fracture happened (Very briefly): 
_______________________________________________________________________________ 
_______________________________________________________________________ 
AFDELING B: BINNE-AARSE DWELM-GEBRUIK / SECTION B: INTRA-VENOUS 
DRUG USE 
Het u al ooit enige dwelm-middels vir uself ingespuit met ‘n naald, 
wat nie deur ‘n dokter voorgeskryf is nie? / Have you ever taken 
any drugs using an injection, that was not prescribed by a docter? 
JA / YES NEE / NO 
AFDELING C: MIV-MEDIKASIE / SECTION C: HIV-MEDICATION 
FIndien u NIE ‘n MIV-positiewe deelnemer is nie, beweeg asseblief aan na Afdeling 
D / If you are NOT a HIV-positive participant, please move on to Section D. 
 
 
Ons wil graag uitvind hoe gereeld u tans antiretrovirale medisyne gebruik, en of u 
dalk ooit vergeet om dit te neem / We would like to know how often you are taking your 
antiretroviral medication, and if you maybe sometimes forget to take it. 
Maak asseblief ‘n sirkel om die opsie hieronder wat u huidige gebruik van MIV-
medikasie die beste beskryf  / Please circle the option below that best describes your 
current use of HIV-medication: 
 
(blaai asb om / please turn to the next page) 
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0 My dokter het nie MIV-medikasie vir my voorgeskryf nie (bv gebruik slegs vitamiene) 
/ My docter has not prescribed me any HIV-medication (antiretroviral medication) 
(for example, only using vitamins) 
1 MIV-medikasie is vir my voorgeskryf, maar ek verkies om dit nie te neem nie / HIV-
medication was was prescribed to me, but I prefer not to use it. 
2 Ek het begin om my MIV-medikasie te neem, maar het intussen heeltemal gestop / 
I have started to use my HIV-medication, but I have now stopped completely. 
3 Ek het begin om MIV-medikasie te gebruik, maar gebruik tans minder as wat 
voorgeskryf is / I have started to use HIV-medication, but I am currently taking less 
than the prescribed amount. 
4 Ek het begin om  MIV-medikasie te gebruik, maar vergeet baie kere om my pille te 
neem (vergeet meer as 2 keer in ‘n week) / I have started using HIV-medication, but 
I often forget to take my dosage (forget more than 2 times per week). 
5 Ek het begin om MIV-medikasie te gebruik en neem dit presies soos die dokter 
voorgeskryf het (ek mis NOOIT meer as 1 tot 2 dosisse in ‘n week nie) / I have 
started using HIV-medication and I take it exactly as the doctor prescribed it ( I 
NEVER miss more than1 to 2 dosages per week). 
 
 
AFDELING D: OEFENING / SECTION D: EXERCISE 
Wanneer u die volgende paar vrae beantwoord, dink asb aan ‘n gewone of tipiese 
week / While answering the next few questions, please consider a usual/typical 
week... 
1. Op ‘n tipiese dag, neem u deel aan ENIGE tipe oefening of fisiese 
aktiwiteit (bv stap, fisiese werk, fietsry, draf ensovoorts) / On a typical 
day, do you participate in ANY type of exercise or physical activity (such 
as walking, physical work, cycling, running etc.)? 
JA / 
YES  
NEE / 
NO 
 
1.1 Indien JA, wat is die aktiwiteit? / If YES, what is the type of activity?   _________ ___ 
 
1.2 Hoeveel dae van die week doen u dit? / How many days of the week do you do this?     
__________________ 
 
1.3 Hoe lank oefen of beweeg u min of meer op ‘n slag (bv “ek stap vir 30 minute”)? / How 
long, on average, do you exercise or move for? (for example “I walk for 30 minutes”): 
___________________ 
AFDELING E: NEERVAL / SECTION E: FALLING 
1. Het u ooit neergeval tydens die laaste jaar 
(daarmee bedoel ek, het u ooit op die 
grond/vloer neergeval, terwyl u gestap het)? / 
Have you had any falls during the last year (by 
that I mean, did you fall to the ground, or to a 
lower level, while walking)? 
JA / YES NEE / NO ONSEKER / 
UNSURE 
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1.1. Indien JA op vraag 1, omtrent hoeveel 
keer het u neergeval in die laaste jaar? / If 
YES to question 1, about how many times did 
you fall in the last year? 
 
   
1.2 Indien JA op vraag 1 – beskryf asseblief 
kortliks waarom u geval het / wat gebeur het / 
If YES to question 1 – please explain why you 
fell/what happened: 
   
2. Het u ooit neergeval tydens die laaste 3 
maande? / Have you had any falls in the last 
three months? 
 
JA / YES NEE / NO ONSEKER / 
UNSURE 
2.1 Indien JA op vraag 2, omtrent hoeveel 
keer het u neergeval in die laaste 3 maande? 
/ If YES to question 2, how many times did you 
fall in the last three months? 
   
2.2 Indien JA op vraag 2 – beskryf asseblief 
kortliks waarom u geval het / wat gebeur het / 
If YES to question 2 – please explain why you 
fell/what happened: 
   
3. Is u ooit BANG DAT U GAAN VAL terwyl u 
loop of staan? / Are you ever AFRAID THAT 
YOU MAY FALL DOWN when walking or 
standing? 
JA / YES NEE / NO ONSEKER / UNSURE 
3.1  Indien u soms bang is om te val, verduidelik asseblief WAAROM u só sê: / If you 
are sometimes afraid of falling, please explain WHY you say this: 
 
 
	
@  U kan hier stop. BAIE DANKIE vir u earlike antwoorde op die vrae – dit is baie 
belangrik vir die sukses van hierdie navorsing! / You may stop here. THANK YOU VERY 
MUCH for your honest answers to the questions – this is crucial for the success of the 
research! 
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MEASUREMENTS 
 
Body weight (kg)  
Height (cm)  
Leg length (ASIS to med 
malleolus) 
 
Foot length (mid heel to tip of 
longest toe) 
 
 
PERIPHERAL SENSORY NEUROPATHY ASSESSMENT OF LOWER LIMBS 
NORMAL 
 
AFFECTED (EXCLUDE) 
 
DOMINANCE (PREFERRED LEG FOR KICKING) 
LEFT 
 
RIGHT 
 
 
GONIOMETRY (only note gross limitations, otherwise tick twice to indicate full 
and functional) 
Movement Position Notes ROM (degrees) 
HIPS Left Right 
Extension 
Prone 
Stabilise pelvis 
/ASIS to remain on 
plinth / knee in E (N 
= 10°~30°) 
  
Flexion Supine (N = 120°~135°)  
  
KNEES Left Right 
Flexion Supine Hip & knee are 
flexed as heel 
moves toward 
buttock (N=135°) 
  
Extension Prone; distal leg on 
bolster 
(N= 0° / hyperE up 
to 10°-15°) 
 
  
ANKLES Left  Right 
Dorsiflexion Prone with knee F (N = 10° with kneeE 
/ 20° with knee F) 
 
  
Plantarflexion Prone with knee E (N = 30°-50°) 
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M
U
SC
LE STR
EN
G
TH
 (H
A
N
D
-H
ELD
 D
YN
A
M
O
M
ETER
) 
M
U
SC
LE 
TR
IAL # 
PEAK (N) 
N
O
TES 
1. H
ip flexors 
1 
L 
R
 
Seated, hands resting in lap. H
ips and knees flexed at 90°. H
H
D
 placed on 
ant aspect of thigh, proxim
al to knee joint. 
2 
L  
R
 
3 (if 
needed) 
L  
R
 
2. Knee extensors 
1 
L  
R
 
Seated, hands resting in lap. H
ips and knees flexed at 90°. H
H
D
 placed on 
ant aspect of shank, prox to ankle joint. PT to stabilize self against w
all.  
2 
L  
R
 
3 (if 
needed) 
L  
 
3. Knee flexors 
1 
L  
R
 
Seated, hands resting in lap.  H
ips and knees flexed at 90°. H
H
D
 placed on 
post aspect of shank, prox to ankle joint. 
2 
L  
R
 
3 (if 
needed) 
L  
R
 
4. H
ip abductors 
1 
L  
R
 
Supine, hips and knees extended. H
H
D
 placed on lat aspect of shank, prox to 
ankle joint.  
2 
L  
R
 
3 (if 
needed) 
L  
R
 
5. Ankle plantarflexors 
1 
L  
R
 
Supine, ankle in plantargrade and hips and knees extended. H
H
D
 placed 
over m
etatarsal heads on sole of the foot. PT to stabilize self against w
all.   
 
2  
L   
R
 
3 (if 
needed) 
L  
R
 
6. Ankle dorsiflexors 
1 
L  
R
 
Supine, w
ith ankle relaxed and hips and knees extended. H
H
D
 placed over 
m
etatarsal heads on dorsum
 of foot.  
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2 
L  
R
 
 
3 (if 
needed) 
L  
R
 
7. H
ip extensors 
1   
L  
R
 
Prone, hips and knees extended. H
H
D
 placed on post aspect of thigh, prox to 
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Biochemical data / information from medical folder 
FOLDER NUMBER: __________________________________ 
		
     Date of HIV diagnosis:     _______________________ 
     ART:       _______________________ 
      
     Other medication:      _______________________ 
     Other blood results:     _______________________ 
     
 Other relevant notes:     
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________	
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APPENDIX M: 
Instructions for instrumented balance and gait analysis 
(field study) 
 
1. Single leg stance (SLST) 
The participant will be instructed as follows (eyes open): “Stand with both feet comfortably 
apart on the pressure mat. When I say “LIFT”, stand on any one leg by lifting the other foot so 
that the foot is ankle-height off the ground. Place your arms across your chest with your hands 
touching your shoulders and do not let your legs touch each other or the ground.  Look straight 
ahead with your eyes open and focus on the cross on the wall (*image of a cross will be fixated 
on a wall about 3 metres in front of the participant). Hold this position as still and for as long 
as possible, or until I say stop”.  
Instructions for the eyes closed condition will be: “Stand with both feet comfortably apart on 
the pressure mat. When I say “LIFT”, stand on any one leg by lifting the other foot so that the 
foot is ankle-height off the ground. Place your arms across your chest with your hands touching 
your shoulders and do not let your legs touch each other or the ground. Close your eyes once 
you have gotten in position. Hold this position as still and for as long as possible, or until I say 
stop”.   
The participant will be instructed as follows for the dual task condition: “Stand with both feet 
comfortably apart on the pressure mat. When I say “START COUNTING”, start counting 
backwards aloud in units of (7/3/2/1 – as previously determined), starting from (random number 
chosen between 80 and 99). Then, when I say “LIFT”, keep counting and stand on any one 
leg by lifting the other foot so that the foot is ankle-height off the ground. Place your arms 
across your chest with your hands touching your shoulders and do not let your legs touch each 
other or the ground. Look straight ahead with your eyes open and focus on the cross on the 
wall. Hold this position as still and for as long as possible, or until I say stop. It is important that 
you focus on counting as accurately as possible while you hold this position”.  
Participants will be allowed a practice trial for all conditions, where after three test trials of 30 
seconds each will be conducted. To prevent injury, a research assistant will stand close to the 
participant throughout the session. Leg dominance does not seem to affect one-legged 
balancing ability and participants will thus be allowed to choose a preferred stance leg 392. 
 
2. Walking gait trials 
The participant will perform a total of nine gait trials (ten metres) at (i) a self-selected speed (= 
3x trials), (ii) fast speed (= 3x trials) and (iii) whilst performing a simultaneous cognitive task (= 
3x trials).  A 10-metre walkway will be marked on the floor with masking tape, with points 
indicated one metre before and after the measured length. Three practice walks will be done 
before the nine recording trials (at normal speed). Participants are to start walking on the 
command “GO”, one metre ahead of the measured walkway, and to stop and wait on the 
command “STOP” (one metre past the end of the walkway). Participants will be asked to turn 
around and repeat the procedure at the same speed three times, at fast speeds three times, 
and three times at preferred speed whilst counting aloud.   
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Instructions will be (normal speed): “Stand on the point marked with the masking tape. When 
I say GO, start walking in a straight line towards the other marker, at a normal, comfortable 
speed. Walk as normal as possible, as you would in everyday life. Only stop walking once I 
say STOP, turn around, and wait for the next instruction”.  
For fast walking, the instruction will be: “Stand on the point marked with the masking tape. 
When I say GO, start walking in a straight line towards the other marker, as fast as you can 
without running; as if trying to catch a bus in time. Only stop walking once I say STOP, turn 
around, and wait for the next instruction”. 
The dual tasking instruction will be: “Stand on the point marked with the masking tape. When 
I say “START COUNTING”, please start counting backwards aloud in units of (7/3/2/1 – as 
previously determined), starting from (random number chosen between 80 and 99). Then, 
when I say GO, keep counting and start walking in a straight line towards the other marker, at 
a normal, comfortable speed. Focus on counting as accurately as possible whilst walking, but 
do not stop walking. Only stop walking and counting once I say STOP, turn around, and wait 
for the next instruction”. 
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Publication PDF: Systematic review article 
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Objective impairments of gait and balance
in adults living with HIV-1 infection: a
systematic review and meta-analysis of
observational studies
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Abstract
Background: Gait and balance deficits are reported in adults with HIV infection and are associated with reduced
quality of life. Current research suggests an increased fall-incidence in this population, with fall rates among middle-
aged adults with HIV approximating that in seronegative elderly populations. Gait and postural balance rely on a
complex interaction of the motor system, sensory control, and cognitive function. However, due to disease
progression and complications related to ongoing inflammation, these systems may be compromised in people
with HIV. Consequently, locomotor impairments may result that can contribute to higher-than-expected fall rates.
The aim of this review was to synthesize the evidence regarding objective gait and balance impairments in adults
with HIV, and to emphasize those which could contribute to increased fall risk.
Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. An electronic search of published observational studies was conducted in March 2016. Methodological
quality was assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
Narrative synthesis of gait and balance outcomes was performed, and meta-analyses where possible.
Results: Seventeen studies were included, with fair to low methodological quality. All studies used clinical tests for
gait-assessment. Gait outcomes assessed were speed, initiation-time and cadence. No studies assessed kinetics or
kinematics. Balance was assessed using both instrumented and clinical tests. Outcomes were mainly related to
center of pressure, postural reflex latencies, and timed clinical tests. There is some agreement that adults with HIV
walk slower and have increased center of pressure excursions and -long loop postural reflex latencies, particularly
under challenging conditions.
Conclusions: Gait and balance impairments exist in people with HIV, resembling fall-associated parameters in the
elderly. Impairments are more pronounced during challenging conditions, might be associated with disease
severity, are not influenced by antiretroviral therapy, and might not be associated with peripheral neuropathy.
Results should be interpreted cautiously due to overall poor methodological quality and heterogeneity. Locomotor
impairments in adults with HIV are currently insufficiently quantified. Future research involving more
methodological uniformity is warranted to better understand such impairments and to inform clinical
decision-making, including fall-prevention strategies, in this population.
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Background
In Southern Africa, about 18.9% of adults aged 15–
49 years are HIV-1-seropositive [1]. Both globally and in
Sub-Saharan Africa, life-expectancy in people living with
HIV (PLHIV) is now comparable to that of seronegative
adults [2–4]. HIV/AIDS has evolved into a chronic con-
dition due to the success of highly-active antiretroviral
therapy (HAART) [2], but this is paralleled by increasing
morbidity. In 1990, HIV/AIDS was the 33rd most im-
portant cause of disability-adjusted life years (DALYs)
globally, but has since increased to fifth position [5]. In
Sub-Saharan Africa, a high prevalence of HIV-associated
disability, including impairments in mobility and motor
function, is reported in PLHIV [6].
Gait and balance deficits have been reported in PLHIV
despite controlled viral load [7–10] and are associated
with reduced quality of life (QOL) [11, 12]. Current
HAART regimes have less neurotoxic effects than older
versions, and thus there is a lower risk of developing
peripheral neuropathy [13]. However, the prevalence of
peripheral neuropathy remains quite high among PLHIV
(between 30% and 62%), and the prevalence of locomotor
impairments remains a concern [14–17]. PLHIV have an
increased incidence of falls [18–20], and fall rates among
middle-aged PLHIV are comparable to that of seronega-
tive older adults, aged 65 years and older [18]. These falls
are attributed to balance impairments [20].
HIV-1 infection may compromise motor function at mul-
tiple levels of the nervous system [13]. Structural MRI-
studies have shown that PLHIV present with white matter
alterations, including reduced pontocerebellar tract integ-
rity, leading to gait and postural instability [21]. It remains
unclear whether gait and balance impairments noted in
PLHIV are due to the disease process or its treatment [22].
One hypothesis is that these deficits occur as a complica-
tion of ongoing inflammation [14, 23, 24]. PLHIV, although
adherent to treatment, experience non-AIDS defining com-
plications resembling geriatric processes at an earlier than
expected age [23, 25]. Chronic immune activation may be
an underlying mechanism [23]. This accelerated aging
manifests in middle-aged PLHIV as the accumulation of
various co-morbidities, including frailty [23, 26].
Of further concern is that PLHIV are four times more at
risk of fractures due to accelerated bone demineralization
[27] and sarcopenia [28], and the proposed interplay
between these conditions [29]. Low bone mineral density
and sarcopenia are associated with balance problems and
falls [28, 30]. These complications may be intrinsic to HIV
infection (e.g. due to metabolic changes) or HAART-
induced [31]. It has been suggested that the loss in bone
mineral density is a result of increased bone turnover,
especially during the first 12 to 24 months after HAART-
initiation [32–34]. Various protease inhibitor (PI) or
nucleoside reverse transcriptase inhibitor (NRTI) type
antiretroviral therapies (ART) show a correlation with
mitochondrial toxicity [22], damaging the structure and
function of muscles. In addition, reduced central activa-
tion of muscles has also been reported in PLHIV, likely
due to impaired oxygen utilisation [35].
Information is building that PLHIV demonstrate gait and
balance impairments. However, owing to the variety of ob-
servational data, it is difficult to quantify the extent of
impairment and to gain insight into which parameters are
truly affected and clinically relevant. In elderly populations,
several gait and balance parameters have been identified as
independent predictors of fall risk, including spatiotempo-
ral, kinetic, kinematic and clinical [36–39]. To the authors’
knowledge, no previous systematic review has yet investi-
gated objective impairments of gait and balance in PLHIV.
The aim of this review is therefore to synthesize the
evidence of objective impairments of gait and balance
associated with HIV-1 infection, and to emphasize those
which could contribute to increased fall risk. We also aimed
to describe the evidence in relation to disease severity,
treatment effects, task difficulty, and peripheral neuropathy.
Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [40].
Criteria for considering studies for this review
Cohort, case-control and cross-sectional studies published
in English as peer-reviewed journal articles were considered.
Studies were included if they aimed to assess instrumented
or non-instrumented objective parameters of gait and/or
balance in adults (18–65 years of age) with HIV-1 infection,
irrespective of gender. Given the expectation that there
would be a paucity of information, studies with and without
comparison groups were considered. Quantitative gait out-
comes included, but were not limited to, kinematics, kinet-
ics, spatiotemporal measures or clinical tests. Quantitative
balance outcomes included, but were not limited to, bio-
mechanical parameters such as center of pressure (COP)
measures, and temporal measures via clinical tests. Studies
were excluded if participants’ age exceeded 65 years, as the
prevalence of locomotor impairments is known to increase
in older age even in healthy populations [41]. Studies aiming
to assess HIV-Associated Neurocognitive Disorder using a
neuropsychological test battery were also excluded, regard-
less of the use of a gross motor component, in an attempt
to focus on studies with the primary aim of objectively
assessing and describing gait or balance in PLHIV.
Search methods for identification of studies
Information sources
Six computerized bibliographic databases were searched,
namely PubMed, Science Direct, EBSCOhost (CINAHL,
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MEDLINE, Africa-Wide Information), Scopus, ProQuest
Medical Library and Google Scholar. Following a prelimin-
ary search of PubMed, a comprehensive search strategy,
including all relevant key word/terms and medical subject
headings (MeSH) was developed and adapted for use in
subsequent searching of the remaining databases. Search
terms included: (HIV-1 OR HIV Infection*) AND (motor
function OR biomechanical phenomena OR gait OR
postural balance OR locomotor function). The search was
restricted to papers published from inception of the
database to March 2016. Reference lists of all identified
documents were hand-searched to identify additional
relevant evidence. In the event of missing data, an attempt
was made to contact the authors.
Study selection
Titles and abstracts of all initial hits were screened by one
reviewer (KB). When necessary, consultation with a second
reviewer (QL) was pursued. All potential full texts were
subsequently screened by these two reviewers, and eligibil-
ity criteria were applied independently. Any discrepancies
regarding eligibility were discussed between reviewers to
reach consensus.
Data collection and analysis
Methodological quality appraisal
One reviewer (KB) appraised the methodological quality
of each included study using the National Institutes of
Health (NIH) Quality Assessment Tool for Observational
Cohort and Cross-Sectional Studies [42]. The tool is
designed to aid appraisal of internal validity (potential risk
of selection-, information-, or measurement bias, or
confounding) of cross-sectional and cohort studies and
was therefore appropriate for this review. It comprizes 14
criteria. All criteria can be answered as “yes”, “no”, “cannot
determine”, “not applicable” or “not reported”. All
responses other than “yes” indicate risk of bias. Inherent
to the design, cross-sectional studies automatically score
“not applicable” on criteria 6, 7, 10 and 13. After all 17
articles were scored by the first reviewer, two of these were
randomly selected for audit and independently scored by a
second reviewer (LM). The scores assigned by each
reviewer were compared by specifically discussing those
criteria with discrepant scores. Consistent discrepancies
were noted specifically for criteria 6, 10 and 13 for both
studies – which were resolved after agreeing that these
criteria should be scored as “not applicable” as per the
instrument’s instructions. Resultant total scores were
similar; thus it was not deemed necessary for the second
reviewer to score the remaining 15 articles as well. Each
criterion was weighted equally in the overall grading, and
studies were not excluded based on quality score, due to
the expected dearth of information.
Data extraction
Data extracted from each study were summarized using a
customized Excel spreadsheet, based on Cochrane forms.
Information about sample demographics as well as the
study aims, study design, known confounders to gait and
balance, descriptors of HIV-disease, gait or balance
analysis tool or test used, specific objective gait or balance
outcomes, dose-response evidence, treatment effects, as-
sociation of disease severity, association of peripheral
neuropathy, findings and limitations of each study were
extracted. Principle summary measures were means and
standard deviations (SD).
Data analysis or synthesis
Narrative description of data was done using text
summaries or tables as appropriate. For outcomes that
were reported in at least two studies, a meta-analysis was
conducted in Revman version 5.2, provided that homo-
geneity in the outcomes and samples existed regarding
units of measurement, test conditions, gender and disease
severity. Mean differences and 95% confidence intervals
(CI) were calculated via a random effects model, provided
that means and SD were reported, and were presented
graphically as forest plots. Symptomatic (presenting with
various symptoms of chronic HIV disease) and asymp-
tomatic (asymptomatic HIV infection/clinically latent
phase of HIV) subgroups of PLHIV were analyzed.
Results
Study selection
The initial search in March 2016 produced 799 total hits
(Fig. 1). After removing duplicates and applying eligibility
criteria, 93 potential titles remained. Thirty studies were
subsequently excluded upon reading the abstracts. The
main reasons for exclusion were that the outcome mea-
sures were not relevant to the review question, participants
were not within the specified age range, and study design
was inappropriate. Following full text review, the number
of studies for inclusion was reduced to 17. Primary reasons
for exclusion were inability to obtain full text, ineligible
participants, no raw data and outcomes that were not
relevant to the review question.
Study characteristics
Critical appraisal of study quality
Table 1 presents the methodological quality appraisal
scores of the included studies, which ranged from fair to
poor. A mean score of 40.34% was obtained, ranging from
7.14% (lowest internal validity amongst the included
studies) to 57.14% (strongest internal validity amongst the
included studies).
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 3 of 26
Stellenbosch University  https://scholar.sun.ac.za
Study sample description
Participant numbers varied from 19 to 447. Six studies
did not include a control group [8–10, 12, 18, 35]. Mean
ages ranged from 28 to 54.7 years. Two studies included
males only [35, 43]. Only one study [44] was conducted
in Sub-Saharan Africa. Table 2 summarizes the sample
characteristics of all participants, while HIV-specific
sample characteristics are presented in Table 3.
Study design, aims and outcomes
Sixteen studies were cross-sectional, and one was a
prospective cohort [9]. Study aims varied (Table 4), but all
included objective measurement of balance and/or gait as
part of the primary aim. Balance was assessed using both
clinical and instrumented tests. All studies used timed
clinical tests for assessing gait. No studies assessed gait kin-
etics or kinematics. Outcomes varied substantially. Table 5
(balance) and Table 6 (gait) present the outcomes assessed
per study. Summaries of the results for individual outcomes
are presented briefly in Table 7 (balance) and Table 8 (gait),
and presented in more detail as additional files (see
Additional file 1 for balance and Additional file 2 for gait).
Static balance Five studies assessed static balance using
clinical tests. One study [45] assessed Romberg eyes-
closed-on-foam and found the frequency of impairment
to be higher in PLHIV. Tandem stance time was normal
in PLHIV [21]. Four studies assessed single leg stance time
[8, 9, 21, 22]. Impairments were noted either only with
eyes closed, or with synergistic obesity, or when standing
on the non-preferred leg (eyes open and closed).
One study [46] assessed COP sway path using a force
plate, and found the incidence of increased values to be
larger in advanced stages of infection and task difficulty.
Sway velocity was examined by another study [47]. A
significant increase was found in neurologically symp-
tomatic PLHIV regardless of visual condition, and about
25% of PLHIV with asymptomatic HIV infection also
demonstrated increased values.
Average velocity in anterior-posterior (AP) and average
velocity in lateral (LAT) directions were assessed by one
study [48]. PLHIV with asymptomatic HIV infection had
significantly increased AP only in the eyes closed condi-
tion, while PLHIV with symptoms of chronic HIV dis-
ease had significantly increased AP both with eyes open
and eyes closed, as well as significantly increased LAT
(only with eyes closed).
Two studies [47, 48] assessed the coefficient of the pref-
erential direction of movement (AP/LAT ratio) and found
this to be normal in PLHIV. Romberg ratio of area (RA)
Fig. 1 PRISMA flow diagram of literature search and selection process
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 4 of 26
Stellenbosch University  https://scholar.sun.ac.za
Ta
bl
e
1
M
et
ho
do
lo
gi
ca
lq
ua
lit
y
ap
pr
ai
sa
l
Tr
en
kw
al
de
r
19
92
[4
6]
Ar
en
dt
19
94
[4
7]
Be
ck
le
y
19
98
[5
0]
Ba
ue
r
20
05
[7
]
D
el
le
pi
an
e
20
05
[4
8]
Si
m
m
on
ds
20
05
[4
9]
Sc
ot
t
20
07
[3
5]
Ri
ch
er
t
20
11
[8
]
Ba
ue
r
20
11
[2
2]
Su
lli
va
n
20
11
[2
1]
Er
la
nd
so
n
20
12
a
[1
0]
Er
la
nd
so
n
20
12
b
[1
8]
Co
he
n
20
12
[4
5]
Be
an
s
20
13
[4
3]
M
ba
da
20
13
[4
4]
Ri
ch
er
t
20
14
[9
]
Er
la
nd
so
n
20
14
[1
2]
1
Re
se
ar
ch
qu
es
tio
n/
ob
je
ct
iv
e
cl
ea
rly
st
at
ed
?
N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
2
St
ud
y
po
pu
la
tio
n
cl
ea
rly
sp
ec
ifi
ed
an
d
de
fin
ed
?
N
N
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
3
Pa
rt
ic
ip
at
io
n
ra
te
of
el
ig
ib
le
pe
rs
on
s
at
le
as
t
50
%
?
CD
CD
CD
CD
CD
CD
CD
N
CD
CD
Y
Y
Y
Y
CD
N
CD
4
Al
ls
ub
je
ct
s
re
cr
ui
te
d
fro
m
sim
ila
r
po
pu
la
tio
ns
?
El
ig
ib
ili
ty
cr
ite
ria
pr
e-
sp
ec
ifi
ed
an
d
ap
pl
ie
d
un
ifo
rm
ly
?
N
R
N
N
Y
N
R
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
5
Ju
st
ifi
ca
tio
n
of
sa
m
pl
e
siz
e?
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
6
Ex
po
su
re
(s
)m
ea
su
re
d
pr
io
rt
o
ou
tc
om
e(
s)
?a
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
7
Su
ffi
ci
en
t
tim
ef
ra
m
e
to
se
e
an
as
so
ci
at
io
n
be
tw
ee
n
ex
po
su
re
an
d
ou
tc
om
e?
a
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
8
D
iff
er
en
t
le
ve
ls
of
th
e
ex
po
su
re
m
ea
su
re
d,
as
re
la
te
d
to
th
e
ou
tc
om
e?
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
9
Ex
po
su
re
m
ea
su
re
s
cl
ea
rly
de
fin
ed
,v
al
id
,
re
lia
bl
e,
an
d
im
pl
em
en
te
d
co
ns
ist
en
tly
?
N
R
Y
Y
Y
N
R
Y
Y
Y
Y
Y
Y
Y
Y
N
R
Y
Y
Y
10
Ex
po
su
re
(s
)
as
se
ss
ed
m
or
e
th
an
on
ce
ov
er
tim
e?
a
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
CD
N
11
O
ut
co
m
e
m
ea
su
re
s
cl
ea
rly
de
fin
ed
,
va
lid
,r
el
ia
bl
e,
an
d
im
pl
em
en
te
d
co
ns
ist
en
tly
?
CD
N
R
N
R
N
R
CD
Y
Y
N
R
Y
N
R
N
N
N
Y
Y
N
R
CD
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 5 of 26
Stellenbosch University  https://scholar.sun.ac.za
Ta
bl
e
1
M
et
ho
do
lo
gi
ca
lq
ua
lit
y
ap
pr
ai
sa
l(
Co
nt
in
ue
d)
12
O
ut
co
m
e
as
se
ss
or
s
bl
in
de
d
to
ex
po
su
re
st
at
us
?
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
13
Lo
ss
to
fo
llo
w
-u
p
af
te
r
ba
se
lin
e
≤
20
%
?a
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
14
Ke
y
po
te
nt
ia
l
co
nf
ou
nd
er
s
m
ea
su
re
d
an
d
st
at
ist
ic
al
ly
ad
ju
st
ed
fo
r?
N
N
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
To
ta
lC
AT
sc
or
e
/1
4
1
3
3
7
2
6
7
6
6
6
7
7
7
7
7
8
6
To
ta
lC
AT
%
7.
14
21
.4
3
21
.4
3
50
14
.2
9
42
.8
6
50
42
.8
6
42
.8
6
42
.8
6
50
50
50
50
50
57
.1
4
42
.8
6
Ab
br
ev
ia
tio
ns
:C
D
ca
nn
ot
de
te
rm
in
e,
N
R
no
t
re
po
rt
ed
a C
ro
ss
-s
ec
tio
na
la
na
ly
se
s
pr
ov
id
e
w
ea
ke
r
ev
id
en
ce
th
an
co
ho
rt
st
ud
ie
s
re
ga
rd
in
g
a
po
te
nt
ia
lc
au
sa
lr
el
at
io
ns
hi
p
be
tw
ee
n
ex
po
su
re
s
an
d
ou
tc
om
es
.F
or
cr
os
s-
se
ct
io
na
la
na
ly
se
s,
th
e
an
sw
er
to
Q
ue
st
io
ns
6,
7,
10
&
13
sh
ou
ld
be
“N
o”
.A
ll
st
ud
ie
s
w
er
e
cr
os
s-
se
ct
io
na
l,
ex
ce
pt
fo
r
Ri
ch
er
t
20
14
(p
ro
sp
ec
tiv
e
lo
ng
itu
di
na
lc
oh
or
t)
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 6 of 26
Stellenbosch University  https://scholar.sun.ac.za
Table
2
Sam
ple
characteristics,allparticipants
Study
ID
Country,
setting
Serostatus
&
sam
ple
size
(N
)
G
ender
(%
)
Age
(years)
(SD
)
BM
I(kg/m
2)
(SD
)
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as well as Way (average velocity of movement) was found
to be increased in all HIV groups [48].
Sensory Organisation Test (SOT) sway strategy score
was found to be lower (which is worse, as it indicates
more reliance on the hip strategy as opposed to the ankle
strategy) for bilateral stance (eyes closed) in PLHIV [22].
Two studies [7, 22] reported on SOT Equilibrium
Quotient (EQ) and reported significant impairments in
PLHIV during the most difficult SOT subtests (eyes closed
or inaccurate visual input).
Table 3 Sample characteristics, PLHIV
Study ID Disease staging CD4 cell count,
cells/mm3 (SD)
Viral load (SD) Treatment
Trenkwalder
1992 [46]
WR I-II (N = 17); WR III-V
(N = 19); WR VI (N = 14)
NR NR NR
Arendt
1994 [47]
CDC II (N = 12); CDC III (N = 12);
CDC IV C1 (N = 5); CDC IV C2 (N = 5);
CDC IV D (N = 2); CDC IV B (N = 10)
NR NR NR
Beckley
1998 [50]
ASX (N = 2); CDC Stage A (N = 2);
CDC Stage B (N = 2); CDC Stage
C (N = 3)
Range 65–701; 5
participants had
AIDS-defining CD4
counts (<200)
NR Most were on zidovudine maintenance
therapy
Bauer
2005 [7]
NR NRx: 351 (282);
NNRTI: 457 (375);
PI: 320 (200)
HIV burden × 1000 copies/ml:
NRx: 93.8 (163); NNRTI: 35.5
(102); PI: 20.1 (48.2)
NRx: N = 28; NNRTI: N = 25;
PI: N = 37
Simmonds
2005 [49]
Based on CD4 count
ASX (CD4 > 200) (N = 52);
AIDS (CD4 < 200) (N = 48)
Range 189.83 (183.27)
- 386.36 (302.39)
Virions:
ASX 33545.25; AIDS
193401.00
NR
Dellepiane
2005 [48]
CDC classificationASX (N = 15);
AIDS (group IV) (N = 15)
NR NR NR
Scott
2007 [35]
NR 408 (293) log copies/ml
2.18 (0.94)
All were on a NRTI-based regimen,
with 82% receiving a PI as a third agent
Richert
2011 [8]
CDC category C: 23% a520 (348, 709) <500 copies/ml: 83% 89%
Bauer
2011 [22]
NR BMI <21: 280 (52); BMI
21–29: 422 (40);
BMI > 29: 361 (64)
Log10 viral load
BMI <21: 3.06 (0.34);
BMI 21–29: 2.19
(0.26); BMI > 29: 2.08 (0.39)
% no ART/NNRTI-based ART/ PI-based ART:
BMI <21: 38.2/26.5/35.3; BMI 21–29:
31.7/26.7/
41.7; BMI > 29: 37.0/18.5/44.4
Sullivan
2011 [21]
NR M 537.4 (258.97); F
583.4 (103.55)
M 13597.6 (4654.88);
F 4609.7 (3226.36)
HAART: N = 25; Non-HAART: N = 6;
NRx: N = 9
Erlandson
2012a [10]
NR a551 (361, 768) Detectable
(≥48 copies/mL): 5%
NR
Erlandson
2012b [18]
NR 594 (16) 95% had plasma HIV-1
RNA < limits of detection
Any didanosine: Non-fallers: 57 (23);
Single fallers: 10 (23); Recurrent fallers:
24 (36) Any stavudine: Non-fallers: 93 (37);
Single fallers: 22 (51); Recurrent fallers: 33
(50) Efavirenz: Non-fallers: 86 (34); Single
fallers: 10 (23); Recurrent fallers: 22 (33)
Cohen
2012 [45]
NR 556.4 (284) Log10HIV RNA:
a3.50 (2.68, 4.42)
HAART: 76.9%
Beans
2013 [43]
NR a445 (265, 531) Non-detectable
(<400 copies/ml): 91%
Majority were receiving cART
Mbada
2013 [44]
All: Clinical stage I of HIV/AIDS
(ASX HIV infection, with PGL)
NR NR 100% HAART
Richert
2014 [9]
CDC stage C 24% a506 (340, 715) HIV RNA level < 500
copies/ml: 84%
89% on ART
Erlandson
2014 [12]
NR 594 (303) HIV-1 RNA < limits
of detection: 95%
All participants taking effective cART
Abbreviations: AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, ASX asymptomatic, BMI Body Mass Index, cART combination antiretroviral
therapy, CDC Centre for Disease Control, F female, HAART highly active antiretroviral therapy, HIV human immunodeficiency virus, IQR interquartile range, M male,
N number of participants, NA not applicable, NNRTI non-nucleoside reverse transcriptase inhibitor, NR not reported, NRTI nucleoside reverse transcriptase inhibitors,
NRx no treatment, PGL Persistent generalized lymphadenopathy, PI protease inhibitor, PLHIV people living with HI, SD standard deviation, SX symptomatic, WR
Walter Reed staging
aMedian (IQR)
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Meta-analyses (Figs. 2 and 3) were performed for postural
sway area [47, 48]. With eyes open, asymptomatic PLHIV
and controls had similar sway areas, while PLHIV with symp-
toms of chronic HIV disease demonstrated a significant
increase. Overall, sway area was significantly increased in
PLHIV (combined group of those with and without symp-
toms of HIV). With eyes closed, PLHIV with asymptomatic
HIV infection had normal sway areas, while PLHIV with
symptoms of chronic HIV disease demonstrated a significant
increase. Overall, sway area was increased in PLHIV.
Thus, the observed overall treatment effect in the com-
bined group differed across the different subgroups. Homo-
geneity seems to exist between the sample estimates within
the subgroups (I2 = 0% for all groups), while a significant
interaction existed between the subgroups (I2 = 86.4% &
87.9% for the two outcomes, respectively), suggesting that the
population parameters estimated by the subgroups are differ-
ent. It should however be noted that the conjecture about
homogeneity between sample estimates in these subgroup
does not necessarily mean that the presence/absence of
symptoms in PLHIV fully explains the heterogeneity
observed across studies. In fact, the small number of studies
and sample sizes for these outcomes might not provide
adequate statistical power in demonstrating heterogeneity.
A meta-analysis (Fig. 4) was done for Romberg ratio of
sway velocity (sway with eyes closed/sway with eyes open)
[47, 48]. PLHIV with asymptomatic HIV infection had
normal values, while PLHIV with symptoms of chronic
HIV disease demonstrated a significantly larger Romberg
ratio (which is worse as it indicates a higher amount of
visual dependency). Overall, Romberg ratios were similar
between the combined group of PLHIV and controls.
Substantial heterogeneity was found within the combined
group (I2 = 88%, p = 0.004 and I2 = 91%, p = 0.00001, re-
spectively). When splitting the subgroups according to
presence of symptoms, PLHIV with asymptomatic HIV in-
fection still showed evidence of high heterogeneity and non-
significant results regarding impairment, while symptomatic
Table 4 Study aims
Study ID Design Aim
Trenkwalder 1992 [46] Cross-sectional To measure postural performance quantitavely in PLHIV (in different disease stages)
versus seronegative controls, using a force plate.
Arendt 1994 [47] Cross-sectional To determine if stance control is impaired in early versus late HIV infection, using a
force plate, and to compare results with the COG patterns in pyramidal or extrapyramidal disease.
Beckley 1998 [50] Cross-sectional To evaluate postural reflexes with EMG in PLHIV without obvious neurological disease,
in order to determine whether postural reflexes are early markers of CNS involvement.
Bauer 2005 [7] Cross-sectional To assess sensorimotor function in PLHIV and seronegative controls.
Simmonds 2005 [49] Cross-sectional To characterize physical performance in PLHIV, and to examine group differences by pain and fatigue.
Dellepiane 2005 [48] Cross-sectional To investigate whether posturography can detect the presence of possible disorders of
the vestibulo-spinal reflex.
Scott 2007 [35] Cross-sectional To determine the extent of neuromuscular activation of selected lower limb muscles of
male PLHIV receiving ART, and its relationship to performance in clinical functional tests.
Richert 2011 [8] Cross-sectional To provide standardized assessments of locomotor function in PLHIV, focusing on lower
limb muscle performance and balance, and on potential determinants of functional impairment.
Bauer 2011 [22] Cross-sectional To compare balance and gait in participants who differ in BMI and the presence or absence of HIV/AIDS.
Sullivan 2011 [21] Cross-sectional To investigate whether infratentorial brain volume would be marked by regional tissue shrinkage
in PLHIV versus seronegative controls, and whether tissue deficits would be related to impairment
in postural stability or psychomotor speed, using structural MRI and quantitative tests of postural
stability, finger movement, psychomotor speed and dexterity.
Erlandson 2012a [10] Cross-sectional To compare the FFP, SPPB, and 400-m walk in PLHIV.
Erlandson 2012b [18] Cross-sectional To determine fall-rate and -risk factors among PLHIV by correlating fall history, medical diagnoses,
and functional tests.
Cohen 2012 [45] Cross-sectional To determine whether PLHIV on HAART had an increased prevalence of vestibular disorders
versus seronegative controls, using standard screening tests of vestibular and balance function.
Beans 2013 [43] Cross-sectional To compare locomotor function in male PLHIV versus seronegative controls, and test the association
with aerobic exercise capacity.
Mbada 2013 [44] Cross-sectional To compare HRQOL and a performance-based measure of functional capacity between a
homogenous sample of clinical stage I PLHIV versus seronegative controls.
Richert 2014 [9] Prospective cohort To prospectively assess the changes in locomotor function in PLHIV over time and to evaluate the
determinants of variations in lower limb muscle performance.
Erlandson 2014 [12] Cross-sectional To assess the impact of physical function impairments on HRQOL in PLHIV using ART.
Abbreviations: ART antiretroviral therapy, BMI body mass index, CNS central nervous system, COG centre of gravity, EMG electromyography, FFP Fried’s Frailty
Phenotype, HRQOL health-related quality of life, PLHIV people living with HIV, SPPB Short Physical Performance Battery
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Table 7 Summary of objective balance outcomes and results
Study ID Results Method of measurement Outcomes assessed
Trenkwalder
1992 [46]
b,a 4 conditions on force plate: Bilat stance EO + stable;
Bilat stance EC + stable; Bilat stance EO + foam;
Bilat stance EC + foam.
Mean sway path (m/min): EO & EC + foamb
(all PLHIV except WR I-II)/EC + stable or foamb
(all PLHIV)/All other conditions a
Arendt
1994 [47]
b,a 2 conditions on force plate: Bilateral stance EO;
Bilateral stance EC.
Sway velocity (m/s)b / AP/LAT quotient a
Beckley
1998 [50]
b,a Leg reflexes elicited in participants while standing
upright on movable force plate - surface EMG
recordings obtained from left tibialis anterior and
medial gastrocnemius
Onset latencies (SL, ML and LL) (ms) / Normalized amplitude
of MLa/LL-amplitude scaling (predictable a; unpredictable b)
Bauer
2005 [7]
b,a 1) SOT, 3 conditions: EO, EC, inaccurate visual input
2) Forward/backward lean tests
3) (Single-leg stance test)
1) SOT, for each condition: EQ. (EOa, ECb, inaccuratea)
/Number of fallsa/Time before a fall (seconds)a
2) FBOS (Lean amplitude/ft length)b
3) (Single Leg Stance time (s) - results not presented)
Simmonds
2005 [49]
a Loaded forward reach
Unloaded forward reach
Distance reached (cm)a
Richert
2011 [8]
a,c 1) BBS
2) TUG test
3) FR test
4) SLS, EC
5) 5STS
1) Berg scorea
2) TUG time (sec)a
3) Reach distance (cm)a
4) SLS time (sec)c
5) 5STS time (sec)c
Dellepiane
2005 [48]
b, a 1) Static posturography: Romberg’s position on
force plate; EO & EC
2) Dynamic posturography: EO & EC; leg reflexes
elicited via sudden tilts of moveable force plate,
EMG recorded
1) Static:
Way (EO & EC, SXb), Area, AP (ASX in ECb, SX in EOb & ECb),
LAT (SX in ECb), AP/LATa, RW, RAb
2) Dynamic (SL, ML and LL):
Latency (SL: EO & EC, all HIV groupsb) (ML: EO, SX, both legsb;
EO, ASX, left leg b; EC, all groupsa) (LL: EC, SXb; EC, ASXa)/Duration
(SL: EO, all PLHIV a; EC, SX, left legb) (ML: EO, all PLHIVa; EC, all
PLHIV, bilatb) (LL, EC, all PLHIVb) /Amplitudea/Area of single EMGa
Bauer
2011 [22]
b, a 1) SOT, 3 conditions: EO, EC, inaccurate visual input
2) Forward/backward lean tests
3) SLS test
4) 360-degree turn test
5) 5STS test
1) SOT: Dependent variables calculated for each condition were:
EQ (ECb, inaccurate inputb)
Sway strategy score (ECb)
2) LOS (lean amplitude/ft length)b
3) SLST time (seconds) (only obese PLHIV, non-preferred legb)
4) 360 deg. turn time (seconds) (only obese PLHIVb)
5) 5STS time (seconds)a
Sullivan
2011 [21]
b, a Walk-a-Line Battery. Conditions: Stand Heel-to-Toe;
Walk Heel-to-Toe; and SLS.
1) Stand Heel-to-Toe time (seconds)a
2) SLS time (seconds) (non-preferred legb)
3) Walk-Heel-to-Toe - number of steps out of 10 (ECb)
Cohen
2012 [45]
c Romberg tests on stable and on foam, 4 conditions:
EO + stable, EC + stable, EO + foam, EC + foam.
Romberg time, EC + foam (seconds)c
Erlandson
2012a [10]
c Tandem stand and 5STS as part of SPPB 5STS time (part of SPPB score)c/Tandem stance time
(part of SPPB score)c
Erlandson
2012b [18]
c Tandem stand and 5STS as part of SPPB 5STS time (part of SPPB score)c/Tandem stance time
(part of SPPB score)c
Richert
2014 [9]
c 1) 5STS test
2) TUG test
3) SLS test
1) 5STS time (seconds)c
2) TUG time (seconds)c
3) SLS time (seconds)c
Erlandson
2014 [12]
c 5STS 5STS pace (rises/s)c
Outcomes included in meta-analyses are not included in this table
Abbreviations: 5STS 5-times-sit-to-stand, AP Average velocity in anterior-posterior direction, ASX asymptomatic; BBS Berg Balance Scale, Bilat bilateral, COP center of
pressure, deg. degree, EC eyes closed, EMG electromyography, EO eyes open, EQ equilibrium quotient, FBOS functional base of support, FR functional reach, LAT
average velocity in medial-lateral direction, LL long loop, LOS limits of stability, ML medium loop, PLHIV people living with HIV, RW Romberg index reported to
way = ratio of way with EO & EC, RA Romberg index reported to area = ratio of area with EO & EC, SL short loop, SLS single leg stance, SOT sensory organization
test, SX symptomatic, TUG timed-up-and-go
ano significant difference between PLHIV and controls
bPLHIV significantly impaired compared to controls or normative reference values
cNo comparison provided/impairment quantified by reporting proportion of PLHIV with deficits
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PLHIV produced no evidence of heterogeneity (I2 = 0%)
whilst showing significant impairment for this outcome.
The high heterogeneity that exists particularly in the
asymptomatic subgroup of PLHIV might be attributed to
differences in the study populations used by the two stud-
ies. Differences existed in the sample sizes used (36
asymptomatic PLHIV in Arendt (1994) [47] versus only
15 in Dellepiane et al. (2005) [48]). Also, the age of the
asymptomatic participants in these studies differed (mean
of 36.33 versus 28 years). Finally, although both studies
had similar definitions of “symptomatic” participants, only
Arendt (1994) further classified the asymptomatic group
into CDC disease stages.
Dynamic balance Both the Berg Balance Scale [8] and
Timed-Up-And-Go (TUG) test [8, 9] were normal in
PLHIV. For 5-Times-Sit-To-Stand (5STS) time, one study
[22] found no group differences, while another [8] reported
poor performance in PLHIV. The prospective cohort [9]
reported an impaired 5STS time at baseline, and that 31%
of PLHIV had a decline in performance over 1 year that
was greater than the empirically defined threshold. Only
Table 8 Summary of objective gait outcomes and results
Study ID Results Method of assessment Spatiotemporal outcome
Bauer 2005 [7] a 8-m walk (preferred and fast) Gait speed: time (sec) to cover distancea
Cadence (time in sec for 5 steps)a
Simmonds 2005 [49] b 50-ft (15.24-m) walk (preferred and fast) Gait speed: time (sec) to cover distanceb
Scott 2007 [35] b 6MWD Distance covered (m) in 6 minb
Richert 2011 [8] c 6MWD Distance covered (m) in 6 minc
Bauer 2011 [22] b 8-m walk (preferred and fast) Preferredb and fast gait initiation time (sec)
Fastb and preferred gait speed (m/s)
Fast and preferred cadence (time in sec for 5 steps)
Erlandson 2012a [10] c 4-m walk as part of SPPB
400-m walk (fast)
Only presented as part of SPPB score
Gait speed (m/s)c
Erlandson 2012b [18] c 1) 4-m walk as part of SPPB
2) 400-m walk (fast)
1) Only presented as part of SPPB score
2) Gait speed (m/s)c
Beans 2013 [43] d,a 1) 6MWD
2) 400-m long distance corridor walk
1) Distance covered (m) in 6 mina
2) Gait speed: time (sec) to cover distanced
Richert 2014 [9] b 1) 6MWD
2) 10-m walk
1) Distance covered (m) in 6 minb
2) Gait speed (m/s)
Erlandson 2014 [12] c 400-m walk (fast pace) Gait speed (m/s)c
Outcomes included in meta-analyses are not included in this table
Abbreviations: 6MWD 6 min walk distance, m meters, min minutes, sec seconds, SPPB short physical performance battery
aNo significant difference between PLHIV and controls
bPLHIV significantly impaired compared to controls or normative reference values
cNo comparison provided/impairment quantified by reporting proportion of PLHIV with deficits
dControls performed worse
Fig. 2 Meta-analysis of sway area (μVxs) in PLHIV, eyes open
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PLHIV who were also obese performed worse in the 360-
Degree-Turn test [22]. Walk-Heel-To-Toe was significantly
impaired in PLHIV with eyes closed [21]. Two studies [8,
49] evaluated forward-reach distance, with no significant
deficits noted.
The Functional Base of Support (FBOS) or Limits
of Stability (LOS) tests were assessed by two studies
[7, 22]; both reported significant impairments in all
PLHIV.
Duration of postural reflexes was assessed by one study
[48]. With eyes closed, there was a significant reduction
for medium loop (ML) duration and long loop (LL)
duration in all HIV groups. Amplitude of postural reflexes
and area of single electromyography (EMG) potential were
normal in PLHIV [48]. Neurologically intact PLHIV
showed abnormal regulation of postural reflexes (LL amp-
litude scaling) under unpredictable, but not predictable,
perturbations [50].
Meta-analyses were conducted for postural sway latencies
[47, 48, 50] (Figs. 5, 6, 7, 8 and 9). For the left leg, short
loop (SL) latencies for combined PLHIV groups were nor-
mal, with significantly increased values only in PLHIV with
symptoms of chronic HIV disease upon further analysis.
These findings were similar for the right leg. ML latencies,
only assessed in two of the studies [48, 50] and only for the
left leg, were significantly increased in combined PLHIV
groups. In both legs, LL latencies were significantly
increased in symptomatic, but not asymptomatic, PLHIV.
The combined PLHIV group still showed a significant
increase in LL latencies.
Fig. 3 Meta-analysis of sway area (μVxs) in PLHIV, eyes closed
Fig. 4 Meta-analysis of Romberg ratio of sway velocity in PLHIV
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 17 of 26
Stellenbosch University  https://scholar.sun.ac.za
Gait Gait speed was assessed in eight studies [7, 9, 10, 12,
18, 22, 43, 49]. PLHIV demonstrated slowing of fast gait
speeds [18, 43, 49]. One study [7] found no significant dif-
ferences between PLHIV and controls, regardless of pace.
Meta-analysis [44, 49] (Fig. 10) indicated that 6-Minute
Walk Distance (6MWD) was significantly shorter (worse)
in PLHIV compared to controls. The likelihood of high
heterogeneity in this meta-analysis should be considered
(I2 = 65%, p = 0.09) and might be due to the use of histor-
ical controls in one study [49] and differences in disease
staging between the two studies. Among the un-pooled
studies, three reported a decreased (worse) 6MWD [8, 9,
35], and one study found no impairment in PLHIV [43].
One study reported no impairments in PLHIV in cadence
[7] and another reported that only PLHIV who were also
obese were significantly impaired [22]. This study also
reported that PLHIV had significantly delayed (worse)
normal gait initiation time.
Falls One study [50] reported that fall incidence during
unpredictable perturbations was similar in PLHIV versus
controls. Similarly, another study [7] found no group dif-
ferences in falls during SOT conditions. In contrast, one
study reported a similar fall rate in middle-aged PLHIV
(mean 52.0 years) and seronegative older adults (≥65 years)
[18]. Impaired balance was a major associated factor. In
addition, recurrent fallers had significantly slowed gait
versus non-fallers. Furthermore, in a prospective cohort
[9], it was reported that 12% of PLHIV experienced a
minimum of one fall in the previous year. In PLHIV with
recurrent falls, baseline 5STS time and 6MWD were
significantly impaired, compared to non-fallers.
Measurement conditions and task difficulty Twelve
studies included some form of increasing task difficulty,
such as different visual input, stable versus unstable
support surfaces, decreased base of support, predictable
and unpredictable external perturbations, and walking at
preferred versus fast gait speeds. Of these, nine (75%)
demonstrated that both balance and gait impairments were
more evident in more difficult task conditions, when com-
paring PLHIV to controls [7, 10, 18, 21, 22, 45, 46, 49, 50].
Disease severity Fifteen studies reported on the relation-
ship between HIV-disease severity and locomotor per-
formance. Of these, eight (53%) indicated a relationship
between HIV-disease severity and impairments [7, 8, 10,
35, 46–48, 50]. In contrast, seven studies (46%) found no
significant differences based on CD4 counts or viral loads
[9, 21, 22, 43, 45, 49, 50].
Fig. 5 Meta-analysis of left leg postural reflex latencies in PLHIV: short loop latencies (ms)
Fig. 6 Meta-analysis of left leg postural reflex latencies in PLHIV: medium loop latencies (ms)
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Treatment effects Seven studies reported on the relation-
ship between ART and impairments in gait and/or balance,
and none of these found any association [7–10, 21, 22, 35].
Peripheral neuropathy Five studies reported on the as-
sociation between peripheral neuropathy and impairments
in gait and/or balance in PLHIV, and none of these found
statistically significant correlations between peripheral
neuropathy and impairments of gait, dynamic balance or
static balance [7, 8, 21, 46, 47].
Discussion
The aim of this review was to establish the current state
of knowledge regarding objective impairments of gait and
balance in PLHIV, and to emphasize those which could
contribute to increased fall risk. To the authors’ know-
ledge, this is the first work to do so. Our findings indicate
that certain aspects of gait and balance are impaired in
middle-aged PLHIV, resembling those proven to predict
increased fall risk in elderly populations.
The methodological quality of articles ranged from fair
to low, partly as a direct consequence of observational
design. Earlier studies in particular had a high risk of se-
lection bias due to omitting important information such
as participant demographics and exclusion criteria. The
psychometric properties of the different tests used to as-
sess outcomes have not yet been evaluated in PLHIV;
therefore, they cannot be assumed to be valid and reliable
in this specific population. Balance and gait in PLHIV may
be influenced by various factors apart from HIV-status.
Fig. 7 Meta-analysis of left leg postural reflex latencies in PLHIV: long loop latencies (ms)
Fig. 8 Meta-analysis of right leg postural reflex latencies in PLHIV: short loop latencies (ms)
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Although studies on average controlled and adjusted for
many key confounders such as age, gender, BMI, markers
of HIV and co-morbidities, very few reported on covari-
ates such as level of education or adherence to treatment,
and none on level of physical activity.
Various gait and balance parameters, including slowed
gait speed [38], cadence [51], slowed gait initiation time
[52] slowing of postural reflexes [53], and increased
COP displacement and velocity [54] have been estab-
lished to be associated with increased risk of falls in the
elderly. Similarly, some of these variables are associated
with risk of falls in PLHIV, namely slowed gait speed
and impaired dynamic balance [18]. It has been reported
that the best fall risk predictors in PLHIV are those
proven to be predictors of fall risk in the elderly [18].
Static balance
Static balance is often quantified in terms of COP move-
ment [55], which reflects neuromuscular control to keep
the center of mass (COM) within the base of support’s
limits of stability [56–58]. Increased COP movement and
velocity is associated with increased fall risk in the elderly
[54]. In this review, evidence of increased postural sway or
velocity was found in all studies evaluating these parame-
ters, especially under challenging conditions [46–48], and
was confirmed by meta-analyses. Impaired COP sway in
PLHIV with asymptomatic HIV infection may suggest early
involvement of postural control due to direct infection of
the CNS by HIV. However, in neurologically symptomatic
PLHIV, it cannot be assumed that anatomical structures or
direct HIV-involvement of the CNS causes the observed
deficits [46]. Lower limb muscle impairment might impair
a person’s ability to correct a shift in the body’s COP to
effectively prevent a fall [59]. In the elderly, it has been
proposed that increased COP movement may be inter-
preted as an increase in hip abductor muscle activity to
control postural stability on the medial-lateral direction
[59]. It has also been suggested that decreased postural
control with larger body sway increases tibialis anterior/so-
leus muscle co-activation, inducing the hip-strategy to pre-
serve balance [60]. Greater co-activation may be partly be a
compensation for decreased lower limb muscle strength
and power [61]. As lower limb muscle impairments occur
in PLHIV, this might contribute to the impaired COP
parameters observed. HIV-associated vestibular dysfunction
has also been reported [62]. Vestibular disorders have a
deleterious effect on postural stability [63]. However,
vestibular conditions are not characterised by impaired
COP excursion, but rather by an increased frequency of
movement, indicating poor control of COP [63].
A lower sway strategy score (the relative amount of
high-frequency ankle versus low-frequency hip move-
ment) for bilateral stance with eyes closed was found in
PLHIV, albeit only reported in a single study in this review
Fig. 9 Meta-analysis of right leg postural reflex latencies in PLHIV: long loop latencies (ms)
Fig. 10 Meta-analysis of 6-Minute Walk Distance (m) in PLHIV
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[22], indicating a heavier reliance on the hip-strategy. In
the general population, intact individuals will change their
balance strategy from the normally employed ankle strat-
egy, to relying on the hip strategy [56] when faced with
more challenging conditions. Individuals with impaired
balance, who already rely more heavily on the hip strategy,
are less able to adapt to challenging conditions [56].
The SOT Equilibrium Quotient (EQ) is a calculation
of the average COP sway, with lower EQ scores having
been associated with increased fall risk in the elderly
[64]. The two studies evaluating this outcome [7, 22] re-
ported significantly lower EQ scores in PLHIV, especially
with more challenging conditions.
Reduced single leg stance time is predictive of some
(i.e. injurious), but not all, falls in the elderly [65]; how-
ever, the clinical value of this test might be called into
question. The test might suffer from learning effects
[66], leading to possible ceiling effects even in individ-
uals with substantial impairment when only performed
as a clinical test. Due to differences in the reporting of
results among the included studies assessing this out-
come, it is difficult to draw conclusions regarding im-
pairment and the value of the test in PLHIV.
Dynamic balance
Dynamic balance is often assessed using dynamic posturo-
graphy, which involves external perturbations being induced
while a person tries to maintain an upright posture [56]. A
common postural synergy in this scenario is the distal-to-
proximal ankle strategy, involving a short loop (SL) and
medium loop (ML) response in the gastrocnemius, followed
by a long loop (LL) response in the tibialis anterior [67, 68].
Prolonged stance-stabilizing LL responses have been docu-
mented in elderly fallers [69]. Meta-analyses indicated that
LL latencies were increased in symptomatic but not asymp-
tomatic PLHIV, and upon combining all groups of PLHIV,
LL latencies were still significantly increased. It is suggested
that the early-observed prolonged LL latencies in PLHIV
with asymptomatic HIV infection may indicate alterations
in the central dopaminergic system (basal ganglia, caudatus
nucleus and nigrostriatal system) [48].
Scaling of LL latency-amplitude, referring to the ability to
adjust the size of posturally stabilizing reflexes and another
important factor associated with falls [53], was assessed in
one study [50]. Neurologically intact PLHIV showed ab-
normal postural reflex regulation under unpredictable,
but not predictable, perturbations. Under random con-
ditions, PLHIV automatically selected a LL response of
a relatively similar size to one needed for medium
perturbations. This response may not be sufficient to
correct for large perturbations, leading to an increased
risk of falling. However, the authors noted that the
impairment in PLHIV was “mild” and did not appear
clinically significant in early HIV infection.
The Limits of Stability (LOS) or Functional Base of Sup-
port (FBOS) test involves instrumented measurement of a
forward leaning task and evaluates voluntary control of
the center of gravity (COG). Instrumented LOS or FBOS,
unlike the clinical Functional Reach test [8, 49], was im-
paired in PLHIV [7, 22]. Similarly, the Functional Reach
test has been proven not to be an indicator for differenti-
ating elderly fallers from non-fallers [70], while instru-
mented LOS is an early indicator of increased fall risk in
the elderly [71]. These observations may be attributable to
the differences in the task involved in the clinical versus
the instrumented tests (although both assesses LOS) [71].
The 5STS test is an indicator of dynamic balance. Im-
paired performance was noted in two of the three studies
evaluating this outcome [8, 9]. In addition to impaired
central sensorimotor components being proposed to play
a role [9], impaired 5STS time also implies poor lower
limb muscle performance, which is associated with falls
and disability both in HIV-seronegative elderly popula-
tions and in middle-aged PLHIV [8, 18]. Low appendicular
muscle mass is prevalent in PLHIV and associated with
functional impairment [72]. However, a decline in the abil-
ity of muscles to produce strength and power (dynapenia)
might have a bigger contribution to functional decline in
the elderly and is associated with poor chair-rise-time [73]
Intra-muscular impairments, including fatty muscle infil-
tration, and low central activation are reported in PLHIV
[29, 35, 74] and premature expression of genes associated
with muscle aging is upregulated in PLHIV [75]. Grip
strength might correlate with dynapenia in the elderly
[76], and an accelerated decline in grip strength has been
reported in PLHIV [77].
Owing to the dichotomous assessment by clinical tests
of the ability to maintain standing balance, such tests
only detect impaired balance once compensation strat-
egies fail [56]. Selection of effective compensation strat-
egies to restore balance (especially by persons who are
physically active), might hide impairments, potentially
hampering the use of such tests in active individuals or
at an early stage of disease [56]. Level of physical activity
was not assessed by any studies included in this review;
ceiling effects in the results provided by the clinical
balance tests can therefore not be excluded.
Although more suited to quantification of balance, inter-
pretation of the results of instrumented posturography is
complex. Generally, an increase in COP movement is as-
sumed to reflect impaired balance; but this may not be true
[78, 79]. Due to the interdependent relationship of the
underlying systems, selection of an alternative compensation
strategy to maintain stance could lead to observation of ei-
ther increased or decreased COP movement, which in fact
would reflect optimal balance control [56]. Second, altered
COP movement can result from deterioration of several
underlying systems. Thirdly, COP movement is affected by
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training and learning effects, for example, individuals (and
even more so those trained in sports) might be able to
maintain a position very well, despite severe system deterior-
ation, due to becoming familiar with the task or using select-
ing proper strategies for efficient compensation [56].
Results, especially from singular studies, must thus be con-
sidered cautiously and in the context of the assessment
protocol, e.g. number of trials, and participant characteris-
tics, such as activity level.
Gait
In this review, PLHIV exhibited impaired fast, but not pre-
ferred, gait speeds, despite being on successful HAART [10,
12, 22, 49]. PLHIV who were also recurrent fallers, had an
even slower fast-paced gait [18]. Gait speed is reported as a
predictor of falls in geriatric populations, with a linear rela-
tionship between slow gait speed and increased fall risk
often assumed [80–82]. However, a non-linear relation has
also been proposed [38]. Growing evidence show that gait
and cognition, specifically attention and executive function
[83] are interrelated. Neurocognitive decline occur in HIV
[6, 13, 84–86], is in part associated with reduced dopamin-
ergic function [87], and has been associated with slow gait
speeds in this population [88]. Executive function, motor
skills and attention/working memory are some of the
domains that are affected by HIV [89]. Gait slowing is sug-
gested to be an adaptive mechanism to prevent falls, to the
effect that a slow gait speed might actually be associated
with a reduced fall risk [38].
Six-Minute Walk Distance, which is actually an indica-
tor of functional aerobic capacity, has been shown to cor-
relate well with gait speed [90]. Meta-analyses of two
studies [44, 49] suggests decreased 6MWD, and thus de-
creased gait speed under fast conditions, in PLHIV. Six-
Minute Walk Distance was also reported to be decreased
in PLHIV in the majority of un-pooled studies assessing
this outcome [8, 9, 35] – however all of these studies used
predicted values from the literature. This is of concern, as
community-specific or cultural factors influence gait
speed [43]. Gait initiation time was reported to be signifi-
cantly slowed in PLHIV, albeit data from a single study
[22]. Gait initiation time has been associated with in-
creased fall risk in the elderly [52]. Cadence, which also
has an association with gait speed and falls in the elderly
[91], was assessed by two studies [7, 22], but owing to
contradicting results, no firm conclusions can be drawn.
Measurement conditions and task difficulty
Evaluating performance under conditions of varying diffi-
culty can provide more “real-life” insight into the quality
of the specific underlying sensory systems [56, 92]. Studies
assessing balance included in this review employed differ-
ent sensory conditions, eliminating or disturbing the in-
formation of three main sensory systems. These included
variations in visual input, different base-of support sizes
and variations in support surfaces. For dynamic balance
assessments, perturbations of varying amplitudes and pre-
dictability were induced using platform tilts. There was an
overall tendency of PLHIV to perform similar to controls
in easier conditions, and significantly worse with increased
task difficulty. A correlation between static balance deficit
and eyes closed conditions was demonstrated by clinical
as well as instrumented tests [7, 22, 48]. Unstable condi-
tions with eyes closed showed the greatest abnormalities
in postural balance [45, 46]. Sullivan et al. (2011) [21]
found impaired performance among PLHIV during clin-
ical tests involving reduced base of support. Postural reflex
synergies also appear to be task-dependent. Unpredictable
perturbations resulted in worse dynamic balance perform-
ance [50]. It thus seems that PLHIV may have impaired
response to unexpected perturbations or more complex
tasks, predisposing them to falls. In the case of impair-
ment of any of the systems contributing to postural
balance, alternative compensation strategies are used by
an individual to maintain postural control and orientation
[56, 93]. Sensory reweighting comes into play, i.e. the
nervous system will rely on more accurate sensory input,
rather than less accurate, conflicting information [94].
Individuals relying more on one particular balance system
are thus less able to adapt to situations where input to that
system is disturbed, and have to rely on only the
remaining systems [56]. This sensory reweighting seems
impaired in PLHIV. Also, impaired dual-task performance
has been demonstrated in PLHIV [95], although none of
the included studies assessed this condition.
All gait tests in included studies were conducted on level,
unobstructed walkways. During walking, many falls occur
not during normal walking, but rather when negotiation
challenging terrains. Results might have been more clinic-
ally relevant had irregular or unfamiliar surfaces been
assessed, especially since dynamic balance in PLHIV seem
to be more impaired under challenging circumstances.
However, both self-selected and fast gait speed conditions
were evaluated, with group differences mostly found when
comparing fast gait. It has been suggested that walking at
different speeds likely influences both the noise level in
human motor performance as well as dynamic error cor-
rections [96]. Thus, impairments at fast paced conditions
may indicate deficits under more challenging conditions.
Disease severity
A dose–response relationship between HIV disease severity
and locomotor impairment was suggested in 53% of stud-
ies. In addition, subgroup analyses highlighted impairments
in postural reflex latencies that were inconspicuous in a
combined group of all PLHIV, but became apparent in only
those with symptoms of chronic HIV disease when com-
pared to controls. However, methodologically it remains a
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challenge to attribute observed differences between PLHIV
and controls directly to HIV infection, as evident from the
discussion thus far. Comparison populations most likely
always differ in terms of many confounding factors [8]. It
cannot be assumed with certainty that observed impair-
ments are purely related to severity of HIV infection, and
the contribution of various comorbidities and opportunistic
infections should be considered. This is especially true for
the older studies, where eligibility criteria did not control
for various confounders and comorbidities.
Treatment effects: Antiretroviral therapy (ART),
combination antiretroviral therapy (cART) or highly active
antiretroviral therapy (HAART)
The majority of studies reporting on treatment effect
failed to find significant associations to balance or gait
outcomes in PLHIV, regardless of the different combina-
tions of drugs (terms used for combination use of ARV
including ART, cART or HAART). Thus, antiretroviral
therapy does not appear to be a reversing factor with re-
gard to locomotor impairments.
Peripheral neuropathy
None of the five studies reporting on the association be-
tween peripheral neuropathy and locomotor impairments
found any significant relationships. A possible explanation
for balance abnormalities among PLHIV, at least for those
parameters measured by the included studies, might thus
indicate involvement of the central rather than peripheral
nervous system [7, 8, 21, 46, 47]. The fact that eyes closed
conditions were often necessary to elicit group differences
in balance, further motivates CNS dysfunction as an
underlying mechanism [7]. It is reported that deficits in
infratentorial brain tissue volume and disruption of the
pontocerebellar fiber system microstructure, at least in
part, may contribute to locomotor impairments in PLHIV
[21]. It can, however, not be concluded with certainty that
no association exists between gait or balance and periph-
eral neuropathy in PLHIV. It is possible that peripheral
neuropathy adversely affects gait and balance parameters
that were not measured in these studies. For example,
impairments in joint kinematics (assessed by none of the
included studies in this review) have been associated with
peripheral neuropathy in Type 2 diabetic patients [97].
Implications for future research
While the importance of identifying spatiotemporal defi-
cits is acknowledged, the associated kinematic and kinetic
data can provide more insight into underlying mecha-
nisms of the observed impairments. Some locomotor im-
pairments related to early functional decline might be too
small to be detected by visual observation alone in the
clinical setting [51, 98]. These subtle impairments may
however have substantial consequences for the individual.
Thus, there is a need for more robust quantitative assess-
ment, such as three-dimensional biomechanical motion
analysis. We also suggest the use of dual tasking in PLHIV
to assess the subtler changes in function, and adding more
challenging conditions to gait assessments. Furthermore, a
need exists for higher quality research. Carefully selected,
representative samples will make results more homoge-
neous, relevant and generalizable. In addition, valuable in-
formation can be extracted from the geriatric literature
that is likely to inform research in PLHIV, especially with
regards to data on falls and specific movement impair-
ments. This should be further explored, and the psycho-
metric properties of both instrumented and clinical gait
and balance assessments should be determined specifically
in PLHIV. Lastly, we found the lack of studies conducted
in Sub-Saharan Africa, the epicenter of the HIV epidemic,
surprizing. More research is needed in developing coun-
tries to address this gap.
Review limitations
Language bias is likely in this review, as only studies pub-
lished in English were considered. Another limitation of
the review is that only two included articles were appraised
by more than one reviewer, meaning that fifteen of the
seventeen articles were scored for methodological quality
by only one reviewer. In addition, ceiling effects might have
hampered results from clinical tests. No studies in this re-
view measured COM movement, with a subsequent in-
complete representation of balance in PLHIV at present.
Results of this review should be interpreted with caution as
substantial statistical heterogeneity existed between the in-
cluded studies, albeit expected, as evident in the meta-
analyses (indicated by high I2 values). Due to the small
number of studies per outcome, all sources of heterogen-
eity could not be accounted for, but some possible explana-
tions for variation in results have been discussed. Clinical
heterogeneity was evident in the majority of studies, par-
ticularly in terms of setting, sample sizes, age groups, gen-
der distributions, and HIV-staging. A wide variety of study
outcomes and measurement methods were used. Given
the paucity of research on existing impairments and the
optimal method of evaluating these in PLHIV, the wide
variation in assessment tests used was to be expected.
Although the diversity in populations, especially regarding
disease definition and subgroups, might seem surprising, it
must be kept in mind that HIV classification systems have
evolved substantially since the earliest included study and
that HAART regimes did not yet exist in those earlier
periods. Furthermore, publication- and reporting biases are
suspected in this review, due to many authors collaborating
on different papers and the same populations possibly used
in different studies. However, formal assessment using
funnel plots was not possible due to the low number (<10)
studies assessing a similar outcome.
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Conclusions
This review found that young to middle-aged PLHIV have
impairments in certain aspects of gait and balance, which
are similar to those that predispose elderly seronegative
populations to falls. The impairments are more pro-
nounced during challenging conditions, might be associ-
ated with HIV disease severity, are not influenced by ART,
and might not necessarily be associated with peripheral
neuropathy. Results should be interpreted with caution
due to the overall fair to low methodological quality, sub-
stantial heterogeneity and many outcomes being assessed
by singular studies only. The effect of HIV on gait and
balance parameters, and in particular biomechanical
outcomes, are currently insufficiently quantified and
this review provides a first step to inform future re-
search. Further investigation involving more methodo-
logical uniformity is warranted to better identify and
understand relevant locomotor impairments in PLHIV.
Only then can more clinically relevant conclusions,
such as appropriate strategies for fall-prevention in this
population, be drawn.
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